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 Germinal centers (GC) are microstructures where B cells that have been activated by antigen 
undergo a developmental program that involves the somatic diversification of their immunoglobulin 
genes and intense proliferative activity coupled to apoptotic selective events. As a result, from GCs 
emerge plasma cells and memory B cells that bear immunoglobulins with higher affinity for the initi-
ating antigen and with more versatile effector functions. While ensuring a competent humoral im-
mune response, GCs are also a site particularly prone to neoplastic transformation. Indeed, the vast 
majority of human lymphomas arise from GC-experienced B cells. 
 MicroRNAs (miRNAs) are small non-coding RNA molecules that regulate gene expression post-
transcriptionally. In the past years miRNAs have arisen as key regulators of the immune function, 
however little is known of their role in GC B cells. In this work, we have identified miR-217 and miR-
28 as GC microRNAs and have explored their functional impact in GC events and in B cell lym-
phomagenesis. 
 We observed that miR-217 is a positive modulator of the GC response that boosts immuno-
globulin diversification, i.e. the generation of class-switched antibodies and the frequency of somatic 
hypermutation. We found that miR-217 dampens the expression of a DNA damage response and re-
pair gene network and in turn stabilizes Bcl-6 expression in GC B cells. Importantly, miR-217 overex-
pression also promotes mature B-cell lymphomagenesis; this is physiologically relevant as we find 
that miR-217 is overexpressed in aggressive human B-cell lymphomas. 
 In contrast, miR-28 acts as a negative regulator of the GC response that impairs B cell prolifera-
tion and survival through the regulation of a BCR signaling gene network. In addition, we found that 
miR-28 expression is lost in a wide range of GC-derived human malignancies. Further, miR-28 re-
expression dramatically inhibits tumor growth in various lymphoma models, suggesting that miR-28 
is a tumor suppressor for GC-derived neoplasias.    
 Together, we have found that miR-217 and miR-28 provide antagonistic regulatory roles of the 
GC reaction that are intimately intertwined with pathways leading to B cell transformation. In addi-
tion, our results open new perspectives for the development of a novel therapeutic strategy for the 
treatment of B cell tumors based on miR-28 replacement. 
ABSTRACT 
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 Los centros germinales (CG) son microestructuras donde las células B que han sido activadas 
por antígeno llevan a cabo un programa madurativo que implica la diversificación somática de los 
genes de inmunoglobulinas y una intensa actividad proliferativa asociada con procesos de selección 
apoptóticos. Como resultado, de los CG emergen células plasmáticas y células B memoria que portan 
inmunoglobulinas con mayor afinidad por el antigeno iniciador, y con mayor versatilidad funcional. 
Aunque aseguran la eficiencia de la respuesta inmune humoral, los CG son también un entorno parti-
cularmente propenso a la transformación maligna. De hecho, la inmensa mayoría de los linfomas 
humanos tienen su origen en células B que han pasado por un CG.  
 Los microRNAs (miRNAs) son moléculas de RNAs pequeñas y no codificantes que regulan la 
expresión génica post-transcripcionalmente. En los últimos años los miRNAs han surgido como regu-
ladores clave de la función inmune, pero se sabe muy poco de su función en células B de CGs. En este 
trabajo hemos identificado a miR-217 y miR-28 como miRNAs de CG y hemos explorado su impacto 
funcional en los procesos asociados a CGs y a la linfomagénesis B. 
 Observamos que miR-217 es un modulador positivo de la respuesta de CG que aumenta la di-
versificación de anticuerpos, es decir, la generación de cambio de isotipo y la hipermutación somáti-
ca. Encontramos que miR-217 amortigua la expresión de una red de genes implicados en la respuesta 
al daño y la reparación del DNA y a su vez estabiliza la expresión de Bcl-6 en células B de CG. Además, 
la sobreexpresión de miR-217 induce la generación de linfomas B; esta observación es relevante fisio-
lógicamente porque encontramos que miR-217 está sobre-expresado en ciertos linfomas B humanos. 
 Por el contrario, miR-28 actúa como un regulador negativo de la respuesta de CG, que dismi-
nuye la proliferación y la supervivencia de las células B mediante la regulación de la señalización a 
través del BCR. También encontramos que la expresión de miR-28 se pierde en un amplio espectro 
de neoplasias derivadas de CGs. Finalmente, la re-expresión de miR-28 produce una inhibición dra-
mática en el crecimiento tumoral en diversos modelos de linfoma, lo que sugiere que miR-28 es un 
supresor de tumores en neoplasias derivadas de CG. 
 En conjunto, hemos encontrado que miR-217 y miR-28 tienen funciones antagónicas en la re-
gulación del CG y que estas están íntimamente relacionadas con los mecanismos que dan lugar a la 
transformación de las células B . Además, nuestros resultados abren nuevas posibilidades para el 
desarrollo de estrategias terapéuticas para el tratamiento de linfomas B, basadas en la re-expresión 
de miR-28.  
 
RESUMEN 
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Abbreviation Full name 
ABC-DLBCL Activated B cell like Diffuse Large B cell lymphoma 
AID Activation Induced cytidine  Deaminase 
Bcl-2 B-cell lymphoma 2 
Bcl-6 B-cell lymphoma 6 
BCR B cell receptor 
BL Burkitt Lymphoma 
BLIMP1 B-lymphocyte-induced maturation protein1 
CD3 Cluster of differentiation 3 
CLL Chronic lymphocytic leukemia 
CSR Class Switch Recombination 
DLBCL Diffuse Large B Cell Lymphoma 
DOX Doxycycline 
DZ Dark Zone 
ERK Extracellular Signal-Regulated Kinase 
FL Follicular Lymphoma 
GC Germinal Center 
GC-DLBCL Germinal Center B cell like Diffuse large B cell lymphoma 
GFP Green fluorescent protein 
GO Gene Ontology 
H&E Hematoxilin and eosin 
Ig Inmunoglobulin 
IKKB Inhibitor of Nuclear Factor Kappa-B Kinase Subunit Beta 
IL4 Interleuchine four 
IRES  Internal ribosome entry site 
IRF4 Interferon responding factor four 
LPS Lipopolisacharide 
LZ Light Zone 
MCL Mantle cell lymphoma 
miRNA microRNA 
MZL Marginal Zone B cell lymphoma 
NF-ƘB Nuclear Factor Kappa-B 
NGS Next generation sequencing 
NP-CGG nitrophenyl hapten-coupled chicken gamma-globulin 
NSG NOD Scid Gamma 
ORF Open reeding frame 
PAX5 Paired box 5  
PCT Plasmacytoma 
PI Proliferation index 
RFP Red fluoresecent protein 
SBL Small B cell lymphoma 
SHM Somatic Hyper Mutation 
SRBC Sheep red blood cells 
TFH T follicular helper 
UTR Untranslated region 
XBP1 X-Box Binding Protein 1 
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1. B cell differentiation and function 
 1.1. Immune system: innate immunity and adaptive immunity 
The immune system is composed of the cells and molecules in charge of defending the organism 
against infection. There are two fundamental arms in the immune system. Innate (natural) immuni-
ty provides a first line of rapid response against common microorganisms; it does not require previ-
ous exposure to the infectious agent and it does not evolve with subsequent infections. Innate im-
munity involves phagocytic cells, cells that release inflammatory mediators and natural killer cells, 
as well as the complement system, acute-phase proteins, and cytokines such as the interferons.  In 
contrast, acquired (adaptive) immunity occurs during the lifetime of an individual as an adaptation 
to infection with any given pathogen; it is thus a more specialized barrier against infection and con-
fers immunological memory. B and T lymphocytes are the effector cells in adaptive immunity. Their 
activity relies on the expression of surface receptors that can recognize specific molecular structures 
present on the pathogens, called antigens. In the case of T cells the antigen receptor is called T cell 
receptor (TCR) and in the case of B cells the receptor is called B cell receptor (BCR). While T cells 
mediate cellular immunity against intracellular pathogens, B cells are specialized in generating anti-
bodies –the secreted form of the BCR- and thus mount humoral responses against extracellular 
pathogens.  
1.2. B cell differentiation and antibody diversification 
Each individual B cell expresses a single BCR with unique antigen specificity such that the pool of 
mature B cells is capable of producing antibodies that specifically recognize and respond to virtually 
any foreign antigen. The generation of this hugely diverse repertoire of BCR specificities is achieved 
through the somatic diversification of immunoglobulin genes during B cell differentiation in the 
bone marrow, and is subsequently completed as a consequence of antigen encounter in Germinal 
Centers (GC). 
The BCR is composed of two identical immunoglobulin heavy (IgH) chains and two identical im-
munoglobulin light (IgL) chains. The N-terminus of IgH and IgL encode the variable region of the im-
munoglobulins and is responsible of the antigenic recognition. The C-terminus of IgH encodes the 
constant region, which determines the antigen clearance via. The BCR receptor is the main modula-
tor of B cell physiology, and the engagement of an antigen into the BCR can lead to different re-
sponses, including proliferation, cell death or further differentiation depending of the signal 
strength and spatial-temporal contexts (Niiro and Clark 2002). 
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 1.2.1- Early B cell differentiation and primary antibody diversification 
 The genes encoding antibody variable regions are composed of groups of gene segments 
called Variable (V), Diversity (D), and Joining (J) for the IgH locus or V and J for the IgL locus. During B-
cell differentiation, a segment from each V (D) and J group is assembled to give rise to a specific VDJ (or 
VJ) rearrangement; this combinatorial event generates the diversity of the primary antibody repertoire. 
Assembly of antibody genes takes place through a process of site-specific recombination called V(D)J 
recombination that involves the introduction of DNA double-strand breaks (DSBs) at specific recogni-
tion signal sequences (RSS) flanking the V, D, and J elements by recombination activating genes (RAG1 
and RAG2), followed by repair. Developing B cells in the bone marrow (or fetal liver) first assemble their 
IgH locus in two successive steps, DHJH and VHDHJH, at the so-called progenitor B (pro-B) stage. Pro-B 
cells that achieve a productive IgH rearrangement express an Igµ chain together with the surrogate 
chains 5 and VpreB (pre-BCR). pre-BCR expression leads to a phase of vigorous clonal cell expansion of 
precursor B (pre-B) cells and the subsequent rearrangement of the IgL locus by an analogous VDJ re-
combination event. As a result, a mature BCR is expressed for the first time in immature B cells, which 
are then ready to leave the bone marrow and join the peripheral pool of functional B cells.  
Given the stochastic nature of V(D)J recombination, this developmental process is coupled to 
selective events that guarantee that only cells where a rearrangement has given rise to a functional pre
-BCR and BCR receive the appropriate survival signals, whereas the rest undergo apoptosis. In addition, 
central and peripheral tolerance checkpoints ensure the elimination or inactivation of B cells expressing 
BCRs with self-reactive specificities (Rajewsky 1996).  
1.2.2- The Germinal Center reaction and secondary antibody diversification  
Unlike T cells, B cells have a second opportunity to further diversify their primary antibody   
repertoire after antigen encounter. When a mature B cell in the periphery encounters an antigen, it can 
engage in the Germinal Center (GC) reaction, a complex biological process that is absolutely required to 
generate antibody secreting plasma cells (PC) and long lived memory B cells that are highly specific for 
the antigen that elicited the response. GCs are transient microstructures that form within B-cell follicles 
of secondary lymphoid tissues to enable immunoglobulin affinity maturation in response to T-cell-
dependent antigens. Within GCs, B cells undergo clonal expansion and two molecular processes named 
somatic hypermutation (SHM) and class switch recombination (CSR). SHM involves the introduction of 
mutations, usually single-nucleotide substitutions, in the V(D)J rearranged variable region of the IgH 
and IgL chains, thus allowing the production of BCRs with a higher affinity for antigen. Only those B cells 
in which SHM results in the generation of BCRs with improved affinity for their cognate antigen survive 
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and proliferate. CSR is a region-specific recombination reaction that replaces the primary µ constant 
region with a downstream constant region, giving rise to antibodies with different isotypes and there-
fore new capabilities for antigen removal.  
SHM and CSR are both initiated by activation-induced deaminase (AID), which deaminates cy-
tosines on the immunoglobulin locus (Fig. 1). This initial lesion on DNA is subsequently processed by 
DNA repair and recombination factors to allow the fixation of a mutation, in the case of SHM, or the 
generation of a DNA double-strand break and a recombination reaction, in the case of CSR (reviewed in 
(Stavnezer, Guikema et al. 2008) (Peled, Kuang et al. 2008) (de Yebenes and Ramiro 2006) (Di Noia and 
Neuberger 2007). Once these processes are completed, B cells expressing high affinity immunoglobu-
lins are selected for terminal differentiation into antibody secreting PCs (PC) cells or long-lived memory 
B cells. The efficiency of the GC reaction is facilitated by the specialized GC microenvironment that  
supports the close interaction and the rapid movements of various cell types in a confined space.  
Figure 1. The GC reaction: B cells that have successfully undergone V(D)J recombination and that express 
functional BCRs migrate as naive B cells from the bone marrow to the secondary lymphoid organs. Upon en-
counter with an antigen (Ag), naive B cells become activated by interaction with CD4+ T follicular helper (TFH) 
cells and aggregate into primary follicles to form Germinal Centers (GCs). In the GC, B cells undergo secondary 
antibody diversification through somatic hypermutation (SHM) and class switch recombination (CSR) reactions. 
Both reactions are initiated by the activity of activation induced deaminase (AID), which deaminates cytosines 
on the immunoglobulin gene locus to initiate either a mutation (in SHM) or a recombination reaction (in CSR) 
and serve to generate cells with high-affinity antibodies and different effector functions. The outcome of the 
GC reaction is the generation of plasma cells (PC) and long-lived memory B cells with high affinity for the anti-
gen that elicited the response. GCs comprise a dark zone (DZ), where SHM takes place and B cells divide rapid-
ly, and a light zone (LZ) where B cells are in contact with follicular dendritic cells, T cells and macrophages and 
are selected on the basis of the affinity of their BCRs.  
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The GC is anatomically divided into a Dark Zone (DZ) and a Light Zone (LZ). In the DZ B cells di-
vide rapidly, upregulate AID expression and undergo SHM of immunoglobulin variable regions gene-
rating mutants with altered antibody affinity. In the LZ B cell capture antigen from follicular dendritic 
cells and compete for limiting T follicular helper cells. Higher affinity cells survive and either re-enter DZ 
or are exported out of the GC as PC or memory B cell. Lower-affinity GC B cells die by apoptosis and are 
cleared by macrophages. Thus the GC promotes several interactive rounds of mutation and selection 
and, following differentiation into post-GC cells, produces a stepwise increase in the antigen affinity of 
secreted antibodies (De Silva and Klein 2015).  
1.3. The GC transcriptional program 
 
The GC reaction is regulated by a number of key transcription regulators that establish a GC specific 
genetic program and control the timing of the transition from GC B cells to terminal B cell differentia-
tion. 
Bcl-6 
This BTB-zinc finger transcriptional repressor is considered a master regulator of the GC response. Bcl-6 
protein is highly upregulated in GC B cells, where it regulates a broad network of direct target genes 
involved in various cellular processes. Upregulation of Bcl-6 is essential for initiation of the GC reaction 
as Bcl-6 deficient GC precursor B cells fail to enter the follicle (Kitano, Moriyama et al. 2011). Converse-
ly, Bcl-6 downregulation by the transcription factor IRF4 (which is induced by NF-B) represses Bcl-6 
(Saito, Gao et al. 2007) to exit the GC reaction and to allow PC differentiation.  A critical biological func-
tion of Bcl-6 in GC B cells is to facilitate rapid replication and tolerance to the genomic damage occu-
rring during clonal expansion and SHM by directly repressing DNA damage sensing genes and check-
point genes such as ATR and TP53 and modulating apoptosis in GC B cells (Ranuncolo, Polo et al. 2007) 
(Phan and Dalla-Favera 2004). Thus, Bcl-6 provides a permissive environment for physiological AID me-
diated DNA remodeling to occur.  Bcl-6 orchestrates other genes to inhibit cell cycle arrest and prevents 
premature exit from the GC stage by repressing Blimp-1 (Basso and Dalla-Favera 2010) (Basso and Dalla
-Favera 2012). In agreement with these functions Bcl-6 deregulation is associated with a fraction of ma-
ture B cell neoplasms (see below).  
Myc  
Myc is a transcription factor with a crucial role in almost all proliferating cells. Myc supports robust pro-
liferation by regulating diverse processes including cell cycle progression, metabolism and telomere 
maintenance (Dang 2012). Likewise, Myc deregulated expression is oncogenic and has been shown to 
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be sufficient for the generation of GC-derived lymphoma in a mouse model (Erikson, ar-Rushdi et al. 
1983). 
 Within GCs, c-Myc has been shown to be required for both the formation and maintenance of GCs 
(Calado, Sasaki et al. 2012) (Dominguez-Sola, Victora et al. 2012). After GC establishment,  Myc expres-
sion is silenced as a result of transcriptional repression by Bcl-6 (Dominguez-Sola, Victora et al. 2012) 
(Calado, Sasaki et al. 2012), and Myc expression is almost entirely absent in the proliferating B centro-
blast until it is re-expressed in a subpopulation of LZ B cells destined to DZ re-entry in established GCs  
(Basso and Dalla-Favera 2015).  
NF-B 
Nuclear factor-B (NF-B) is a family of transcription factors that play a pivotal role in regulating B 
cell survival and proliferation and whose constitutive activation is recurrently found in B cell malignan-
cies. NF-B activation in B cells occurs transiently downstream of numerous receptors, including the 
BCR, CD40, the BAFF receptor and various Toll-like receptors. NF-B transcription factors are formed by 
homo- and heterodimerization of the subunits p50 (encoded by NF-B1), p52 (encoded by NF-B2), 
p65 (Rel-A), Rel-B, and c-Rel. These factors shuttle between the cytoplasm and the nucleus in a fashion 
that is regulated by diverse intracellular signaling events. Within GCs NF-B signaling is required for GC 
maintenance (Kitano, Moriyama et al. 2011) (Dominguez-Sola, Victora et al. 2012) (Heise, De Silva et al. 
2014) and plays an important role in LZ B cells, were NF-B-mediated upregulation of IRF4 expression 
results in the repression of Bcl-6 transcription and the termination of the GC-associated transcription 
program (Saito, Gao et al. 2007), giving rise to terminal B cell differentiation.  
IRF4 
IRF4 is a member of the interferon regulatory factor superfamily of transcription factors that shows a 
bimodal pattern of expression during GC reaction. IRF4 expression is induced upon BCR ligation and is 
required to initiate the GC program (Klein, Casola et al. 2006) (Sciammas, Shaffer et al. 2006). Addition-
ally,  IRF4 is needed for isotype switching, as IRF4 deficient mice fail to induce AID and promote CSR 
(Sciammas, Shaffer et al. 2006) (Klein, Casola et al. 2006). However, IRF4 it is not required for GC 
maintenance, as deletion in latter points does not impact GC structure (Klein, Casola et al. 2006). Im-
portantly, IRF4 is one of the factors that initiates PC differentiation program, repressing Bcl-6 and in-
ducing Blimp-1. Indeed IRF4 lacking mice fail to generate terminally differentiated PCs (Sciammas, 
Shaffer et al. 2006).  
Blimp-1 and XBP1 
Two transcription factors are essential to orchestrate PC differentiation, Blimp-1 (encoded by the gene 
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PRDM1) and XBP1. Blimp-1 is a transcriptional repressor exclusively expressed in antibody secreting 
plasmablasts and PCs that shuts down all the transcription factors  that were relevant during the pre-
vious stages of B cell differentiation and arrests cell cycle to exit GC program (Turner, Mack et al. 
1994) (Shaffer, Lin et al. 2002) (Shapiro-Shelef, Lin et al. 2003) (Shapiro-Shelef, Lin et al. 2005). XBP1 
acts downstream of Blimp-1 and is not completely required to allow PC generation (Todd, McHeyzer-
Williams et al. 2009). Instead, XBP1 provokes the necessary changes in the B cell metabolism and  
cellular structures to allow the secretion of huge quantities of Ig in the PC by inducing endoplasmic 
reticulum remodeling, autophagic pathways and the induction of the unfolded protein response 
(Shaffer, Shapiro-Shelef et al. 2004) (Engel and Barton 2010).  
1.4. B cell lymphomas 
 1.4.1- Classification and etiology 
Lymphomas are hematological tumors that have their origin in B or T lymphocytes. The World 
Health Organization (WHO) established a classification of two main groups of lymphomas: Hodking 
lymphoma (HL) and non-Hodking lymphoma (NHL). About 90% of the lymphomas are NHLs, compris-
ing a heterogeneous group of malignancies of different biology and prognosis. However, the majority 
of NHLs are from B cell origin, and more specifically the vast majority of B-NHLs arise from mature 
antigen experienced GC B cells (Table 1). B cell NHL subtypes include low grade (indolent) slow grow-
ing lymphomas and high grade (aggressive), quickly growing lymphomas. Low grade B cell NHLs in-
clude follicular lymphoma (FL), mantle cell lymphoma (MCL), marginal zone lymphoma (MZL) and 
small lymphocytic lymphoma (SLL) B-NHLs.  High grade B cell NHLs include Burkitt lymphoma (BL) and 
diffuse large B cell lymphoma (DLBCL). Based on different molecular characteristics DLBCL are subdi-
vided in two major subtypes; a germinal center B-cell-like subtype (GC-DLBCL) and an activated B-cell-
like subtype (ABC-DLBCL). DLBC are the most prevalent form of NHLs, representing one third of all 
NHLs cases (Staudt and Wilson 2002). 
One signature of the GC origin of mature B cell lymphomas is the presence of mutations in the V gene 
segments of immunoglobulin genes (Klein, Klein et al. 1995) (Rockwood, Torrey et al. 2002) (Greeve, 
Philipsen et al. 2003) (Basso and Dalla-Favera 2015). However, the major hallmark of mature B-cell 
lymphomas is the presence of recurrent chromosome translocations that juxtapose one of the Ig loci 
and a proto-oncogene; such as c-Myc in BL, Bcl-6 in DLBCL or Bcl-2 in FL (Basso and Dalla-Favera 
2015) (Table 1). These translocations have been shown to be dependent on AID activity, as they are 
absent in AID-/- B cells (Ramiro, Jankovic et al. 2004) (Robbiani, Bothmer et al. 2008). As a result of the 
translocation, expression of the proto-oncogene is deregulated, usually as a consequence of the  
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transcription driven by Ig regulatory elements. Therefore, translocation events driven by AID are not 
mere markers of B GC neoplasia; indeed deregulated proto-oncogene expression is critical for the etio-
logy of neoplasia generation (Kovalchuk, Qi et al. 2000) (Cattoretti, Pasqualucci et al. 2005). Thus, AID 
activity establishes one direct connection between the GC reaction and lymphomagenic transfor-
mation.  
B cell NHL Frequency 
(%) Origin 
Diagnostic molecular 
features Genetic aberration 
Deregulated 
pathway 
Malignant 
phenotype 
MCL 8 Pre-GC CyclinD1 t(11;14) CyclinD1 t(11;14), BMI1, TP53, CDKN2A, Ink4a/ARF, ATM Bcl-2 S, P, DDR 
CLL/SLL 9 Pre-GC and Post-GCŧ ZAP70
¥ NOTCH1, Myd88, TP53, ATM, miR-15 
- miR-16, BCR, Bcl-2 
S, P, DDR, MS, 
BD 
FL 28 GC Bcl-2 t(14;18) 
Bcl-2 t(14;18), EZH2, TNFRSF14, Fas, 
MEF2B, MEF2C, CREBBP; EP300, 
MLL 
BCR S, P, DDR, MS, 
BD 
BL 1 GC Myc t(8;14) Myc, miR-17-92, CDKN2A, Ink4a/ARF, TP53  S, P, DDR, MS 
ABC-
DLBCL 17 Post-GC 
Gene expression 
profiling 
Myd88, CD79 A and B, Bcl-6 t(3;x), 
CARD11, Myc, Bcl-2, TP53, CDKN2A, 
Ink4a/ARF,TNFAIP3, PRDM1 
NF-κB, IRF4, 
Myc, BCR, TLR-
Myd88, IL-6;10-
JAK/STAT3, 
IFN1, Bcl-6, 
Blimp-1 
S, P, DDR, MS, 
BD, IM 
GC-
DLBCL 19 GC 
Gene expression 
profiling 
Bcl-2 t(14;18), EZH2,  Bcl-6 t(3;x), 
MDM2, miR-17-92,  Myc, MYD88, 
PTEN, Fas, MEF2B, MEF2C, TP53, 
MLL2, CREBBP;EP300 
Bcl-6, Myc S, P, DDR, MS, 
BD, IM 
MZL 
(MALT*) 10 Post-GC AP12-MALT1 t(11;18) 
cIAP2-MALT1 t(11;18), MALT t(14;18), 
Bcl-10, FoxP1, CDKN2A, INK4a/ARF 
NF-κB, Chronic 
infection S, P, DDR, IM 
HCL 1 Post-GC BRAF V600E BRAF  S, P 
PMBL 7 Thymic B cell Gene expression profiling 
JAK2; JMJD2D, PDC1LG2, SOCS1, 
CIITA, TP53, TNFAIP3, 
IL-13-JAK2, NF-
κB, Myc S, DDR, MS, IM 
Table 1. B cell NHL classification and etiology 
 
S: Survival 
P: Proliferation 
DDR: DNA damage response 
MS: Metabolic switch 
BD: Block in differentiation 
IM: Immune modulation 
MCL: Mantle cell lymphoma 
CLL/SLL: Chronic lymphocytic lymphoma / Small B cell lymphoma 
FL: Follicular lymphoma 
BL: Burkitt lymphoma 
DLBCL-ABC: Diffuse Large B cell lymphoma - Activated cell type 
DLBCL-ABC: Diffuse Large B cell lymphoma - Germinal Center cell type 
MZL: Marginal zone lymphoma (MALT is mucosal associated lymphoid 
tissue lymphoma, which is the most common type)* 
HCL: Hairy cell leukemia 
PMBL: Primary mediastinal B cell lymphoma 
¥: ZAP70 is expressed in 50% of CLL/SLL cases. 
Ŧ: The origin of CLL is an antigen experienced B cell, that can be mutated 
(Post-GC origin) or unmutated (Pre-GC origin) in the Ig V region.    
 
Green: Cell cycle regulator 
Light blue: Apoptosis 
Brown: Genomic integrity 
Red: miRNAs 
Purple: Epigenetic modifier 
Black: Signaling factor 
Yellow: Immune regulator 
Grey: Transcription factor 
 1.4.2- Oncogenic signaling 
Besides the AID’s contribution to genomic instability in GC B cells, very often the mechanisms 
that drive normal B cell differentiation and activation are frequently subverted by B cell lymphomas 
for their unlimited growth and survival. The signaling pathways that a normal B cell utilizes to sense 
antigens are frequently derailed in B cell malignancies, leading to constitutive activation of prosur-
vival pathways through different molecular mechanisms. In addition, these malignancies co-opt 
transcriptional regulatory systems that characterize their normal B cell counterparts and frequently 
alter epigenetic regulators of chromatin structure and gene expression (Table 1). 
B cell receptor (BCR) signaling 
One of the signaling pathways that has more impact in B cell physiology is BCR signaling. Im-
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portantly, key signaling pathways downstream the BCR contribute not only to B cell homeostasis, but 
also to transformed B cell survival (Sander, Calado et al. 2012). Thus, normal BCR signaling pathways 
can be hijacked by tumoral B cells to ensure their uncontrolled growth and survival (Küppers 2005) 
(Rickert 2013) (Young, Shaffer et al. 2015). 
Physiological signaling trough the BCR is initiated when the Ig binds the antigen, triggering the phos-
phorylation of the Immunoreceptor Tyrosine-based Activation Motifs (ITAMs) in the cytoplasmic do-
mains of Igα/Igβ (also known as CD79A and CD79B) and the activation of three kinases: Syk, Lyn and 
Btk. Adaptor molecules such as BLNK and BAM32 modulate the progression of the signaling pathway 
with other downstream effector molecules, most notably phosphatidylinositol 3-kinase (PI3K) and 
phospholipase C gamma 2 (PLCgamma2). In this way, PI3K activation results in the formation of phos-
phatidylinositol-3,4,5-trisphosphate (PtdInsP3), which, in turn, recruits the protein serine/threonine 
kinase AKT and the phosphoinositide-dependent kinase 1 (PDK1), to the membrane. Subsequently AKT 
phosphorylates several substrates, including mTORC1 and forkhead/winged helix box class O (FOXO) 
proteins (Werner, Hobeika et al. 2010) with the net effect of enhancing growth and suppression of 
apoptosis (Marshall, Niiro et al. 2000).  On the other hand, PLCgamma2 generates inositol-1,4,5-
trisphosphate (IP3), and diacylglycerol (DAG), which increase intracellular Ca2+ concentration and acti-
vates protein kinase C (PKC). This leads in turn to the activation of MAPKs, specifically, ERK, JNK and 
p38 MAPK, and activation of transcription factors such as NFAT and NF-B, which have important regu-
latory functions in B-cell activation, maturation and survival (Fig. 2). Overall, these different activation 
routes are responsible of different biological outcomes that can be modulated by the BCR (Niiro and 
Clark 2002) (Rickert 2013).  
Signals stemming from the BCR can drive malignant transformation (Rickert 2013) and can involve both 
tonic (independent of ligand) and antigen-dependent BCR signaling. Human malignant B cells typically 
maintain expression of the BCR on the cell surface, suggesting that they may utilize the ability of the 
BCR to engage downstream proliferation and survival pathways (reviewed in (Shaffer, Young et al. 
2012)). Notably, pathogenic BCR signaling in lymphoma has a major impact on the ABC subtype of 
DLBCL, which utilizes a chronic active form of BCR signaling and is dependent on BCR signaling for sur-
vival. Abrogation of BCR signaling in ABC-DLBCL impairs lymphoma growth by diminishing NF-B, AKT, 
ERK, MAP and NF-AT signaling, in keeping with the known activities of the BCR in normal B cells (Davis, 
Ngo et al. 2010). Interestingly, many subtypes of B cell NHL also rely (although in a lower grade) in un-
controlled BCR signaling to maintain their viability (Woyach, Johnson et al. 2012) (Blum 2015) (Table 1).  
The most common path taken by lymphoid malignancies to avoid cell death is constitutive activation of 
the NF-B pathway. The lymphoid malignancies that have been associated with a higher frequency 
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with an altered NF-B signaling are ABC-DLBCL, HL and multiple myeloma. NF-B pathway activates the 
transcription of an antiapoptotic module, including Bcl-2 family members. NF-B pathway deregulation 
in lymphoma occurs through different mechanisms that include activating mutations in the BCR subu-
nits CD79A and CD79B,  somatic mutations targeting MyD88 (an adaptor protein in the Toll-like recep-
tor (TLR) pathway), activating mutations in the scaffold protein CARD11 and also hyperactivation of 
IKKs, which phosphorylate ΙBα (that masks the nuclear localization signal (NLS) of NF-B), thereby pro-
moting its degradation and allowing NF-B transcription factors to enter the nucleus and exert their 
function (Staudt 2010)  (Davis, Ngo et al. 2010) (Lenz, Davis et al. 2008). Indeed, ABC-DLBCL cells are 
addicted to constitutive activity of IKKs in such a way that its inhibition is lethal (Lam, Davis et al. 2005) 
(Ceribelli, Kelly et al. 2014). 
Figure 2. BCR signaling controls B cell physiology: The binding of antigen to the BCR leads to the phosphory-
lation of three kinases: Syk, Lyn and Btk, which activate different signaling pathways by phosphorylating differ-
ent substrates. These signaling pathways determine the outcome of the B cell by controlling a myriad of biolog-
ical functions. PI3K produces PIP3, which leads to AKT recruitment, activating the NF-B pathway. Phosphoryla-
tion of PLCγ2 induces calcium release from the endoplasmic reticulum, which produces the activation of the 
NFAT TF, PKC and Ras, which at the same time induce the activation of ERK. PLCγ2 activates Rac trough SLP-65, 
which produces the activation of JNK and p38. Colored in blue are depicted the kinases, in orange GTPases, in 
green phospholipases, in grey adaptor molecules and in pink transcription factors. 
 1.4.3- Transcriptional regulators and lymphomagenesis 
Transcriptions factors play a key role in a variety of B cell responses that include proliferation, mi-
gration, differentiation and cell death, and consequently, they are exploited by B cell malignancies.  
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As it was noticed in the previous point, deregulated signaling pathways end up with an excess of activa-
tion of the NF-kB transcription factor, which activates transcription of antiapoptotic genes.  Another 
very frequently altered transcriptional regulator in B cell malignancies is Bcl-6, the master regulator of 
GC transcriptional program whose activity is dysregulated by translocation or mutation in a remarkably 
high proportion of DLBCL cases (50%) and in a subset of FL (10%) (reviewed in (Basso and Dalla-Favera 
2010) (Table 1). Constitutive Bcl-6 expression is oncogenic for B cells, as shown in a mouse knockin 
model in which Bcl-6 expression is driven by the Iµ promoter in the IgH locus that results in the genera-
tion of a B cell malignancy akin to human DLBCL (Cattoretti, Pasqualucci et al. 2005). Blimp-1 acts as a 
tumor suppressor in ABC-DLBCL (Pasqualucci, Compagno et al. 2006) (Mandelbaum, Bhagat et al. 2010) 
and in a fraction of ABC-DLBCL tumors, the PRDM1 gene encoding Blimp-1 is disrupted by truncation, 
deletion, and mutation, or it is epigenetically silenced. Accordingly, deletion of PRDM1 in mouse GC B 
cells results in a lymphoproliferative disease that gives rise to DLBCLs with a long latency 
(Mandelbaum, Bhagat et al. 2010) (Calado, Zhang et al. 2010). IRF4 is required for the survival of sever-
al post-GC malignancies (Shaffer, Young et al. 2012). Finally, a cytogenetic hallmark for BL is the Myc-
IgH translocation t(8;14) (q24;q32) and its variants, which juxtapose the Myc oncogene with one of the 
three immunoglobulin loci. Consequently, Myc is deregulated, resulting in massive perturbation of 
gene expression and uncontrolled growth. Importantly, this translocation has been shown to be com-
pletely AID dependent (Ramiro, Jankovic et al. 2004) (Table 1). 
         1.4.4- B cell lymphoma treatment 
In general, chemotherapy and radiation therapy are the principal forms of treatment for B-NHL, alt-
hough radiation is many times used to complement other therapeutic strategies. Nowadays, the chem-
otherapy of choice for many cases is called R-CHOP and consists of a combination of 5 drugs: 1) Rituxi-
mab, is an antibody that recognizes CD20, a molecule expressed by B cells, thereby promoting their 
elimination; 2) cyclophosphamide, which interferes with DNA replication; 3) doxorubicin, a DNA inter-
calating drug; 4) Oncovin, an inhibitor of mitosis; and 5) prednisone, an immunosuppressant. This mul-
tidrug therapy can be very effective, but it has a number of limitations: i) a fraction of the cases is re-
sistant to the treatment (in the case of DLBCL, the most prevalent of aggressive lymphomas, around 40
-45% of patients do not respond to R-CHOP, thus becoming refractory; ii) a proportion of patients re-
lapse after R-CHOP treatment; iii) treatment is highly intensive, which precludes the use in the elderly 
and has a high toxicity including immunosuppression and heart damage. Therefore, there is great inter-
est in the development of novel alternative or complementary therapeutic approaches that allow to 
target better the uncontrolled survival of the lymphoma cells, and to treat refractory and relapsed cas-
es (Lam, Davis et al. 2005) (Wilson, Young et al. 2015). 
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2. miRNA control of the B cell physiology 
2.1. Bases of miRNA biology 
microRNAs (miRNAs) are 21- to 24-nucleotide long single strand RNA molecules that are processed 
from longer RNA precursors and do not encode a protein product, but instead they are biologically ac-
tive as RNA molecules. They function as negative regulators of gene expression by affecting either the 
stability or the translation efficiency of their target mRNAs. miRNA activity on its target mRNAs typical-
ly results in a relatively mild (<two fold) reduction in protein levels, which has led to the view that miR-
NAs act primarily as reinforcers of transcriptional programs conferring robustness to biological process-
es (Ebert and Sharp 2012). However, the regulatory activity of miRNAs is in many aspects similar to 
that of s and transcriptional repressors. Thus, like transcriptional regulators, a single miRNA can poten-
tially regulate many targets to provide coordinated and simultaneous regulation of a network of genes 
in a particular tissue or at a specific developmental stage.  
miRNAs are processed from longer RNA precursors (pri-miRNAs). Pri-miRNAs are either transcribed 
as independent genes or are included within intronic sequences of other genes. Pri-miRNAs fold into 
hairpins that are sequentially cleaved by two RNAseIII endonucleases, called Drosha and Dicer. Drosha 
cleavage generates a ≈ 70-nucleotide long pre-miRNA that is exported to the cytoplasm, where Dicer 
further processes it into a 20–25 bp RNA duplex. One strand of this duplex is the mature miRNA, which 
is loaded onto the miRNA-induced silencing complex (RISC). The main components of the RISC complex 
are Argonaute (AGO) proteins, which pair with the mature miRNA and guide it to its targets. miRNA-
RISC complexes bind to their target mRNAs and they induce their degradation or block the target trans-
lation (Bartel 2009). The most important motif in a mature miRNA for determining target specificity 
resides in the 5′ end, particularly in the stretch from nucleotides 2–7, called the seed. The seed region 
of the miRNA binds to the 3’ untranslated region (UTR) of the target mRNA, which results in the down-
regulation of its expression (Fig. 3). However, sequence complementarity alone is not stringent enough 
to faithfully predict miRNA targets. Indeed, numerous algorithms and predictive tools have been devel-
oped to aid in this task, which incorporate both sequence complementarity and evolutionary conserva-
tion criteria.  
Experimental approaches to decode miRNA-target interactions include chromatin immunoprecipi-
tation of the RISC components, followed by sequencing (HITS-CLIP and PARP-CLIP) (Grosswendt, Filip-
chyk et al. 2014) and high-throughput studies of the shift in gene expression induced by the miRNA (by 
RNA-Seq and/or quantitative proteomics).These analysis have shown that individual miRNAs can pro-
mote the downregulation of hundreds of genes, a large fraction of which are potential direct targets 
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Figure 3: miRNA biogenesis and mechanism of action: miRNA maturation starts in the nucleus with the pro-
duction of the primary miRNA transcript (pri-miRNA) by RNA polymerase II or III and cleavage of the pri-miRNA 
by the microprocessor complex Drosha–DGCR8 (Pasha) in the nucleus. The resulting precursor hairpin, the pre-
miRNA, is exported from the nucleus by Exportin-5–Ran-GTP. In the cytoplasm, the RNase Dicer in complex with 
the double-stranded RNA-binding protein TRBP cleaves the pre-miRNA hairpin to its mature length. The func-
tional strand of the mature miRNA is loaded together with Argonaute (Ago2) proteins into the RNA-induced 
silencing complex (RISC), where it guides RISC to silence target mRNAs through mRNA cleavage or translational 
repression, whereas the passenger strand (black) is degraded.  
Specific expression or regulation of miRNA levels in a particular cell context is considered a faithful 
indication of miRNA biological relevance. In this regard, different studies have analyzed miRNA ex-
pression profiles in distinct B cell subsets by small RNA library sequencing (Landgraf, Rusu et al. 2007) 
(Basso, Sumazin et al. 2009) and miRNA next-generation sequencing techniques (Kuchen, Resch et al. 
2010) providing valuable data resources. Functional validation of miRNAs involve relatively standard 
gain and loss of function analysis, like viral transduction or generation of mouse models, and more 
particular ones, like the use of antagomir or sponge approaches for miRNA inhibition  (Gentner, Schi-
ra et al. 2009)  (de Yebenes, Bartolome-Izquierdo et al. 2013). 
2.2. miRNA control of B cell function 
The global function of miRNAs in B cell differentiation has been addressed in several works 
where the generation of mature miRNAs is abrogated by the deletion of Dicer or Drosha endonucle-
ases. Thus, when B cells are deprived of miRNAs at a very early stage of differentiation using the mb1
-Cre driver for Dicer deletion, a dramatic block at the pro-B- to pre-B transition ensues, revealing that 
miRNAs are essential for B cells to transit to further stages of differentiation (Koralov, Muljo et al. 
(Selbach, Schwanhäusser et al. 2008) (Mihailovich, Bremang et al. 2015).  
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2008).  A later deletion of Dicer with the CD19-Cre driver, showed that late B cell differentiation and 
the establishment of immune tolerance are also dependent on miRNAs (Belver, de Yébenes et al. 
2010). Finally, Dicer deletion in GC B cells impaired the GC response and the generation of memory B 
and PCs (Xu, Guo et al. 2012).  
In addition, a number of studies have contributed to identify and characterize individual miRNAs 
that play key roles in B cell development and function. miRNAs have been shown to act as positive 
(miR17-92) (Xiao, Srinivasan et al. 2008) or negative (miR34a (Rao, O'Connell et al. 2010), miR-150 
(Xiao, Calado et al. 2007), miR-125 (Chaudhuri, So et al. 2012)) regulators of B-cell generation in the 
bone marrow (see Fig. 4). These works have also revealed the intimate connection between transcrip-
tion factors and miRNAs, making the regulatory loops more complex. This could reflect the need of 
subtle changes in the expression of master regulators of the B cell program. Interestingly, alterations in 
the expression of these miRNAs in the bone marrow appear to principally affect the pro-B to pre-B 
transition, probably reflecting the importance of an optimal balance between proliferation and cell 
death at the developmental checkpoint governed by pre-BCR expression (Fig. 4).  
Figure 4. miRNAs play crucial roles in B-cell development. Scheme depicting the developmental Stages of B-
cell differentiation in which particular miRNAs have been shown to play a role.  
Regarding mature B-cell biology, miR-181b and miR-155, have been linked to the GC reaction. Inter-
estingly, both miR-181b and miR-155 can target the SHM and CSR initiating enzyme, AID. miR-181b 
was identified in our group through a functional screening of a miRNA library. We found that ectopic 
expression of miR-181b during B-cell activation decreased the CSR rate through the direct targeting 
of AID mRNA (de Yebenes, Belver et al. 2008).  
miR-155 is upregulated in GC B cells and is required for the GC response (Tam 2001) (Thai, Calado et 
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al. 2007) (Rodriguez, Vigorito et al. 2007) (Vigorito, Perks et al. 2007) (Basso, Sumazin et al. 2009) 
(Kuchen, Resch et al. 2010). miR-155-germline-deficient mice have an impaired humoral response to 
immunization (Rodriguez, Vigorito et al. 2007) (Thai, Calado et al. 2007), and conversely mice that con-
ditionally overexpress miR-155 in mature B cells had increased numbers of GC B cells and showed high 
antigen-specific antibody secretion upon T-cell dependent immunization (Thai, Calado et al. 2007). Two 
of the confirmed putative miR-155 targets are PU.1 (Vigorito, Perks et al. 2007) and AID (Dorsett, 
McBride et al. 2008). miR-125b, expressed by a subset of GC B cells (Gururajan, Haga et al. 2010), was 
shown to directly target Blimp-1 and IRF4, two transcription factors essential for post-GC plasma B-cell 
differentiation (Gururajan, Haga et al. 2010). Accordingly, overexpression of miR-125b in B cells inhibit-
ed plasma B-cell differentiation and Ig secretion in vitro (Gururajan, Haga et al. 2010).  
Overall, these studies indicate that AID levels in B cells are controlled by different miRNAs with non-
overlapping functions. Thus, whereas miR-181b would prevent premature AID activity in resting B cells 
and allow proper AID transcriptional activation upon stimulation, miR-155 would prevent excessive 
accumulation of AID transcripts in activated B cells. In addition, miRNAs can also control the time win-
dow of the GC reaction, preventing premature exit from GC by inhibition of the PC program, as it is the 
case of miR-125b in B cells. 
 2.3. miRNAs in mature B cell lymphomagenesis 
  Deregulation of miRNA expression is a common event in cancer, including B-cell lymphomas, and 
miRNA profiling is increasingly recognized as a valuable tool for cancer classification (Lu, Getz et al. 
2005) (Volinia, Calin et al. 2006) (Calin and Croce 2006). Different studies have contributed to identify 
the gene pathways and critical targets affected by miRNA deregulation in B cells lymphomas (reviewed 
in Table 2). These include increase in BCR signaling and the PI3K/AKT pathway, the inhibition of pro-
apoptotic genes, the increase in proliferation and the deregulated expression of key transcription fac-
tors. 
miRNA Disregulation Lymphoma 
type 
Targeted genes / Path-
ways Referencies 
miR-155 Upregulated DLBCL / FL / 
MCL / CLL 
AID / PU.1 / SHIP-1 /  In-
crease PI3K/AKT pathway Eis P, PNAS 2005 / Costinean S, Blood 2009 
miR-21 Upregulated DLBCL / FL PTEN / PDCD4 / 
Increase PI3K/AKT pathway 
Lawrie C, Int J Cancer 2007 / Medina P, Nature 
2010 
miR-17-92 Upregulated DLBCL / FL / 
MCL / BL 
BIM / PTEN / E2F1 / 
Increase PI3K/AKT pathway 
O’Donnell KA, Nature 2005, Ventura A, Cell 
2008 / Xiao C, Nat Immunol. 2008 
miR-150 Downregulated DLBCL / FL / 
MCL / CLL MYB Xiao C, Cell 2007 / Malumbres R, Blood 2009 
miR-15a-16-1 Downregulated CLL / DLBCL / 
MCL Bcl-2 / TP53 
Calin GA, PNAS 2002 / Cimmino A, PNAS 2005 / 
Eis P, PNAS 2005 
miR-181b Downregulated CLL AID / Bcl-2 / MCL1 / TCL1 de Yébenes VG, J Exp Med 2008 / Bisone R, 
Blood 2011 
miR-34a Downregulated 
DLBCL / 
MALT / FL / 
CLL 
FOXP1 / Axl / Bcl-2 / Bcl-6 / 
B-MYB / CDK6 / Sirt1 
Zenz T, Blood 2009 / Zenz T, Blood 2009 /  / 
Yamakuchi M, PNAS 2008 / Craig VJ, Blood 2011 
Table 2: Deregulated miRNAs in human B cell malignancies 
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Nevertheless, formal proof of the direct role of miRNAs in tumor development involves the genera-
tion of animal models in which alterations to miRNA expression levels has an impact on the incidence 
of the neoplasia under study.  These studies have fostered the concepts of oncogenic (oncomiRs) and 
tumor suppressor miRNAs. However, very few miRNAs until the beginning of this work have been 
demonstrated to play a direct role in de development of mature B cell lymphomagenesis (see Table 
3). The development of miRNA overexpressing mouse models has allowed to stablish that miR-155, 
miR-21, miR-29 and miR-125b are oncomiRs for B cell lymphocytes that when overexpressed lead to 
the generation of B cell leukemia or inmature B cell lymphoma. miR-15a-16-1 has been shown to be 
a tumor suppressor miRNA, whose deletion leads to B cell leukemia development. However, until the 
beginning of this work they were no miRNA shown to be oncomiRs or tumor suppressors for mature 
GC derived B cell lymphoma. 
microRNA miRNA 
porperties Mouse model B cell neoplasia Subtype Referencies 
miR-155 OncomiR Eµ/VH miR-155 Inmature lymphoma 
ALL/high-grade 
lymphoma 
Costinean S. PNAS 2006 / 
Costinean S. Blood 2009 
miR-21 
  
OncomiR 
  NesCre8/miR-21
LSL-Tet-off Inmature lymphoma Pre-B expansion Medina P, Nature 2010 
miR-29 OncomiR Eµ/VH miR-29 Leukemia CLL Santanam U, PNAS, 2010 
miR-125b OncomiR Eµ/VH miR-125b Leukemia CLL Enomoto Y, Leukemia, 2011 
miR-15a-16-1 Tumor 
supressor MDR ko Leukemia CLL Klein U, Cancer Cell,  2010 
Table 3: miRNAs whose genetic deregulation causes B cell neoplasms. 
2.4. miRNA mediated therapeutics 
miRNA therapeutics is based on the finding that some of the aberrantly expressed miRNAs play 
key roles in the development of human disease, and on the rationale that correcting these miRNA 
alterations by either antagonizing or restoring miRNA function may provide a therapeutic benefit 
(Sibley, Seow et al. 2010).  miRNAs possess several advantages to be exploited as therapeutic tools: 
they are short, easy to be chemically modified and very importantly, they are able to target multiple 
genes. This last property allows a single therapeutic agent to target at the very same time various 
signaling cascades that contribute to the illness onset and maintenance. Moreover, miRNA therapy 
(both restoring and inhibiting endogenous miRNAs) has another yet and fundamental benefit, which 
is that nonspecific off-target effects are unlikely as miRNAs are expected to behave like the natural 
counterpart for which the proper miRNA-mRNA interactions have evolved over a billion years. 
Although naked delivery of the therapeutic RNA molecules is possible, various non-viral vectors 
can be used to deliver small RNA, including small interfering RNA (siRNA) and miRNAs and miRNA 
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inhibitors (Yin, Kanasty et al. 2014). This vectors aim to improve the targeted delivery of the miRNA or 
the miRNA inhibitor by encapsulation in different types of nanoparticles, such as lipidic particles or 
charged nanoparticles (Yin, Kanasty et al. 2014). Exosomal delivery is also started to be explored as a 
more physiological way of delivering miRNAs into immune cells (Momen-Heravi, Bala et al. 2014). 
 Synthetic miRNA inhibitors are single stranded reverse complement sequences of the mature tar-
geted miRNA that have different types of chemical modifications that  prevent RISC-induced cleavage, 
enhance binding affinity and provide resistance to nucleolytic degradation (Krützfeldt, Rajewsky et al. 
2005) (Esau 2008) (Davis, Propp et al. 2009). When delivered to a cell, binding of endogenous mature 
miRNAs to these complementary synthetic target sites is thought to be irreversible, thus these inhibi-
tors are presumed to sequester the endogenous miRNA, making it unavailable for normal function 
(Davis, Propp et al. 2009). The delivery of synthetic anti-miRNAs inhibitors is being successfully used as 
a novel therapeutic approach to inhibit the expression of oncomiRs in hepatocellular carcinoma (Kota, 
Chivukula et al. 2009) (Elmen, Lindow et al. 2008) and precursor B cell lymphomas (Babar, Cheng et al. 
2012) (Cheng, Bahal et al. 2015).  
miRNA replacement can technically be achieved by viral or synthetic miRNA mimic administration 
(Bader, Brown et al. 2010). These approaches are especially attractive to re-express tumor suppressor 
miRNAs whose expression is lost in specific neoplasias. The biggest difference among the mechanism 
of action between miRNA inhibitors and mimics is that unlike miRNA inhibitors, miRNA mimics are 
double stranded RNAs that require integration into the RNAi machinery  (Søkilde, Newie et al. 2015). 
If they are not loaded into the RISC they are not functional. Although miRNA repalcement is being cur-
rently developed for the treatment of solid tumors (Daige, Wiggins et al. 2014), its application for B 
cell lymphoma treatment is starting to be explored nowadays.  
To sum up, the current knowledge of the field suggests that deregulation of certain miRNAs could 
have great impact in the outcome of the GC reaction and in consequence in B cell lymphomagenesis. 
In this way, understanding miRNA mediated regulation of the GC reaction could help to the diagnosis 
and prognosis of certain subtypes of B cell lymphomas. Importantly, this knowledge could potentially 
be used to develop new treatment possibilities for GC derived B cell lymphomas based on the manipu-
lation of key miRNAs in vivo. 
 
 
 
         OBJECTIVES 
OBJECTIVES 
This work focused on the identification and characterization of microRNAs that could act as regula-
tors of germinal centers (GC). Based on expression-profiling criteria we selected miR-217 and miR-
28 to pursue their functional impact on the biology of GC B cells with the following specific objec-
tives,   
 
1-Role of miR-217 in GC reaction and in B cell lymphomagenesis 
-Generate mouse models for B cell specific miR-217 overexpression. 
-Analyze miR-217 function in GC B cells by using gain and loss of function approaches. 
-Identify miR-217 targets by transcriptome analysis and characterize molecular       
  mechanisms of miR-217 activity.  
-Assess the contribution of miR-217 to B cell lymphomagenesis. 
2- Role of miR-28 in GC reaction and in B cell lymphomagenesis 
- Analyze miR-28 function in GC B cells by using gain and loss of function approaches. 
-Characterize the molecular mechanisms of miR-28 activity by combining transcriptome  
   and proteome profiling. 
- Characterize the tumor suppressor potential of miR-28 in GC B cells. 
   MATERIALS & METHODS 
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Human lymphomas and control samples 
Samples of human BL and DLBCL were collected before patients received therapy and diagnosed by a 
panel of three hematopathologists (Di Lisio, Sánchez-Beato et al. 2012). Control samples included 
tonsils, lymph nodes and isolated CD19+ B cells from peripheral blood of healthy donors. The project 
was approved by the ethics committee of the Instituto de Salud Carlos III (ISCIII). 
Mice 
To generate miR-217TG mice, a construct encoding the mouse miR-217 precursor, IRES and GFP was 
inserted within regulatory elements of the IgΚ gene. The miR-217 precursor genomic sequence was 
PCR-amplified from C57BL/6 mouse genomic DNA with the primers: forward 5’-
ttggatcctatatttggggagtttggggg-3’and reverse 5’-aactcgagaataaagatagctgctttagt-3’, subcloned into the 
pGEMT vector (Promega) and inserted into the BamHI/XhoI site of pMX-PIE vector 3. The miR-217 
precursor-IRES-GFP fragment was PCR amplified with the primers: forward 5’-
aaggcgcgcctatatttggggagtttggggg-3’ and reverse 5’-agttaattaattacttgtacagctcgtccat-3’ and subcloned 
into Asc/Pac sites a modified Igƙ vector (Robbiani, Colon et al. 2005). The plasmid backbone was re-
moved with MluI and NotI prior to pronuclear injection into C57BL/6 × (C57BL/6 × CBA) oocytes.   
miR-217KI  mice were generated by insertion of a construct encoding mouse miR-217 precursor into 
the Rosa26 IRES-GFP targeting vector (Nyabi, Naessens et al. 2009). miR-217 precursor sequence was 
PCR amplified from C57BL/6 mouse genomic DNA with the primers: forward 5’-
aactcgaggaaaaagtaaaagagaatgcgttg-3’; reverse 5’-gtgaattcaaagttccaggctaataaagatag-3’, cloned into 
the pENTR/D-TOPO Gateway vector (Invitrogen), and recombined into the Rosa26 targeting vector. 
The construct was electroporated into hybrid 129/C57BL/6 ES cells and positive clones were identi-
fied by Southern blot of EcoRV-digested genomic DNA hybridized with a 5’-arm Rosa26 probe.  
miR217KI mice were crossed with CD19 CreKI/+mice (Rickert, Roes et al. 1997)  to promote expression 
of miR-217 in B cells. 
 For tumor suppressor pathways studies, miR-217KI mice were breed with Ink4A/ARFKO and p53KO 
mice, kindly provided by Dr. M. Serrano. λ-MYC transgenic mice (Kovalchuk, Qi et al. 2000) were 
kindly provided by Dr. Miguel Campanero. NOD/SCID/IL-2rgnull (NSG) mice, C57BL/6 (Harlan) mice 
and CD45.1 C57BL/6 were provided and maintained by the animal facility.  
 miR-217 SPG or miR-28 SPG mouse chimeras were generated by retroviral transduction of bone 
marrow cells (see technical details below) from CD45.1+ C57BL/6 mice with miR-217 sponge / miR-28 
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sponge or a control GFP retroviral vector, and transferring these cells to lethally irradiated CD45.2+ 
C57BL/6 mice.  
 All the mice were bred in house under pathogen-free conditions and all procedures are conformed to 
European Union Directive 2010/63EU and Recommendation 2007/526/EC regarding the protection of 
animals used for experimental and other scientific purposes, enforced in Spanish law under Real De-
creto 1201/2005. 
Isolation and analysis of B cell subsets 
To obtain lymphoid tissue, mice were sacrificed under hypoxic conditions in a CO2 chamber and the 
spleen, lymph nodes, Peyer’s patches and femurs were extracted.  The organs were maintained on ice 
in the presence of RPMI-1460 medium (Sigma-Aldrich) supplemented with 10% fetal calf serum (FCS), 
penicillin (50 U/ml) and streptomycin (50 ug/ml) antibiotics, which is called RPMI complete medium. 
Spleens, lymph nodes and Peyer’s patches were mechanically desegregated in a 70 µm cell strainer to 
obtain a cell suspension. After centrifugation (10’ / 400 x g / 4ºC), the cells from organs with low ery-
throcyte presence (lymph nodes and Peyer’s patches) were resuspended in PBS with 10%FCS. Splenic B 
cells were treated with ACK erythrocyte lysis buffer (Biowhittaker) for 4 minutes at room temperature 
and washed with cooled complete RPMI medium to stop the lysis. After recovering the cells by centri-
fugation (10’ / 400 x g / 4ºC) the cells were resuspended in PBS 1% FCS. To obtain bone marrow cells, 
the femurs were perfused with the help of a syringe. After centrifugation erythrocytes were lysed as 
described before and resuspended in PBS 1%FCS.  
 Mouse primary B cells were purified from spleens of 6-8 weeks C57/BL6 mice by anti-CD43 immuno-
magnetic depletion (Miltenyi Biotech) and recovering the negative fraction, following the manufactur-
er instructions. To isolate B cell subsets ex-vivo, flow-activated cell sorting in a FACS Aria cell sorter (BD 
Biosciences) was used. GC B cells and naïve B cells were obtained from immunized spleens or Peyer’s 
patches by staining the cells with the appropriate antibody combination (see below) and separating by 
sorting the naive cells (CD19+Fas-GL7-) and GC B cells (CD19+Fas+GL7+). Transduced cells were also sep-
arated from the total population in cell culture by using GFP or RFP reporter genes. 
 Analysis of lymphoid populations from bone marrow, lymph nodes, spleen and Peyer’s patches was 
performed by preparing suspensions of live cells and incubating the cells with unlabeled anti-mouse 
CD16/CD32 antibodies (BD Pharmingen) to block Fc receptors. The cells were then labeled with spe-
cific combinations of the following antibodies and analyzed as soon as possible to maintain cell viabil-
ity. 
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ANTIBODY REACTIVITY COMPANY FLUROCHROME 
B220 (CD45R) Mouse BD Biosciencies BV421 
GL7 Mouse BD Biosciencies FITC 
IgD Mouse BD Biosciencies FITC 
Ig Mouse BD Biosciencies FITC 
CD21 Mouse BD Biosciencies PE 
CD138 Mouse BD Biosciencies PE 
IgM Mouse Invitrogen PE 
Fas Mouse BD Biosciencies PE 
IgM Human BD Biosciencies PE 
Igқ Mouse BD Biosciencies PE 
CD45.2 Mouse BD Biosciencies PerCpCy5.5 
CD45.1 Mouse BD Biosciencies PerCpCy5.5 
GL7 Mouse BD Biosciencies Alexa647 
GL7 mouse & human eBioscience Alexa660 
CD19 Mouse BD Biosciencies APC 
CD3 Mouse BD Biosciencies APC 
CD45 (total) Mouse BD Biosciencies APC 
CD93 Mouse eBioscience APC 
ANTIBODY REACTIVITY COMPANY 
CD19 Mouse BD Biosciencies 
CD23 Mouse BD Biosciencies 
IgM Mouse BD Biosciencies 
IgA Mouse BD Biosciencies 
IgG1 Mouse BD Biosciencies 
IgD Mouse SouthernBiotech 
CD43 Mouse BD Biosciencies 
ANTIBODY COMPANY 
PE-Cy7 BD Biosciencies 
PE BD Biosciencies 
APC BD Biosciencies 
FITC BD Biosciencies 
Table 6. Avidins 
Table 4. Antibodies conjugated to flurochromes 
Table 5. Antibodies conjugated to biotin 
Cell culture 
Mouse primary B cells were cultured in RPMI-1460 medium (Sigma-Aldrich) supplemented with 10% 
fetal calf serum (FCS), penicillin (50 U/ml) and streptomycin (50 µg/ml) antibiotics, which is called 
RPMI complete medium complete, supplemented with 10mM Hepes (Gibco and 50 µM β-
mercaptoethanol (Gibco). Activation of the cells in order to switch to IgG1 was obtained by culturing 
the primary B cells at a concentration of 1.3 x 106 cells/ml and by adding 25 µg/ml LPS (Sigma) and 
10 ng/ml IL-4 (Peprotech) to the RPMI complete medium. To ensure the survival of the culture Blyss 
(R&D systems) was also added at a final concentration of 20 ng/ml. Switch was analyzed at different 
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time points depending on the experiment, but always between 2 and 5 days after activation.  
Bone marrow cells were cultured at 1.1 x 106 cells/ml concentration in IMDM medium (Gibco) 20% FCS 
in the presence of penicillin (50 U/ml) and streptomycin (50 ug/ml) and supplemented with IL6 (20 ng/
ml), IL-3 (50 ng/ml), SCF (50 ng/ml), β-mercaptoethanol (50 µM) and HEPES (10 µM) to maintain the 
stem cell potential of the hematopoietic progenitors.  
The NIH-293T and 3T3 cell lines were cultured in DMEM (Gibco) containing 10% FCS in the presence of 
penicillin (50 U/ml) and streptomycin (50 ug/ml) antibiotics. The human B cell lymphoma cell lines 
(Ramos, Raji, Daudi, Farage, Riva, Namalwa, HBL1 and MD901) and the Jurkat T cell line were cultured 
in complete RPMI medium containing 10mM Hepes (Gibco) at a concentration of 200000 cells/ml. 
Expression constructs and transductions 
Retroviral constructs 
For retroviral overexpression of miR-217 and miR-28, the DNA fragment containing their precursor se-
quence and their corresponding flanking 50-bp-long genomic context were cloned in XhoI-EcoRI sites 
of the pre-miRNA GFP vector, as previously described (de Yebenes, Belver et al. 2008). The empty p-
miRNA Control vector was generated by liberating the insert, generating blunt ends with T4 polymer-
ase and religating with T4 ligase. For retroviral inhibition of the endogenous miRNA, miR-217 and miR-
28 sponges were generated.  Briefly, 4 complementary sequences to the mature miR-217 5p or miR-28 
5p were cloned in tandem within the 3’UTR of GFP into the MGP vector by annealing and subsequent 
extension with Klenow DNA polymerase (New England Biolabs) of two partially complementary oligo-
nucleotides: For miR-217 sponge (forward) 5’tcgactagctagaacgcggccgctccagtcagttcctgatgcagtagattccag-
tcagttcctgatgcagtaaccggttccagt-3’; (reverse) 5’gaagtcagtccgattctcgagtactgcatcaggaactgactggagtga-
tactgcatcaggaactgactggaaccggttactgcatc-3’. In the case of miR-28 sponge (forward) 5’ tcgactagcta-
gaacgcggccgcctcaatagactgtgagctccttcgatctcaatagactgtgagctccttaccggtctcaat-3’(reverse) 5’gaagtcag-
tccgattctcgagaaggagctcacagtctattgaggtgaaaggagctcacagtctattgagaccggtaaggagctc-3’. Retroviral su-
pernatants were produced by transient calcium phosphate transfection of NIH-293T cells with pCL-ECO 
(Imgenex) and the wanted p-miRNA or sponge retroviral vectors. Mouse splenic B cells and total bone 
marrows were transduced with retroviral supernatants for 16-20h in the presence of 8 μg/ml 
polybrene (Sigma-Aldrich).   
Lentiviral constructs 
For inducible expression of miR-28, its precursor sequence was cloned into the pTRIPZ vector (Thermo 
scientific) in a Tet-on configuration. The pre-miRNA sequence was replaced by a scramble sequence to 
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obtain the pTRIPZ scramble Control. Lentiviral supernatants were obtained by transient calcium phos-
phate transfection of NIH-293T cells with VSVG, Δ9.8 and pTRIPZ. Human lymphoma cell lines were 
transduced with lentiviral supernatants for 16h in the presence of 8 μg/ml polybrene. 48h later, selec-
tion of the infected cells was achieved by adding 0.4 µg/ml puromycin to the culture medium for 3 
days. For the induction of miR-28 or the Scramble sequence 0.5 µg/ml doxycycline was added and RFP+ 
was measured in a Facs Calibur cytometer. 
Bone marrow reconstitution 
5x106 total bone marrow cells from CD45.1 C57BL/6, donor mice were injected intravenously into 8- to 
12-week-old CD45.2 C57BL/6 mice that had been lethally irradiated (2 x 550 cGy) 24hr before the re-
constitution. Neomycin (2 mg/ml) was added in the drinking water of the mice until complete reconsti-
tution.  
Immunizations 
T cell dependent immunizations were performed with two different immunogens; an NP (nytrophenil) 
hapten conjugated to chicken gamma globulin (CGG) via amide bonds to lysine (NP-CGG) or with sheep 
red blood cells (SRBC). In the case of NP-CGG, groups of 6-11 littermate mice were immunized by foot-
pad injection with 50 µg of NP-CGG (Biosearch Technologies) in complete Freund’s adjuvant. In second-
ary immunizations mice were reimmunized with 50 µg of NP-CGG in incomplete Freund’s adjuvant. For 
immunizations with SRBC, 108 cells were intravenously injected in the tail vain of 6-11 littermate mice 
per group and mice were sacrificed between 3-14 days later, as indicated in the corresponding experi-
ment. Mice injected with PBS were used as non-immunized controls. 
Cellular assays 
Apoptosis was measured using Annexin V eFluor450 kit (eBioscience) and anti- active Caspase-3 stai-
ning (conjugated to FITC, Clone C92-605) from BD Pharmingen. Proliferation was assessed with Cell 
Trace Violet or CFSE (both from Invitrogen) and analysis was performed using the FlowJo proliferation 
platform or by BrdU icorpation assays, using FITC-BrdU Flow Kit (BD Pharmingen). Cell cycle analysis 
was performed with propidium iodide or DAPI (1 µg/ml) staining. To induce genotoxic stress a range of 
2 to 10 µM etoposide treatment was used for 6 hours and cell cycle was analyzed with DAPI afterword.  
Immunoblotting (WB) 
For immunoblotting, Ramos transduced cell pellets were incubated on ice for 20 min in lysis buffer con-
taining 50 mM Tris, 150 mM NaCl, 0.1% SDS,  0.5% sodium deoxycholate and 1% RIPA in the presence 
of protease and phosphatase inhibitors (Roche and Cell signaling, respectively) and lysates were 
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cleared by centrifugation (15’ / 16000 x g / 4ºC) . 5% β-mercaptoethanol was added. Total protein from 
a fraction of the lysate was sized-fractioned by SDS-PAGE on 10% acrylamide-bisa- crylamide gel and 
transferred to Protran nitrocellulose membrane (Whatman) in transfer buffer (0.19 M glycine, 25 mM 
Tris base, and 0.01% SDS) containing 20% methanol. Gels were transferred for 1hr at 0.4A. Membranes 
were probed with anti-human Bcl-6 (N-3; Santa Cruz Biotechnology), anti-human tubulin (Sigma-
Aldrich), anti-human ERK1/2 (Cell signaling), anti-human p-ERK1/2 (Cell signaling) and anti-human p-
AKT (Cell signaling). Then, membranes were incubated with corresponding secondary HRP-conjugated 
antibodies (Dako) and developed with Amersham ECL Western Blotting Detection reagent (Amersham). 
Band intensity was analyzed by Image-J program.  
Bcl-6 protein detection by intracellular staining and FACS analysis 
First, the cell suspension was membrane stained with surface antibodies to detect GC B cells (CD19+, 
GL7+, Fas+, as described before). Next, intracellular flow cytometry staining of Bcl-6 was performed 
with anti-Bcl-6 antibody (clone K112-91, BD Pharmingen) after cell fixation and permeabilization with 
the Foxp3 staining kit from eBioscience. Bcl-6 positive cells were detected and gated within GC B Cells 
by analyzing them on a FACS Canto flow cytometer (BD Biosciences) with FACS Diva software. 
AKT phosphorylation upon BCR stimulation 
miR-28 transduced or scrambled transduced Ramos cells were in vitro activated with 10 µg/ml of solu-
ble anti-human-IgM (Rockland) 5 minutes at 37ºC. Then, cooled complete RPMI medium was added to 
wash the cells and stop the stimulation. The cells were recovered by centrifugation (400 x g / 10’ / 4ºC) 
and fixed and permeabilized with IC Fixation buffer and permeabilization buffer (eBioscience), follow-
ing manufacturer instructions. Ramos cells were then labelled with anti-phospho-AKT (S473) 
(eBioscience) 20’ in dark and at room temperature. After washing and recovering the cells, phospho-
AKT levels upon BCR stimulation were analyzed FACS Canto flow cytometer (BD Biosciences) with FACS 
Diva software.  
Somatic mutation analysis 
For Sμ amplifications genomic DNA was amplified for 26 cycles with Pfu Ultra polymerase (Stratagene) 
with the primers (forward) 5’-aatggatacctcagtggtttttaatggtgggttta-3’ and (reverse) 5’-
gcggcccggctcattccagttcattacag-3’. For JH4 intron mutations, DNA was amplified first for 11 cycles with 
the primers (forward) 5’-actatgctatggac-3’ and (reverse) 5’-ctggactttcggtttggtg-3’, and then for 19 cy-
cles with the primers (forward) 5’-ggtcaaggaacctcagtca-3’ and (reverse) 5’-tctctagacagcaactac-3’, using 
Pfu Ultra polymerase (Stratagene). 
V(D)J recombination analysis 
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Genomic DNA was isolated from total spleen of miR-217KI mice with B-cell lymphomas, and the rear-
ranged VH sequences were amplified by PCR, using a degenerate forward primer that anneals to the 
framework region III of the most abundantly used VHJ558 family (5’-(ag)gcctggg(ag)cttcagtgaag-3’), and 
a reverse primer that anneals immediately downstream of the JH4 gene (5’-aggctctgagatccctagacag-3’). 
PCR products were gel purified, cloned in pGEM-T vector (Promega) and sequenced. >10 clones were 
sequenced per spleen sample. Assignment of V(D)J rearrangements was done with NCBI IgBLAST pro-
gram (http://www.ncbi.nlm.nih.gov/igblast/data) using the IMGT V domain delineation system. Clonal-
ity was assigned when the same rearrangement, including its V(D)J junction, was repeatedly found in a 
significant fraction of the sequenced clones. Rearranged V(D)J genes were scored as SHM+ when nucle-
otide substitutions were found in the VH gene with respect to the assigned gene. 
Analysis of mRNA expression levels by RT-qPCR 
For the analysis of the expression levels of messenger RNAs, total RNA was extracted with Trizol 
(Invitrogen). 1 μg of the RNA was retrotranscribed to cDNA by using Random hexamers (Applied bio-
systems) as primers and the inverse retrotranscriptase Superscript II (Invitrogen), following manufac-
turer instructions. The obtained cDNA was next amplified by RT-qPCR using SYBER green PCR master 
mix (Applied Biosystems) and 0.4 mM of the specific pair of primers of the wanted messenger RNA tar-
get (reviewed in the table below). The obtained results were normalized to the expression of the 
housekeeping gene GAPDH. The amplification was performed in a 7900HT fast real-time PCR system 
(Applied Biosystems).  
 
 
 
OLIGONUCLEOTIDE SENSE ANTISENSE ORGANISM 
GAPDH 5'-GAAGGTGAAGGTCGGAGTC-3' 5'-GAAGATGGTGATGGGATTTC-3' human 
GFP 5'-AGAAGAACGGCATCAAGGTGA-3' 5'-ATGTGATCGCGCTTCTCGT-3' human 
LIG4 5'-GCTGGGATTCTCTGGTTCACA-3' 5'-GCGGTGATGAATCTTCTCGTTT-3' human 
NBS1 5'-TGCACTCACCTTGTCATGGTATC-3' 5'-CGTCCACAAATGAGTGCACAT-3' human 
PDS5B 5'-AAGCCACTTTGGCAGTGCTACT-3' 5'-TTCCAGGCGGATTGGTACAT-3' human 
XRCC2 5'-AATCTGTTTGCTGATGAAGAT-3' 5'-CTGGGCCATGAAATTCAAGAA-3' human 
CCDC50 5'-GAAGAAGGATGAGGACATAGC-3' 5'-CTCTGGAAAGTGTTTCTTTCTC-3' human 
CD44 5'-CCAACTCTAATGTCAATCGTTCC-3' 5'-ATCAGCCATTCTGGAATTTGG-3' human 
CELSR3 5'-CAGAAAGCGAGGACAATGG-3' 5'-TTGCCATCCACATCTTTGG-3' human 
FOSB 5'-GAACGTCTGGAGTTTGTGC-3' 5'-AGGACTTGAACTTCCTCCG-3' human 
JAK3 5'-CTTCTTCTGCAAGGAGGTG-3' 5'-CAAAGTCCAGAGTGATGGG-3' human 
VAV3 5'-CTCTGCAGTTTCCATACAAGG-3' 5'-TTGGACTTAACAAGCTGTTGC-3' human 
NFKB2 5'-GTGCATAAACAGTATGCCA-3' 5'-CAGAAACACTGTTACAGGC-3' human 
BCL2 5'-GAGAACAGGGTACGATAACC-3' 5'-CTGCGACAGCTTATAATGG-3' human 
IKBKB 5'-AGACGGCAAGTTAAATGAG-3' 5'-AGATCTGAGTCTCATAGGTG-3' human 
Table 7. Primers for mRNA amplification by q-RT-PCR 
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miRNA detection by q-RT-PCR  
RNA was extracted with Trizol (Invitrogen). For detection of mouse and human mature miR-217-5p 
and miR-28-5p by qRT-PCR, miRCURY LNA primers (Exiqon) were used with the sequences UACUG-
CAUCAGGAACUGAUUGGA (product number 204010) and AAGGAGCUCACAGUCUAUUGAG (product 
number 204322), respectively. U6 amplification was used as normalization control. The amplifica-
tion was performed in a 7900HT fast real-time PCR system (Applied Biosystems).  
miR-217 RNAseq 
GC (CD19+Fas+GL7+) B cells from pooled Peyer’s patches (4-6 animals per genotype) from control 
and miR-217TG mice were isolated by cell sorting. Total RNA was extracted with Trizol (Invitrogen) 
and sequenced by RNAseq. RNA samples were processed through the "Ovation RNA-seq sys-
tem" (NuGEN) and then retrotranscribed, and cDNA was amplified by the SPIA isothermal linear 
amplification procedure. The resulting ds-cDNA was fragmented to a range of 150-200bp in a Co-
varis S2 shearing instrument. cDNA (200ng of per sample) was processed through succeeding enzy-
matic treatments of end-repair, dA-tailing, and ligation to indexed adapters, according to "TruSeq 
DNA Sample Preparation Guide" (Illumina). Ligation products were purified with AMPure XP Beads. 
Adapter-ligated libraries were amplified by PCR with Illumina PE primers for 10 cycles. The resulting 
purified DNA libraries were applied to an Illumina flow cell for cluster generation, and sequenced on 
the Illumina Genome Analyzer IIx with SBS TruSeq v5 reagents. Sequences were converted to FASTQ 
read format, filtered with FastX Toolkit (http://hannonlab.cshl.edu/fastx_toolkit/index.html) and 
aligned with Tophat 2.0.4 (Kim, Pertea et al. 2013). Differential expression analysis was done using 
the edgeR package from Bioconductor (Gentleman, Leclercq et al. 2004) and genes with p ≤ 0.05 
were considered for analysis. Pathway analysis of the significantly up- and downregulated genes in 
miR-217TG vs control GC B cells was performed by Ingenuity pathway analysis software (Ingenuity 
Systems). Significantly downregulated genes in miR-217TG GC B cells were analyzed for the presence 
of 835 different miRNAs target sites based on predicted and experimentally validated miRNA-mRNA 
interactions. Scores for every predictive algorithm were normalized, and the compound score of 
predictive and experimental databases was calculated (Muniategui, Nogales-Cadenas et al. 2012).  
miR-28 RNAseq 
6 pairs of RFP+ sorted Ramos cells transduced with the miR-28 or Scrambled lentiviral construct in 3 
independent infections were used for RNAseq analysis. Total RNA was extracted from 107 Ramos 
transduced cells with Rneasy colums (Qiagen) and sequenced by RNAseq. For library preparation, 
500 ng of total RNA were used to generate barcoded RNAseq libraries using the TruSeq RNA sample 
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preparation kit v2 (Illumina). Briefly, poly A+ RNA was purified using poly-T oligo- attached magnetic 
beads using two rounds of purification followed by fragmentation and first and second cDNA strand 
synthesis. Next, cDNA 3’ ends were adenylated and the adapters were ligated followed by PCR library 
amplification. Finally, the size of the libraries was checked using the Agilent 2100 Bioanalyzer DNA 
1000 chip and their concentration was determined using the Qubit® fluorometer (Life Technologies). 
Libraries were sequenced on a HiSeq2500 (Illumina) to generate 60 bases single reads. FastQ files for 
each sample were obtained using CASAVA v1.8 software (Illumina).   
Sequencing reads were pre-processed by means of a pipeline that used FastQC  (Krueger, Andrews et 
al. 2011), to asses read quality, and Cutadapt v1.9 (Criscuolo and Brisse 2014) to trim sequencing 
reads, eliminating Illumina adaptor remains, and to discard reads that were shorter than 30 bp. The 
resulting reads were mapped against the human transcriptome (GRCh38, release 76; aug2014 ar-
chive) and quantified using RSEM v1.17 (Li and Dewey 2011). Data were then processed with a differ-
ential expression analysis pipeline that used Bioconductor package EdgeR (Robinson, McCarthy et al. 
2010) for normalization and differential expression testing, taking into account the paired design of 
the experiment. 12725 genes were identified and of those 1202 were differentially expressed (568 
downregulated and 634 upregulated) between miR-28 expressing and control cells, with a cut off-of 
p ≤ 0.05 (non adjusted).  
iTRAQ quantitative analysis 
Sample preparation and peptide isobaric labelling 
For proteomics analysis, eight Ramos cell pellets (107 cells; 4 pairs of miR-28 transduced and scram-
bled transduced samples, from 2 independent infections) were homogenized in Lysis Buffer (50 mM 
Tris-HCl pH 8.0 – 4% SDS – 50 mM DTT), boiled for 10 min, sonicated and lysed with agitation for 15 
min at room temperature. Cell lysates were centrifuged (13000 g, 15 min) to eliminate cell debris at 
13000g for 15 minutes, and protein concentration in the supernatant was determined by the Di-
rectDetect IR spectrometer (Millipore). The cleared lysates were stored at -80ºC. The four biological 
replicates for each condition were independently analyzed by using an iTRAQ 8-plex experiment. For 
that end, 160 μg of total protein for each sample were digested using the FASP protocol as previously 
described (Cardona, Lopez et al. 2015), with minor modifications. 
For stable isobaric labeling, the resulting tryptic peptides from the 4 pairs of biological replicates 
were dissolved in Triethylammonium bicarbonate (TEAB) buffer, and the concentration of peptides 
was determined by measuring amide bonds with the Direct Detect system (Millipore). Equal amounts 
of each peptide sample were labeled using the 8-plex iTRAQ Reagents Multiplex Kit (Applied Biosys-
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tems, Foster City, CA, USA) according to manufacturer's protocol.  
Identification by LC-MS/MS 
Labeled peptides were loaded into the LC-MS/MS system for on-line desalting onto C18 cartridges and 
analyzing by LC-MS/MS using a C-18 reversed phase EASY nano-column (75 µm I.D. x 50 cm, 2 µm par-
ticle size, Acclaim PepMap RSLC, 100 C18; Thermo Fisher Scientific, USA) in a continuous acetonitrile 
gradient consisting of 0-30% B in 360 min, 50-90% B in 3 min (A= 0.5% formic acid; B=90% acetonitrile, 
0.5% formic acid). A flow rate of 200 nl/min was used to elute peptides from the RP nano-column to 
an emitter nanospray needle for real time ionization and peptide fragmentation on a Q-Exactive mass 
spectrometer (Thermo Fisher). An enhanced FT-resolution spectrum (resolution=70.000) followed by 
the MS/MS spectra from the 15 most intense parent ions were analyzed along the chromatographic 
run. Dynamic exclusion was set at 40 s. 
 iTRAQ data analysis.  
For peptide identification, all spectra were analyzed with Proteome Discoverer (version 1.4.0.29, Ther-
mo Fisher Scientific) using SEQUEST-HT (Thermo Fisher Scientific). For database searching at the Uni-
prot database containing all sequences from human and crap contaminants (March 06, 2013; 70024 
entries), the parameters were selected as follows: trypsin digestion with 2 maximum missed cleavage 
sites, precursor and fragment mass tolerances of 2 Da and 0.02 Da, respectively, carbamidomethyl 
cysteine, iTRAQ modifications at N-terminal and Lys residues as fixed modifications, and methionine 
oxidation as dynamic modification. Peptide identification was validated using the probability ratio 
method (Martinez-Bartolome, Navarro et al. 2008); false discovery rate (FDR) was calculated using 
inverted databases, and the refined method (Navarro and Vazquez 2009) with an additional filtering 
for precursor mass tolerance of 15 ppm (Bonzon-Kulichenko, Garcia-Marques et al. 2015).  
 Protein quantification from reporter ion intensities and statistical analysis of quantitative data were 
performed using QuiXoT based on the WSPP statistical model previously described (Navarro, Trevisan-
Herraz et al. 2014). In this model protein log2-ratios are expressed in form of the standardized varia-
bles, i.e., in units of standard deviation according to their estimated variances (Zq values). From the 4 
pairs of miR-28 transduced and scrambled transduced Ramos samples, 7324 proteins were identified 
with an FDR of 1%. From those, we stablished a cut off 10% FDR to group significantly changed pro-
teins, obtaining 276 changed proteins (107 were downregulated and 169 upregulated by miR-28 ex-
pression).  
Functional protein analysis and the systems biology triangle 
The significantly changed 276 proteins found by ITRAQ were subjected to Ingenuity pathway analysis 
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(IPA) (Ficenec, Osborne et al. 2003), to uncover the relationships and pathways among the miR-28 re-
gulated products.  
To depict the sigmoid representation and apply the systems biology triangle, first proteins were anno-
tated using Ingenuity Knowledge Database (IPA) (Ficenec, Osborne et al. 2003) (Calvano, Xiao et al. 
2005),   CORUM (Ruepp, Brauner et al. 2008) and DAVID (Huang da, Sherman et al. 2009). The latter 
repository included 15 functional databases, such as KEGG, REACTOME, Gene Ontology and Panther, 
among others. Analysis of altered categories was evaluated as described in (Cardona, Lopez et al. 
2015). Alterations in the abundance of functional categories were visualized by comparing the cumula-
tive frequency (sigmoid) plots of the standardized variable with that of the normal distribution, as in 
previous works (Cardona, Lopez et al. 2015) (Isern, Martin-Antonio et al. 2013). The system biology 
algorithsms was applied to determine the statistical significance that any protein belonging to a cate-
gory deviates from the coordinated behavior of the rest of the proteins of the same category. This al-
gorithm was developed by García-Marqués and colleagues in Jesus Vazquez’s lab (Garcia-Marqués et 
al., Mol Cel Proteom, under first revision).  Briefly, they developed a method that allows the detection 
of coordinated protein behaviors by applying sequentially the generic integration algorithm (GIA) 
(Navarro, Trevisan-Herraz et al. 2014) in a manner that discards the outliers. In this last integration, the 
category-all outliers correspond to the categories that are significantly altered by the perturbation as a 
consequence of the coordinated behavior of their proteins. 
Lymphoma xenograft and allograft models 
Subcutaneous xenografts  
NOD Scid Gamma (NSG) mice (8-14 weeks) received subcutaneous flank injections of lymphoma cells (2 
x 106 of WT non-transduced Ramos cells or 107 cells in the case of the lentiviraly transduced human 
tumoral B cells) resuspended in 100 µL PBS and mixed with 100 µl Matrigel (BD Biosciences) at 1:1 pro-
portions. When the transduced cells were used, doxycycline (Sigma-Aldritch) was administered to the 
animals one week before the xenograft injection (tumor development experiment) or once  the tumors 
reached 200 mm3 (tumor regression experiments) at a concentration of 0.04% through their drinking 
water. 
Subcutaneous primary lymphoma allografts 
 To establish subcutaneous λ-MYC primary tumors, first enlarged lymph nodes were extracted from 4-
to-8 months-old λ-MYC sick animals and single cell suspensions were prepared in 1% FCS PBS using a 
cell strainer as previously described. The phenotype of the tumoral cells was analyzed by FACS and by 
immunohistochemistry staining before allograft injection.  107 mouse primary λ-MYC lymphoma cells 
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were subcutaneously injected in the 2 flanks of NSG mice. Tumor growth was measured 3 times per 
week with a digital caliper using the following formula: volume = (width)2 x length/2. Animals were 
sacrificed if the tumor compromised their wellness (usually when tumor reached around 2000 mm3). 
The tumors were extracted for further FACS and histopathological analysis. 
Intravenous primary lymphoma allograft model 
Primary Burkitt lymphoma cells were obtained from ill λ-MYC transgenic mice as described above.  2 
x 106 of λ-MYC lymphoma cells were intravenously injected in the tail vain of receptor NSG mice. All 
the animals were sacrificed 17 days after the injection of the tumoral cells.  
B cell lymphoma treatment by synthetic miR-28 mimic administration 
miR-28 mimic (Ambion) was used in vivo to replace endogenous miR-28 function. From a stock solu-
tion of 1 mM mimic, the specific quantity of HPLC purified miR-28 mimic (Ambion) is mixed with 
RNAse free water to prepare a 3mg/ml solution. Then, this solution is mixed at 1:1 proportions in 
complexation buffer (Ambion) and the resulting solution with Invivofectamin (Ambion) in 1:1 propor-
tions. The solution was incubated at 50ºC 30 minutes and dialyzed with a Por-Float-A-Lyzer cassette 
with an 8-10 KDa diameter pore, following manufacturer instructions. Then is diluted with RNAse 
free PBS (Lonza) to the needed final volume. For intratumoral treatment 0.1 nmoles or 0.5 nmoles 
were injected in 50 µl PBS per tumor, 3 times after tumor establishment separated by 3-4 days. Intra-
venous treatment was achieved by injecting in the tail vain two doses of 7 nmoles (in 100 µl PBS so-
lution per mouse, which is equivalent to 5 mg/kg concentration), separated by 4 days.  
Histopathology and toxicity studies 
Organs were fixed in 10% buffered formalin and embedded in paraffin. Sections were stained with 
hematoxylin and eosin (Sigma), anti-Pax5 (Santa Cruz Biotechnology), anti-CD3ε (Santa Cruz Biotech-
nology), anti-KI-67 (Abcam), anti-Bcl-6 (Santa Cruz Biotechnology), anti-Bcl-2 (Dako) or anti Caspase-3 
(RyD systems). Quantifications were performed using Image-J. Neoplasms where classified by a 
pathologist according to their histopathological and immunophenotypic profile following the criteria 
of the consensus international system. miR-28 related toxicity studies consisted in tissue damage 
analysis by immunihistochemistry and clinical biochemistry of the plasma of the treated mice. Tissue 
damage was assessed by H&E staining of kidney, liver, heart and spleen from treated mice. Clinical 
biochemistry included blood counts in the Abacus Junior hematology analyzer and biochemical pro-
file of different indicators of liver, kidney and heart function. These indicators are AST/GOT, ALT/GPT, 
GGT, total cholesterol, alkaline phosphatase, triglycerides levels, glucose and albumin levels.  
Statistical analysis 
Cytometry results, RT-qPCR results, WB densitometry results, tumor volume and weight were analyzed 
with Student’s T test. Survival curves were analyses by Kaplan-Meier curves and statistical significance 
was calculated with a long-Rank. All the analysis were performed using the Graphpad Software. Statis-
tical significance was stablished at p<0.05. Statistical analysis of quantitative proteomics data were per-
formed using QuiXoT based on the WSPP statistical model previously described (Navarro, Trevisan-
Herraz et al. 2014). Differential expression in the RNAseqs was assessed for each gene using the Bio-
conductor EdgeR package, that uses an exact test analogous to Fisher's exact test, but adapted for 
overdispersed data (Robinson, McCarthy et al. 2010) (Robinson and Smyth 2008) (Gentleman, Carey et 
al. 2004) .  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
RESULTS 
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1. Role of miR-217 in Germinal Center reaction and in B cell 
lymphomagenesis 
 1.1. miR-217 expression is upregulated in activated B cells 
 To identify miRNAs that play a role during B-cell activation, we profiled miRNA expression in 
mature B cells during in vitro activation with lipopolysaccharide (LPS) + interleukin (IL) 4, which pro-
motes AID expression, SHM in the switch regions, and CSR. Microarray analysis showed that one of 
the few miRNAs whose expression is upregulated during this process is miR-217 (de Yebenes, Belver 
et al. 2008). Induction of precursor and mature miR-217 during B-cell activation in vitro was con-
firmed by qRT-PCR (Fig. 5A). In addition, we generated GCs in vivo by immunizing mice with sheep 
red blood cells (SRBC) and conducted qRT-PCR on purified resting and GC B cells. miR-217 precursor 
and mature miR-217 expression increased by five- and eightfold, respectively, in GC cells (Fig. 5B). 
Similarly, we found that miR-217 expression is increased in GC human B cells compared with resting 
B cells (Fig. 5C). Together, these results show that miR-217 expression is induced during B-cell activa-
tion both in mouse and humans.  
Figure 5. miR-217 expression is upregulated in activated B cells. (A) qRT-PCR analysis of the expression of the 
(left) miR-217 precursor and (right) mature miR-217 in B cells after 1 (open bars) and 3 days (filled bars) of acti-
vation with LPS + IL4. Data from 3 (miR-217 precursor) and 2 (mature miR-217) independent experiments are 
shown (p = 0.05 for miR-217 precursor and p = 0.27 for miR-217). Each experiment was performed with 2 indi-
vidual mice. (B) qRT-PCR of miR-217 precursor (left) and mature miR-217 (right) in resting (open bars) or GC 
(filled bars) B cells isolated from spleens of wild-type C57BL/6 mice 10 days after immunization with sheep red 
blood cells (SRBC). Data are means 6 standard deviation from 2 independent experiments with 10 total immu-
nized mice (p = 0.0002 for miR-217 precursor and p = 0.01 for miR-217). Two-tailed Student t test: p values: *p 
<0.05. (C) Quantification of miR-217 expression in human resting (CD19+CD27+IgD+) and GC (CD19+CD10+) sam-
ples as measured by miRNA array hybridization (data were obtained from GSE29493, p = 0.003, 2-tailed Stu-
dent t test). 
 1.2. Generation of B cell specific mouse models 
To investigate the role of miR-217 during B-cell activation, we generated 2 independent mouse mod-
els of B cell-specific miR-217 overexpression. In the first, 4 independent transgenic mouse lines were 
generated with a construct encoding the miR-217 precursor and a GFP reporter gene under the con-
trol of regulatory elements of the mouse kappa light chain (Ig) gene (miR-217TG) (Fig. 6A, upper   
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construct). In the second strategy, the miR-217 precursor/GFP construct was preceded by a transcrip-
tional stop cassette flanked by LoxP sites and inserted within the endogenous Rosa26 locus 
(ROSA26miR217ki/+mice) (Fig. 6A, lower construct); specific expression of miR-217 in B cells was achieved 
by crossing ROSA26miR217ki/+ mice with CD19-Creki/+ mice (hereafter, miR-217KI mice). ROSA26miR217+/+ 
CD19-Creki/+ mice were used as controls. B cells from miR-217TG and miR-217KI mice showed full GFP 
and miR-217 expression in mature splenic B cells (Fig. 6B-C). GFP expression was not detected in non-B-
cell lineages, such as T, myeloid, or epithelial cells (data not shown). The proportions and absolute num-
bers of bone marrow and peripheral B cells in the miR-217TG and miR-217KI models were similar to 
those in wild-type littermate controls (Fig. 7), indicating that the miR-217TG and miR-217KI mouse mod-
els allow B cell-specific miR-217 overexpression without perturbing B-cell differentiation. 
Figure 6. Generation of B cell specific mouse models. (A) Constructs used to generate the miR-217TG and 
ROSA26miR217KI specific mouse models. For miR-217TG (represented in light blue), a construct encoding miR-
217 precursor and GFP is expressed under the control of the Vқ21 promoter; for miR-217KI (represented in 
dark blue), the miR-217 precursor construct is inserted within the Rosa26 locus, preceded by a transcriptional 
stop flanked by LoxP sites. miR-217KI mice were crossed with CD19-CreKI/+ mice. (B) Representative FACS ana-
lysis of GFP expression in bone marrow and spleen B-cell subsets from control (black histograms) and miR-
217TG or miR-217KI mice (green histograms). (C) q-RT-PCR quantification of miR-217 expression in bone ma-
rrow B cell precursors and splenic B cells isolated from control (open bars), miR-217TG (filled light blue bars, 
left graph) and miR-217KI mice (filled dark blue bars, right graph). Data are from three mice per genotype. 
n.d., not detectable. 
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Figure 7. B cell specific miR-217 mouse models allow normal B cell development in the bone marrow. (A) 
Representative fluorescence-activated cells sorting (FACS) analysis of bone marrow from miR-217TG, miR-217KI 
and littermate control mice. Plots show the expression of B220/CD19 in total live lymphocytes (left), IgD/IgM 
gated in B220+CD19+ cells (center), and CD25/B220 gated in B220+CD19+IgM+IgD+ cells (right). The proportion of 
cells within B220+ cells is indicated in each gate. (B) Quantification of the proportions (left) and absolute cell 
numbers (right) of developing bone marrow B-cell subsets in control (open bars), miR-217TG (light blue filled 
bars), and miR-217KI mice (dark blue filled bars). The proportions of different B-cell subsets were quantified 
within the B220+ population. 
 1.3. miR-217 expression enhances the GC reaction 
To address the role of miR-217 expression during B-cell activation in GCs, we analyzed the B-cell re-
sponse to a T cell-dependent antigen in miR-217TG mice. We first immunized miR-217TG mice and 
wildtype littermate controls with NP-CGG. As an immunization control, mice were injected with 
phosphate-buffered saline (PBS). The lymph nodes of NP-CGG-immunized wild-type mice contained 
GC B cells (Fas+GL7+) and B cells that had undergone CSR (IgG1+); but in miR-217TG mice, the response 
to NP-CGG immunization was greater, with 22% more GC B cells (p = 0.01) and 20% more IgG1+ B 
cells (p = 0.08; Fig. 8). A similarly enhanced GC response to NP-CGG immunization was found in miR-
217KI mice (not shown). 
Figure 8. miR-217 expression in B 
cells enhances the GC response after 
primary immunization. (A) Repre-
sentative FACS analysis of B220+ lym-
phocytes in lymph nodes after primary 
T cell dependent immunization with 
NP-CGG of miR-217TG mice or litterma-
te controls. (B) miR-217TG mice (closed 
circles) or littermate controls (open 
circles) were immunized by subcuta-
neous injection of NP-CGG in com-
plete Freund’s adjuvant.  
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 Figure 8 (continuation): 14 days after immunization, lymph nodes were analyzed for the presence of GC B cells 
(Fas+GL7+) and switched B cells (IgG1+). Mice injected with PBS (open triangles) were used as non-immunized 
controls. Each symbol represents an individual mouse. Data were normalized to the mean value of control mice 
in each experiment; results are shown for a total of 4 experiments performed with 4 independent miR-217TG 
mouse lines (p = 0.01 for GC B cells and p = 0 .08 for switched B cells). 
 
We next analyzed the secondary B-cell immune response in control and miR-217TG mice. The en-
hancement of the GC reaction in miR-217TG mice was notably greater in secondary immunization a-
ssays, with 40% more Fas+GL7+ B cells and 60% more IgG1+-switched B cells than controls (p = 0.019 
and 0.018, respectively; Fig. 9. In addition, we found that the proportion of CD138+ plasma cells is 
larger in miR-217TG mice than in controls (not shown).  
Figure 9. miR-217 expression in B cells en-
hances the GC response after secondary im-
munization. Fourteen days after primary im-
munization, miR-217TG mice (closed circles) or 
littermate controls (open circles) were re-
immunized by subcutaneous injection of NP-
CGG and analyzed 7 days later. (A) Repre-
sentative FACS analysis of B220+ lymphocytes 
in lymph nodes after secondary NP-CGG im-
munization of miR-217TG mice or littermate 
controls. (B) Quantification of the immuniza-
tion response. Data from 2 independent ex-
periments are normalized to the mean value 
of control mice in each experiment (p = 0.019 
for GC and p = 0 .018 for switched B cells).  
To analyze the influence of miR-217 overexpression on the long-lived memory B-cell compartment, 
we quantified IgG1+ B cells in spleens from control and miR-217KI mice 1 year after immunization. The 
proportion of memory B cells was 40% higher in miR-217KI mice than in controls (p = 0.003; Fig. 10). 
Figure 10. miR-217 expression increases the frequency of memory B cells after long term immunization. miR-
217KI mice or littermate controls were immunized with NP-CGG and immunization response was analyzed 1 
year later. (A) Representative FACS plots showing the frequency of spleen memory IgG1+ B cells gated within 
B220+ cells. (B) Quantification of the proportion of memory B cells in the control group (open circles), miR-217KI 
(closed circles) and in the non-immunized PBS injected (open triangles) group (p = 0.003). 
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 To further characterize the role of miR-217 in the GC reaction, we examined the extent of SHM 
in miR-217TG mice in vivo. We isolated Fas+ GL7+ GC B cells from Peyer’s patches of control and miR-
217TG mice and quantified the mutation frequency in an intronic DNA region downstream of the JH4 
segment of the IgH locus, a region that accumulates mutations but cannot be subject to affinity ma-
turation events (Fig. 11A). Conventional Sanger sequencing of the JH4 intronic region showed that 
miR-217TG B cells have a higher mutation load than wild type controls (control, 2.1 x 10-3/bp and miR-
217TG, 3.7 x 10-3/bp, p = 0.028; Fig. 11B). Likewise, GC B cells from miR-217KI mice accumulated more 
mutations downstream of JH4 than did wild-type controls (not shown). Similar results were obtained 
when we analyzed SHM frequency at the JH4 intronic region by Next Generation Sequencing (NGS), 
which allows large numbers of mutations to be analyzed at very high depth (Perez-Duran, Belver et 
al. 2012). No mutations were detected in B cells isolated from AID-/- mice, used as negative control. 
We detected total mutation frequencies of 1.7 x 10-3/bp in control animals and 3.7 x 10-3/bp in miR-
217TG mice (p = 1.9 x 10-9), a 2.2-fold difference (Fig. 11C). This difference was even higher (2.7-fold) 
when the analysis was limited to cytosines located in AID mutational hotspots RGYW/WRCY (where R 
= A/G, Y = C/T, and W = A/T) (5.8 X 10-3/bp in controls vs 15.6 x 10-3/bp in miR-217TG; Fig. 11C), con-
firming that miR-217 overexpression in B cells increases the load of SHM in GCs. These results indi-
cate that overexpression of miR-217 in B cells increases the efficiency of GC formation, CSR and SHM, 
and the generation of terminally differentiated B cells in vivo. 
 
Figure 11. miR-217 expression in B cells enhances SHM. (A) SHM was quantified by sequencing the JH4 intro-
nic region of the IgH locus of GC B cells isolated from Peyer’ patches. 6 control and 6 miR-217TG mice were 
pooled to perform Sanger and NGS analyses. (B) Sanger sequencing analysis of SHM. Segment sizes in the pie 
charts are proportional to the number of sequences carrying the number of mutations indicated at the peri-
phery. Mutation frequencies are indicated below each chart, and the total numbers of independent sequences 
analyzed are indicated in the chart centers. Statistical significance was determined by a 2-tailed Student t test 
(p = 0.028). (C) NGS quantification of the total JH4 mutation frequency and of the mutation frequency at cyto-
sines within the RGYW/WRCY AID hotspots in JH4 sequences in GC B cells from control (open bars) and miR-
217TG mice (filled light blue bars). The mutation frequency in the JH4 sequence of AID
-/- splenic B cells is shown 
in hatched bars. A total of 300.000 kb/genotype was sequenced. Statistical significance of the mean mutation 
frequency at each position was determined by a paired Student t test (p = 1.9 x 10-9 for total mutation frequen-
cy and p = 0.002 for mutation frequency at WRCY hotspots). 
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 1.4. Inhibition of endogenous miR-217 impairs the GC reaction in vivo 
 To address whether endogenous miR-217 expression plays a physiological role in GCs, we gen-
erated bone marrow mouse chimeras in which endogenous miR-217 expression was inhibited by the 
expression of a miR-217 sponge (miR-217 SPG) construct (Fig. 12A), where sequences complemen-
tary to miR-217 were cloned in tandem within the 3’untranslated region of a reporter gene and thus 
function as competitive inhibitors for the binding of the miRNA to its endogenous binding sites 
(Ebert, Neilson et al. 2007) (Rao, O'Connell et al. 2010). Bone marrow cells from wild-type mice were 
transduced with miR-217 SPG or control retroviruses and transferred into lethally irradiated CD45.1 
congenic recipient mice and immunized 4 weeks later with NP-CGG (Fig. 12B). Chimeric mice injected 
with PBS were used as immunization negative controls. 
Figure 12. Schematic representation of the experimental approach used to inhibit endogenous miR-217 ex-
pression in vivo. (A) Retroviral construct used for miR-217 inhibition (miR-217 sponge (SPG)). Four miR-217 
complementary sites (217-T) separated by 4-nt spacers were placed downstream of the GFP reporter gene in 
the MGP vector. (B) Generation of chimeric mice that lack endogenous miR-217. Bone marrow cells from 
CD45.2 mice were transduced with the miR-217 SPG or empty control vectors, and transferred into lethally 
irradiated CD45.1 recipient mice. After 1 month of reconstitution, chimeric mice were immunized with a T cell 
dependent antigen and the GC response was analyzed 14 days later. 
When we analyzed the spleen and lymph nodes from immunized miR-217 SPG mice we noticed that 
they contained fewer GC and IgG1+ switched B cells than immunized control chimeric mice, and in-
deed, the proportions of these cell subsets in immunized miR-217 SPG mice were as low as in PBS 
injected, non-immunized animals (Fig. 13).  
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Figure 13. Inhibition of endogenous 
miR-217 expression in B cells impairs 
the GC response. Efficiency of GC 
(Fas+GL7+) and switched (IgG1+) B cells 
isolated from lymph nodes 14 days after 
NP-GCC immunization of mouse chime-
ras reconstituted with control (open 
circles) or miR-217 SPG (in red) retrovi-
rally transduced bone-marrow precur-
sors. (A) Representative plots and (B) 
the respective quantifications are 
shown. Non-immunized mice injected 
with PBS (triangles) were included as 
immunization controls. Data are from 
two independent experiments, and are 
normalized to the mean response of 
control mice in each experiment. Statis-
tical significance was determined by a 
two-tailed t test, *p < 0.05). 
We next analyzed SHM in Peyer’s patch GC B cells from miR-217 SPG and control chimeric mice by 
NGS. We found that miR-217 SPG GC B cells had a 25% lower mean mutation frequency than control 
B cells at the JH4 intronic region (p = 3.7 x 10
-5; Fig. 14). Very similar results were obtained when we 
analyzed the mutation load in a fragment of the µ switch region (Sµ) of IgH (p = 4 x 10-4), where mu-
tations accumulate concomitantly with CSR (Fig. 14). These results thus show that inhibition of en-
dogenous miR-217 attenuates the GC reaction and decreases the frequency of somatic mutations 
associated with both the SHM and the CSR reactions. 
Figure 14. Inhibition of endogenous miR-217 
impairs SHM.  NGS quantification of mutations 
in JH4 (left) and Sµ (right) sequences in 
GFP+CD45.1+ GC (Fas+GL7+) B cells isolated from 
pooled Peyer’s of 8 control (open bars) and 8 miR
-217SPG (red bars) mouse chimeras. Data are from 
two (JH4) and one (Sµ) independent experiments. 
At least 190 000 kb were sequenced per geno-
type. Statistical significance of the mean total 
mutation frequency at each position was deter-
mined by a paired Student t test (p = 3.7 X 10-5 for 
JH4 SHM and p = 4 X 10
-4 for Sµ SHM).  
66 
 1.5. miR-217 regulates a DNA damage response and repair gene network and 
stabilizes Bcl-6 expression in GC B cells  
1.5.1-Analysis of gene expression profile changes induced by miR-217 in GC B cells 
To identify the genes regulated by miR-217 in activated B cells, we performed a genome-wide com-
parison of the gene expression profiles of miR-217TG and wild-type GC B cells by RNAseq. Comparison 
of GC B cells from Peyer’s patches of miR-217TG and wild-type mice identified 1740 differentially ex-
pressed genes with p ≤ 0.05 (see annex 1 to have the complete list of changed genes), 1236 of 
which were downregulated. This set of downregulated genes was significantly enriched in predicted 
miR-217 targets (p = 9.75 x 10-7; Fig. 15A), suggesting that a high proportion of the downregulated 
genes identified in miR-217TG GC B cells are direct miR-217 targets. To identify the gene networks 
altered by miR-217 expression in GC B cells, we performed a bioinformatics analysis on the genes 
differentially expressed in miR-217TG vs control GC (Fas+GL7+) B cells.  
Figure 15. Identification of gene networks regulated by miR-217 in GC B cells. RNAseq analysis of genome-
wide gene expression in control and miR-217TG GC B cells isolated from Peyer’s patches. (A) Enrichment in miR-
217 predicted targets within the 1236 mRNAs whose expression was downregulated in miR-217TG versus con-
trol GC B cells. (B) Ingenuity Pathway Analysis of the genes differentially expressed in control versus miR-217TG 
GC B cells, showing enrichment for a DNA replication and repair gene network among the genes regulated by 
miR-217. Downregulated genes are shown in green, upregulated genes in red (p < 0.001). 
 
Ingenuity Pathway Analysis revealed that miR-217 regulates a DNA damage response (DDR) and re-
pair gene network in GC B cells (p = 10-31; Fig. 15B). Interestingly, this gene network contained 2 
main hubs, RNA pol II and replication protein A, which are directly linked to AID activity (Chaudhuri, 
Khuong et al. 2004) (Kenter 2012) (Nambu, Sugai et al. 2003) (Pavri, Gazumyan et al. 2010) (Vuong 
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and Chaudhuri 2012). The miR-217-regulated gene network included a number of genes linked to the 
DDR (Nbs1 and Rad50 components of the Mre11-Rad50-Nbs1 [MRN] complex) (Stracker and Petrini 
2011) DNA repair and CSR (Wrn, Lig4, and Xrcc2) (Robbiani and Nussenzweig 2013) (Ramiro, Reina San-
Martin et al. 2007) (Bothmer, Rommel et al. 2013) and genes of the cohesin complex (SMC2, SMC3, 
PDS5B, and SA2) involved in chromatid cohesion, as well as in DNA replication, transcription, recombi-
nation, and repair (Merkenschlager and Odom 2013) (Remeseiro and Losada 2013); all of them were 
downregulated by miR-217. 
1.5.2-Analysis of the DNA damage response and Bcl-6 expression in miR-217 overexpressing 
B cells upon genotoxic stress 
Bcl-6 expression is regulated by the DDR through a signaling pathway that promotes Bcl-6 degradation 
(Phan, Saito et al. 2007). As we found that miR-217 downregulates the expression of a number of 
genes involved in DDR and repair in GC B cells, we hypothesized that miR-217 could stabilize Bcl-6 ex-
pression in these cells. To test this hypothesis, we transduced Ramos cells, a human Burkitt lymphoma 
(BL) GC B-cell line, with miR-217-GFP and control retroviral vectors and analyzed Bcl-6 expression on 
genotoxic stress induction. We first verified that genes linked to the DDR and downregulated by miR-
217 expression in mouse GC B cells (Nbs1, Xrcc2, Lig4, and Pds5b) were also downregulated by miR-
217 in human Ramos cells (Fig. 16). 
 
Figure 16. The DDR pathway is downregulated upon miR-217 expression in Ramos cells. Quantification of 
Nbs1, Xrcc2, Lig4, and Pds5b expression in Ramos cells transduced with control (open bars) or miR-217 (filled 
bars) retrovirus analyzed by q-RT-PCR. Two-tailed Student t test was used to calculate p values (*p ≤  0.05). 
 
To determine if miR-217 impacts on the response to genotoxic stress, we analyzed the effect of 
etoposide treatment on the cell cycle of control- and miR-217-transduced Ramos cells. Expectedly, 
we found that etoposide induced DDR promoted an increase in the fraction of cells in the S phase of 
the cell cycle, consistent with a replicative delay (Fig. 17). However, this S phase increase was milder 
in miR-217-transduced cells (Fig. 17B), which suggested that miR-217 may contribute to bypass the 
DDR response induced by etoposide.  
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Figure 17. miR-217 expression attenuates the DDR response to etoposide-induced genotoxic stress. Cell cycle 
analysis of etoposide-treated control and miR-217- transduced Ramos cells. (A) Representative cell cycle plots 
of untreated (-Etop) or etoposide treated (6 hours, 10 mM) (+Etop) Ramos cells. The mean and standard devia-
tion of the fraction of cells in S cycle are annotated in the plots. (B) Quantification of the change in the propor-
tion of cells at each phase of cell cycle in response to etoposide treatment (open bars, control-transduced cells; 
black bars, miR-217-transduced cells). Bars represent means and standard deviations from 3 independent ex-
periments (p = 0.004) (2-tailed Student t test). 
 
Immunoblot analysis showed that etoposide treatment of control Ramos cells rapidly induced Bcl-6 
degradation (Fig. 18), in agreement with previous results (Phan, Saito et al. 2007). However, Ramos 
cells overexpressing miR-217 were partially protected against genotoxic stress-induced Bcl-6 degra-
dation and showed increased Bcl-6 expression levels (Fig. 18, upper panel). Caffeine treatment pro-
tected miR-217 Ramos cells from etoposide induced Bcl-6 degradation, indicating that an ataxia te-
langiectasia mutated/ataxia telangiectasia and Rad3-related–dependent pathway is involved in this 
process (Fig. 18, lower panels).  
Figure 18. miR-217 dampens Bcl-6 degradation in GC B 
cells upon genotoxic stress. (Upper) Immunoblot of Bcl-
6 in Ramos cells transduced with control or miR-217 
retrovirus treated for 6 hours with the indicated doses of 
etoposide. (Lower) Immunoblot of Bcl-6 in miR-217-
transduced cells left untreated (-Etoposide) or treated 
with 10 mM Etoposide for 6 hours (+Etoposide) in the 
presence of increases doses of caffeine (0 mM [-], 2 mM 
[+], and 5 mM [++]).  
 
Analysis of Bcl-6 protein levels in GC B cells from control and miR-217KI mice further confirmed that 
miR-217 expression promotes the accumulation of Bcl-6 (Fig. 19). Finally, quantification of Bcl-6 ex-
pression in spleens from miR-217TG and control mice revealed that miR-217TG mice have larger Bcl-6+ 
follicle areas in spleens (p = 0.0008; Fig. 20). Overall, these data indicate that miR-217 regulates the 
69 
GC reaction by modulating the expression levels of a gene network involved in DDR and repair and by 
dampening genotoxic stress-induced Bcl-6 degradation in GC B cells.  
Figure 19. Analysis of Bcl-6 expression in miR-217KI GC cells by flow cytometry. (A) Representative dot plots 
of Fas, GL7, and Bcl-6 staining of Peyer’s patch B cells. (B) Quantification of Bcl-6 expression levels in 
B220+Fas+GL7+GC B cells from Peyer’s patches of littermate controls (white bar) and miR-217KI mice (black bar) 
(MFI, mean fluorescence intensity; 3 mice per genotype, p = 0.0006, 2-tailed Student t test). 
Figure 20. Aged miR-217TG mice have 
bigger Bcl-6+ areas per follicle. Immuno-
histochemical analysis of the proportion 
of Bcl-6+ areas per follicles. 205 and 201 
spleen follicles of control and 10 miR-
217TG mice were quantified, respective-
ly. Statistical significance was deter-
mined by 2-tailed Student t test. 
 1.6. Deregulated miR-217 expression promotes mature B cell lymphomas 
 GC B cells are highly prone to oncogenic transformation. Our results show that miR-217 is a 
positive regulator of the GC reaction, presumably by downregulating the expression of DNA repair 
genes and by stabilizing Bcl-6 expression, which could enhance the susceptibility of these cells to on-
cogenic events. To test whether miR-217 overexpression in B cells affects the development of mature 
B-cell lymphomas, we monitored the incidence of B-cell lymphoma in a group of 34 control and 40 
miR-217KI mice. Mice were euthanized and analyzed at an end-point of 90 weeks or earlier if they 
showed signs of disease. miR-217KI mice had larger spleens than control animals, with a fraction 
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showing clear splenomegaly (20% vs 0% spleens larger than 20 mm; Fisher’s exact test, p = 0.0058; Fig. 
21A; Table 8). 
Figure 21. miR-217 overexpression promotes mature B cell lymphomas. 34 control and 40 miR-217KI mice 
were monitored over 90 weeks for the appearance of B cell lymphoma. (A) Representative pictures of a non-
tumoral control spleen (right) and a miR-217KI spleen with splenomegaly (left). (B) Quantification of B cell lym-
phoma incidence in control mice (open bars) and miR-217KI mice (filled bars). P value was determined by two-
tailed t test (p = 0.028). 
Figure 22.  Immunohistochemical characterization of the B cell lymphomas found in miR-217KI mice. All the 
tumors were stained for H&E (left), Pax5, CD3 and Bcl-6 and classified by a pathologist. Representative cases of 
the different B cell lymphomas generated are shown. Scale bar is 50 µm. NT, non-tumoral; SBL, small B-cell 
lymphoma. 
Histopathological evaluation of the spleens showed that a large proportion (33%) of miR-217KI mice de-
veloped B-cell lymphoma (p = 0.028 vs control mice; Fig. 21B). We found that lymphomas in miR-217KI 
mice had features of mature GC or post-GC B-cell origin. To classify the lymphomas, paraffin-embedded 
samples were stained with H&E and a B cell marker (Pax5), a T cell marker (CD3) and a GC marker (Bcl-
6). Most neoplasias (70%) were classified as follicular lymphomas (FL), although we also observed other 
mature B-cell lymphomas, such as DLBCL and B-cell plasmacytomas (PCT) (Fig. 21B and Fig. 22; Table 8).  
71 
Mouse 
IDa 
B cell lymphomab Gradec Spleno-
megalyd 
Phenotypee 
BPT048 FL     Mature B cell, B220
+ CD19+ sIgM+ sIgκ+ Fas+GL7+, 
Pax5low  BCL-6+; numerous infiltrating T cells. 
BPT100 FL   Yes Mature B cells, Pax5+  BCL-6- and N/A 
BPT105 FL     Mature B cell,   B220
+ CD19+ sIgM-  sIgκ+, Pax5+  BCL-
6+ 
BPT106 FL     Mature B cell,  B220
+ CD19+ sIgM-  sIgκ+, Pax5low  BCL-
6+ 
BPT109 PCT Aggressive   Mature B cell, Pax5- BCL-6- and N/A 
BPT124 FL Aggressive   Mature B cell,  B220
low CD19+ sIgMhigh sIgκ+, Pax5low  
BCL-6- 
BPT137 FL     Mature B cell, B220
+ CD19+ sIgMlow sIgκ+, Pax5+  BCL-
6- 
BPT148 DLBCL Aggressive Yes Mature B cell, B220
+ CD19+ sIgMlow sIgκ+, Pax5low BCL-
6+; numerous infiltrating T cells. 
BPT224 DLBCL Aggressive Yes Mature B cell, B220
+ CD19+ sIgMlow sIgκlow, Pax5low 
BCL-6+; numerous infiltrating T cells. 
BPT226 FL Aggressive Yes Mature B cell, B220
+ CD19+ sIgMlow sIgκlow, Pax5low 
BCL-6+; numerous infiltrating T cells. 
BPT234 SBL     Mature B cell, B220
+ CD19+ sIgMhigh sIgκ+,  Pax5+ BCL-
6- 
BPT263 FL   Yes Mature B cell, B220
high CD19+ sIgM+  sIgκ+, Pax5+  BCL-
6+ 
BPT266 FL Aggressive   Mature B cell, B220
+ CD19+ sIgMlow sIgκ+, Pax5low BCL-
6- 
Table 8. Characterization of B cell lymphomas in miR-217KI mice 
a: Mouse identification number 
b: B cell lymphoma type: FL: follicular lymphoma; DLBCL: diffuse large B cell lymphoma; SBL: small B -cell lymphoma 
and PCT: plasmacytoma 
c: Lymphoma classification grade 
d: Splenomegaly: spleens larger than 20mm length. 
e: Phenotype of tumoral cells determined by morphological features, flow cytometry and immunohistochemica stain-
ings. N/A: not analyzed 
Flow cytometry analysis of the spleens and lymph nodes showed that lymphomas from miR-217KI 
mice presented frequent alterations in the expression of the B-cell surface molecules B220, IgD, IgM, 
and Igқ (Table 8). To further characterize the origin of these lymphomas, we performed molecular 
analysis of their V(D)J rearrangements by PCR amplification and sequencing. We found that a frac-
tion of the lymphomas yielded unique amplification bands (Fig. 23), which were confirmed to corre-
spond with single rearrangements (Table 8), thus providing proof of their clonal origin. In addition, 
all of the rearrangements subject to this analysis contained mutations (SHM+) in their V genes (Table 
9), confirming their GC/post-GC origin. 
 
Figure 23. Evidences of clonality in miR-217 promot-
ed B cell lymphomas. PCR analysis of V(D)J rear-
rangements in tumor samples from miR-217KI mice. 
DNA was isolated from total spleen and amplified 
using a V-degenerate primer in combination with an 
antisense primer downstream of JH4. Sequencing 
results are shown in Table 9. Mouse IDs are shown. 
MW, molecular weight marker. 
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Mouse IDa V geneb D geneb J geneb V-D-J junction SHMc 
BPT105 IGHV1-66*01 IGHD2-5*01 IGHJ4*01 GGGGGCTATAGTCAAATGAGGGGG + 
BPT124 IGHV1S16*01 IGHD1-2*01 IGHJ2*01 GAGGGGATTACTACGGCTACC + 
BPT137 IGHV1S127*01 IGHD4-1*02 IGHJ2*01 GACTGGGACGTCGG + 
BPT234 IGHV1-47*01 IGHD2-4*01 IGHJ1*01 ATGATTACGACCACC + 
Table 9. Analysis of VDJ gene rearrangements in clonal B-cell lymphomas of miR-217KI mice 
a: Mouse identification number 
b: Assignment of V, D and J genes by NCBI/IGBLAST according to IMGT database. 
c: Somatic hypermutation 
1.6.1- Role of p53 and Ink4a/Arf tumor suppressors in miR-217 induced lymphomagenesis 
 To examine the contribution of tumor suppressor pathways to limiting the B-cell lym-
phomagenesis induced by miR-217, we analyzed the incidence of B-cell lymphoma in miR-217KI mice 
in the Ink4a/Arf -/- and p53-/- backgrounds. Ink4a/Arf -/- and p53-/- mice often developed histiocytic 
sarcomas (40%) and T-cell lymphomas (70%), respectively (data not shown). In addition, we found 
that roughly 20% of both control Ink4a/Arf-/- and p53-/- tumor suppressor-deficient mice generated B
-cell lymphomas. This incidence was not significantly altered by miR-217 overexpression in the p53-/- 
background, but in the Ink4a/Arf -/- background, miR-217 overexpression increased B-cell lymphoma 
incidence to 43% (Fig. 24A), although the mean survival of miR-217KI  Ink4a/Arf -/- mice was not sig-
nificantly altered (Fig. 25). A similar molecular and histochemical characterization to that performed 
with miR-217KI tumors was done with the Ink4a/Arf-/- tumors. B-cell lymphomas in miR-217KI Ink4a/
Arf -/- mice showed histopathological features of mature GC or post-GC B-cell lymphomas (Fig. 24B). 
These results suggest that the Ink4a/Arf, but not the p53, tumor suppressor pathway acts as a sur-
veillance mechanism against the lymphomagenic events induced by miR-217 in mature B cells. 
Figure 24.  Loss of Ink4a/Arf but not p53 increases the frequency of the miR-217 induced B cell lymphomas.  
(A) Quantification of B-cell lymphoma incidence in control (open bars) and miR-217KI (filled bars) Ink4a/Arf-/- and 
p53-/-mice. Statistical significance was determined by 2-tailed Student t test (p = 0.03 in miR217KI Ink4a/Arf-/- vs 
control Ink4a/Arf-/- and p = 0.33 in miR217KI p53-/- vs control p53-/-). (B) Representative H&E and immunohisto-
chemical stainings for Pax5 and CD3 from spleens of assorted  to miR-217KI  Ink4a/Arf -/-  lymphomas. Original 
pictures were taken at 40X. 
73 
Figure 25. miR-217 does not affect overall 
survival of the Ink4a/Arf -/-. Survival of con-
trol Ink4a/Arf -/- (37 mice, in dark blue) and 
miR-217KI Ink4a/Arf-/- (44 mice, in light blue) 
mice and of control (33 mice, in dark green) 
and miR-217KI mice (40 mice, in light green), 
observed for 90 weeks. 
1.6.2- Alterations of miR-217 expression in human GC derived B cell lymphomas 
 To determine if miR-217 expression levels are altered in mature B-cell human lymphomas, we 
conducted a qRT-PCR analysis of miR-217 expression in a collection of BL and DLBCL samples. Expre-
ssion of miR-217 was higher in BL and DLBCL than in control tonsil, lymph node, and peripheral blood 
B-cell samples (BL vs control, p = 0.05; Fig. 26). In agreement with these findings, analysis of pu-
blished data of copy number variation in a cohort of DLBCL cases revealed that the genomic region 
that contains the miR-217 chromosomal location (MCR 1694) is amplified in a fraction of the cases 
(GSE111318) (Lenz, Wright et al. 2008). Together, these data indicate that miR-217 gain of function is 
associated with human mature B-cell lymphomas. 
Figure 26. Increased miR-217 expression in human GC 
derived lymphomas. miR-217 relative expression in hu-
man control samples (open circles, peripheral blood CD19+ 
B cells; open squares, tonsils; open triangles, lymph 
nodes), in BL samples (closed circles) and in DLBCL sam-
ples (closed triangles, GC B GCB-DLBCL; closed squares, 
activated B cell, ABC-DLBCL) as determined by qRT-PCR. 
Statistical significance was determined by 2-tailed Student 
t test (p = 0.05 for BL). 
Overall, our results identify miR-217 as a positive regulator of the GC reaction and as an oncogene in 
B cells that promotes B cell lymphomas of GC origin. miR-217 attenuates the DNA damage response 
stabilizing Bcl-6 and facilitating the molecular events that give rise to secondary antibody diversifica-
tion. However, its upregulation promotes mature B cell lymphomagenesis. Importantly, we have 
found that there is an association between high miR-217 levels and human B cell lymphomas. Thus, 
miR-217 is a novel molecular link between the GC response and B-cell transformation and provides 
an in vivo model of mature B-cell lymphomagenesis. 
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2.  Role of miR-28 in GC reaction and in B cell lymphomagenesis 
 2.1. miR-28 is a GC specific miRNA  
 Based on the hypothesis that significant miRNA expression in a particular tissue or at a specific 
differentiation stage very likely reflects functional relevance, we searched for GC specific miRNAs in 
databases that profile miRNA expression in lymphocyte subsets and found that miR-28 is expressed 
specifically in both mouse and human GC in B cells (Kuchen, Resch et al. 2010) (Schneider, Setty et 
al. 2014). Indeed, miR-28 expression is almost absent in other tissues except in in vivo GC B cells 
(Kuchen, Resch et al. 2010). To confirm this finding, we first analyzed miR-28 expression in GC B Cells 
by q-RT-PCR in naive pre-GC cells (CD19+Fas-GL7-IgA-), GC cells (CD19+Fas+GL7+IgA-) and in post-GC B 
cells (CD19+Fas-GL7-IgA+) sorted from Peyer’s Patches of wild time C57BL/6 mice. We found that miR
-28 is transiently induced in GC B cells (a 12.75-fold increase compared to the pre-GC naïve B cells) 
and downregulated immediately afterwards, in switched IgA+ cells (Post-GC, Fig. 27A). Next, we per-
formed miR-28 expression kinetics analysis upon in vivo B cell activation by immunizing C57BL/6 
mice with SRBC and sorting splenic GC B cells at different time points after the immunization.  miR-
28 expression levels were measured by q-RT-PCR in early GC B cells (4-6 days after SRBC injection), 
and in late GC B cells (10-14 days after immunization). We found that miR-28 expression increases as 
the GC reaction progresses (7.45-fold increase at day 14 versus day 4) (Fig. 27B).  These results 
demonstrate that miR-28 is upregulated upon in vivo B cell activation and that its expression is accu-
mulated as the GC reaction progresses. 
 
Figure 27. miR-28 is a GC specific miRNA. (A) 
miR-28 expression was assessed by qRT-PCR in 
naïve (CD19+Fas-GL7-IgA-), GC (CD19+Fas+GL7+) 
and  post-GC (CD19+Fas-GL7-IgA+) switched B 
cells from Peyer’s patches (2 independent ex-
periments) or (B) in splenic GC (B220+Fas+GL7+) 
B cells at the indicated days after immunization 
with SRBC. Pools of at least 4 animals were used 
at each time point. Data from 2 independent 
experiments are shown . 
 2.2. miR-28 is a negative regulator of the GC reaction 
 To study the role of miR-28 during B cell activation, we first performed in vitro miR-28 gain of 
function experiments. Naïve B cells were isolated from spleens of C57BL/6 mice and were retrovi-
rally transduced with a vector encoding miR-28 precursor and GFP or with an empty GFP control 
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and cultured in the presence of LPS and IL4. These culture conditions promote AID induction, CSR and 
induce proliferation of B cells, thus mimicking a physiological GC reaction. After transduction, CSR effi-
ciency to IgG1 was assessed by flow cytometry within GFP+, transduced cells. We found that miR-28 
expressing B cells showed a mild but consistent reduction of CSR to IgG1 compared to the control GFP+ 
cells (p = 0.039, Fig. 28). These results show that miR-28 impairs CSR to IgG1, suggesting that miR-28 is 
a negative regulator of the GC reaction.  
Figure 28. miR-28 impairs CSR. Spleen B cells were stimulated in the presence of LPS and IL4 and trans-
duced with control or miR-28-containing retroviral constructs. CSR to IgG1 was assessed by FACS analysis 3 
days after transduction. (A) Representative FACS plot; (B) quantification. Statistical significance was calcula-
ted with unpaired T test (*p < 0.05). Data from 5 independent experiments are shown.  
To determine whether the role of miR-28 is physiologically relevant during a GC reaction in vivo, we 
inhibited endogenous miR-28 expression in GC B cells with a miR-28 sponge (miR-28 SPG) construct. 
We generated the miR-28 SPG construct (Fig. 29A) by cloning four complementary sequen-ces of 
miR-28 in tandem into the GFP-containing MGP vector. We then transduced CD45.1 bone marrow 
precursors with miR-28 SPG or with a control vector and performed bone marrow chimera experi-
ments by injecting the transduced cells into lethally irradiated CD45.2 congenic receptor mice.  
Four weeks after bone marrow transfer, we immunized the chimeric mice with SRBC and analyzed 
the immune response 7-9 days afterwards by flow cytometry. As an immunization control, mice 
were injected with PBS. We found that mice reconstituted with miR-28 SPG had a general increased 
response to immunization compared to control mice, with 34% more Fas+GL7+ GC B cells (p = 
0.015) cells, 14% more IgG1+ switched B cells (p = 0.027) and 47% more CD138+ plasma B cells (p = 
0.024) in the spleen (Fig. 29C). These results demonstrate that inhibition of endogenous miR-28 en-
hances the GC reaction, and therefore that miR-28 is a negative regulator of GCs.  
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Figure 29. Inhibition of endogenous miR-28 
boosts the GC reaction. (A) Scheme of the 
miR-28 sponge (miR-28 SPG) retroviral con-
struct used for miR-28 inhibition. Four miR-28 
complementary sites (28-T), separated by 4-
nt spacers, were cloned downstream of GFP 
in the MGP vector. (B) and (C) miR-28 inhibi-
tion enhances the immunization response. 
Mouse chimeras of bone marrow cells trans-
duced with miR-28 SPG or empty control vec-
tors were analyzed by FACS 7-9 days after 
immunization with a T cell dependent anti-
gen. Representative plots of GC B cells (B, 
upper panels), IgG1 switched B cells (middle 
panels) and plasma (bottom panels) cells are 
shown. (C) Quantification of FACS analysis 
shown in (B). Each symbol represents an indi-
vidual mouse. PBS, non-immunized chimeric 
mice. Data are normalized to the response of 
PBS injected mice of 2 independent experi-
ments. *p < 0.05, unpaired t test.  
 2.3. miR-28 expression is downregulated in GC derived B cell neoplams 
 The finding that miR-28 is a negative regulator of the GC reaction prompted us to explore the 
connection between miR-28 expression and B cell lymphomagenesis. Analysis of a miRNA expression 
dataset from human GC-derived B cell neoplasms (GSE 29493 (Di Lisio, Sánchez-Beato et al. 2012)) 
revealed that miR-28 expression is lost in various lymphoma subtypes, such as in BL (p = 6.93 x 10-11), 
DLBCL (p = 2.64 x 10-18), FL (p = 9.25 X 10-16) and in CLL leukemia, which is an heterogeneous malig-
nancy with GC origin (p = 1.65 x 10-10) (Fig. 30A). miR-28 downregulation is also a common event in 
established GC derived B cell lines, such as the Ramos (p = 0.0015) and Raji BL cell lines (p = 0.0012) 
and the MD901 DLBCL cell line (p = 0.0038) (Fig. 30B). These data show that miR-28 downregulation 
is very frequently associated with GC B cell transformation, which could be suggestive of a tumor 
suppressor role of miR-28. 
Figure 30. miR-28 is downregulated in human GC derived neoplasms. (A) Relative miR-28 expression in prima-
ry human B cell malignancies and (B) in immortalized human GC B cell lymphoma cell lines.   
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Figure 30 (continuation); (A) miR-28 microarray expression data (GSE29193) in cohorts of Chronic lymphocytic 
leukemia (CLL, 18 samples), Diffuse large B cell lymphoma (DLBCL, 29 samples), Burkitt lymphoma (BL, 12 sam-
ples) and Follicular lymphoma (FL, 23 samples). Human naive B cells (CD19+ IgD+ CD27-) (3 samples, in orange) 
and human GC B cells (CD10+ CD19+) (4 samples, open circles) extracted from tonsils of healthy donors were used 
as controls. Adjusted P values are calculated with Benjamini & Hochberg. (B) q-RT-PCR analysis of miR-28 expre-
ssion in a collection of human BL and DLBCL cell lines is represented relative to GC B cell levels (2 independent 
experiments).  *p < 0.05, unpaired t test. 
 2.4. miR-28 expression regulates BCR signaling, proliferation and apoptosis in 
B cells  
        2.4.1- Quantitative proteomics and transcriptomics analysis upon miR-28 expression in BL 
cells 
To identify the genes regulated by miR-28 in B cells, we performed transcriptome and proteome 
analysis in the human BL cell line Ramos, where miR-28 expression is greatly reduced compared to 
normal GC B cells (Fig 30B). To re-express miR-28 in Ramos cells we made use of a pTRIPZ lentiviral 
vector encoding miR-28 precursor along with “red fluorescent protein” (RFP) under a Tet-on promo-
ter, which allows the induction of this cassette by doxycycline (Dox) treatment. In addition, trans-
duced cells can be selected with puromycin (Fig. 31A).  Ramos cells were transduced with either miR-
28 or scrambled control pTRIPZ vectors, selected with puromycin, induced with Dox for 48 hours, and 
RFP+ cells were isolated by flow cytometry cell sorting. Cells were then subjected to RNAseq or 
iTRAQ analysis for transcriptome and proteome profiling, respectively (Fig. 31B).  
Figure 31. Pipeline used to identify miR-28 targets by quantitative proteomics and transcriptomic analysis. (A) 
Lentiviral constructs used to express miR-28 or a scrambled sequence.  
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Figure 31 (continuation); the construct encodes for puromycin resistance gene and is inducible by doxycyclin. 
(B) Schematic representation of the experimental strategy used to identify miR-28 targets in Ramos BL cells.  
RNAseq analysis revealed that miR-28 expression in BL cells induced changes in the expression of 
1202 transcripts (p < 0.05), 568 of which were downregulated (Fig. 32A) (see complete list of changed 
genes in annex 2).  
Figure  32. Volcano plots showing global differences in the transcriptome and proteome induced by miR-28 
expression in BL cells. Volcano representation of 6 replicate RNAseq data and 4 replicate iTRAQ data used to 
identify changes in Ramos BL cells upon miR-28 re-expression. Points under the cut-off line (red) are significant-
ly altered upon miR-28 expression. (A) RNAseq expression data represented as log2 fold change (FC) (miR-28/
Scramble, X axis) versus statistical significance (log2 p value, Y axis) in transduced Ramos BL cells. 1202 genes 
were identified as differentially expressed (568 down, shown in red, and 634 up, in green) in miR-28 expressing 
cells with a p ≤ 0.05. (B) Protein expression data represented as log2 FC (miR-28/Scramble, X axis) versus False 
Discovery Rate (FDR) (Y axis). 276 proteins were identified as differentially in miR-28 expressing cells with FDR ≤ 
10%, of which 107 (in red) were downregulated and 169 up (in green).  
We found that transcripts downregulated by miR-28 were significantly enriched in in silico miR-28 pre-
dicted targets by Gene Set Enrichment analysis (GSEA) (Fig. 33A), which suggests that a high proportion 
of the downregulated genes identified by RNAseq are direct miR-28 targets. Downregulation induced 
by miR-28 expression identified in the RNAseq analysis was verified by qRT-PCR analysis for a number 
of transcripts, including CD44, CCDC50, CELSR3, VAV3, FOSB and JAK3 (Fig. 33B).
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Figure 33 (continuation). Transcripts downregulated by miR-28 expression in BL cells are enriched in miR-28 
predicted targets. (A) Gene Set Enrichment analysis of miR-28 targets as predicted by at least four independ-
ent prediction software against the differentially expressed genes identified in the RNAseq analysis. (B) Relative 
expression of six representative genes significantly downregulated in the RNAseq analysis measured by q-RT-
PCR . Data from 2 independent experiments is shown (*p < 0.05, unpaired t test).  
iTRAQ quantification of protein level changes induced by miR-28 expression in BL cells identified 276 
differentially expressed proteins (10% FDR) (see annex 3 to have the complete list of changed pro-
teins), 107 of which were downregulated (Fig. 32, right panel). We subjected the miR-28 regulated 
transcripts and proteins to Gene Ontology cellular function pathway identification analysis. Im-
portantly, we found that both the transcriptome and proteome changes induced by miR-28 grouped 
in the same cellular functions pathways (Fig. 34. The most represented Gene Ontology cellular fun-
ctions affected by miR-28 expression at the mRNA and protein levels were cell cycle, chromatin a-
ssembly, DNA replication and cell cycle. 
Figure 34. Transcriptome and proteome analysis identify similar cellular functions regulated by miR-28 in BL 
B cells. Bubble plot representation of the functional annotation of transcripts (left) and proteins (right) 
changed by miR-28. Categories correspond to the Gene Ontology Consortium of biological function database. 
Total number of genes/proteins inside each category are plotted on X axis; Y axis represents the proportion of 
each GO category found  to be changed  at the transcript (left) or protein (right) level; bubble area is propor-
tional to the number of elements in each category relative to the total number of genes (left) or proteins (right) 
depicted.  
Next, we subjected quantitative proteome data to Systems Biology Triangle analysis, a novel func-
tional class scoring algorithm that identifies alterations in functional categories produced by coordi-
nated protein responses in high-throughput quantitative proteomics experiments (Garcia-Marques 
et al submitted).  We found that miR-28 expression in Ramos BL cells induced the coordinated down-
regulation of different cellular pathways on cell cycle progression; including cell cycle G1/S check-
point regulation, G2/M phase transition, cyclins and cyclins dependent kinase activity and mitosis of 
tumor cell lines. In addition, the analysis revealed that miR-28 expression resulted in a coordinated 
upregulation of proteins from the p53 tumor suppressor pathway (Fig. 35).  
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Figure 35. miR-28 expression indu-
ces the coordinated downregulation 
of cell cycle proteins and the upre-
gulation of p53 tumor suppressor 
pathway proteins. Distribution 
curves of the standardized variable 
of proteins (Zqa values, X axis), 
plotted separately in the different 
functionally changing categories.  
To gain more insight into the gene networks that could be significantly altered by miR-28 in BL B 
cells, we performed Ingenuity pathway analysis on the proteins differentially expressed in BL cells 
transduced with miR-28 and found that miR-28 regulates the BCR signaling pathway. This gene net-
work contained four main hubs, BCR, PI3K, AKT and ERK1/2 that play pivotal functions in B cell biolo-
gy and regulate the induction of cell cycle and apoptosis regulatory molecules such as CDC6, 
CDC25C, tnfsf11 and ILF3 (Fig. 36). These results suggest that reintroducing miR-28 in lymphoma 
cells affects the signaling network that emanates from the BCR and whose hyperactivation is recu-
rrently linked to B cell lymphomagenesis (Rickert 2013) (Davis, Ngo et al. 2010, Young, Shaffer et al. 
2015). 
Figure 36. miR-28 regulates BCR signaling pathway. Ingenuity Pathway Analysis of proteins differentially ex-
pressed as a result of miR-28 expression in BL cells shows enrichment in BCR signaling pathway (p = 10-46). Up-
regulated proteins are depicted in green, downregulated in red and nodes in blue.  
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2.4.2- Impact of miR-28 expression in the BCR signaling pathway of BL cells 
As our proteome analysis revealed that miR-28 expression regulates the expression of BCR 
signaling related proteins, we next analyzed the functional impact of miR-28 expression in the key 
kinases downstream BCR signaling. Western Blott (WB) analysis of the phosphorylated and active 
forms of AKT (p-AKT) and ERK (p-ERK) showed that miR-28 expression in B cells dampens BCR signal-
ing. We found a tendency to have reduced p-ERK levels upon miR-28 expression (32.5% in miR-28 
RFP+ compared to scrambled RFP+ Ramos BL cells, p = 0.1) (Fig. 37A). Similarly, p-AKT phosphoryla-
tion in serine 472 was reduced by 34% in miR-28 RFP+ cells compared with control scrambled RFP+ 
cells (p = 0.022). In addition, flow cytometry analysis of AKT phosphorylation in response to BCR stim-
ulation with anti-IgM revealed that miR-28 expressing cells had a reduction of a 23% in p-AKT levels 
when compared with controls (Fig. 37B) (p = 0.042). Overall, these data show that miR-28 expression 
dampens BCR signaling in BL cells. 
Figure 37. miR-28 expression dampens BCR sig-
naling in BL cells. In vitro cultured miR-28 or con-
trol transduced Ramos BL cells 48h after induction 
with doxycycline. (A) Immunoblot analysis of p-
ERK1/2, ERK1/2 and p-AKT in extracts from Ramos 
cells transduced with miR-28 or a scrambled con-
trol. Numbers underneath the bands show protein 
levels after normalization to the -tubulin loading 
control signal (p-AKT and p-ERK1/2). Bar graphs 
show data from two independent experiments. (B) 
AKT phosphorylation measured by flow cytometry 
after anti-IgM stimulation of Ramos-miR-28 RFP+ 
or Scramble RFP+ cells. Representative examples 
of flow cytometry plots are shown in the left. 
Quantification from 4 independent experiments is 
shown on the right. MFI, mean fluorescence inten-
sity. *p < 0.05, unpaired t test. 
 
Human malignant B cells are dependent on “tonic” BCR signaling for proliferation and survival 
(Shaffer, Young et al. 2012). Following a stringent candidate selection proteomics approach, we have 
found that miR-28 expression impacts on BCR signaling network and indeed impairs BCR signaling in 
human B cell lymphoma. We wondered if other components of molecular pathways that play key 
roles in the generation and/or maintenance of human mature B cell malignancies could have been 
overlooked in our proteome analysis but were nonetheless altered by miR-28 expression. To assess 
this issue we followed a hypothesis-driven approach and directly analyzed the expression of genes 
frequently deregulated in GC-derived malignancies (extracted from (Shaffer, Young et al. 2012)) in 
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our RNAseq data sets. We found that the expression of 3 genes (NFKB2, IKKB and BCL2) that have re-
current gain-of–function genetic aberrations in GC-derived malignancies was downregulated by miR-
28 expression in Ramos BL cells. NF-B2 and IKKB are components of the NF-B pathway, the most 
common gene pathway found to be altered in lymphoid malignancies and whose constitutive activa-
tion results in the inhibition of cell death pathways. BCL2 gene encodes for Bcl-2, an integral outer mi-
tochondrial membrane protein that blocks the apoptotic cell death in lymphocytes and whose expres-
sion is induced through NF-B and other signaling pathways downstream of the BCR. Bcl-2 gain of 
function due to genetic alterations is a molecular feature of a number of mature B cell malignancies, 
including CLL, FL, the GC subtype of DLBCL and MCL. The downregulation of NFKB2, IKKB and BCL2 
transcripts induced by miR-28 expression in Ramos BL cells was confirmed by quantitative RT-PCR (Fig. 
38).  
 
Figure 38. miR-28 negatively regulates tran-
script expression of the Bcl-2 pro-survival 
gene and of NF-B2 and IKKB. Q-RT-PCR of Bcl
-2 (left graph), NF-B2 (middle) and IKKB (right 
graph) in Ramos BL cells transduced with miR-
28 or a scrambled control lentivirus and main-
tained in the presence of doxycycline for two 
days in vitro. Data are representative from 3 
independent experiments. *, p < 0.05, un-
paired t test. 
 
Overall, these results show that miR-28 expression downregulates the expression of a gene network 
downstream of BCR signaling that plays key roles in B lymphocyte proliferation and survival, and 
whose expression is frequently upregulated in GC-derived malignancies.  
2.4.3- miR-28 expression diminishes B cell proliferation  
Given that miR-28 dampens BCR signaling and targets genes involved in the regulation of cell cycle 
and survival, we next analyzed whether miR-28 expression has an impact on the proliferation of B 
cells. First, we analyzed the effect of miR-28 expression in the proliferation of non-transformed B 
cells by retroviral transduction of naive mouse splenic B cells that had been labeled with violet cell 
tracer to monitor cell division.  Interestingly, we found that mouse primary B cells overexpressing 
miR-28 had a lower proliferation index (PI) and an increased proportion of cells with low divisions (0-
2) that control B cells (Fig. 39). 
 
83 
Figure 39. miR-28 impairs proliferation of primary B cells. Splenic B cells were labeled with violet cell tracer, 
transduced with miR-28 or an empty control retroviral vector and cultured in vitro with LPS+IL4. Cell divisions 
were monitored by FACS analysis. (A) Representative histograms 2 days after retroviral transduction (open line, 
control; shaded histogram, miR-28). PI, proliferation index. (B) Quantification of the proportion of cells that 
have undergone 0 to 5 divisions. *, p < 0.05, unpaired t test. 
Next, we analyzed the impact of miR-28 expression on cell cycle and proliferation of transformed 
human BL cells. Propidium Iodide (PI) cell cycle analysis and BrdU incorporation assays in Ramos miR-
28 or control transduced RFP+ cells revealed that miR-28 expressing cells had a significant decrease in 
the proportions of proliferating cells, both in terms of reduced proportion of cells in cycling S+G2/M 
phases (p = 0.02) and a reduced proportion of BrdU incorporating cells (p = 0.0078) (Fig. 40). These 
results show that miR-28 expression reduces B cell proliferation both in primary mouse B cells and in 
transformed human B cell lymphoma.  
Figure 40. miR-28 impairs cell cycle 
progression. In vitro cultured miR-28 
or control transduced Ramos BL cells 
48h after induction with doxycycline 
were assessed for cell cycle progre-
ssion. (A) Propidium iodide cell cycle 
analysis and (B) BrdU incorporation 
assays analyzed 30 minutes after 
pulse. Representative plots are de-
picted.  Data from 4 independent 
experiments are shown. *, p < 0.05, 
unpaired t test. 
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2.4.4- miR-28 promotes apoptosis of BL cells 
 
 Next, we assessed whether the expression of miR-28 impacts cell death by apoptosis in BL cells. 
We found that miR-28 expression in Ramos BL cells promotes a significant increase in both the pro-
portions of active caspase 3+ cells (a 3.16-fold increase compared to the control; p = 0,037) and a-
nnexin V+ 7AAD- early apoptotic cells (2.1-fold increase in control versus miR-28 RFP+ cells; p = 0.015) 
(Fig. 41). Thus, these results demonstrate that miR-28 expression promotes cell death by apoptosis in 
human BL cells. 
Figure 41. miR-28 expression promotes apoptosis in Ramos BL cells. (A) Active caspase 3 (data from 6 inde-
pendent experiments) and (B) 7AAD and Annexin V stainings (data from 2 independent experiments) in in vitro 
cultured miR-28 or control transduced Ramos BL cells 48h after induction with doxycycline. Representative 
plots are shown on the left and the respective quantifications on the right. *, p < 0.05, unpaired t test. 
2.5 - miR-28 is a tumor suppressor in human GC derived neoplasms 
2.5.1- miR-28 expression impairs BL and DLBCL cell growth in vitro 
 As we have found that miR-28 impairs proliferation and survival of B cells and is frequently lost 
in human GC derived neoplasias we decided to assess whether miR-28 has tumor suppressor activity. 
First, we analyzed the effect of miR-28 replacement in the cell growth potential of different human 
BL and DLBCL lymphomas in vitro. We transduced the Ramos and Raji BL and the MD901 ABC-DLBCL 
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cell lines, with an inducible lentiviral pTRIPZ construct encoding miR-28 or a scramble control. Lympho-
ma growth was monitored by counting live cells during 5-6 days in in vitro cultures in the presence of 
doxycycline. We found that mir-28 significantly decreased the growth of all B cell lymphoma cell lines. 
MD901 ABC-DLBCL cell number was reduced by 40% and Raji and Ramos BL cell numbers were reduced 
by 45% and 77%, respectively, after 5-6 days of culture (Fig. 42A). Importantly, we found that the 
growth inhibitory effect of miR-28 expression was B cell specific, as the cell numbers of Jurkat tumoral 
T cells and NIH/3T3 fibroblasts were not affected by miR-28 expression (Fig. 42B). These results suggest 
that miR-28 acts as a tumor suppressor for GC derived B cell lymphomas.  
Figure 42. miR-28 is a tumor suppressor for GC derived B cell lymphomas. (A) GC derived human lymphoma 
cell lines MD901 (DLBCL), Raji (BL) and Ramos (BL), and (B), non B cell lines Jurkat T cell line and 3T3 fibroblasts, 
were lentivirally transduced with pTRIPZ vectors containing the miR-28 precursor sequence (purple circles) or a 
scrambled sequence as negative control (black circles). After transduction cells were selected with antibiotic, 
induced with doxycycline for two days and RFP+ cells were isolated by preparative flow cytometry. Cells were 
cultured in complete medium and cell number was calculated everyday by live cell counting. Data of at least 
two independent experiments are shown.  
2.5.2- miR-28 expression prevents BL and DLBCL growth in vivo 
 To analyze whether miR-28 impairs B cell lymphoma growth in vivo, we generated xenograft 
models of BL and ABC-DLBCL where miR-28 expression can be induced by doxycycline administration. 
First, Ramos BL cells were transduced with miR-28 or scramble pTRIPZ lentiviral vectors, selected 
with puromycin, induced with doxycyclin, and 100% pure RFP+ cells were injected subcutaneously 
into NOD Scid Gamma (NSG), immunodeficient mice. miR-28 expressing cells were injected in the left 
flank and the control RFP+ lymphoma cells were injected in the right flank of the mice (Fig. 43A). To 
ensure continuous expression of the constructs, doxycycline was added in the drinking water of the 
host mice one week prior to cell injection and maintained throughout the experiment (Fig. 43A). Tu-
mor volume was assessed every two days. Notably, we found that miR-28 expression slowed the 
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growth of Ramos (Fig. 43B) and increased the survival of mice, defined as the fraction of mice with a 
tumor burden smaller than 20 mm in any of the three dimensions (Fig. 43C). Indeed, tumor weight at 
end-point was dramatically reduced when miR-28 was re-expressed in Ramos cells, as compared to 
control transduced cells (Fig. 44). miR-28 replacement in  Raji BL and MD901 ABC-DLBCL cells also re-
sulted in a delay in tumor growth (Fig. 45), indicating that antitumoral activity of miR-28 is not restrict-
ed to a single BL cell line or to a single B cell lymphoma type.  
Figure 43. miR-28 impairs Ramos BL growth in vivo and extends the survival of transplanted mice. (A) Sche-
matic representation of the experimental approach. 107 lentivirally transduced Ramos miR-28 RFP+ (purple 
circles) and control RFP+ (black circles) cells were injected subcutaneously at each flank of NOD scid gamma 
(NSG) mice. Doxycycline was administered in the drinking water a week before injection and throughout the 
experiment. Tumor growth was monitored every two days with a caliper and volume was calculated as (width)
2 x length/2. Each dot is a tumor. (B) Tumor growth over time. Tumor volume was measured at the indicated 
times ***p < 0.001, each dot is a tumor.  (C) Kaplan-Meyer survival plot of transplanted mice. End-point was 
performed when tumors reached ≥ 20 mm in any of the 3 dimensions. Data from two independent experi-
ments are shown. P value calculated with Paired t test. 
 
Figure 44. miR-28 reduces tumor weight of BL 
xenografts. 107 lentivirally transduced Ramos miR
-28 RFP+ (closed purple circles) and control RFP+ 
(open circles) cells were injected subcutaneously 
at each flank of NSG mice. Doxycycline was ad-
ministered in the drinking water a week before 
injection and throughout the experiment. Upper 
panel, representative images of Ramos xenograft 
tumors transduced with control (upper row) or 
miR-28 (lower row) lentiviruses. Tumor weight 
(lower panel) was determined 26 days after injec-
tion, ***p < 0.001, paired t test. 
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Figure 45. miR-28 delays ABC-DLBCL and BL growth in vivo. (A) MD901 ABC-DLBCL cells and (B) Raji BL cells 
were lentivirally transduced with miR-28 (closed purple circles) or control (open circles) and 107 control or 
miR-28 cells were injected subcutaneously at each flank of NSG mice. Doxycycline was administered in the 
drinking water a week before injection and throughout the experiment. Tumors were measured with a cali-
per at the indicated times and volume was calculated (width)2x length/2. *, p < 0.05, paired t test, each dot is 
a tumor.  
Immunohistochemical analysis of the tumors revealed that miR-28 expressing Ramos BL tumors had 
reduced proportions of Ki67 proliferating cells and of Bcl-2+ cells.  In contrast, an increase in the pro-
portion of apoptotic caspase 3+ cells was observed in miR-28 expressing BL cells (Fig. 46). These re-
sults show that miR-28 is a tumor suppressor in BL and ABC-DLBCL GC-derived lymphomas and that 
its expression is sufficient to impair lymphoma establishment in vivo.
Figure 46. miR-28 expression reduces proliferation and Bcl-2 expression and increases apoptosis in BL xeno-
grafts. 107 lentivirally transduced Ramos miR-28 RFP+ (closed purple circles) and control RFP+ (open circles) cells 
were injected subcutaneously at each flank of NSG mice. Doxycycline was administered in the drinking water a 
week before injection and throughout the experiment. 26 days after injection mice were sacrificed and tumors 
were stained with the proliferation marker Ki67, with anti-Caspase-3 for apoptosis detection and with the pro-
survival factor Bcl-2. Left, representative micrographs of control and miR-28 -transduced xenografts. Right, 
quantification of Caspase-3 and Bcl-2 staining. Bars show average values, p = 0.017**, Paired t test. Scale bar is 
100 µm and 25 µm (in the inset). 
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2.6. Therapeutics of GC derived lymphomas by miR-28 replacement 
  2.6.1- Treatment of established BL xenografts by lentiviral miR-28 replacement 
 We have found that prophylactic expression of miR-28 is sufficient to impair the growth of B 
cell lymphoma in xenograft models; thus we next wanted to address whether miR-28 could be use-
ful as a therapeutic agent, to interfere with the growth of already established lymphomas. First, we 
performed lentiviral miR-28 replacement in Ramos human BL xenografts. We transduced Ramos 
cells with miR-28 or scramble lentiviral vectors, selected transduced cells in the presence of puro-
mycin and injected the cells subcutaneously into NSG mice prior to induction of the constructs with 
doxycycline treatment. Tumors were allowed to grow till they reached a volume of 200 mm3 and 
doxycycline was then administered to the mouse in the drinking water and tumor growth moni-
tored for several weeks (Fig. 47A). We found that Ramos BL tumors replaced with miR-28 expres-
sion had a significantly slower growth rate compared to control tumors (Fig. 47B and 47C). Tumor 
mass was reduced by 47%-58% in miR-28 expressing lymphoma cells at all time points analyzed (*p 
≤ 0.05). These results show that lentiviral delivery of miR-28 is therapeutically useful for the treat-
ment of established BL tumors.   
Figure 47. miR-28 impairs the growth of established human BL. (A) Schematic representation of the experi-
ment. Ramos cells were transduced with lentivirus containing miR-28 or scrambled sequences and injected 
subcutaneously in NOD scid gamma mice. miR-28 expression was induced by doxycycline administration in 
drinking water after xenografts were 200 mm3. (B) Graphs represent volume of individual tumors and aver-
age values at the indicated times before (-Dox) and after (+Dox) doxycycline administration. Note that Y axes 
on the left and right graphs are set at different scales. (C) miR-28 expression reduces tumor weight. Graph 
shows the tumor weights of Ramos xenografts (as described in (A) at day 39. Statistical significance was calcu-
lated with unpaired T test *, p < 0.05 (each dot is a tumor). 
2.6.2- Treatment of established BL xenografts by synthetic miR-28 replacement 
To avoid viral delivery to replace miR-28 expression, we assayed the therapeutic activity of syn-
thetic miR-28 mimics in a series of experiments in BL xenograft models.  miRNA mimics are ana-
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logs of the physiological miRNAs that have been chemically modified to enhance their stability (Sibley, 
Seow et al. 2010) (Yin, Kanasty et al. 2014). Wild type Ramos BL cells were injected subcutaneously in 
NSG mice, tumors were allowed to reach a volume of 200 mm3 and mice were then treated with miR-
28 mimic by intratumoral injection (Fig. 48A). Two different concentrations of miR-28 mimic (0.1 
nmoles and 0.5 nmoles) were injected intratumorally 3 times within a week. We found that treatment 
with both concentrations of miR-28 mimic delayed the growth of established BL tumors, which showed 
reduced volumes at all analyzed time points (Fig. 48B). This effect was highly statistically significant at 
end-point analysis of tumor weight (Fig. 48C). 
Figure 48. Synthetic miR-28 intratumoral administration reduces the growth of established BL tumors. (A) 
Schematic representation of the experiment. Wild type Ramos cells were injected subcutaneously into NSG 
mice, tumors were allowed to establish and synthetic miR-28 (miR-28 mimic) or scrambled control oligonucleo-
tides (mimic) was administered intratumorally. (B) Graphs show tumor volumes at the indicated times before 
and after treatment (indicated with arrows) with 0.1 nmoles mimic (left) or 0.5 nmoles mimic (right). (C) Vol-
ume-at-endpoint/volume-before-treatment ratio is represented for the indicated conditions. Statistical signifi-
cance was calculated with student’s unpaired t test. Data from two independent experiments are shown. 
We next assayed the efficacy of miR-28 mimic intravenous administration to treat human BL in xeno-
graft models. Ramos BL cells were injected subcutaneously in NSG mice and once the tumors had 
reached a volume of 200 mm3 mice were treated with miR-28 or scramble (control) mimic oligonucle-
otides (7 nmoles) by two intravenous injections separated 3 days (Fig. 49). Four days after the first 
intravenous mimic injection the slower growth of miR-28 treated mice was already notable (Fig. 
49B). To determine if intravenous miR-28 mimic administration entails organic toxicity we performed 
histopathological and biochemical analysis of miR-28 and control-treated NGS mice. Histopathologi-
cal analysis of kidney, liver, heart and spleen showed no evidence of macroscopic or microscopic to-
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xicity (not shown).  Likewise, we found no evidence of hematologic, renal or hepatic toxicity, as deter-
mined by complete blood counts, blood chemistry, liver function tests and thyroid hormone testing 
(Table 9). These data indicate that treatment of BL by intravenous administration of synthetic miR-28 
mimic is not associated to a significant toxic activity. 
Figure 49. Intravenous injection of synthetic miR-28 (miR-28 mimic) reduces the growth of BL xenografts. 
(A) Schematic representation of the experiment. Ramos BL xenografts were established by injecting subcu-
taneously the BL cells in NOD scid gamma mice and treated by intravenous administration of miR-28 or 
scrambled (control) mimic oligonucleotides (7 nmoles). (B) Graph shows tumor volumes at the indicated 
times. Statistical significance was calculated with student’s unpaired T test, **p < 0.005. 
Table 9. Biochemical analysis of BL xenografted NGS mice intratumorally treated with miR-28 or 
control mimic. 
2.6.3- Primary BL treatment by miR-28 replacement with synthetic miR-28 mimic 
 To extend our study of miR-28 therapeutic potential to primary lymphomas we made use of 
the lambda/MYC (-MYC) transgenic mouse model (Kovalchuk, Qi et al. 2000), in which the Myc pro-
to-oncogene is constitutively expressed under the regulatory elements of the immunoglobulin  light 
chain gene and recapitulates in the mouse much of the pathogenesis of human BL. First, we analyzed 
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miR-28 expression in naïve B cells, normal GC B cells and tumoral B cells from -MYC mice, and ob-
served that expectedly, miR-28 is upregulated in normal GC B cells. Importantly, and in agreement with 
the human lymphoma data, miR-28 is lost in transformed B cells, thus validating the use of the  MYC 
model for our analysis (Fig. 50). 
Figure 50. miR-28 expression is downregulated 
in B cell lymphomas developed in λ-MYC trans-
genic mice. Quantitative RT-PCR analysis show-
ing miR-28 expression in naïve B cells and GC B 
cells sorted from Peyer’s patches of young λ-
MYC mice and in B cell tumors from older λ-MYC 
mice. 
To assess the therapeutic potential of miR-28 replacement therapy in primary BL in vivo we used 
-MYC mice as donors of primary BL lymphomas, which we employed to generate local and syste-
mic BL models in NSG host mice. In the local tumor model we performed subcutaneous injection of 
-MYC BL cells and 0.5 nmoles of miR-28 mimic was administrated intratumorally 3 times within a 
week (Fig. 51A). We observed from 3 days after the first mimic injection of primary BL (from d10, 
Fig . 51B) that miR-28 treated tumors showed a clear growth reduction and were significantly 
smaller than those in mice treated with control miRNA mimics at the end of the treatment (Fig. 
51C).  
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Figure 51 (continuation); Synthetic miR-28 intratumoral administration reduces the volume of murine prima-
ry BLs. (A) Schematic representation of the experiment. Subcutaneous mouse lymphomas were established 
by injection of 107 cells from enlarged spleen and/or lymph nodes of sick λ-MYC transgenic mice. Once tumors 
were detectable (> 200mm3), miR-28 or control mimics were administered intratumorally at 0,5 nmoles in 50 µl 
at the indicated days. (B) Tumor volume over time. The arrows indicate mimic injection days. (C) Representa-
tive tumor photos and quantification of the tumor mass. Statistical significance was calculated with student’s 
unpaired T test, *p < 0.05. 
In the systemic primary BL model, we performed intravenous injection of BL cells from enlarged 
spleens or lymph nodes from sick -MYC mice into NSG recipient mice and miR-28 mimics or scram-
ble control were administrated intravenously 7 nmoles of miR-28 mimic or control mimic at day 10 
and 14 after tumor injection (Fig. 52A). Recipient mice were sacrificed 17 days after the injection of 
the primary BL cells and the effect of miR-28 on BL growth was assessed. We found that the spleens 
of the mice treated with miR-28 mimics were notably smaller than those treated with control mimic 
(Fig. 52B) and contained a reduced proportion of BL B cells (Fig. 52C). Immunohistochemistry analy-
sis of the spleens revealed that mice treated with miR-28 mimic had increased proportions of caspa-
se 3+ apoptotic cells.  
Figure 52. Intravenous delivery of miR-28 mimic reduces the volume of mouse primary lymphomas.  
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Figure 52 (continuation); (A) Schematic representation of the experiment. 2x106 tumor cells from enlarged 
spleen and/or lymph nodes of -MYC transgenic mice were injected intravenously into NSG recipient mice and 
treated with intravenous injection of miR-28 mimic or scrambled control 10 days and 14 days after tumor injec-
tion. (B) Spleen weight quantification and representative spleen images obtained from mice after treatment. (C) 
Percentage of lymphoma B cells in the blood of transplanted mice treated with control or miR-28 mimics. Open 
circles, scrambled control-treated, closed purple circles, miR-28-treated. Student t test (5 mice per group). (D) 
Left, representative images of caspase 3 staining at 10X and 40X magnification (inset). Right, quantification of 
caspase 3 positive cells. Scale bar is 100 µm and 25 µm for the insets. *p < 0.05, unpaired t test.  
 In summary, we have used a number of different in vivo lymphoma models (including human 
BL and DLBCL xenografts and primary BL allografts) and different methods to achieve miR-28 expres-
sion in lymphoma cells (including lentiviral transduction, intratumoral and intravenous synthetic miR-
28 administration) to assess the therapeutic potential of miR-28 in GC-derived lymphomas. Our re-
sults show that miR-28 replacement therapy is effective for the treatment of GC-derived neoplasms 
and provide a promising and novel approach for the treatment of human B cell NHLs.  
    DISCUSSION 
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 In this thesis work we have focused on understanding the role of miR-217 and miR-28 as regu-
lators of the biology of GC B cells, and on their putative contribution to mature B cell lymphomagene-
sis. Interestingly, we have found that miR-217 and miR-28 have antagonistic functions; while miR-217 
is a positive regulator of the GC reaction and promotes B lymphomagenesis, miR-28 is a negative re-
gulator of the GC reaction with tumor suppressor activity in mature B cell lymphomas (Fig. 53). In ad-
dition, we have explored whether miR-28 re-expression in lymphomas can be a useful strategy to de-
velop new therapeutic approaches.  
Figure 53. Working model for miR-217 and miR-28 control of the GC reaction and B cell lymphomagenesis. 
Both miR-217 and miR-28 are expressed in GC B cells and are needed to ensure a proper immune response 
against T cell dependent antigens. miR-217 is a positive regulator that boosts the GC response by dampening 
DDR and stabilizing Bcl-6. Importantly, miR-217 is an oncomiR whose overexpression causes mature B cell lym-
phomas. miR-28 is a negative regulator of GC that reduces B cell proliferation and BCR signaling, and promotes 
apoptosis in both murine and human B cells. The relevance of our findings is highlighted by the fact that the 
expression of both miR-217 and miR-28 are deregulated in human GC derived malignancies; miR-217 is overex-
pressed in certain types of aggressive B cell lymphomas, while miR-28 expression is absent in a wide range of B 
cell neoplasms. Moreover, we have successfully explored the therapeutic benefit that miR-28 replacement (by a 
synthetic miR-28 mimic as it is depicted in the model, or by other techniques) in lymphoma cells could have to 
treat this kind of aggressive cancer type, opening new treatment possibilities against mature B cell lymphomas. 
 1. miR-217 is a positive modulator of the GC reaction 
We have identified miR-217 as a positive regulator of the GC reaction. miR-217 is specifically 
upregulated as a result of B-cell stimulation in the context of the GC reaction during the immune re-
sponse, and the gain and loss of function approaches developed in the study directly establish the 
functional relevance of miR-217 in vivo. We generated mature B cell specific miR-217 overexpressing 
mouse models. miR-217 overexpression boosted the number of GC B cells and promoted the SHM 
and CSR reactions, and conversely, inhibition of endogenous miR-217 limited these events. Inter-
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estingly, miR-217 gain of function did not promote any measurable alterations in B-cell differentiation, 
suggesting that the function of miR-217 in the B-cell lineage is restricted to the context of GCs and anti-
body diversification.  
 
  2. Molecular mechanisms of miR-217 activity 
On the basis of sequence complementarity, individual miRNAs can be predicted to target hun-
dreds or thousands of mRNAs, a finding that very early led to the development of in silico prediction 
tools to facilitate the task of miRNA-target identification. However, these prediction analyses of miRNA 
targets suffer from a high rate of false positives, due to the incomplete sequence complementarity be-
tween miRNAs and their targets and the large heterogeneity of 3’ UTRs, as revealed by next generation 
sequencing technology (Yatsenko, Marrone et al. 2014) (Mihailovich, Bremang et al. 2015). In addition, 
a substantial fraction of these predicted interactions may depend on cell type and context (Bartel 
2009) (Ebert and Sharp 2012) (Pelaez and Carthew 2012) and on the binding of additional cofactors 
(Lujambio and Lowe 2012). Furthermore, an even smaller subset of target interactions is expected to 
affect tumor development and progression in vivo.  These limitations make it critical to combine in sili-
co predictions with experimental data. In our case, we performed genome wide analysis of the B cells 
transcriptomes upon perturbation of miR-217 levels in GC B cells and merged the results with those 
obtained with a compound algorithm for miRNA target prediction. 
 
Our analysis performed in GC B cells from miR-217KI  and littermate controls showed that miR-217 regu-
lates the expression of a gene network involved in DDR and repair, including Rad50, Nbs1, Wrn, Lig4, 
and XRCC2, as well as a set of genes of the cohesin complex, all of which are downregulated by miR-
217. GC B cells are intrinsically prone to genome instability: (1) they are programmed to undergo AID-
mediated gene remodeling; (2) the intense proliferation of GC B cells subjects them to replicative 
stress (Victora and Nussenzweig 2012); and (3) the GC reaction depends on Bcl-6, a master transcrip-
tional repressor that dampens the DDR in GC B cells and whose deregulation generates B-cell lympho-
mas (Pasqualucci, Bhagat et al. 2008) (Cattoretti, Pasqualucci et al. 2005). Our data show that miR-217 
downregulates a network of genes that sense and repair genotoxic events on DNA, which in turn can 
increase the tolerance of GC B cells to DNA damage, very much like Bcl-6. Notably, we found that miR-
217 protects Bcl-6 from genotoxic stress-induced degradation (Phan, Saito et al. 2007), suggesting that 
both molecules are part of the same network that renders GC cells permissive to genomic instability 
and prone to malignant transformation. 
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 3. miR-217 is an oncogene in B cells 
 Consistent with the idea that miR-217 diminishes DDR and stabilizes Bcl-6 in B cells we found 
that miR-217 overexpression promotes B-cell lymphomagenesis. Interestingly, mice that overexpress 
miR-217 resemble Bcl-6-overexpressing Iµ-HABCL6 mice in that both show increased GC formation and 
develop long latency mature B-cell lymphomas (Cattoretti, Pasqualucci et al. 2005). We also found that 
Ink4a/Arf but not p53 loss sensitizes B cells to miR-217-promoted lymphomagenesis. Although it is po-
ssible that a protective role of p53 is masked by the early appearance of T-cell lymphomas in p53-/- 
mice, our data suggest that Ink4a rather than the Arf-p53 oncogenic stress pathway plays the predomi-
nant role in protecting GC B cells against the transforming activity of miR-217. This result is in agree-
ment with the finding that Ink4a protein is frequently lost through gene methylation or deletion in a-
ggressive B-cell lymphomas, whereas ARF silencing is a rarer event (Baur, Shaw et al. 1999). 
Deregulation of miRNA expression in human B-cell lymphomas has been extensively documented 
(Eis, Tam et al. 2005, Lawrie, Soneji et al. 2007) (Xiao, Calado et al. 2007) (Calin, Dumitru et al. 2002)
reviewed in the introduction, Table 1). In some instances, the functional relevance of miRNA deregu-
lation has been tested in genetically modified mouse models ((Medina, Nolde et al. 2010) (Costinean, 
Zanesi et al. 2006) (Enomoto, Kitaura et al. 2011) (Santanam, Zanesi et al. 2010) reviewed in the in-
troduction, Table 2). This gives formal proof of the lymphomagenic potential of the miRNA. Prior to 
our work, evidence for miRNAs involved in GC or post-GC lymphomagenesis was absent. During this 
years a significant amount of papers have appeared regarding the lymphomagenic potential of miR-
17-92, which is far restricted to the combined action of the whole miR-17-92 miRNA cluster to give 
rise to DLBCL in a frequency of 10% (while around 30% of the ill mice had leukemias) (Sandhu, Fassan 
et al. 2013). Other mouse models of miRNA deregulation that give rise to mature B cell lymphomas 
combine the overexpression of some members of the miR-17-92 cluster with the expression of Myc 
oncogene (He, Thomson et al. 2005). In our work we have found that miR-217 overexpression in B 
cells promotes lymphomas of GC or post-GC origin, what supposes the 92% of the generated lympho-
mas, most likely by impinging on the regulation of the DDR and Bcl-6. Accordingly, we found in-
creased levels of miR-217 in BL and DLBCL, two of the most aggressive lymphomas arising from GCs. 
Overall, our results identify miR-217 as a novel molecular link between the GC response and B-cell 
transformation, provide an in vivo model of mature B-cell lymphomagenesis and point to miR-217 
inhibition as a potential new therapeutic strategy for the treatment of two aggressive subtypes of 
human mature B cell lymphomas. 
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 4. miR-28 is a GC miRNA 
 We initially selected miR-28 as a potentially relevant miRNA for GC reaction from a very exten-
sive miRNA-Seq study that characterized the miRNA profile in human and mouse lymphopoiesis 
(Kuchen, Resch et al. 2010) and where miR-28 was found as being highly expressed in GC B cells from 
immunized mice. We confirmed these results and additionally found that miR-28 expression is transi-
ent –it is shut down when the B cells exit the GC- and that its expression is progressively increased with 
the progression of the GC reaction.  
Interestingly, miR-28 was not identified in our original expression profiling performed in in vitro acti-
vated B cells that served for miR-217 identification (de Yebenes, Belver et al. 2008). Likewise, miRNA-
seq analysis of B cells activated in vitro failed to detect a significant increase of miR-28 levels ((Kuchen, 
Resch et al. 2010) and our unpublished results). This apparent contradiction very likely reflects that in 
vitro conditions for B cell stimulation, although experimentally useful, are not completely faithful in 
mimicking the transcriptional program induced in an in vivo immune response, including the expres-
sion of miR-28. Although we have not approached the regulation of miR-28 expression, it is plausible 
that costimulatory molecules that mediate B-T cell crosstalk in vivo could be triggering regulatory ele-
ments involved in its transcriptional activation.   
 
 5. miR-28 is a negative regulator of GCs 
 We next analyzed the role of miR-28 in mature B cell activation and the GC reaction. Using in 
vitro miR-28 gain of function assays we found that miR-28 expression negatively regulates CSR; which 
implies that even though miR-28 is not naturally induced in these conditions, some or all of its targets 
must be expressed in vitro that exert the miRNA’s functional effect. Conversely, loss of function miR-28 
vivo assays show increased CSR, GC and PC B cell generation. Our results reveal that miR-28, a GC spe-
cific miRNA, is a negative regulator of the GC reaction in B cells may seem counterintuitive. We hypo-
thesize that miR-28 expression could be required to limit or finish GC reactions in vivo, and that this 
negative regulation would represent a brake for B cell transformation. In agreement with this idea, we 
detect that miR-28 expression is a late event during the progression of the GC, and that the loss of miR-
28 expression is a frequent event in mature B cell neoplasms, as discussed below. 
 
 6. miR-28 is lost in GC-derived neoplasms 
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 A notable feature of miR-28 expression is its strong downregulation in an extensive variety of 
human mature GC-derived B cell neoplasms; including CLL leukemia and various B cell NHL subtypes, 
such as FL and the aggressive DLBCL and BL. This observation is in agreement with the finding report-
ed during the development of this work by K. Basso and co-workers, which showed reduced miR-28 
expression in various human GC-derived lymphomas (Schneider, Setty et al. 2014). We found that miR
-28 expression is lost both in primary tumor biopsies as well as in a variety of immortalized cell lines 
derived from BL and DLBCL human B cell lymphomas. In addition, we found that miR-28 expression is 
downregulated in tumoral B cells from -Myc transgenic mouse. Interestingly, miR-28 dowregulation 
in this BL mouse model occurs only in transformed BL cells, as miR-28 downregulation is not observed 
in non tumoral  -Myc TG+ GC B cells. The specific loss of miR-28 expression in GC-derived B cell neo-
plasms suggests that miR-28 could be a tumor suppressor for GC B cells. 
Although the mechanisms that account for the loss of miR-28 expression in GC-derived neoplasms 
have not been addressed specifically, there are some evidences that point to genomic deletions and 
transcription factor deregulation as plausible mechanisms. miR-28 is an intronic miRNA, encoded in 
the Lipoma Preferred Partner (LPP) gene on chromosome 3q27, and very close to the Bcl-6 gene. Ge-
nomic deletions affecting the LPP locus have been reported in FL (Schwaenen, Viardot et al. 2009). 
Moreover, a genomic region that is likely involved in regulating miR-28 and LPP expression has been 
identified as a susceptibility locus associated with increased risks of B cell NHL, such as DLBCL, in the 
Chinese population (Tan, Foo et al. 2013). In addition, K. Basso and co-workers have found that Myc 
expression negatively regulates the expression of LPP and miR-28 (Schneider, Setty et al. 2014). As 
Myc gain of expression is a common event in a proportion of GC-derived lymphomas, mainly BL and 
ABC-DLBCL, it would expectably contribute to miR-28 downregulation. Nevertheless, we have found 
here that in -MYC mice the loss of miR-28 expression is an event that associates with B cell transfor-
mation, suggesting that increased Myc expression alone is not sufficient to result in impaired miR-28 
expression in vivo.  
 
 7. Molecular mechanisms of miR-28 activity 
 To identify the genes regulated by miR-28 expression in B cells we have combined genome wide 
transcriptomic analysis by RNA-Seq with quantitative proteomic profiling analysis by iTRAQ. As gene 
expression regulation by miRNAs can involve either diminishing mRNA stability or inhibiting mRNA 
translation, transcriptome profiling alone would fail to detect genes regulated by translational inhibi-
tion (Selbach, Schwanhausser et al. 2008) (Mihailovich, Bremang et al. 2015). On the other hand, gi-
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ven the relatively subtle changes in gene expression promoted by miRNAs, proteome analysis would 
very likely miss a number of targets for lack of enough sensitivity. Therefore we decided that the com-
bination of these two techniques was the preferable choice for miRNA target identification. Notably, 
we have found a high overlap in the cellular function of the genes regulated by miR-28 both at the 
transcriptome and at the proteome level. Our results show that miR-28 expression in BL B cells regu-
lates genes involved in immune system regulation, cell cycle and proliferation, DNA replication, recom-
bination and repair, and cell death by apoptosis. Importantly, we have functionally verified that miR-28 
expression impacts proliferation and apoptosis in both human and mouse B cells, as we find that miR-
28 expressing B cells have reduced proliferation and increased cell death in vitro and in vivo. 
Causal network analysis of proteome profiling has shown that miR-28 significantly alters the expression 
of genes involved in the BCR signaling network, the key signaling pathway that regulates B cell prolife-
ration and cell death. We have found that tonic and anti-IgM mediated BCR signaling is dampened in 
miR-28 expressing B cells, as we find reduced phosphorylation of key mediators of the BCR signaling, 
such as AKT and ERK, reduced expression of NF-ҚB2 and IKKB mediators and of the anti-apoptotic 
effector Bcl-2. Therefore, our data support the notion that miR-28 modulates the strength of BCR sig-
naling promoting a deficient or slower proliferative activity together with impaired survival, which in 
turn would account for the defect in CSR  (Rush, Liu et al. 2005) (Celeste, Petersen et al. 2002) . Howe-
ver, we cannot rule out that other targets, unrelated to BCR signaling could also contribute to the func-
tional effect of miR-28. 
Importantly, BCR signaling has also been shown to play a central role the survival of neoplasic B cells. 
Indeed several B cell lymphomas, such as BL (Schmitz, Ceribelli et al. 2014) (Rickert 2013) and DLBCL 
(Young, Shaffer et al. 2015) (Davis, Ngo et al. 2010) rely on BCR signaling to sustain lymphoma growth. 
Accordingly, different current therapeutic strategies for mature B cell lymphoma treatment are based 
in the inhibition of key intermediates of the BCR signaling network such as NF-қB and IKKB (Baldwin 
2001) (Ceribelli, Kelly et al. 2014).  
Overall our expression profiling shows that miR-28 regulates a number of key physiological processes 
in GC B cells, including BCR signaling, proliferation and apoptosis, that are required to fine tune and 
limit the extent of GC responses. In addition, these results suggest that miR-28 could have tumor su-
ppressive activity for GC derived B cell tumors. 
 8. miR-28 tumor suppressive activity in GC B cells 
 Two important evidences obtained during the development of the project suggested that miR-28 
could have tumor-suppressor activity in GC derived tumors: (1) the finding that miR-28 promotes cell 
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death, reduces proliferation and dampens BCR signaling in immortalized BL cells suggest that miR-28 
expression could impair B cell lymphoma growth; and (2) the loss of miR-28 expression in a large num-
ber of GC-derived human B cell neoplasms, as well in mouse BL cells, suggests that miR-28 could be a 
tumor suppressor for B cell tumors. 
Although formal proof that miR-28 is a tumor suppressor miRNA for GC B cells would require the deve-
lopment of loss of function mouse models in which the absence of miR-28 expression in GC cells leads 
to B cell lymphomagenesis, the results obtained in this work unequivocally demonstrate that miR-28 
expression has tumor suppressor activity in GC-derived BL and DLBCL lymphomas.  
We have tested the tumor suppressor potential of miR-28 by replacing miR-28 expression in GC-
derived lymphomas where its expression had been lost –presumably during the transformation pro-
cess. We found that miR-28 re-expression promotes a dramatic block in tumor growth in vitro and in 
xenograft models. miR-28 re-expression diminishes proliferation and promotes apoptosis of lymphoma 
cells in vivo, as revealed by decreased Ki67 and increased active caspase 3 expression in BL xenografts. 
It is very likely that different genes found to be regulated by miR-28 in BL cells, including elements of 
the BCR signaling pathway such as AKT, ERK, IKKB, NF-қB2 and Bcl-2 account for miR-28 tumor suppres-
sor activity, as they have been shown to be involved in the establishment or maintenance of different 
GC-derived lymphomas. For example, constitutive activation of BCR pathway has been reported in BL 
and in DLBCL, correlating with a poor clinical outcome (Kloo, Nagel et al. 2011)  (Sander, Calado et al. 
2012) (Schmitz, Young et al. 2012). ABC-DLBCL, which is one of the lymphomas with a poorer prognosis 
and a high incidence of relapses, has gain of function mutations that enhance the PI3K signaling and NF
-қB signaling (Davis, Ngo et al. 2010) (Kloo, Nagel et al. 2011) (Young, Shaffer et al. 2015). In addition, 
the anti-apoptotic effector Bcl-2 has been shown to be a clinically relevant target for the treatment of a 
significant number  of GC-derived B cell neoplasms (reviewed in (Braun, de Carne Trecesson et al. 
2013) (Musilova and Mraz 2015) (Lin, Mao et al. 2015)).  Importantly, we found decreased Bcl-2 ex-
pression in BL xenografts overexpressing miR-28, indicating that one of the mechanism that con-
tributes to miR-28 induced apoptosis of lymphoma cells in vivo is the downregulation of the anti-
apoptotic effector molecule Bcl-2.  
Here we have been able to show lymphoma growth block by miR-28 both when using viral vehicles and 
with miRNA mimics, which are thought to be the safest way to reintroduce a miRNA in a therapeutic 
setting. In addition, we found that both intratumoral and intravenous administration of miR-28 mimic 
were effective to reduce BL growth in vivo. Interestingly, the growth inhibiting effect of miR-28 expres-
sion seems to be B cell specific, as other types of transformed cells such as Jurkat T cells or NIH 3T3 
fibroblasts were not affected in their growth by miR-28 overexpression. In addition, we found no evi-
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dence of hematologic, renal or hepatic toxicity associated to in vivo mi-28 mimic administration, sug-
gesting that this approach could be a feasible therapeutic strategy for mature B cell lymphoma treat-
ment. Although therapeutic development requires a number of exhaustive analysis to thoroughly 
prove the safety of the treatment, our data, together with the point that this therapeutic strategy aims 
at replacing the normal levels of miR-28 that were once lost by the tumor cells rather than at a broad 
elimination of B cells, suggest that the toxicity of miR-28 will be considerably lower than current strate-
gies for the treatment of B cell neoplasms. 
In this regard, it is important to note that BL and DLBCL are often refractory to conventional chemo-
therapy, usually based on R-CHOP administration (Lenz, Wright et al. 2008) (Flodr, Latalova et al. 2014). 
In recent years the functional impact of miRNAs in cancer development have made them very attrac-
tive candidates for therapeutic strategies (Review in (Braicu, Calin et al. 2013) (Bader, Brown et al. 
2010)). miRNA-based therapeutics can provide a higher level of target specificity compared to other 
chemotherapy agents, thanks to the intrinsic sequence-dependent targeting of microRNAs. In addition, 
the potential to simultaneously regulate multiple pathways and processes altered in cancer may make 
miRNA-based therapy less susceptible to developing drug resistance. Indeed, a number of microRNA 
inhibitors are already in clinical trials, and one clinical trial is also approved for the use of miR-34 mimic 
for the treatment of hepatocarcinoma. A next stage towards a clinical application of miR-28 replace-
ment therapy would involve to compare miR-28 replacement and conventional R-CHOP treatment in 
terms of efficacy and toxicity, as well as to assess whether the combination of both therapeutics can 
improve the efficacy of the individual treatments. In addition, the finding that miR-28 expression is lost 
also in other B cell neoplasms, such as FL and CLL, makes it likely that miR-28 based therapeutic ap-
proaches could be useful to treat a wider range B cell neoplasms. 
 
 9. Final considerations 
 Overall, our work has identified miR-217 and miR-28 as crucial modulators of the GC response 
and whose deregulation is mechanistically linked to the generation of GC-derived B cell neoplasms. In 
addition, our work provides the generation of new tools that can be useful for the development of in-
novative therapeutic strategies for the treatment of B cell NHL; a novel mouse model of GC derived 
lymphomagenesis based on B cell specific miR-217 overexpression and the experimental basis for the 
development of miR-28 replacement therapies.  
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1. miR-217 is a positive regulator of the GC reaction that promotes CSR, SHM and the generation of     
GC B cells.  
 
2. miR-217 regulates a DNA damage response and repair gene network and stabilizes Bcl-6 in GC B 
cells.  
 
3. miR-217 is an oncogene in mature B cells and is overexpressed in aggressive human B-cell lympho-
mas.  
 
4. The generation of mature B cell specific miR-217 overexpressing mice provides an in vivo model of 
GC-derived B cell lymphomagenesis.  
 
5. miR-28 is a negative regulator of the GC reaction that inhibits CSR and the generation of GC B cells. 
 
6. miR-28 is lost in various human GC derived malignancies, including BL, DLBCL, FL and CLL.  
 
7. miR-28 expression dampens BCR signaling, inhibits proliferation and induces cell death in human 
and mouse B cells.  
 
8. miR-28 re-expression in lymphoma cells inhibits tumor growth, which indicates that it has tumor 
suppressor activity and opens the possibility of a new therapeutic strategy for the treatment of matu-
re B cell neoplasms.  
 
9. miR-217 and miR-28 molecularly link the GC reaction and B cell lymphomagenesis. 
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CONCLUSIONES 
 
1. miR-217 es un regulador positivo de la reacción de centro germinal, cuya expresión promueve la 
reacción de cambio de isotipo, la hipermutación somática y la generación de células B de CG.  
 
2. miR-217 atenúa la expresión de una red de genes implicados en la respuesta al daño y la reparación 
del ADN, y estabiliza la expresión de Bcl-6 en células B de CG.  
 
3. miR-217 es un oncogén en linfocitos B maduros y su expresión se encuentra incrementada en linfo-
mas B agresivos humanos.  
 
4. La generación de un modelo murino de sobre-expresión de miR-217 específico de linfocitos B madu-
ros provee de un modelo in vivo de linfomas B derivados de CG.  
 
5. miR-28 es un regulador negativo de la reacción de centro germinal que inhibe la reacción de cambio 
de isotipo y la generación de células B de CG. 
 
6. La expresión de miR-28 se pierde en varias neoplasias humanas derivadas de CG, incluyendo BL, 
DLBCL, FL, y CLL.  
 
7. La expresión de miR-28 disminuye la señalización a través de BCR, inhibe la proliferación e induce la 
muerte celular en células B murinas y humanas.  
 
8. La re-expresión de miR-28 en células de linfoma inhibe el crecimiento tumoral, lo que indica que miR
-28 tiene actividad supresora de tumores y abre la posibilidad de una nueva estrategia terapéutica pa-
ra tratar neoplasias B maduras.  
 
9. miR-217 y miR-28 vinculan a nivel molecular la reacción de CG y los procesos linfomagénicos de los 
linfocitos B.  
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   ANNEX 
 Gene Fold_Change P_Value 
ankrd55 -6,82 0,01 
acacb 6,51 0,02 
utp20 -6,10 0,00 
ccdc33 6,29 0,03 
trcg1 -5,74 0,03 
tsnaxip1 -5,33 0,01 
kcne3 7,28 0,00 
stx19 -7,30 0,00 
prkx -6,66 0,00 
dusp28 -3,05 0,05 
cldn23 -7,46 0,00 
lrrc7 4,46 0,02 
map3k2 3,30 0,03 
slc34a2 -4,19 0,01 
xkr9 -7,77 0,00 
setmar 4,24 0,01 
cd5 3,58 0,02 
tspan1 -6,44 0,02 
gm15760 -5,57 0,01 
4933439k11rik -5,83 0,03 
glyctk 3,37 0,04 
ush2a -6,01 0,03 
olfr352 7,99 0,00 
clcn1 7,28 0,00 
d630037f22rik -4,03 0,02 
gm5420 -6,09 0,03 
slc2a5 -6,01 0,02 
lrrc36 -7,61 0,00 
fbxo48 -5,10 0,01 
nbn -3,44 0,03 
ccdc57 -6,67 0,01 
olfr1507 7,07 0,01 
rnd3 5,72 0,04 
oplah 8,47 0,00 
gm10336 -5,93 0,03 
csrnp3 -6,72 0,01 
hiatl1 -3,46 0,04 
ifrd1 -5,00 0,01 
dsg4 6,70 0,02 
ugt1a9 -7,00 0,01 
obfc2a -6,36 0,00 
zfp661 6,21 0,02 
Annex 1.Table of the differentially expressed genes in miR-217TG GC B cells vs Control GC B cells 
tbc1d24 3,27 0,05 
zfp407 -4,03 0,03 
fam199x -3,37 0,04 
cbs -6,31 0,03 
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gm10565 7,51 0,00 
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mir217 7,73 0,00 
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syt4 -6,31 0,02 
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map4k5 -3,88 0,04 
rab17 -6,01 0,04 
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slc10a1 -5,52 0,04 
rttn -4,79 0,01 
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1700054n08rik 3,48 0,03 
olfr1120 -6,24 0,02 
cldn4 -6,38 0,01 
gm5077 -5,63 0,05 
odz4 -3,51 0,05 
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dnajc6 -5,74 0,05 
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etv1 7,51 0,00 
lynx1 -6,24 0,02 
actn1 -4,04 0,03 
4930570g19rik -5,63 0,04 
4930558g05rik -5,63 0,04 
zfp354c -5,63 0,04 
slc10a2 6,37 0,02 
olfr456 -5,93 0,03 
gm6320 -5,63 0,04 
mfsd6 -4,26 0,03 
tnfrsf11a 4,52 0,01 
zfp940 -5,03 0,01 
qpct -7,20 0,01 
usp44 -6,72 0,01 
loc100504608 5,83 0,05 
atp2b4 -5,63 0,05 
efcab4b -6,77 0,01 
4933411g11rik 4,09 0,02 
scube2 5,83 0,05 
spic 6,70 0,02 
olfr1188 -6,50 0,01 
slc6a13 -6,24 0,02 
st8sia4 -6,01 0,00 
trim33 -4,14 0,02 
mmp16 -6,01 0,04 
aqp4 -7,34 0,01 
5730577i03rik 3,99 0,05 
csnk1g3 -7,52 0,00 
b3gnt1 -3,37 0,04 
slamf8 3,81 0,03 
ndst3 -6,09 0,02 
siah1b -3,52 0,04 
tram2 -6,38 0,01 
drd1a 5,85 0,00 
atp8b1 -6,62 0,01 
scg5 -6,01 0,03 
ky -5,03 0,01 
gatm -4,28 0,01 
dok2 -3,56 0,04 
diap3 -4,19 0,02 
polq -6,01 0,03 
zfp52 -8,71 0,00 
olfr878 3,77 0,03 
klf17 7,12 0,01 
vwce -6,24 0,03 
1700074p13rik 8,11 0,00 
slc9a3r2 6,29 0,02 
alk 4,68 0,03 
slc30a9 4,74 0,01 
zfp85-rs1 -6,91 0,01 
egfl7 -7,55 0,00 
gpx7 7,73 0,00 
gramd2 -6,77 0,01 
4933413g19rik 6,29 0,03 
5430427o19rik -5,53 0,00 
spata19 -5,63 0,04 
lpar3 6,70 0,01 
mgat3 8,07 0,00 
map3k7 -5,39 0,00 
ptbp2 -7,37 0,01 
cyp2d22 -5,93 0,03 
cct6b -5,74 0,03 
d330045a20rik -5,83 0,03 
magi3 -6,37 0,00 
senp8 -9,06 0,00 
elmod2 -7,74 0,00 
tppp3 -6,01 0,02 
zdhhc13 -4,26 0,02 
bbs10 -8,63 0,00 
pias2 -3,44 0,03 
rdh16 6,70 0,01 
gstm2 -5,63 0,05 
cypt3 -6,72 0,01 
1300017j02rik 6,13 0,03 
cbln2 -6,87 0,01 
prss55 6,03 0,02 
ankar -6,31 0,02 
fbln7 -6,09 0,03 
armc4 -6,01 0,03 
rasal1 -5,04 0,01 
liph -6,82 0,01 
pgc -5,74 0,03 
oas2 -6,31 0,02 
capn5 -4,71 0,01 
slc15a1 -3,47 0,05 
samd3 7,70 0,00 
jam3 -6,77 0,01 
plekha3 -3,97 0,02 
dnmt3a -3,88 0,02 
sos1 -4,26 0,02 
gm1322 -7,88 0,00 
serpinc1 7,02 0,01 
hyal1 -7,23 0,00 
2610018g03rik -8,26 0,00 
olfr1444 -6,72 0,01 
atp11c -8,28 0,00 
gm505 -6,17 0,02 
jrk -4,17 0,02 
cenpo -3,16 0,05 
shq1 -5,97 0,00 
bc030307 6,13 0,03 
ikbke -7,04 0,01 
dgkh -7,40 0,01 
cngb3 3,74 0,05 
armcx5 -4,32 0,01 
pus3 -9,48 0,00 
dnaja4 4,02 0,02 
als2cr11 -5,74 0,05 
phkb -4,71 0,02 
adra1a -6,01 0,02 
kif17 8,22 0,00 
gm5127 6,40 0,00 
pter -7,81 0,00 
mlh3 -6,25 0,00 
pank3 -4,93 0,01 
cd36 -6,50 0,00 
0610007p08rik -3,57 0,04 
tmem151b -7,23 0,00 
kcna1 -6,17 0,02 
rdh5 -6,31 0,02 
ces1g 6,58 0,02 
hsd3b3 -7,16 0,01 
0610040j01rik -5,09 0,01 
eif2c4 -4,43 0,03 
zfp941 6,98 0,01 
abca17 7,07 0,01 
cln8 -6,44 0,01 
lcor 6,65 0,00 
il18r1 -6,96 0,01 
gm10767 6,92 0,01 
a230046k03rik -5,89 0,00 
zfp119b -8,04 0,00 
epha10 -7,20 0,00 
nr6a1 -3,27 0,03 
2210019i11rik 7,24 0,01 
tmem67 -8,49 0,00 
cntn3 -6,96 0,01 
4930542c21rik -5,83 0,04 
cyp7a1 -6,96 0,01 
lpcat2 5,09 0,01 
golt1a -4,63 0,02 
bend4 7,47 0,01 
slamf9 -7,12 0,01 
smpd3 -3,63 0,04 
zfp420 -6,96 0,01 
olfr262 -7,37 0,00 
dmbt1 -5,93 0,04 
sag 6,08 0,00 
ttc37 5,01 0,01 
arhgap28 5,49 0,01 
a630033h20rik -6,56 0,01 
ints6 -3,18 0,04 
ppp1r3c 8,43 0,00 
enc1 -6,01 0,04 
erap1 -3,59 0,04 
ypel1 6,51 0,02 
rph3al -5,83 0,03 
eea1 -5,17 0,01 
rapgefl1 -7,23 0,00 
tas2r125 -7,00 0,01 
hyls1 -8,53 0,00 
col5a2 6,21 0,02 
spin2 -6,56 0,02 
ebf4 -6,01 0,02 
efhd1 -6,38 0,01 
af529169 -6,56 0,01 
fam45a -4,95 0,01 
fermt2 5,94 0,04 
itgb4 -6,72 0,01 
gpr52 5,83 0,05 
fam59a -7,16 0,00 
fjx1 7,21 0,00 
tmem139 -7,23 0,01 
hsd17b6 -5,74 0,05 
zfp715 -5,00 0,01 
megf10 -6,50 0,02 
tmem161b -5,22 0,00 
gstm3 -7,95 0,00 
lrp3 7,28 0,01 
phex -7,72 0,00 
penk 6,58 0,01 
odf2l -8,15 0,00 
slc13a2 -7,00 0,01 
scamp5 -6,72 0,01 
loxl3 -3,97 0,03 
cyp2s1 7,40 0,01 
adam21 -7,69 0,00 
oas3 -6,96 0,01 
e130311k13rik 4,52 0,01 
samd4 -5,83 0,04 
4833422f24rik 7,94 0,00 
trim62 -6,17 0,03 
gm16861 -7,23 0,01 
creld1 -6,05 0,00 
zfp866 5,18 0,00 
cacna1f -6,31 0,03 
trip6 -4,15 0,05 
8430410k20rik -4,63 0,03 
aa388235 -5,63 0,04 
bc027231 -5,26 0,01 
srpx2 -6,01 0,02 
rad50 -3,53 0,05 
rhoj -7,30 0,00 
gltpd2 4,78 0,03 
lrrc46 7,40 0,01 
cidec -6,77 0,01 
pcm1 -6,17 0,00 
hrasls -6,96 0,01 
tmem143 -3,21 0,05 
oasl2 7,12 0,00 
zfp146 7,44 0,00 
pde3b -3,08 0,05 
mastl -5,52 0,00 
krt71 -5,83 0,03 
armcx6 2,98 0,04 
av051173 -6,17 0,03 
rnase12 -6,67 0,01 
zfp345 5,94 0,04 
trib3 6,70 0,01 
rnf186 6,57 0,00 
slc22a15 -5,31 0,01 
col6a2 5,83 0,03 
cntd1 -5,74 0,05 
hephl1 -6,67 0,02 
tdrd7 -5,52 0,05 
adora1 -4,21 0,03 
axl 5,94 0,03 
e130008d07rik -5,74 0,05 
f13b -5,83 0,03 
wdr35 -4,29 0,02 
kcna2 4,81 0,02 
mageb3 6,92 0,01 
usp46 -8,56 0,00 
xirp1 6,58 0,02 
scml4 -4,03 0,05 
1700063d05rik 5,83 0,05 
tubb4a -5,74 0,04 
slc25a35 -5,03 0,01 
spg11 -6,21 0,00 
efna1 -7,34 0,00 
zfp280b -3,91 0,02 
unc5c 5,83 0,05 
slc6a15 -6,38 0,02 
st8sia6 -5,31 0,01 
lig4 -6,96 0,00 
cstad -7,04 0,01 
tmprss11d -5,83 0,04 
lrrn3 -8,06 0,00 
cd302 6,64 0,01 
fmn2 6,29 0,02 
fancb -9,10 0,00 
f8 -7,16 0,01 
nckap5 -6,01 0,03 
myo5a -3,29 0,04 
2210009g21rik -7,55 0,00 
atp8b3 -5,63 0,04 
rtkn2 4,73 0,02 
gab3 -5,63 0,04 
dsc3 -7,04 0,01 
dok4 7,64 0,00 
ttll3 -7,00 0,01 
fnbp1l -5,52 0,01 
bc030336 -3,41 0,05 
tiam2 -6,44 0,02 
cd209a 7,28 0,01 
col5a3 -5,93 0,03 
g630016d24rik -6,01 0,02 
luzp2 5,57 0,00 
zfp445 -3,62 0,05 
zfp318 -5,13 0,01 
serpinb9 6,34 0,00 
phf1 -5,65 0,00 
cml5 -5,52 0,04 
apol9a -6,17 0,02 
d830013o20rik -5,52 0,04 
kpna2 -8,06 0,00 
per2 -7,20 0,00 
dbndd2 -4,45 0,02 
c230035i16rik 7,57 0,00 
tgs1 -4,50 0,01 
uba3 -6,59 0,00 
magee1 -6,67 0,00 
plxnb3 -6,72 0,01 
slfn1 -6,91 0,01 
trip10 -4,86 0,01 
fstl1 8,65 0,00 
nhsl1 -7,30 0,00 
pomt2 -7,93 0,00 
zscan12 -6,31 0,03 
engase -7,08 0,01 
gucy1a2 8,11 0,00 
sun3 7,78 0,00 
dpep3 5,94 0,04 
fgf15 8,28 0,00 
gm20408 -6,24 0,02 
cdh12 3,46 0,04 
c530008m17rik -6,50 0,02 
5033406o09rik 3,92 0,01 
rlbp1 -4,26 0,04 
mir5104 5,60 0,04 
mlf1 -8,87 0,00 
ttc23 -8,12 0,00 
pcdhb21 -6,09 0,02 
ahcyl2 -4,65 0,01 
kcnn3 -4,32 0,03 
lrrc47 -4,59 0,03 
npdc1 7,64 0,00 
ccdc68 6,51 0,01 
col4a4 -7,99 0,00 
fsd1l -8,70 0,00 
dcaf12l1 -6,24 0,03 
1700081h04rik -5,74 0,03 
zfp473 -5,63 0,01 
b230217c12rik -4,28 0,01 
bnc2 7,51 0,00 
1700001l05rik -7,30 0,01 
gm5129 6,51 0,01 
ncrna00086 4,16 0,03 
2200002j24rik -6,91 0,01 
mpzl3 7,51 0,00 
zfp418 7,51 0,00 
c2 -6,24 0,03 
osbpl5 -3,67 0,04 
eml5 -8,99 0,00 
ppap2b -7,12 0,01 
paqr4 -7,37 0,01 
fam196a -6,38 0,01 
ercc6 -6,61 0,00 
ccrl2 -3,86 0,05 
ric3 -6,44 0,02 
ccdc157 3,86 0,03 
utp14b -4,35 0,02 
l1cam -7,43 0,00 
gen1 -7,30 0,01 
fam69b -5,63 0,04 
zfp943 -8,97 0,00 
arl4d -7,16 0,00 
rbp7 -6,72 0,01 
xirp2 -6,24 0,02 
srxn1 -3,97 0,04 
1700025g04rik -4,07 0,02 
slc25a36 -8,40 0,00 
adh6a -7,99 0,00 
nckipsd -4,72 0,01 
popdc3 6,70 0,02 
kcnab1 6,21 0,02 
atp13a4 -6,31 0,02 
kdm4d 6,75 0,00 
zfp280c 6,29 0,02 
1700009j07rik -6,44 0,01 
5430411k18rik 4,07 0,02 
ceacam13 6,51 0,02 
gtf2ird2 -3,89 0,03 
9130011e15rik -8,76 0,00 
lrrn4 -6,09 0,02 
prrx1 -5,52 0,04 
cntn5 -6,91 0,01 
slc18a2 -7,40 0,01 
gm9897 -5,20 0,01 
lair1 8,94 0,00 
adnp2 -4,34 0,02 
2010106e10rik -6,91 0,01 
igll1 6,21 0,03 
1700022p22rik 5,94 0,03 
d3ertd254e 4,82 0,01 
ttll4 -3,69 0,03 
rlf -8,48 0,00 
gm10248 -8,58 0,00 
2410004p03rik 7,44 0,00 
hfm1 5,94 0,04 
zfp820 -5,74 0,05 
hspb6 -3,34 0,03 
sipa1l3 -7,46 0,00 
fhl2 -5,63 0,04 
hibch -4,60 0,01 
ttc21b -3,91 0,03 
chst1 -6,17 0,03 
9330182l06rik -4,37 0,03 
parp12 6,37 0,02 
lass6 -6,08 0,00 
kynu -8,69 0,00 
golga7b 6,21 0,03 
klhl8 -6,24 0,02 
stap2 -7,72 0,00 
mmaa 4,63 0,02 
chrm1 6,37 0,02 
sst -5,52 0,04 
mefv 5,83 0,05 
apol9b -4,41 0,03 
smok2a 4,78 0,03 
bc006965 -6,09 0,02 
itgb6 -7,77 0,00 
sirpa -3,78 0,03 
kbtbd8 -4,35 0,03 
tbx6 -6,87 0,01 
susd2 -7,49 0,00 
sync -5,74 0,05 
fndc7 7,28 0,01 
spon1 6,64 0,01 
pgbd1 7,20 0,00 
ly6g5b 6,40 0,00 
hnf4a -7,49 0,00 
gbp7 -5,40 0,00 
4930455b14rik -6,17 0,02 
olfr957 5,83 0,03 
i830012o16rik -6,09 0,02 
kl -5,93 0,03 
4632428n05rik -3,98 0,03 
6720489n17rik -6,18 0,00 
ngef 8,09 0,00 
cdh13 9,07 0,00 
cend1 -6,62 0,01 
etd 5,94 0,04 
fam20c -6,77 0,01 
tnnt3 3,03 0,05 
klhl14 -4,35 0,02 
naip5 -6,87 0,01 
cntnap5a -5,63 0,04 
zfat -9,02 0,00 
kif13b -6,87 0,01 
rasef 5,83 0,03 
zfyve16 -8,40 0,00 
osr2 -7,74 0,00 
col4a5 5,60 0,05 
veph1 -5,74 0,05 
ifi203 3,23 0,03 
suv39h2 6,76 0,01 
dcaf12l2 -6,17 0,02 
ldlrap1 -7,81 0,00 
zfp474 -6,09 0,02 
fam169a 5,46 0,01 
nrn1 -7,12 0,00 
hbb-bh1 -10,62 0,00 
haus6 -4,44 0,02 
krt18 -3,96 0,02 
ptchd1 -4,63 0,03 
wbscr17 -6,56 0,01 
ednrb -8,37 0,00 
eno3 3,86 0,01 
zfp518a -3,90 0,03 
dll1 8,74 0,00 
ubash3a 9,14 0,00 
2010107g23rik 4,78 0,02 
llgl2 -6,96 0,01 
paqr5 -6,72 0,01 
creb3l1 5,72 0,03 
heatr3 -3,86 0,03 
2310068j16rik 4,68 0,03 
gpr37l1 -5,52 0,04 
siglec1 6,29 0,02 
vmn1r228 7,50 0,00 
ugt1a1 -5,74 0,05 
pgm2l1 -6,82 0,01 
angel1 -9,11 0,00 
tmem184a -6,56 0,01 
aard 7,36 0,01 
zfp697 -5,74 0,04 
sowahc -7,30 0,01 
bmp4 7,51 0,00 
grin2a 7,47 0,01 
atp13a5 -5,93 0,04 
d630032n06rik -4,75 0,02 
rps18 -5,96 0,00 
ceacam14 7,78 0,00 
gm4636 -4,65 0,01 
aqp8 -7,46 0,00 
slc22a21 -6,09 0,02 
gjd4 7,40 0,01 
fam23a -5,83 0,04 
ppp1r9a 5,94 0,04 
ifih1 8,88 0,00 
pcdh12 -6,01 0,04 
cdc14a -3,82 0,04 
atp8b5 6,03 0,04 
cdk12 -3,70 0,03 
4732491k20rik 6,21 0,02 
fam122b -8,19 0,00 
d630039a03rik -6,31 0,03 
dppa2 -5,74 0,03 
olfr1201 8,09 0,00 
zfp248 -9,23 0,00 
cdkl1 -3,86 0,02 
gpd1 -8,38 0,00 
fam70a -4,46 0,03 
polr3b -3,89 0,03 
1190007f08rik -5,52 0,04 
olfr862 -6,38 0,01 
gdpd1 -4,74 0,01 
sdc1 -5,63 0,04 
fyco1 -4,50 0,02 
vmn1r184 -7,23 0,01 
kif5c -7,77 0,00 
smok2b -6,91 0,01 
zfp101 -5,63 0,01 
prl7a2 -5,83 0,04 
ddx10 -6,84 0,00 
gpr55 -5,52 0,04 
ppt2 -7,97 0,00 
pyroxd1 -8,37 0,00 
2610020h08rik -8,87 0,00 
slc44a5 -5,83 0,03 
vasn 3,99 0,03 
cldn12 4,90 0,01 
zdhhc17 -5,75 0,00 
ai428936 6,51 0,02 
gdap10 -6,38 0,01 
c130060k24rik 5,83 0,05 
smarca2 -5,59 0,00 
dlgap1 8,30 0,00 
cep76 -6,31 0,02 
slfn3 -5,74 0,03 
zfp60 -4,61 0,01 
ace2 -6,50 0,01 
lrrc25 -5,63 0,04 
plk1s1 -8,82 0,00 
capn9 -5,74 0,03 
phf13 -7,23 0,01 
gbp8 5,35 0,00 
catsper3 -5,52 0,04 
msh3 -8,98 0,00 
olfr958 -6,62 0,01 
pde1a -5,93 0,03 
sh2d2a -5,67 0,00 
pign -4,12 0,03 
zfp451 -3,60 0,04 
acadsb -6,24 0,02 
1700048o20rik 3,32 0,03 
zbtb26 -8,49 0,00 
sec14l2 -7,16 0,00 
ttpa -7,30 0,00 
tbc1d13 -3,14 0,04 
gm13031 5,72 0,03 
art2a-ps 6,82 0,01 
eif5b -3,78 0,03 
tmem87a -3,53 0,04 
ddo 7,44 0,00 
pdp1 -7,84 0,00 
tprg -5,93 0,03 
spink6 6,21 0,03 
ccdc135 -5,63 0,04 
pbx1 -5,80 0,00 
bc052040 -6,22 0,00 
app 3,63 0,04 
fam132b 3,55 0,05 
ifi204 -6,31 0,02 
slc16a13 6,58 0,01 
rhpn2 -7,95 0,00 
rnase1 -6,31 0,02 
slc2a13 6,03 0,03 
zkscan1 3,51 0,02 
piwil1 -7,23 0,00 
wdr93 -7,00 0,01 
asb2 3,00 0,05 
yod1 -9,02 0,00 
tdo2 5,89 0,01 
avpi1 7,36 0,00 
chst14 -6,77 0,01 
epb4.1l3 -8,66 0,00 
zfp873 5,04 0,00 
phf21b -6,01 0,03 
wdr38 -5,93 0,03 
mageh1 -7,64 0,00 
rdh9 8,90 0,00 
1700016c15rik 7,24 0,01 
robo3 7,28 0,01 
gpr113 5,72 0,03 
9230112d13rik -6,31 0,02 
gm7538 6,92 0,01 
5830416i19rik -6,01 0,03 
zfp945 -7,55 0,00 
atp12a 6,51 0,02 
ehf -6,82 0,01 
capsl 6,44 0,01 
sorbs1 -3,42 0,04 
ugt3a1 6,37 0,02 
4930578m01rik -5,74 0,04 
xylb -3,30 0,04 
maml2 -6,06 0,00 
tmtc4 -6,09 0,03 
hhat 7,24 0,01 
adipoq -6,01 0,03 
ar -5,83 0,04 
onecut2 -6,16 0,00 
zbed6 -6,01 0,04 
p2ry10 -3,77 0,04 
notum 6,70 0,02 
krt23 6,58 0,02 
efcab5 -6,09 0,03 
gatsl2 -6,56 0,02 
nom1 -4,46 0,01 
fam164a -8,14 0,00 
pex26 -5,83 0,04 
acot4 -6,96 0,01 
ctbs 7,44 0,00 
larp1b -6,96 0,01 
calr3 -6,09 0,03 
ccr1 -7,58 0,00 
gprc5c 8,04 0,00 
e130309f12rik 7,60 0,00 
nr0b2 -6,50 0,01 
sep-04 6,87 0,01 
gopc -4,41 0,01 
bloc1s3 4,51 0,01 
enox2 3,62 0,03 
cdkl2 -7,69 0,00 
2310014l17rik -6,82 0,01 
mcoln3 -7,04 0,01 
epb4.1l4a -6,38 0,02 
clrn3 -8,49 0,00 
pds5b -3,19 0,04 
gdpd2 -6,17 0,02 
gm949 -5,93 0,04 
pnliprp1 6,13 0,03 
tmem198 -5,74 0,05 
nhedc1 6,29 0,03 
zfp647 -6,50 0,02 
sh2d5 4,92 0,01 
4930511m11rik -5,63 0,04 
a730090n16rik -6,31 0,02 
2210407c18rik -3,74 0,04 
sbk2 -6,38 0,01 
dusp18 9,20 0,00 
chrnb3 -6,31 0,02 
caprin2 -6,45 0,00 
fsip1 5,83 0,05 
cldn13 -6,31 0,02 
1600029o15rik -3,97 0,04 
gsdmc2 -6,09 0,02 
zfp846 5,51 0,00 
olfr1353 -6,72 0,01 
4632415k11rik -4,23 0,02 
uba6 -6,24 0,00 
zfp719 -4,55 0,01 
bcl6b -8,53 0,00 
srl 5,68 0,01 
ubd 3,60 0,02 
2900056m20rik -4,14 0,02 
1700003e16rik -5,83 0,03 
hmgn2 -4,04 0,01 
sh3gl3 7,54 0,00 
opcml 8,84 0,00 
st3gal1 -3,76 0,03 
khnyn -3,20 0,05 
gm5108 5,72 0,03 
gja8 -6,72 0,01 
nmnat1 -4,86 0,02 
6330409n04rik 8,72 0,00 
mtap -8,06 0,00 
ttc26 4,43 0,01 
ltbr 5,60 0,01 
bag3 -8,65 0,00 
gm13032 -5,93 0,03 
josd1 -3,63 0,03 
tsga10 -6,09 0,03 
fbxl16 7,70 0,00 
ptprf 5,89 0,01 
lclat1 -7,00 0,00 
pus10 -6,97 0,00 
uevld -8,26 0,00 
rfx2 7,94 0,00 
cyp4b1 7,20 0,01 
nol8 -4,44 0,01 
prl7d1 -5,74 0,05 
tm7sf3 -3,23 0,05 
kcng1 -6,17 0,02 
cmpk2 -6,82 0,01 
mid2 -6,44 0,02 
trim15 -7,77 0,00 
sema3b -7,37 0,00 
vwa3a 6,82 0,01 
omd 5,04 0,02 
xpo4 -6,17 0,03 
c1rl 6,03 0,04 
il28ra -7,61 0,00 
gjb2 7,97 0,00 
gm129 -6,91 0,01 
tchp -7,55 0,00 
bean1 -6,82 0,01 
4933433g15rik -6,17 0,02 
p2ry1 7,44 0,01 
ret -3,44 0,05 
uprt -7,97 0,00 
nts -8,65 0,00 
dock3 -6,62 0,01 
tcam1 5,83 0,03 
nexn 7,20 0,01 
naa15 -6,25 0,00 
d830005e20rik -7,72 0,00 
gchfr -5,63 0,04 
efna5 -4,21 0,03 
emilin2 5,60 0,04 
myl9 6,82 0,01 
onecut3 6,15 0,00 
ddhd1 -7,27 0,01 
4930512b01rik -5,83 0,04 
hmox1 -4,43 0,02 
bc022687 -6,82 0,01 
oxsm -4,59 0,02 
vmn2r82 -5,93 0,03 
acsl4 -4,72 0,01 
dsel -6,01 0,02 
man2c1 -3,22 0,04 
ankrd22 -5,52 0,04 
spam1 5,83 0,04 
ly6a -5,35 0,00 
d230030e09rik -5,63 0,04 
fam184a 6,37 0,02 
bmi1 -4,21 0,01 
gabpa -6,50 0,00 
sep-05 -6,72 0,01 
tada2a -4,83 0,01 
rbm41 -6,56 0,00 
tnfrsf12a -4,15 0,03 
epb4.1l4b 4,59 0,01 
atl1 -5,74 0,05 
zfp449 -7,30 0,01 
a730036i17rik -5,83 0,04 
gm16516 -7,00 0,01 
mapk8 -4,24 0,02 
hemt1 -6,01 0,02 
il10 3,65 0,03 
1200009i06rik -8,33 0,00 
hmmr -3,93 0,03 
ceacam20 -3,29 0,05 
4930458l03rik -6,44 0,01 
wdr67 -6,29 0,00 
ube2q2 -6,77 0,01 
ovol1 -4,51 0,02 
4933430n04rik 4,83 0,03 
gm2518 -4,15 0,04 
bmpr1a -8,10 0,00 
nos1ap -6,09 0,02 
zfp182 -7,97 0,00 
gm12886 -6,01 0,02 
d130017n08rik 4,52 0,04 
4930422g04rik -4,70 0,01 
spock2 -6,62 0,02 
2610034b18rik -4,68 0,02 
aldh1a2 7,60 0,00 
spag17 -5,83 0,04 
abp1 5,20 0,00 
acvr1b -3,47 0,03 
zim3 6,03 0,04 
zfp799 -5,93 0,04 
mcc -6,17 0,03 
fkbp5 -3,66 0,03 
ccdc113 6,13 0,03 
dhrs13 -3,64 0,05 
fgfr3 8,24 0,00 
akap17b -7,34 0,00 
pxt1 -6,67 0,01 
sec14l4 -6,38 0,01 
esrp2 -5,93 0,03 
vgf -5,52 0,04 
tmod2 8,22 0,00 
selm -5,74 0,05 
cdr2 4,14 0,01 
il1r1 -5,63 0,04 
rgs1 -8,33 0,00 
zdhhc5 -3,38 0,04 
klf3 -3,74 0,03 
msln -5,74 0,04 
kcnq1ot1 -3,47 0,03 
wdr16 6,76 0,01 
slc26a2 -8,17 0,00 
coil -3,76 0,03 
siglece -4,55 0,02 
zfp385b 6,29 0,03 
e230019m04rik -7,08 0,01 
zscan20 -7,49 0,00 
il12b 4,89 0,01 
aadacl2 -6,09 0,03 
meis1 7,51 0,00 
cc2d2a 4,78 0,02 
bco2 -5,52 0,05 
olfr1056 -6,17 0,02 
5830417i10rik -5,83 0,03 
tm7sf4 8,43 0,00 
gm11545 -5,63 0,04 
epb4.1l5 -3,07 0,05 
serpind1 -6,09 0,03 
cdh20 -6,17 0,02 
naalad2 7,24 0,01 
tmem55a -5,36 0,01 
braf -6,89 0,00 
sidt1 -6,09 0,02 
myo3b 6,87 0,01 
4732490b19rik 4,75 0,01 
scfd2 -3,44 0,04 
ehbp1 -7,23 0,01 
klhl21 7,47 0,01 
gm16023 -6,44 0,02 
rapsn 5,60 0,04 
sardh -6,31 0,02 
pglyrp2 4,23 0,03 
ccdc76 -7,69 0,00 
cyyr1 6,76 0,01 
sgk1 3,40 0,03 
cnnm2 -6,72 0,01 
gm11696 -4,45 0,01 
setbp1 -4,20 0,01 
arsb -6,09 0,03 
kif21a -5,93 0,04 
zkscan16 8,36 0,00 
mospd1 3,60 0,03 
4931417g12rik -7,12 0,01 
car4 -5,63 0,04 
dram1 -7,12 0,01 
4930506m07rik -7,93 0,00 
fam164c -6,38 0,01 
il1b -7,52 0,00 
lyplal1 -6,44 0,01 
mbd6 -3,89 0,02 
zfp59 -6,24 0,03 
napb -6,62 0,01 
mis12 -4,49 0,01 
wdr44 -5,64 0,00 
1700008j07rik -6,01 0,02 
4930528f23rik 7,78 0,00 
gm1568 -5,89 0,00 
tmem53 5,23 0,01 
harbi1 -5,67 0,01 
rab3d 5,34 0,00 
narg2 -4,32 0,02 
rgl1 -4,21 0,04 
alpk2 -6,31 0,02 
osbpl1a -6,01 0,03 
lilra5 9,23 0,00 
vsig8 5,60 0,04 
aox3 -5,74 0,04 
parp16 -5,12 0,01 
ppil4 -3,86 0,03 
yap1 -6,01 0,03 
sox12 -7,04 0,01 
gdpd4 -5,52 0,04 
4931430n09rik -6,91 0,01 
clca1 -7,08 0,01 
clec7a -7,84 0,00 
gsdmc4 6,87 0,01 
gm11602 -4,86 0,02 
mtap2 -7,08 0,01 
smarca5 -4,30 0,01 
lingo2 5,83 0,03 
tmem180 -7,69 0,00 
sgms2 -4,03 0,04 
mycs 6,76 0,01 
rpgrip1 4,78 0,03 
fgfbp3 7,73 0,00 
astl 7,64 0,00 
ush1c -6,56 0,01 
vmn1r45 8,41 0,00 
rtp2 7,81 0,00 
dync2li1 6,92 0,01 
ak7 -6,67 0,01 
tmem125 -7,66 0,00 
sorcs3 -6,01 0,02 
kctd11 -7,91 0,00 
pcnxl2 -5,93 0,03 
fcer1a 6,29 0,03 
9530027j09rik -6,09 0,03 
mras 5,94 0,04 
bc030870 -6,87 0,01 
fam167a 4,84 0,02 
prf1 8,36 0,00 
gm15708 -6,34 0,00 
lysmd2 6,76 0,01 
golga3 -3,62 0,04 
myh3 7,02 0,01 
wdr17 -6,17 0,02 
steap1 6,29 0,03 
pkd1 -4,22 0,01 
nuak1 -6,09 0,02 
aim1 -4,28 0,02 
xylt2 -7,04 0,01 
als2cl -6,01 0,02 
pafah2 -8,10 0,00 
usp28 -3,13 0,05 
oosp1 -6,24 0,03 
1700028k03rik -5,74 0,04 
nfib -6,01 0,03 
wdr96 4,14 0,03 
iqck -6,82 0,01 
igsf11 6,29 0,03 
ntn4 6,29 0,03 
fbp1 -3,94 0,04 
ap4e1 -5,15 0,01 
asb5 3,52 0,04 
gm20098 6,13 0,03 
4930527f14rik 5,83 0,05 
thy1 -5,96 0,00 
sema3d -5,63 0,04 
arl11 7,36 0,00 
zbtb33 -6,56 0,00 
2610316d01rik -6,24 0,03 
hcn1 -6,17 0,03 
lrrtm4 -6,01 0,04 
zfp948 7,84 0,00 
d630045j12rik 8,13 0,00 
ptch1 -5,83 0,04 
gm3414 -4,03 0,04 
actr3b -4,21 0,04 
il18bp 3,15 0,04 
vmn2r112 6,29 0,03 
mipol1 -4,83 0,02 
tmem225 8,02 0,00 
zeb1 -5,98 0,00 
acp2 -8,19 0,00 
9330151l19rik -6,24 0,03 
gm17762 8,02 0,00 
vmn2r84 5,94 0,04 
slc7a15 -7,52 0,00 
kdelc1 -5,63 0,04 
pard3 -5,74 0,03 
dach1 6,51 0,02 
kcnb2 7,28 0,01 
tmem54 -6,31 0,02 
tmem30b -6,31 0,03 
dlg4 -6,67 0,02 
map3k10 4,58 0,04 
ctps2 -3,35 0,05 
oog3 7,07 0,01 
cdkl5 6,76 0,01 
resp18 -6,31 0,02 
dbpht2 6,98 0,01 
prss39 6,92 0,01 
ccnb1ip1 -3,39 0,04 
casc4 -7,81 0,00 
tmem38a 6,04 0,00 
rasl10a -6,17 0,03 
trim45 8,20 0,00 
ctnna1 -3,46 0,02 
camsap2 -4,04 0,03 
cpeb1 4,00 0,04 
4930529f22rik -5,52 0,04 
ttc8 -5,09 0,01 
ang4 -5,63 0,04 
gfpt1 -6,35 0,00 
gm12216 -4,15 0,03 
hc -6,38 0,02 
plekhg6 -6,77 0,01 
zscan18 -6,01 0,04 
itga1 8,30 0,00 
pmel -5,93 0,03 
lrrc29 -5,77 0,00 
dpp4 -5,48 0,00 
nrbp2 -6,77 0,01 
abcb9 7,07 0,01 
kif18a -9,86 0,00 
kctd4 -6,38 0,01 
a230073k19rik 5,70 0,00 
fkbp7 -7,00 0,01 
mphosph8 -4,06 0,02 
aa986860 -7,30 0,01 
bod1 -6,67 0,01 
adora2b -4,15 0,03 
slc30a1 -6,44 0,02 
cdhr2 -5,71 0,00 
sprr2j-ps -5,93 0,03 
ulk2 -5,17 0,01 
olfr127 7,44 0,01 
rpl29 -4,51 0,02 
ccdc30 -7,16 0,01 
b130006d01rik -6,17 0,03 
cdk6 -4,79 0,02 
lxn -9,76 0,00 
golga4 -5,48 0,01 
myh4 7,02 0,01 
cxcr3 -7,77 0,00 
stag3 -8,14 0,00 
slc26a4 6,58 0,02 
rapgef5 -6,91 0,01 
steap2 5,30 0,01 
rep15 -6,31 0,02 
pkd2 -6,56 0,02 
hist2h3c1 -7,08 0,01 
pla1a 3,93 0,02 
strn -5,10 0,01 
olfr894 -5,83 0,04 
slc2a2 -7,79 0,00 
gucy1b2 8,57 0,00 
slc25a18 -6,17 0,02 
ccdc162 -6,09 0,03 
abcc3 6,13 0,02 
plcg1 -7,81 0,00 
gm10509 -6,82 0,01 
gramd1c -5,23 0,01 
jmy 7,20 0,01 
mr1 7,60 0,00 
mmgt1 -5,43 0,01 
3110047p20rik -6,31 0,02 
olfr131 7,16 0,01 
a530088e08rik -4,93 0,02 
mtmr1 -3,98 0,03 
zfp955a 5,73 0,00 
parvb 7,28 0,00 
mcph1 -3,48 0,03 
zfp37 -6,96 0,01 
dock6 -3,82 0,04 
ccdc78 4,40 0,01 
zfp157 -3,29 0,04 
rnf32 -7,66 0,00 
gnb3 -6,01 0,04 
gxylt2 5,46 0,05 
fam120c -4,67 0,01 
zeb2 -6,67 0,01 
gm9159 6,21 0,03 
gas2l1 6,44 0,02 
vash1 6,76 0,01 
ihh -6,72 0,01 
a330040f15rik 6,29 0,02 
nln -5,81 0,00 
b230323a14rik -5,93 0,03 
efcab9 -6,17 0,03 
4930478p22rik -5,63 0,04 
prss16 5,54 0,01 
rims1 6,37 0,02 
hoxa3 -8,10 0,00 
zfp428 -6,56 0,02 
tmem178 5,46 0,05 
dus4l -4,15 0,02 
alg10b -3,50 0,05 
pde6g -6,17 0,02 
a430033k04rik -3,85 0,04 
dlg5 -4,52 0,01 
olfr1206 8,11 0,00 
fpgt -9,27 0,00 
1700095a21rik -5,52 0,04 
lamc1 -4,49 0,02 
ano10 -3,53 0,02 
kcnj2 -5,93 0,03 
mn1 -6,67 0,01 
bc037704 -5,31 0,01 
hhip -6,17 0,03 
lipt1 -8,06 0,00 
trim46 -6,72 0,01 
megf9 8,78 0,00 
nlrp6 -7,20 0,01 
mypn 5,94 0,04 
4930430f08rik -6,38 0,02 
alg6 -4,00 0,02 
c030016d13rik 5,46 0,05 
tmem120b 4,45 0,01 
kalrn -3,87 0,02 
1500009c09rik -6,82 0,01 
apod -6,09 0,02 
gpr83 -6,77 0,01 
1700125g22rik 4,08 0,05 
gfpt2 -7,34 0,01 
ttc23l 6,03 0,04 
ppp1r2-ps7 9,04 0,00 
extl1 -7,04 0,01 
hnf4g -5,63 0,04 
ccdc116 -7,04 0,01 
wrn -8,44 0,00 
mphosph9 -5,37 0,00 
fa2h -6,38 0,02 
dnajc25 -6,09 0,02 
6430573f11rik 6,70 0,02 
1810014b01rik -4,32 0,01 
zfp110 -3,13 0,04 
akr1b7 4,52 0,01 
fam187b -4,59 0,02 
lphn1 -7,49 0,00 
6030422m02rik -6,50 0,02 
treml4 7,84 0,00 
mib2 6,58 0,02 
lrig1 -5,26 0,01 
tsga14 -3,21 0,04 
siglech 6,29 0,02 
dgkq -6,91 0,01 
nxn -4,46 0,03 
apaf1 -5,49 0,00 
plekhh1 7,32 0,01 
cttnbp2nl 5,83 0,03 
atg14 -4,26 0,02 
6430531b16rik -6,17 0,02 
elavl2 -5,54 0,00 
zfp14 -7,49 0,00 
ptpn14 -7,52 0,00 
scn3a 6,69 0,00 
rbak 5,68 0,00 
ddx43 3,59 0,04 
asb7 -7,37 0,00 
lin7a -8,32 0,00 
1700109h08rik -5,74 0,05 
olfr1258 -6,31 0,03 
acad12 -3,65 0,04 
cep135 -5,59 0,01 
igsf9 -4,90 0,01 
cd80 -6,09 0,02 
akr1c14 -6,77 0,01 
rcan1 -7,64 0,00 
anxa3 -5,20 0,01 
2010002m12rik -7,12 0,01 
a130049a11rik -6,50 0,01 
zfp955b -5,31 0,01 
gli3 6,82 0,01 
sdr42e1 -7,61 0,00 
scn11a 3,68 0,04 
faah -5,05 0,01 
gm16897 -7,20 0,00 
pygl -5,83 0,03 
oit1 -7,00 0,01 
osgin1 -3,74 0,03 
dnajb7 -5,83 0,03 
atg4c -7,95 0,00 
slco1a4 -5,74 0,03 
smc2 -3,78 0,03 
car7 -6,91 0,01 
slc25a23 -6,96 0,01 
rims2 4,98 0,01 
2310047b19rik 3,92 0,03 
neu3 -8,15 0,00 
kdm3a -6,12 0,00 
4930448c13rik 6,58 0,02 
rpusd2 -3,94 0,03 
fert2 -6,20 0,00 
d030045p18rik -5,93 0,03 
gm6377 -8,65 0,00 
nudcd1 -4,85 0,00 
e230029c05rik -5,93 0,03 
poc1b -4,67 0,01 
arrb1 -4,43 0,01 
ift88 -7,40 0,01 
slc27a5 -6,44 0,01 
mtus1 -6,62 0,01 
c87977 8,07 0,00 
efnb3 -6,96 0,01 
vmn1r24 -6,72 0,01 
pex5 -6,52 0,00 
4930487h11rik -6,38 0,01 
myo15 -6,38 0,01 
st14 -3,00 0,05 
pla2g4c -5,63 0,04 
ocln -7,88 0,00 
sema6d -5,74 0,05 
clca4 -6,31 0,02 
rab36 -4,02 0,03 
tmcc1 -3,52 0,05 
tbk1 -3,76 0,04 
pgr15l -6,62 0,01 
gpr84 4,73 0,03 
itga3 4,03 0,05 
fcho2 -4,20 0,03 
gabrb2 -7,00 0,01 
extl2 -5,31 0,01 
1700067k01rik -6,24 0,03 
hsd17b13 7,54 0,00 
cdc42bpa -6,56 0,01 
rab4a -6,09 0,02 
9330159f19rik -6,67 0,02 
cdkn2b -6,62 0,01 
polk -7,66 0,00 
agt -6,01 0,02 
sfxn4 -3,89 0,02 
gm9833 -6,09 0,03 
1300015d01rik 7,51 0,00 
slc22a8 -5,93 0,04 
xrcc2 -8,33 0,00 
cdx1 4,55 0,02 
rps6kc1 -3,73 0,04 
b3gat2 7,67 0,00 
mbnl1 -3,32 0,04 
ulk4 -4,86 0,02 
abca1 -4,77 0,01 
pcgf3 -8,35 0,00 
zfp783 -8,48 0,00 
tlcd1 -7,40 0,01 
lphn2 3,54 0,02 
gml 6,37 0,01 
rgs5 -5,52 0,04 
rnf144a 3,40 0,04 
cldn22 7,32 0,01 
lipo1 -7,61 0,00 
adcy8 -3,84 0,05 
slc26a6 -3,62 0,03 
nradd -4,21 0,04 
cfi 5,72 0,03 
rbm18 -5,76 0,00 
mmrn2 6,64 0,02 
3200001d21rik 7,40 0,00 
frmd7 4,20 0,02 
kremen2 7,32 0,01 
adam34 7,02 0,01 
cyp2t4 3,67 0,02 
gm16548 -5,83 0,03 
fbxo47 -6,50 0,01 
lrrc16a 6,98 0,01 
fam135a -6,37 0,00 
ccbl2 -5,63 0,04 
slc4a3 4,40 0,03 
bbs7 -7,23 0,01 
tyrp1 -6,17 0,02 
arhgap5 -7,72 0,00 
gpr174 -4,60 0,02 
fbln1 -3,27 0,04 
1110017d15rik 6,37 0,02 
chm -7,77 0,00 
id1 -7,12 0,01 
hrh1 -8,02 0,00 
hs2st1 5,72 0,04 
klhl25 -7,20 0,01 
clgn -5,63 0,04 
mblac1 3,00 0,05 
darc -6,31 0,02 
zfyve1 -3,78 0,03 
timp2 5,83 0,03 
gm5069 -5,93 0,03 
osgin2 -5,01 0,01 
yy2 -9,79 0,00 
c5ar1 -7,43 0,01 
a3galt2 3,25 0,05 
shisa2 -6,09 0,02 
rhoc -3,48 0,03 
gas2l3 -9,05 0,00 
trpm5 -8,51 0,00 
papd7 -5,69 0,00 
thnsl1 -3,73 0,04 
smc3 -4,14 0,02 
car8 8,88 0,00 
h2-t3 -4,49 0,01 
4933408b17rik 6,37 0,02 
figla 5,94 0,04 
sntb1 6,13 0,03 
2210417k05rik -6,62 0,02 
catsperg1 6,13 0,03 
dbn1 -3,81 0,03 
2010109a12rik -6,01 0,02 
plcb2 -6,67 0,01 
tnfrsf26 -2,95 0,04 
sema4a -6,17 0,03 
antxr2 5,24 0,00 
lgr6 4,52 0,04 
nrip1 -4,35 0,01 
map3k13 6,45 0,00 
gm12250 -3,60 0,03 
pcdh9 -5,74 0,03 
slc27a6 6,44 0,02 
gm16576 -6,87 0,01 
tctex1d1 5,94 0,04 
olfm4 6,52 0,00 
txlng -6,17 0,03 
ascl2 -5,63 0,04 
spn -6,77 0,01 
taf1 -6,31 0,00 
uaca 7,70 0,00 
grin3b -7,20 0,01 
il15 -7,27 0,00 
mapkbp1 6,44 0,02 
bcl9 -7,40 0,01 
thsd7a -6,96 0,01 
fn3krp -7,27 0,00 
4930430d24rik 6,76 0,01 
bc051142 -7,08 0,01 
srr -5,83 0,04 
mmp11 3,85 0,02 
tbc1d2 -4,37 0,02 
rg9mtd1 -7,48 0,00 
agphd1 -7,00 0,01 
socs5 3,20 0,03 
aldh1a7 -6,67 0,02 
laptm4b -3,92 0,05 
cdc42bpb -6,24 0,03 
atoh1 6,03 0,04 
olfr1212 -6,38 0,02 
arhgap22 -5,74 0,04 
lman2l -5,76 0,00 
gm16998 6,37 0,01 
cyp2c65 -5,12 0,01 
casd1 -4,40 0,02 
mrvi1 -5,93 0,03 
zfp458 -8,40 0,00 
gm10785 -5,15 0,01 
 
Annex 2. Genes changed upon miR-28 expression in BL cells versus Scrambled control BL cells 
Gene ID hgnc_symbol logFC P.Value 
ENSG00000207651 MIR28 10,211 1,95E-39 
ENSG00000129128 SPCS3 -0,877 2,38E-17 
ENSG00000116044 NFE2L2 -0,567 2,45E-09 
ENSG00000132846 ZBED3 -0,604 1,32E-06 
ENSG00000136111 TBC1D4 0,693 1,35E-06 
ENSG00000172995 ARPP21 1,405 2,47E-06 
ENSG00000198888 MT-ND1 -0,611 3,38E-06 
ENSG00000123472 ATPAF1 -0,474 1,38E-05 
ENSG00000198886 MT-ND4 -0,524 1,66E-05 
ENSG00000198763 MT-ND2 -0,520 2,19E-05 
ENSG00000114026 OGG1 0,547 2,61E-05 
ENSG00000198727 MT-CYB -0,483 3,10E-05 
ENSG00000212907 MT-ND4L -0,487 3,16E-05 
ENSG00000225630 MTND2P28 -0,542 3,27E-05 
ENSG00000248527 MTATP6P1 -0,437 3,43E-05 
ENSG00000110934 BIN2 -0,459 4,01E-05 
ENSG00000228253 MT-ATP8 -0,453 4,11E-05 
ENSG00000124813 RUNX2 1,168 4,60E-05 
ENSG00000175567 UCP2 0,800 6,90E-05 
ENSG00000198899 MT-ATP6 -0,435 7,00E-05 
ENSG00000169136 ATF5 -0,672 8,79E-05 
ENSG00000134109 EDEM1 -0,421 9,98E-05 
ENSG00000105639 JAK3 -0,859 1,04E-04 
ENSG00000237973 MIR6723 -0,578 1,08E-04 
ENSG00000026103 FAS -0,562 1,20E-04 
ENSG00000163947 ARHGEF3 1,048 1,23E-04 
ENSG00000211898 IGHD 0,954 1,30E-04 
ENSG00000198712 MT-CO2 -0,450 1,50E-04 
ENSG00000198208 RPS6KL1 -0,785 1,67E-04 
ENSG00000119042 SATB2 0,563 1,69E-04 
ENSG00000226849  -1,360 1,85E-04 
ENSG00000166822 TMEM170A -0,374 1,88E-04 
ENSG00000131471 AOC3 -0,568 1,99E-04 
ENSG00000048052 HDAC9 0,578 2,08E-04 
ENSG00000176771 NCKAP5 -1,245 2,23E-04 
ENSG00000198938 MT-CO3 -0,408 2,45E-04 
ENSG00000120896 SORBS3 -0,915 2,48E-04 
ENSG00000237296 SMG1P1 0,408 2,52E-04 
ENSG00000120889 TNFRSF10B -0,452 2,85E-04 
ENSG00000125834 STK35 -0,393 2,92E-04 
ENSG00000187699 C2orf88 0,457 3,03E-04 
ENSG00000146072 TNFRSF21 1,042 3,11E-04 
ENSG00000271699  0,486 3,13E-04 
ENSG00000054654 SYNE2 0,415 3,23E-04 
ENSG00000142798 HSPG2 0,386 3,32E-04 
ENSG00000236152 MRPS36P1 -1,526 3,71E-04 
ENSG00000267426  -1,242 3,71E-04 
ENSG00000117461 PIK3R3 0,512 3,81E-04 
ENSG00000127666 TICAM1 0,396 4,09E-04 
ENSG00000117091 CD48 0,504 4,23E-04 
ENSG00000232573 RPL3P4 1,075 4,32E-04 
ENSG00000106348 IMPDH1 -0,342 4,46E-04 
ENSG00000029364 SLC39A9 -0,404 4,84E-04 
ENSG00000198804 MT-CO1 -0,440 4,89E-04 
ENSG00000205307 SAP25 -0,916 4,92E-04 
ENSG00000161011 SQSTM1 -0,417 5,09E-04 
ENSG00000131153 GINS2 0,497 5,23E-04 
ENSG00000160796 NBEAL2 -0,407 5,29E-04 
ENSG00000197063 MAFG -0,578 5,43E-04 
ENSG00000182836 PLCXD3 0,619 5,61E-04 
ENSG00000211772 TRBC2 0,508 5,62E-04 
ENSG00000138778 CENPE 0,392 5,85E-04 
ENSG00000141441 GAREM 0,537 5,88E-04 
ENSG00000133739 LRRCC1 0,577 5,97E-04 
ENSG00000185215 TNFAIP2 -0,821 6,07E-04 
ENSG00000111247 RAD51AP1 0,475 6,39E-04 
ENSG00000123453 SARDH 0,525 6,39E-04 
ENSG00000145907 G3BP1 -0,392 6,68E-04 
ENSG00000210082 MT-RNR2 -0,499 6,69E-04 
ENSG00000235174 RPL39P3 -3,205 6,93E-04 
ENSG00000267368 UPK3BL -0,762 7,12E-04 
ENSG00000256043 CTSO -0,592 7,37E-04 
ENSG00000165304 MELK 0,402 7,49E-04 
ENSG00000163312 HELQ 0,463 7,52E-04 
ENSG00000160326 SLC2A6 0,431 7,90E-04 
ENSG00000116514 RNF19B 0,340 8,00E-04 
ENSG00000128886 ELL3 0,500 8,04E-04 
ENSG00000210112 MT-TM -0,988 8,07E-04 
ENSG00000157734 SNX22 0,532 8,65E-04 
ENSG00000182718 ANXA2 -0,359 8,80E-04 
ENSG00000198858 R3HDM4 -0,315 8,86E-04 
ENSG00000001167 NFYA -0,460 9,21E-04 
ENSG00000165092 ALDH1A1 -1,258 9,33E-04 
ENSG00000008300 CELSR3 -0,484 9,41E-04 
ENSG00000110427 KIAA1549L 0,473 9,66E-04 
ENSG00000157764 BRAF -0,340 9,72E-04 
ENSG00000188277 C15orf62 -0,690 1,00E-03 
ENSG00000071794 HLTF 0,418 1,01E-03 
ENSG00000104936 FOSB -0,482 1,02E-03 
ENSG00000186472 PCLO 0,514 1,04E-03 
ENSG00000258947  0,435 1,07E-03 
ENSG00000113070 HBEGF 0,785 1,09E-03 
ENSG00000186716 BCR 0,371 1,09E-03 
ENSG00000177409 SAMD9L -0,472 1,11E-03 
ENSG00000147234 FRMPD3 0,500 1,15E-03 
ENSG00000072778 ACADVL -0,361 1,15E-03 
ENSG00000180834 MAP6D1 0,579 1,16E-03 
ENSG00000134602 RBM4B -0,310 1,17E-03 
ENSG00000168078 PBK 0,395 1,18E-03 
ENSG00000107938 EDRF1 0,554 1,23E-03 
ENSG00000152332 UHMK1 -0,414 1,25E-03 
ENSG00000108798 ABI3 0,591 1,29E-03 
ENSG00000109805 NCAPG 0,382 1,37E-03 
ENSG00000106479 ZNF862 -0,441 1,37E-03 
ENSG00000164849 GPR146 0,598 1,39E-03 
ENSG00000103647 CORO2B 0,862 1,45E-03 
ENSG00000272410  -1,000 1,47E-03 
ENSG00000186951 PPARA -0,365 1,48E-03 
ENSG00000150054 MPP7 0,398 1,52E-03 
ENSG00000169100 SLC25A6 0,472 1,53E-03 
ENSG00000167995 BEST1 -0,699 1,56E-03 
ENSG00000136286 MYO1G 0,499 1,57E-03 
ENSG00000198106 SNX29P2 0,366 1,60E-03 
ENSG00000059145 UNKL -0,411 1,60E-03 
ENSG00000165905 GYLTL1B 0,877 1,62E-03 
ENSG00000105613 MAST1 0,764 1,62E-03 
ENSG00000152492 CCDC50 -0,644 1,68E-03 
ENSG00000129048 ACKR4 0,460 1,70E-03 
ENSG00000224420 ADM5 -0,666 1,70E-03 
ENSG00000033170 FUT8 0,393 1,72E-03 
ENSG00000108515 ENO3 -0,621 1,72E-03 
ENSG00000198624 CCDC69 0,337 1,75E-03 
ENSG00000184661 CDCA2 0,430 1,77E-03 
ENSG00000090975 PITPNM2 0,364 1,78E-03 
ENSG00000122224 LY9 -0,599 1,82E-03 
ENSG00000074266 EED 0,326 1,87E-03 
ENSG00000072571 HMMR 0,405 1,91E-03 
ENSG00000092470 WDR76 0,522 1,93E-03 
ENSG00000174428 GTF2IRD2B -0,387 1,97E-03 
ENSG00000198840 MT-ND3 -0,332 2,02E-03 
ENSG00000213199 ASIC3 -0,775 2,04E-03 
ENSG00000197746 PSAP -0,303 2,06E-03 
ENSG00000263528 IKBKE 0,409 2,12E-03 
ENSG00000263136  0,450 2,13E-03 
ENSG00000204681 GABBR1 -0,793 2,13E-03 
ENSG00000183604 SMG1P5 0,363 2,15E-03 
ENSG00000166326 TRIM44 -0,454 2,15E-03 
ENSG00000209082 MT-TL1 -0,856 2,15E-03 
ENSG00000024526 DEPDC1 0,342 2,17E-03 
ENSG00000140848 CPNE2 0,380 2,20E-03 
ENSG00000197747 S100A10 -0,494 2,21E-03 
ENSG00000225373 WASH5P -0,446 2,21E-03 
ENSG00000198695 MT-ND6 -0,422 2,23E-03 
ENSG00000126787 DLGAP5 0,389 2,24E-03 
ENSG00000128274 A4GALT 0,349 2,25E-03 
ENSG00000091592 NLRP1 -0,544 2,26E-03 
ENSG00000100162 CENPM 0,438 2,29E-03 
ENSG00000104972 PODNL1 0,559 2,34E-03 
ENSG00000065308 TRAM2 -0,303 2,38E-03 
ENSG00000243207 PPAN-P2RY11 -1,298 2,45E-03 
ENSG00000107742 SPOCK2 -0,485 2,46E-03 
ENSG00000196422 PPP1R26 -0,713 2,47E-03 
ENSG00000147905 ZCCHC7 0,342 2,50E-03 
ENSG00000121152 NCAPH 0,367 2,60E-03 
ENSG00000114841 DNAH1 -0,990 2,73E-03 
ENSG00000161939 RNASEK-C17orf49 -1,582 2,78E-03 
ENSG00000198786 MT-ND5 -0,408 2,93E-03 
ENSG00000228590  0,813 2,95E-03 
ENSG00000163382 APOA1BP 0,372 2,95E-03 
ENSG00000228716 DHFR 0,389 2,95E-03 
ENSG00000157933 SKI -0,428 2,98E-03 
ENSG00000005844 ITGAL 0,396 3,00E-03 
ENSG00000196517 SLC6A9 -0,310 3,05E-03 
ENSG00000197385 ZNF860 0,563 3,05E-03 
ENSG00000142347 MYO1F -0,991 3,06E-03 
ENSG00000108375 RNF43 0,311 3,08E-03 
ENSG00000077150 NFKB2 -0,338 3,13E-03 
ENSG00000118193 KIF14 0,340 3,15E-03 
ENSG00000112308 C6orf62 -0,338 3,15E-03 
ENSG00000148341 SH3GLB2 0,386 3,16E-03 
ENSG00000136213 CHST12 0,803 3,18E-03 
ENSG00000108984 MAP2K6 1,208 3,18E-03 
ENSG00000114554 PLXNA1 -0,398 3,24E-03 
ENSG00000128335 APOL2 -0,478 3,28E-03 
ENSG00000114529 C3orf52 0,437 3,29E-03 
ENSG00000160685 ZBTB7B -0,358 3,29E-03 
ENSG00000187210 GCNT1 0,367 3,31E-03 
ENSG00000249319  -1,415 3,31E-03 
ENSG00000269728  0,404 3,32E-03 
ENSG00000144645 OSBPL10 0,374 3,40E-03 
ENSG00000196189 SEMA4A 0,346 3,41E-03 
ENSG00000130779 CLIP1 -0,370 3,41E-03 
ENSG00000113448 DPYSL3 -0,949 3,42E-03 
ENSG00000103249 CLCN7 -0,369 3,50E-03 
ENSG00000197530 MIB2 -0,390 3,56E-03 
ENSG00000213402 PTPRCAP 0,417 3,60E-03 
ENSG00000061337 LZTS1 0,491 3,62E-03 
ENSG00000187621 TCL6 0,447 3,68E-03 
ENSG00000072310 SREBF1 -0,323 3,78E-03 
ENSG00000149115 TNKS1BP1 -0,351 3,80E-03 
ENSG00000168961 LGALS9 -0,793 3,86E-03 
ENSG00000132359 RAP1GAP2 0,425 3,87E-03 
ENSG00000182010 RTKN2 0,392 3,88E-03 
ENSG00000139200 PIANP 0,652 3,91E-03 
ENSG00000226958 RNA28S5 -0,406 3,96E-03 
ENSG00000163618 CADPS 0,388 3,99E-03 
ENSG00000160298 C21orf58 0,472 4,00E-03 
ENSG00000166135 HIF1AN -0,321 4,05E-03 
ENSG00000100365 NCF4 0,416 4,05E-03 
ENSG00000126003 PLAGL2 -0,320 4,12E-03 
ENSG00000264558  -1,237 4,13E-03 
ENSG00000068489 PRR11 0,405 4,17E-03 
ENSG00000254413 CHKB-CPT1B -0,501 4,27E-03 
ENSG00000182087 TMEM259 -0,345 4,30E-03 
ENSG00000079313 REXO1 -0,305 4,31E-03 
ENSG00000188486 H2AFX 0,343 4,37E-03 
ENSG00000095397 DFNB31 -0,691 4,41E-03 
ENSG00000149970 CNKSR2 0,551 4,42E-03 
ENSG00000130589 HELZ2 -0,426 4,44E-03 
ENSG00000156471 PTDSS1 0,376 4,45E-03 
ENSG00000134215 VAV3 -0,487 4,45E-03 
ENSG00000134057 CCNB1 0,338 4,49E-03 
ENSG00000182986 ZNF320 -0,551 4,52E-03 
ENSG00000226029  -0,864 4,59E-03 
ENSG00000166803 KIAA0101 0,489 4,67E-03 
ENSG00000131778 CHD1L 0,382 4,73E-03 
ENSG00000239219  0,579 4,74E-03 
ENSG00000051341 POLQ 0,346 4,84E-03 
ENSG00000114450 GNB4 0,362 4,86E-03 
ENSG00000204946 ZNF783 -0,522 4,88E-03 
ENSG00000149054 ZNF215 0,404 4,88E-03 
ENSG00000250506 CDK3 -0,740 4,92E-03 
ENSG00000154229 PRKCA 0,323 5,02E-03 
ENSG00000111445 RFC5 0,371 5,04E-03 
ENSG00000211896 IGHG1 -0,820 5,04E-03 
ENSG00000131462 TUBG1 0,391 5,07E-03 
ENSG00000123360 PDE1B -0,765 5,09E-03 
ENSG00000062282 DGAT2 -0,533 5,21E-03 
ENSG00000180867 PDIA3P1 -0,868 5,21E-03 
ENSG00000198520 C1orf228 -0,805 5,23E-03 
ENSG00000115677 HDLBP -0,276 5,26E-03 
ENSG00000225889  -0,463 5,27E-03 
ENSG00000102760 RGCC 0,468 5,29E-03 
ENSG00000083454 P2RX5 0,335 5,29E-03 
ENSG00000169220 RGS14 0,420 5,32E-03 
ENSG00000164916 FOXK1 -0,379 5,33E-03 
ENSG00000184226 PCDH9 0,332 5,39E-03 
ENSG00000182095 TNRC18 -0,362 5,40E-03 
ENSG00000140534 TICRR 0,400 5,40E-03 
ENSG00000139636 LMBR1L -0,376 5,44E-03 
ENSG00000215252 GOLGA8B -0,389 5,45E-03 
ENSG00000114346 ECT2 0,298 5,46E-03 
ENSG00000179532 DNHD1 -0,391 5,47E-03 
ENSG00000145979 TBC1D7 0,431 5,51E-03 
ENSG00000242539  0,364 5,54E-03 
ENSG00000238164  -0,537 5,57E-03 
ENSG00000189057 FAM111B 0,333 5,59E-03 
ENSG00000117724 CENPF 0,302 5,63E-03 
ENSG00000142765 SYTL1 -0,408 5,63E-03 
ENSG00000177542 SLC25A22 -0,312 5,64E-03 
ENSG00000197256 KANK2 0,337 5,65E-03 
ENSG00000262526  -1,939 5,72E-03 
ENSG00000188985 DHFRP1 0,463 5,78E-03 
ENSG00000149499 EML3 -0,313 5,79E-03 
ENSG00000262728  0,789 5,81E-03 
ENSG00000104413 ESRP1 -0,598 5,84E-03 
ENSG00000028277 POU2F2 0,343 5,84E-03 
ENSG00000276043 UHRF1 0,370 5,85E-03 
ENSG00000011275 RNF216 -0,351 5,87E-03 
ENSG00000163006 CCDC138 0,322 5,88E-03 
ENSG00000042062 FAM65C 0,852 5,91E-03 
ENSG00000148834 GSTO1 0,394 5,96E-03 
ENSG00000104081 BMF -0,341 6,03E-03 
ENSG00000137135 ARHGEF39 0,515 6,04E-03 
ENSG00000148773 MKI67 0,292 6,05E-03 
ENSG00000111674 ENO2 -0,773 6,07E-03 
ENSG00000164815 ORC5 0,294 6,08E-03 
ENSG00000111665 CDCA3 0,362 6,09E-03 
ENSG00000173991 TCAP -0,895 6,16E-03 
ENSG00000049541 RFC2 0,389 6,17E-03 
ENSG00000242265 PEG10 0,368 6,20E-03 
ENSG00000151725 CENPU 0,465 6,21E-03 
ENSG00000088986 DYNLL1 -0,333 6,23E-03 
ENSG00000160408 ST6GALNAC6 -0,380 6,25E-03 
ENSG00000259772  0,468 6,32E-03 
ENSG00000205542 TMSB4X -0,285 6,32E-03 
ENSG00000068137 PLEKHH3 0,485 6,38E-03 
ENSG00000048471 SNX29 0,339 6,38E-03 
ENSG00000112715 VEGFA -0,310 6,39E-03 
ENSG00000082641 NFE2L1 -0,289 6,43E-03 
ENSG00000183137 CEP57L1 0,394 6,45E-03 
ENSG00000274292  -0,839 6,48E-03 
ENSG00000141956 PRDM15 0,361 6,48E-03 
ENSG00000129173 E2F8 0,358 6,60E-03 
ENSG00000079462 PAFAH1B3 0,584 6,61E-03 
ENSG00000174371 EXO1 0,390 6,61E-03 
ENSG00000111452 GPR133 0,420 6,64E-03 
ENSG00000112293 GPLD1 0,335 6,65E-03 
ENSG00000185963 BICD2 0,305 6,72E-03 
ENSG00000112312 GMNN 0,330 6,73E-03 
ENSG00000147535 PPAPDC1B -0,368 6,77E-03 
ENSG00000142583 SLC2A5 0,380 6,87E-03 
ENSG00000244342 LINC00698 -1,011 6,96E-03 
ENSG00000215769 MIR6080 -0,559 6,97E-03 
ENSG00000127838 PNKD 0,362 6,99E-03 
ENSG00000167900 TK1 0,444 7,03E-03 
ENSG00000182158 CREB3L2 0,412 7,04E-03 
ENSG00000100479 POLE2 0,520 7,05E-03 
ENSG00000080839 RBL1 0,322 7,05E-03 
ENSG00000196586 MYO6 -0,751 7,16E-03 
ENSG00000164050 PLXNB1 -0,739 7,21E-03 
ENSG00000137404 NRM 0,537 7,24E-03 
ENSG00000140941 MAP1LC3B -0,367 7,25E-03 
ENSG00000014138 POLA2 0,486 7,30E-03 
ENSG00000211897 IGHG3 -0,682 7,30E-03 
ENSG00000142102 ATHL1 -0,636 7,33E-03 
ENSG00000188070 C11orf95 -0,313 7,50E-03 
ENSG00000244165 P2RY11 -0,522 7,51E-03 
ENSG00000197774 EME2 -0,380 7,53E-03 
ENSG00000092036 HAUS4 0,484 7,56E-03 
ENSG00000152409 JMY -0,371 7,60E-03 
ENSG00000131480 AOC2 -0,649 7,67E-03 
ENSG00000042980 ADAM28 -0,652 7,68E-03 
ENSG00000182013 PNMAL1 0,318 7,72E-03 
ENSG00000234769 WASH4P -0,387 7,78E-03 
ENSG00000205544 TMEM256 0,462 7,79E-03 
ENSG00000106537 TSPAN13 0,607 7,80E-03 
ENSG00000093009 CDC45 0,399 7,88E-03 
ENSG00000035720 STAP1 0,299 7,91E-03 
ENSG00000080986 NDC80 0,321 7,92E-03 
ENSG00000157557 ETS2 -0,301 7,96E-03 
ENSG00000196338 NLGN3 -0,950 8,00E-03 
ENSG00000135740 SLC9A5 -0,869 8,06E-03 
ENSG00000175782 SLC35E3 0,369 8,07E-03 
ENSG00000078804 TP53INP2 -0,443 8,21E-03 
ENSG00000146263 MMS22L 0,380 8,29E-03 
ENSG00000142197 DOPEY2 0,358 8,32E-03 
ENSG00000136492 BRIP1 0,389 8,36E-03 
ENSG00000113387 SUB1 -0,284 8,37E-03 
ENSG00000124243 BCAS4 0,291 8,39E-03 
ENSG00000269968  0,415 8,53E-03 
ENSG00000270898 TMIGD2 1,996 8,57E-03 
ENSG00000177646 ACAD9 0,456 8,60E-03 
ENSG00000153936 HS2ST1 0,351 8,72E-03 
ENSG00000231925 TAPBP -0,288 8,73E-03 
ENSG00000125245 GPR18 0,524 8,78E-03 
ENSG00000261604  -0,617 8,85E-03 
ENSG00000121621 KIF18A 0,306 8,87E-03 
ENSG00000137078 SIT1 0,323 8,88E-03 
ENSG00000157470 FAM81A 0,414 9,01E-03 
ENSG00000225828 FAM229A -0,628 9,08E-03 
ENSG00000183044 ABAT -0,311 9,08E-03 
ENSG00000185022 MAFF -0,663 9,19E-03 
ENSG00000250067 YJEFN3 -0,691 9,20E-03 
ENSG00000135093 USP30 0,403 9,22E-03 
ENSG00000081320 STK17B 0,427 9,23E-03 
ENSG00000103066 PLA2G15 0,320 9,24E-03 
ENSG00000101144 BMP7 0,302 9,27E-03 
ENSG00000109674 NEIL3 0,370 9,35E-03 
ENSG00000145386 CCNA2 0,314 9,37E-03 
ENSG00000153815 CMIP 0,248 9,41E-03 
ENSG00000231443  -0,909 9,42E-03 
ENSG00000112658 SRF -0,298 9,44E-03 
ENSG00000070371 CLTCL1 0,785 9,46E-03 
ENSG00000123219 CENPK 0,345 9,46E-03 
ENSG00000197961 ZNF121 -0,360 9,48E-03 
ENSG00000138160 KIF11 0,288 9,49E-03 
ENSG00000121413 ZSCAN18 -0,427 9,51E-03 
ENSG00000213413 PVRIG 0,443 9,65E-03 
ENSG00000258727  -0,546 9,79E-03 
ENSG00000169607 CKAP2L 0,292 9,80E-03 
ENSG00000139684 ESD 0,278 9,81E-03 
ENSG00000104903 LYL1 0,374 9,87E-03 
ENSG00000105486 LIG1 0,316 9,88E-03 
ENSG00000123352 SPATS2 0,284 9,90E-03 
ENSG00000163536 SERPINI1 0,403 9,93E-03 
ENSG00000132326 PER2 -0,368 9,94E-03 
ENSG00000237594  0,886 9,95E-03 
ENSG00000137310 TCF19 0,359 1,00E-02 
ENSG00000104805 NUCB1 0,337 1,00E-02 
ENSG00000020577 SAMD4A -0,453 1,01E-02 
ENSG00000138834 MAPK8IP3 -0,388 1,01E-02 
ENSG00000221978 CCNL2 -0,336 1,01E-02 
ENSG00000119711 ALDH6A1 -0,295 1,01E-02 
ENSG00000196199 MPHOSPH8 -0,294 1,02E-02 
ENSG00000163322 FAM175A 0,404 1,02E-02 
ENSG00000128944 KNSTRN 0,352 1,03E-02 
ENSG00000198826 ARHGAP11A 0,292 1,03E-02 
ENSG00000176871 WSB2 -0,436 1,04E-02 
ENSG00000139291 TMEM19 0,379 1,05E-02 
ENSG00000196664 TLR7 0,439 1,05E-02 
ENSG00000260916 OCM -0,271 1,05E-02 
ENSG00000183741 CBX6 -0,500 1,05E-02 
ENSG00000135473 PAN2 -0,358 1,06E-02 
ENSG00000111602 TIMELESS 0,351 1,06E-02 
ENSG00000007312 CD79B 0,320 1,06E-02 
ENSG00000183048 SLC25A10 0,555 1,06E-02 
ENSG00000137393 RNF144B 0,501 1,06E-02 
ENSG00000136141 LRCH1 0,318 1,06E-02 
ENSG00000163808 KIF15 0,343 1,06E-02 
ENSG00000161912 ADCY10P1 -0,711 1,06E-02 
ENSG00000145687 SSBP2 0,309 1,06E-02 
ENSG00000267680 ZNF224 -0,368 1,07E-02 
ENSG00000187796 CARD9 -0,723 1,08E-02 
ENSG00000111640 GAPDH 0,345 1,08E-02 
ENSG00000099899 TRMT2A 0,351 1,08E-02 
ENSG00000079691 LRRC16A 0,317 1,08E-02 
ENSG00000165832 TRUB1 -0,253 1,09E-02 
ENSG00000079257 LXN 0,536 1,09E-02 
ENSG00000169016 E2F6 -0,318 1,09E-02 
ENSG00000158402 CDC25C 0,431 1,09E-02 
ENSG00000082805 ERC1 0,279 1,09E-02 
ENSG00000072135 PTPN18 0,336 1,10E-02 
ENSG00000203668 CHML 0,348 1,10E-02 
ENSG00000126562 CERS5 -0,852 1,11E-02 
ENSG00000188827 SLX4 0,283 1,11E-02 
ENSG00000168970 JMJD7-PLA2G4B -0,459 1,13E-02 
ENSG00000123485 HJURP 0,276 1,13E-02 
ENSG00000211459 MT-RNR1 -0,354 1,14E-02 
ENSG00000069956 MAPK6 -0,267 1,15E-02 
ENSG00000101444 AHCY 0,372 1,16E-02 
ENSG00000171320 ESCO2 0,314 1,17E-02 
ENSG00000196990 FAM163B 0,397 1,18E-02 
ENSG00000127603 MACF1 0,283 1,18E-02 
ENSG00000168246 UBTD2 -0,282 1,18E-02 
ENSG00000203667 COX20 -0,271 1,18E-02 
ENSG00000102384 CENPI 0,353 1,19E-02 
ENSG00000026508 CD44 -1,043 1,19E-02 
ENSG00000259529  -0,589 1,19E-02 
ENSG00000148343 FAM73B -0,287 1,20E-02 
ENSG00000140525 FANCI 0,314 1,20E-02 
ENSG00000181817 LSM10 0,290 1,20E-02 
ENSG00000198885 ITPRIPL1 0,388 1,20E-02 
ENSG00000117399 CDC20 0,339 1,22E-02 
ENSG00000196367 TRRAP 0,242 1,23E-02 
ENSG00000124257 NEURL2 0,804 1,23E-02 
ENSG00000187954 CYHR1 -0,296 1,24E-02 
ENSG00000272335  -0,618 1,24E-02 
ENSG00000213722 DDAH2 -0,625 1,26E-02 
ENSG00000166004 KIAA1731 0,263 1,26E-02 
ENSG00000047644 WWC3 0,325 1,27E-02 
ENSG00000171617 ENC1 0,578 1,27E-02 
ENSG00000135441 BLOC1S1 0,346 1,27E-02 
ENSG00000139734 DIAPH3 0,309 1,28E-02 
ENSG00000077454 LRCH4 -0,299 1,28E-02 
ENSG00000183624 HMCES 0,322 1,28E-02 
ENSG00000171298 GAA -0,405 1,28E-02 
ENSG00000122188 LAX1 0,326 1,29E-02 
ENSG00000126067 PSMB2 -0,256 1,29E-02 
ENSG00000168502 MTCL1 0,324 1,29E-02 
ENSG00000184271 POU6F1 -0,526 1,29E-02 
ENSG00000235621 LINC00494 -0,525 1,30E-02 
ENSG00000145476 CYP4V2 -0,390 1,30E-02 
ENSG00000163535 SGOL2 0,292 1,30E-02 
ENSG00000236144  -0,275 1,30E-02 
ENSG00000147168 IL2RG -0,321 1,31E-02 
ENSG00000184207 PGP 0,306 1,31E-02 
ENSG00000145779 TNFAIP8 0,300 1,31E-02 
ENSG00000173950 XXYLT1 0,344 1,32E-02 
ENSG00000096746 HNRNPH3 -0,337 1,32E-02 
ENSG00000148154 UGCG -0,293 1,32E-02 
ENSG00000170365 SMAD1 0,361 1,33E-02 
ENSG00000163093 BBS5 -0,644 1,35E-02 
ENSG00000144331 ZNF385B 0,401 1,35E-02 
ENSG00000174123 TLR10 0,307 1,36E-02 
ENSG00000000938 FGR 0,442 1,36E-02 
ENSG00000253733 LZTS1-AS1 0,799 1,37E-02 
ENSG00000161888 SPC24 0,393 1,37E-02 
ENSG00000132680 KIAA0907 -0,295 1,37E-02 
ENSG00000155629 PIK3AP1 0,253 1,38E-02 
ENSG00000111981 ULBP1 -0,298 1,38E-02 
ENSG00000178685 PARP10 -0,294 1,38E-02 
ENSG00000185101 ANO9 -0,374 1,38E-02 
ENSG00000106415 GLCCI1 0,371 1,38E-02 
ENSG00000123473 STIL 0,282 1,38E-02 
ENSG00000168404 MLKL 0,598 1,38E-02 
ENSG00000205189 ZBTB10 -0,301 1,39E-02 
ENSG00000006576 PHTF2 0,300 1,39E-02 
ENSG00000068831 RASGRP2 -0,264 1,39E-02 
ENSG00000101224 CDC25B 0,263 1,41E-02 
ENSG00000078487 ZCWPW1 -0,441 1,41E-02 
ENSG00000133678 TMEM254 -0,689 1,41E-02 
ENSG00000272899  -0,811 1,41E-02 
ENSG00000157514 TSC22D3 -0,298 1,42E-02 
ENSG00000085999 RAD54L 0,479 1,42E-02 
ENSG00000253729 PRKDC 0,251 1,43E-02 
ENSG00000223745  -0,344 1,43E-02 
ENSG00000103021 CCDC113 -0,573 1,44E-02 
ENSG00000092068 SLC7A8 -0,437 1,44E-02 
ENSG00000147434 CHRNA6 -0,383 1,44E-02 
ENSG00000102096 PIM2 -0,306 1,48E-02 
ENSG00000174130 TLR6 -0,433 1,48E-02 
ENSG00000166292 TMEM100 0,868 1,49E-02 
ENSG00000100403 ZC3H7B -0,262 1,50E-02 
ENSG00000164463 CREBRF -0,403 1,50E-02 
ENSG00000164002 EXO5 0,614 1,50E-02 
ENSG00000254815  -0,627 1,50E-02 
ENSG00000156042 TTC18 -0,658 1,51E-02 
ENSG00000267194  1,033 1,51E-02 
ENSG00000168528 SERINC2 0,456 1,52E-02 
ENSG00000172869 DMXL1 0,248 1,52E-02 
ENSG00000228171  0,737 1,52E-02 
ENSG00000100219 XBP1 0,326 1,52E-02 
ENSG00000111424 VDR 0,588 1,53E-02 
ENSG00000100368 CSF2RB 0,391 1,53E-02 
ENSG00000175348 TMEM9B -0,260 1,53E-02 
ENSG00000148700 ADD3 0,289 1,53E-02 
ENSG00000213213 CCDC183 -0,765 1,54E-02 
ENSG00000101255 TRIB3 -0,302 1,54E-02 
ENSG00000100320 RBFOX2 0,241 1,56E-02 
ENSG00000186480 INSIG1 -0,273 1,56E-02 
ENSG00000144749 LRIG1 0,289 1,56E-02 
ENSG00000153551 CMTM7 0,460 1,56E-02 
ENSG00000154556 SORBS2 0,249 1,57E-02 
ENSG00000261087  -0,623 1,58E-02 
ENSG00000178162 FAR2P2 0,261 1,58E-02 
ENSG00000224578 HNRNPA1P48 0,420 1,58E-02 
ENSG00000125170 DOK4 -0,571 1,58E-02 
ENSG00000005059 CCDC109B 0,274 1,59E-02 
ENSG00000258168  0,331 1,59E-02 
ENSG00000092140 G2E3 0,261 1,59E-02 
ENSG00000085719 CPNE3 0,240 1,59E-02 
ENSG00000097046 CDC7 0,282 1,60E-02 
ENSG00000165476 REEP3 -0,370 1,60E-02 
ENSG00000106404 CLDN15 -0,369 1,60E-02 
ENSG00000089685 BIRC5 0,270 1,60E-02 
ENSG00000180096 SEPT1 -0,295 1,61E-02 
ENSG00000138376 BARD1 0,294 1,61E-02 
ENSG00000115355 CCDC88A 0,260 1,61E-02 
ENSG00000134508 CABLES1 -0,251 1,61E-02 
ENSG00000185811 IKZF1 0,329 1,61E-02 
ENSG00000104517 UBR5 0,252 1,62E-02 
ENSG00000256618 MTRNR2L1 -0,571 1,62E-02 
ENSG00000167513 CDT1 0,418 1,62E-02 
ENSG00000139193 CD27 0,532 1,63E-02 
ENSG00000260032 LINC00657 -0,298 1,63E-02 
ENSG00000120093 HOXB3 -0,552 1,63E-02 
ENSG00000164713 BRI3 -0,283 1,64E-02 
ENSG00000172340 SUCLG2 0,340 1,64E-02 
ENSG00000175643 RMI2 0,346 1,65E-02 
ENSG00000101199 ARFGAP1 -0,256 1,65E-02 
ENSG00000132003 ZSWIM4 -0,314 1,65E-02 
ENSG00000095002 MSH2 0,315 1,65E-02 
ENSG00000220201 ZGLP1 -0,609 1,65E-02 
ENSG00000259522  -0,700 1,66E-02 
ENSG00000167925 GHDC -0,245 1,66E-02 
ENSG00000137807 KIF23 0,288 1,67E-02 
ENSG00000104889 RNASEH2A 0,338 1,67E-02 
ENSG00000186638 KIF24 0,308 1,67E-02 
ENSG00000112234 FBXL4 0,267 1,67E-02 
ENSG00000138757 G3BP2 -0,239 1,67E-02 
ENSG00000257594 GALNT4 -1,659 1,68E-02 
ENSG00000133612 AGAP3 0,429 1,68E-02 
ENSG00000243335 KCTD7 0,289 1,68E-02 
ENSG00000173281 PPP1R3B -0,309 1,68E-02 
ENSG00000196118 C16orf93 0,360 1,69E-02 
ENSG00000048028 USP28 0,255 1,69E-02 
ENSG00000164611 PTTG1 0,280 1,70E-02 
ENSG00000153066 TXNDC11 0,400 1,70E-02 
ENSG00000138796 HADH 0,331 1,70E-02 
ENSG00000130413 STK33 0,611 1,71E-02 
ENSG00000214655 ZSWIM8 -0,328 1,71E-02 
ENSG00000258674  -0,745 1,72E-02 
ENSG00000146918 NCAPG2 0,265 1,72E-02 
ENSG00000140854 KATNB1 0,297 1,72E-02 
ENSG00000260853  -0,719 1,73E-02 
ENSG00000108528 SLC25A11 0,352 1,73E-02 
ENSG00000103966 EHD4 0,260 1,74E-02 
ENSG00000166851 PLK1 0,321 1,74E-02 
ENSG00000249003 CLUHP4 -0,822 1,74E-02 
ENSG00000005243 COPZ2 -0,648 1,74E-02 
ENSG00000164850 GPER1 0,310 1,75E-02 
ENSG00000109063 MYH3 -0,696 1,75E-02 
ENSG00000127415 IDUA -0,441 1,76E-02 
ENSG00000182054 IDH2 0,447 1,76E-02 
ENSG00000155008 APOOL -0,309 1,76E-02 
ENSG00000198771 RCSD1 0,263 1,76E-02 
ENSG00000137070 IL11RA -0,609 1,76E-02 
ENSG00000170476 MZB1 0,271 1,77E-02 
ENSG00000160058 BSDC1 -0,304 1,78E-02 
ENSG00000159496 RGL4 -0,671 1,79E-02 
ENSG00000102738 MRPS31 -0,277 1,79E-02 
ENSG00000137766 UNC13C 0,291 1,79E-02 
ENSG00000185359 HGS -0,293 1,80E-02 
ENSG00000198554 WDHD1 0,318 1,80E-02 
ENSG00000144354 CDCA7 0,588 1,81E-02 
ENSG00000123329 ARHGAP9 -0,288 1,81E-02 
ENSG00000008710 PKD1 -0,279 1,81E-02 
ENSG00000167766 ZNF83 -0,284 1,81E-02 
ENSG00000182934 SRPR -0,266 1,82E-02 
ENSG00000159588 CCDC17 -0,546 1,82E-02 
ENSG00000267924  -0,407 1,82E-02 
ENSG00000048991 R3HDM1 0,266 1,82E-02 
ENSG00000126804 ZBTB1 -0,263 1,82E-02 
ENSG00000025708 TYMP -0,467 1,83E-02 
ENSG00000124496 TRERF1 0,390 1,83E-02 
ENSG00000151148 UBE3B -0,281 1,83E-02 
ENSG00000234771  -0,460 1,84E-02 
ENSG00000137411 VARS2 -0,333 1,84E-02 
ENSG00000101194 SLC17A9 -0,238 1,85E-02 
ENSG00000108785 HSD17B1P1 -0,754 1,86E-02 
ENSG00000094804 CDC6 0,284 1,86E-02 
ENSG00000242802 AP5Z1 -0,284 1,87E-02 
ENSG00000121671 CRY2 -0,277 1,87E-02 
ENSG00000112081 SRSF3 0,249 1,88E-02 
ENSG00000124920 MYRF -0,694 1,89E-02 
ENSG00000147010 SH3KBP1 0,320 1,89E-02 
ENSG00000152455 SUV39H2 0,289 1,90E-02 
ENSG00000274272  -0,465 1,90E-02 
ENSG00000130810 PPAN -0,348 1,90E-02 
ENSG00000104852 SNRNP70 -0,321 1,90E-02 
ENSG00000185760 KCNQ5 0,313 1,90E-02 
ENSG00000127423 AUNIP 0,384 1,91E-02 
ENSG00000139370 SLC15A4 0,277 1,92E-02 
ENSG00000171204 TMEM126B 0,249 1,92E-02 
ENSG00000048140 TSPAN17 -0,244 1,92E-02 
ENSG00000158805 ZNF276 -0,334 1,93E-02 
ENSG00000197724 PHF2 -0,255 1,93E-02 
ENSG00000042286 AIFM2 -0,385 1,93E-02 
ENSG00000124429 POF1B -0,519 1,93E-02 
ENSG00000166128 RAB8B -0,239 1,94E-02 
ENSG00000215301 DDX3X -0,317 1,94E-02 
ENSG00000124208 TMEM189-UBE2V1 -2,939 1,96E-02 
ENSG00000144043 TEX261 -0,227 1,96E-02 
ENSG00000106991 ENG -0,638 1,96E-02 
ENSG00000197498 RPF2 -0,278 1,97E-02 
ENSG00000156831 NSMCE2 0,313 1,97E-02 
ENSG00000013810 TACC3 0,256 1,98E-02 
ENSG00000023839 ABCC2 -0,714 1,98E-02 
ENSG00000055609 KMT2C 0,239 1,98E-02 
ENSG00000116062 MSH6 0,296 1,99E-02 
ENSG00000100307 CBX7 -0,282 1,99E-02 
ENSG00000158711 ELK4 -0,313 1,99E-02 
ENSG00000032444 PNPLA6 -0,287 2,00E-02 
ENSG00000174151 CYB561D1 -0,345 2,00E-02 
ENSG00000198169 ZNF251 -0,275 2,00E-02 
ENSG00000240024 LINC00888 0,401 2,00E-02 
ENSG00000164989 CCDC171 0,305 2,01E-02 
ENSG00000175873  0,685 2,01E-02 
ENSG00000171202 TMEM126A 0,268 2,02E-02 
ENSG00000231424  0,548 2,02E-02 
ENSG00000205978 NYNRIN 0,843 2,02E-02 
ENSG00000260083 MIR4519 -0,525 2,02E-02 
ENSG00000174500 GCSAM 0,397 2,04E-02 
ENSG00000224597 PTCHD3P1 0,577 2,04E-02 
ENSG00000076248 UNG 0,331 2,04E-02 
ENSG00000035499 DEPDC1B 0,292 2,05E-02 
ENSG00000253200  -0,535 2,05E-02 
ENSG00000150991 UBC -0,286 2,07E-02 
ENSG00000162739 SLAMF6 0,279 2,09E-02 
ENSG00000242125 SNHG3 -0,314 2,09E-02 
ENSG00000157483 MYO1E 0,317 2,09E-02 
ENSG00000196092 PAX5 0,251 2,10E-02 
ENSG00000159753 RLTPR -0,249 2,10E-02 
ENSG00000173727  0,366 2,11E-02 
ENSG00000271119  -0,693 2,11E-02 
ENSG00000142556 ZNF614 -0,312 2,12E-02 
ENSG00000163141 BNIPL -0,728 2,12E-02 
ENSG00000255339  -0,531 2,12E-02 
ENSG00000173366  0,320 2,12E-02 
ENSG00000108256 NUFIP2 -0,329 2,14E-02 
ENSG00000249679  0,422 2,14E-02 
ENSG00000144711 IQSEC1 0,249 2,14E-02 
ENSG00000137496 IL18BP -0,528 2,15E-02 
ENSG00000162063 CCNF 0,266 2,15E-02 
ENSG00000165169 DYNLT3 -0,283 2,16E-02 
ENSG00000162062 C16orf59 0,319 2,17E-02 
ENSG00000167700 MFSD3 0,407 2,17E-02 
ENSG00000145425 RPS3A 0,256 2,17E-02 
ENSG00000167747 C19orf48 0,428 2,18E-02 
ENSG00000186104 CYP2R1 0,442 2,18E-02 
ENSG00000023697 DERA 0,330 2,18E-02 
ENSG00000158882 TOMM40L 0,306 2,19E-02 
ENSG00000269982  -0,652 2,19E-02 
ENSG00000145088 EAF2 0,302 2,20E-02 
ENSG00000140105 WARS -0,259 2,21E-02 
ENSG00000146143 PRIM2 0,271 2,21E-02 
ENSG00000255641  0,795 2,22E-02 
ENSG00000085840 ORC1 0,409 2,22E-02 
ENSG00000196363 WDR5 -0,244 2,22E-02 
ENSG00000127564 PKMYT1 0,329 2,24E-02 
ENSG00000126005 MMP24-AS1 0,365 2,24E-02 
ENSG00000196967 ZNF585A -0,284 2,24E-02 
ENSG00000107796 ACTA2 -0,609 2,24E-02 
ENSG00000240038 AMY2B -0,546 2,25E-02 
ENSG00000134574 DDB2 0,423 2,26E-02 
ENSG00000130005 GAMT 0,441 2,26E-02 
ENSG00000011426 ANLN 0,263 2,26E-02 
ENSG00000075826 SEC31B -0,375 2,28E-02 
ENSG00000214562 NUTM2D -0,677 2,28E-02 
ENSG00000160201 U2AF1 -0,249 2,28E-02 
ENSG00000109079 TNFAIP1 -0,266 2,28E-02 
ENSG00000143314 MRPL24 -0,277 2,28E-02 
ENSG00000164045 CDC25A 0,252 2,29E-02 
ENSG00000119969 HELLS 0,244 2,29E-02 
ENSG00000028137 TNFRSF1B 0,860 2,29E-02 
ENSG00000119509 INVS 0,258 2,29E-02 
ENSG00000175048 ZDHHC14 0,293 2,30E-02 
ENSG00000131470 PSMC3IP 0,324 2,30E-02 
ENSG00000261556 SMG1P7 -0,437 2,30E-02 
ENSG00000260917  -0,346 2,31E-02 
ENSG00000085465 OVGP1 -0,634 2,32E-02 
ENSG00000099377 HSD3B7 -0,670 2,32E-02 
ENSG00000101246 ARFRP1 0,358 2,33E-02 
ENSG00000131127 ZNF141 -0,623 2,34E-02 
ENSG00000130164 LDLR -0,297 2,35E-02 
ENSG00000090861 AARS -0,240 2,35E-02 
ENSG00000007923 DNAJC11 -0,274 2,35E-02 
ENSG00000123933 MXD4 0,281 2,35E-02 
ENSG00000071575 TRIB2 -0,222 2,36E-02 
ENSG00000254087 LYN 0,255 2,36E-02 
ENSG00000068400 GRIPAP1 -0,281 2,36E-02 
ENSG00000251357  -0,818 2,36E-02 
ENSG00000143387 CTSK -0,671 2,37E-02 
ENSG00000165025 SYK 0,288 2,39E-02 
ENSG00000210135 MT-TN -0,456 2,40E-02 
ENSG00000143850 PLEKHA6 -0,594 2,41E-02 
ENSG00000121440 PDZRN3 0,607 2,42E-02 
ENSG00000053371 AKR7A2 0,377 2,43E-02 
ENSG00000095539 SEMA4G -0,707 2,43E-02 
ENSG00000116761 CTH -0,261 2,44E-02 
ENSG00000277449  -0,358 2,45E-02 
ENSG00000129187 DCTD -0,221 2,46E-02 
ENSG00000174437 ATP2A2 -0,252 2,46E-02 
ENSG00000269751  -0,361 2,46E-02 
ENSG00000010361 FUZ 0,347 2,47E-02 
ENSG00000004897 CDC27 0,224 2,47E-02 
ENSG00000153044 CENPH 0,371 2,48E-02 
ENSG00000183814 LIN9 0,279 2,48E-02 
ENSG00000224645  -0,726 2,49E-02 
ENSG00000113328 CCNG1 0,261 2,50E-02 
ENSG00000089280 FUS -0,246 2,51E-02 
ENSG00000273841 AK6 -0,575 2,51E-02 
ENSG00000198839 ZNF277 0,296 2,51E-02 
ENSG00000141391 SLMO1 0,335 2,51E-02 
ENSG00000168016 TRANK1 0,228 2,51E-02 
ENSG00000173276 ZBTB21 -0,292 2,53E-02 
ENSG00000127663 KDM4B -0,250 2,54E-02 
ENSG00000104375 STK3 0,428 2,55E-02 
ENSG00000256269 HMBS 0,290 2,55E-02 
ENSG00000245857  0,623 2,55E-02 
ENSG00000151553 FAM160B1 -0,271 2,56E-02 
ENSG00000250575  -0,914 2,56E-02 
ENSG00000168071 CCDC88B -0,302 2,56E-02 
ENSG00000171132 PRKCE 0,270 2,56E-02 
ENSG00000182484 WASH6P -0,279 2,56E-02 
ENSG00000134330 IAH1 0,280 2,57E-02 
ENSG00000176208 ATAD5 0,254 2,58E-02 
ENSG00000131389 SLC6A6 0,225 2,58E-02 
ENSG00000224051 GLTPD1 0,272 2,58E-02 
ENSG00000104361 NIPAL2 -0,251 2,59E-02 
ENSG00000198382 UVRAG 0,268 2,59E-02 
ENSG00000141965 FEM1A -0,371 2,59E-02 
ENSG00000048462 TNFRSF17 0,517 2,59E-02 
ENSG00000124831 LRRFIP1 0,256 2,60E-02 
ENSG00000104312 RIPK2 0,281 2,60E-02 
ENSG00000102057 KCND1 -0,637 2,60E-02 
ENSG00000172264 MACROD2 0,431 2,61E-02 
ENSG00000146830 GIGYF1 -0,268 2,61E-02 
ENSG00000111012 CYP27B1 -0,480 2,62E-02 
ENSG00000136379 ABHD17C -0,674 2,62E-02 
ENSG00000142188 TMEM50B -0,288 2,63E-02 
ENSG00000100503 NIN 0,220 2,63E-02 
ENSG00000257433  -0,642 2,64E-02 
ENSG00000115163 CENPA 0,311 2,65E-02 
ENSG00000107829 FBXW4 -0,240 2,66E-02 
ENSG00000113739 STC2 -0,252 2,67E-02 
ENSG00000076555 ACACB 0,475 2,67E-02 
ENSG00000073464 CLCN4 0,303 2,68E-02 
ENSG00000152061 RABGAP1L 0,245 2,69E-02 
ENSG00000134138 MEIS2 0,294 2,69E-02 
ENSG00000188917 TRMT2B -0,276 2,70E-02 
ENSG00000198056 PRIM1 0,366 2,70E-02 
ENSG00000162004 CCDC78 -0,383 2,70E-02 
ENSG00000143126 CELSR2 -0,392 2,71E-02 
ENSG00000166024 R3HCC1L 0,256 2,73E-02 
ENSG00000255389  -0,536 2,74E-02 
ENSG00000067533 RRP15 -0,288 2,75E-02 
ENSG00000213599 SLX1A-SULT1A3 -0,352 2,75E-02 
ENSG00000228315 GUSBP11 -0,371 2,76E-02 
ENSG00000166401 SERPINB8 -0,529 2,77E-02 
ENSG00000139433 GLTP -0,242 2,77E-02 
ENSG00000136280 CCM2 0,299 2,77E-02 
ENSG00000172493 AFF1 0,266 2,78E-02 
ENSG00000271303 SRXN1 -0,248 2,78E-02 
ENSG00000105397 TYK2 -0,233 2,79E-02 
ENSG00000178999 AURKB 0,267 2,81E-02 
ENSG00000130511 SSBP4 0,279 2,82E-02 
ENSG00000276710 CSPG4P8 -0,436 2,82E-02 
ENSG00000152253 SPC25 0,327 2,82E-02 
ENSG00000088280 ASAP3 -0,370 2,83E-02 
ENSG00000196372 ASB13 0,323 2,84E-02 
ENSG00000123374 CDK2 0,233 2,84E-02 
ENSG00000014641 MDH1 0,274 2,84E-02 
ENSG00000138430 OLA1 0,287 2,85E-02 
ENSG00000160753 RUSC1 0,314 2,85E-02 
ENSG00000118482 PHF3 0,246 2,85E-02 
ENSG00000142046 TMEM91 -0,671 2,85E-02 
ENSG00000132361 CLUH -0,268 2,85E-02 
ENSG00000170734 POLH 0,219 2,86E-02 
ENSG00000115956 PLEK -0,241 2,88E-02 
ENSG00000131401 NAPSB 0,294 2,88E-02 
ENSG00000120053 GOT1 -0,239 2,88E-02 
ENSG00000196843 ARID5A -0,346 2,88E-02 
ENSG00000138180 CEP55 0,247 2,89E-02 
ENSG00000101412 E2F1 0,256 2,90E-02 
ENSG00000005022 SLC25A5 0,260 2,90E-02 
ENSG00000171067 C11orf24 0,253 2,90E-02 
ENSG00000214425 LRRC37A4P 0,243 2,91E-02 
ENSG00000104381 GDAP1 0,345 2,92E-02 
ENSG00000161010 C5orf45 -0,278 2,92E-02 
ENSG00000215717 TMEM167B -0,230 2,92E-02 
ENSG00000008128 CDK11A -0,313 2,92E-02 
ENSG00000156970 BUB1B 0,220 2,93E-02 
ENSG00000175197 DDIT3 -0,249 2,93E-02 
ENSG00000260852 FBXL19-AS1 -0,449 2,93E-02 
ENSG00000166197 NOLC1 -0,245 2,94E-02 
ENSG00000112232 KHDRBS2 0,749 2,94E-02 
ENSG00000255182  -0,593 2,94E-02 
ENSG00000165457 FOLR2 0,447 2,96E-02 
ENSG00000213339 QTRT1 -0,328 2,98E-02 
ENSG00000154237 LRRK1 0,223 2,99E-02 
ENSG00000065615 CYB5R4 0,246 3,00E-02 
ENSG00000213983 AP1G2 -0,282 3,00E-02 
ENSG00000172167 MTBP 0,278 3,00E-02 
ENSG00000253778  0,633 3,02E-02 
ENSG00000049323 LTBP1 0,256 3,02E-02 
ENSG00000151503 NCAPD3 0,235 3,02E-02 
ENSG00000133392 MYH11 -0,540 3,03E-02 
ENSG00000152240 HAUS1 0,298 3,03E-02 
ENSG00000083799 FAM134C -0,241 3,03E-02 
ENSG00000138346 DNA2 0,249 3,04E-02 
ENSG00000197442 MAP3K5 0,311 3,04E-02 
ENSG00000184524 CEND1 0,248 3,05E-02 
ENSG00000072736 NFATC3 0,218 3,05E-02 
ENSG00000132424 PNISR -0,285 3,05E-02 
ENSG00000157227 MMP14 -0,606 3,05E-02 
ENSG00000258388 PPT2-EGFL8 -0,597 3,06E-02 
ENSG00000172349 IL16 0,224 3,06E-02 
ENSG00000186469 GNG2 0,296 3,07E-02 
ENSG00000111885 MAN1A1 -0,236 3,07E-02 
ENSG00000198890 PRMT6 0,264 3,08E-02 
ENSG00000180353 HCLS1 -0,250 3,08E-02 
ENSG00000146416 AIG1 0,617 3,08E-02 
ENSG00000173715 C11orf80 0,299 3,08E-02 
ENSG00000092853 CLSPN 0,299 3,08E-02 
ENSG00000233822 HIST1H2BN -0,578 3,08E-02 
ENSG00000122483 CCDC18 0,242 3,09E-02 
ENSG00000162231 NXF1 -0,296 3,09E-02 
ENSG00000008952 SEC62 0,238 3,10E-02 
ENSG00000084092 NOA1 0,314 3,10E-02 
ENSG00000269693  -0,470 3,10E-02 
ENSG00000131747 TOP2A 0,251 3,11E-02 
ENSG00000065328 MCM10 0,264 3,11E-02 
ENSG00000227671 MIR3916 -0,265 3,11E-02 
ENSG00000224565  0,461 3,12E-02 
ENSG00000171425 ZNF581 0,288 3,12E-02 
ENSG00000184678 HIST2H2BE -0,591 3,13E-02 
ENSG00000166432 ZMAT1 -0,384 3,14E-02 
ENSG00000151006 PRSS53 -0,567 3,14E-02 
ENSG00000176890 TYMS 0,289 3,15E-02 
ENSG00000136122 BORA 0,279 3,15E-02 
ENSG00000109685 WHSC1 0,229 3,15E-02 
ENSG00000173812 EIF1 -0,232 3,16E-02 
ENSG00000182446 NPLOC4 -0,247 3,16E-02 
ENSG00000168003 SLC3A2 -0,230 3,16E-02 
ENSG00000275591 XKR5 0,557 3,16E-02 
ENSG00000177548 RABEP2 0,286 3,17E-02 
ENSG00000149743 TRPT1 0,334 3,17E-02 
ENSG00000187741 FANCA 0,209 3,18E-02 
ENSG00000214595 EML6 -0,313 3,18E-02 
ENSG00000064547 LPAR2 -0,444 3,19E-02 
ENSG00000198496 NBR2 -0,329 3,20E-02 
ENSG00000164306 PRIMPOL 0,387 3,21E-02 
ENSG00000259583  0,427 3,21E-02 
ENSG00000106077 ABHD11 0,465 3,21E-02 
ENSG00000135205 CCDC146 -0,556 3,23E-02 
ENSG00000089558 KCNH4 -0,553 3,23E-02 
ENSG00000132510 KDM6B -0,298 3,24E-02 
ENSG00000113552 GNPDA1 -0,236 3,24E-02 
ENSG00000170142 UBE2E1 0,251 3,24E-02 
ENSG00000172766 NAA16 0,240 3,24E-02 
ENSG00000198589 LRBA 0,205 3,24E-02 
ENSG00000163975 MFI2 0,400 3,25E-02 
ENSG00000178966 RMI1 0,255 3,25E-02 
ENSG00000272620 AFAP1-AS1 -0,617 3,25E-02 
ENSG00000227517  0,647 3,25E-02 
ENSG00000173706 HEG1 -0,480 3,27E-02 
ENSG00000161013 MGAT4B -0,214 3,27E-02 
ENSG00000173334 TRIB1 0,451 3,27E-02 
ENSG00000057935 MTA3 0,230 3,29E-02 
ENSG00000211751 TRBV25-1 0,520 3,29E-02 
ENSG00000155367 PPM1J 0,634 3,30E-02 
ENSG00000214783 POLR2J4 -0,515 3,30E-02 
ENSG00000154822 PLCL2 0,265 3,30E-02 
ENSG00000136159 NUDT15 0,250 3,30E-02 
ENSG00000197062 ZSCAN26 0,466 3,30E-02 
ENSG00000184677 ZBTB40 -0,296 3,30E-02 
ENSG00000261434  0,446 3,31E-02 
ENSG00000171097 CCBL1 0,352 3,32E-02 
ENSG00000274561  -0,633 3,32E-02 
ENSG00000071051 NCK2 0,267 3,33E-02 
ENSG00000147130 ZMYM3 0,215 3,33E-02 
ENSG00000084112 SSH1 0,225 3,33E-02 
ENSG00000265241 RBM8A -0,246 3,34E-02 
ENSG00000137842 TMEM62 0,346 3,35E-02 
ENSG00000197329 PELI1 0,302 3,35E-02 
ENSG00000204305 AGER -0,458 3,35E-02 
ENSG00000230266 XXYLT1-AS2 0,539 3,36E-02 
ENSG00000140750 ARHGAP17 0,326 3,37E-02 
ENSG00000111206 FOXM1 0,243 3,38E-02 
ENSG00000166963 MAP1A 0,485 3,39E-02 
ENSG00000119866 BCL11A 0,304 3,40E-02 
ENSG00000133265 HSPBP1 -0,259 3,40E-02 
ENSG00000073921 PICALM 0,216 3,41E-02 
ENSG00000153029 MR1 -0,248 3,42E-02 
ENSG00000261611  -0,910 3,42E-02 
ENSG00000077152 UBE2T 0,247 3,43E-02 
ENSG00000160094 ZNF362 -0,786 3,44E-02 
ENSG00000145012 LPP -0,332 3,44E-02 
ENSG00000141736 ERBB2 -0,442 3,44E-02 
ENSG00000205413 SAMD9 -0,289 3,47E-02 
ENSG00000273154  -0,320 3,47E-02 
ENSG00000090104 RGS1 -0,248 3,47E-02 
ENSG00000087995 METTL2A 0,234 3,47E-02 
ENSG00000096060 FKBP5 0,244 3,49E-02 
ENSG00000175792 RUVBL1 0,251 3,49E-02 
ENSG00000052749 RRP12 -0,291 3,50E-02 
ENSG00000180712  -0,346 3,50E-02 
ENSG00000140443 IGF1R -0,271 3,51E-02 
ENSG00000151623 NR3C2 0,580 3,51E-02 
ENSG00000198947 DMD -0,322 3,52E-02 
ENSG00000128203 ASPHD2 -0,240 3,52E-02 
ENSG00000156976 EIF4A2 -0,235 3,52E-02 
ENSG00000103404 USP31 -0,402 3,52E-02 
ENSG00000100241 SBF1 -0,297 3,52E-02 
ENSG00000187486 KCNJ11 0,515 3,53E-02 
ENSG00000198176 TFDP1 0,266 3,54E-02 
ENSG00000198538 ZNF28 -0,248 3,54E-02 
ENSG00000143033 MTF2 0,240 3,55E-02 
ENSG00000096070 BRPF3 -0,255 3,56E-02 
ENSG00000169442 CD52 0,243 3,56E-02 
ENSG00000169499 PLEKHA2 0,221 3,57E-02 
ENSG00000084652 TXLNA -0,238 3,59E-02 
ENSG00000071054 MAP4K4 0,222 3,60E-02 
ENSG00000169668 BCRP2 0,459 3,61E-02 
ENSG00000255857 PXN-AS1 0,479 3,62E-02 
ENSG00000263264  0,300 3,63E-02 
ENSG00000196365 LONP1 -0,230 3,64E-02 
ENSG00000166548 TK2 -0,268 3,64E-02 
ENSG00000109881 CCDC34 0,288 3,65E-02 
ENSG00000157110 RBPMS -0,592 3,65E-02 
ENSG00000229474 PATL2 -0,546 3,66E-02 
ENSG00000185386 MAPK11 -0,449 3,68E-02 
ENSG00000170871 KIAA0232 -0,260 3,68E-02 
ENSG00000163931 TKT 0,289 3,68E-02 
ENSG00000172748 ZNF596 -0,494 3,69E-02 
ENSG00000204248 COL11A2 -0,702 3,70E-02 
ENSG00000134242 PTPN22 0,216 3,70E-02 
ENSG00000180035 ZNF48 0,257 3,70E-02 
ENSG00000160285 LSS -0,304 3,72E-02 
ENSG00000167325 RRM1 0,251 3,72E-02 
ENSG00000005469 CROT -0,295 3,73E-02 
ENSG00000102172 SMS 0,295 3,73E-02 
ENSG00000211640 IGLV6-57 0,355 3,73E-02 
ENSG00000177728 KIAA0195 -0,230 3,75E-02 
ENSG00000064225 ST3GAL6 0,508 3,75E-02 
ENSG00000162073 PAQR4 0,385 3,75E-02 
ENSG00000167972 ABCA3 -0,483 3,76E-02 
ENSG00000197093 GAL3ST4 -0,534 3,76E-02 
ENSG00000168906 MAT2A -0,243 3,76E-02 
ENSG00000277972 CISD3 0,313 3,77E-02 
ENSG00000117650 NEK2 0,251 3,78E-02 
ENSG00000052802 MSMO1 -0,279 3,79E-02 
ENSG00000259040 BLOC1S5-TXNDC5 0,326 3,79E-02 
ENSG00000169762 TAPT1 0,247 3,80E-02 
ENSG00000157637 SLC38A10 -0,238 3,80E-02 
ENSG00000143811 PYCR2 -0,206 3,81E-02 
ENSG00000273230  -0,614 3,81E-02 
ENSG00000124357 NAGK -0,241 3,81E-02 
ENSG00000182985 CADM1 0,257 3,81E-02 
ENSG00000104980 TIMM44 -0,213 3,81E-02 
ENSG00000149636 DSN1 0,206 3,82E-02 
ENSG00000004838 ZMYND10 -0,566 3,82E-02 
ENSG00000099331 MYO9B 0,203 3,83E-02 
ENSG00000163534 FCRL1 0,211 3,86E-02 
ENSG00000116698 SMG7 0,216 3,86E-02 
ENSG00000101104 PABPC1L -0,279 3,86E-02 
ENSG00000152192 POU4F1 0,669 3,86E-02 
ENSG00000148835 TAF5 0,275 3,87E-02 
ENSG00000198964 SGMS1 0,229 3,88E-02 
ENSG00000254870 ATP6V1G2-DDX39B -1,394 3,88E-02 
ENSG00000249437 NAIP 0,358 3,89E-02 
ENSG00000152487 ARL5B-AS1 -0,651 3,89E-02 
ENSG00000147471 PROSC -0,233 3,89E-02 
ENSG00000130254 SAFB2 -0,249 3,90E-02 
ENSG00000258130  0,706 3,90E-02 
ENSG00000112511 PHF1 -0,227 3,90E-02 
ENSG00000151079  0,472 3,91E-02 
ENSG00000105204 DYRK1B 0,409 3,91E-02 
ENSG00000160584 SIK3 0,197 3,92E-02 
ENSG00000131069 ACSS2 0,241 3,93E-02 
ENSG00000116685 KIAA2013 0,242 3,93E-02 
ENSG00000165097 KDM1B 0,216 3,94E-02 
ENSG00000114107 CEP70 0,283 3,94E-02 
ENSG00000169826 CSGALNACT2 0,214 3,96E-02 
ENSG00000099821 POLRMT -0,240 3,96E-02 
ENSG00000226479 TMEM185B -0,405 3,98E-02 
ENSG00000077044 DGKD 0,259 3,99E-02 
ENSG00000119333 WDR34 0,293 3,99E-02 
ENSG00000165966 PDZRN4 0,716 4,00E-02 
ENSG00000186710 CCDC42B 0,585 4,00E-02 
ENSG00000113273 ARSB -0,275 4,00E-02 
ENSG00000165684 SNAPC4 -0,281 4,01E-02 
ENSG00000262001 DLGAP1-AS2 -0,585 4,01E-02 
ENSG00000136982 DSCC1 0,280 4,01E-02 
ENSG00000088899  -0,345 4,01E-02 
ENSG00000272994  -0,416 4,01E-02 
ENSG00000127946 HIP1 0,219 4,03E-02 
ENSG00000258839 MC1R -0,367 4,03E-02 
ENSG00000125520 SLC2A4RG 0,343 4,03E-02 
ENSG00000105723 GSK3A -0,207 4,03E-02 
ENSG00000112290 WASF1 0,261 4,04E-02 
ENSG00000105647 PIK3R2 0,449 4,04E-02 
ENSG00000169718 DUS1L -0,236 4,05E-02 
ENSG00000081692 JMJD4 0,447 4,08E-02 
ENSG00000181544 FANCB 0,329 4,08E-02 
ENSG00000171604 CXXC5 0,354 4,08E-02 
ENSG00000164615 CAMLG 0,282 4,08E-02 
ENSG00000150347 ARID5B 0,239 4,09E-02 
ENSG00000164751 PEX2 -0,207 4,09E-02 
ENSG00000188846 RPL14 0,297 4,10E-02 
ENSG00000078674 PCM1 0,223 4,10E-02 
ENSG00000112118 MCM3 0,230 4,11E-02 
ENSG00000136205 TNS3 0,544 4,11E-02 
ENSG00000078808 SDF4 -0,208 4,12E-02 
ENSG00000112576 CCND3 0,267 4,12E-02 
ENSG00000171700 RGS19 0,268 4,12E-02 
ENSG00000108786 HSD17B1 -0,426 4,12E-02 
ENSG00000110395 CBL 0,200 4,12E-02 
ENSG00000164362 TERT 0,535 4,12E-02 
ENSG00000148660 CAMK2G 0,330 4,14E-02 
ENSG00000153406 NMRAL1 0,313 4,14E-02 
ENSG00000171206 TRIM8 0,212 4,15E-02 
ENSG00000087586 AURKA 0,250 4,15E-02 
ENSG00000128536 CDHR3 0,659 4,15E-02 
ENSG00000105136 ZNF419 -0,408 4,16E-02 
ENSG00000133316 WDR74 -0,221 4,16E-02 
ENSG00000270015  -0,388 4,16E-02 
ENSG00000088305 DNMT3B 0,280 4,17E-02 
ENSG00000228830  -0,376 4,19E-02 
ENSG00000168421 RHOH 0,234 4,20E-02 
ENSG00000264343 SMG8 -0,369 4,20E-02 
ENSG00000131067 GGT7 -0,284 4,21E-02 
ENSG00000173320 GDAP1 0,297 4,21E-02 
ENSG00000184014 DENND5A 0,261 4,22E-02 
ENSG00000165271 NOL6 -0,291 4,22E-02 
ENSG00000143369 ECM1 -0,626 4,24E-02 
ENSG00000134986 NREP 0,235 4,24E-02 
ENSG00000163938 GNL3 -0,236 4,24E-02 
ENSG00000172216 CEBPB -0,247 4,25E-02 
ENSG00000100983 GSS 0,242 4,25E-02 
ENSG00000113013 HSPA9 -0,216 4,26E-02 
ENSG00000170325 PRDM10 0,222 4,26E-02 
ENSG00000158987 RAPGEF6 0,206 4,27E-02 
ENSG00000111254 AKAP3 -0,574 4,27E-02 
ENSG00000223496 EXOSC6 -0,275 4,28E-02 
ENSG00000054967 RELT 0,300 4,28E-02 
ENSG00000166860 ZBTB39 -0,255 4,28E-02 
ENSG00000149196 C11orf73 0,222 4,29E-02 
ENSG00000176390 CRLF3 0,212 4,29E-02 
ENSG00000166153 DEPDC4 0,561 4,29E-02 
ENSG00000175189 INHBC -0,397 4,32E-02 
ENSG00000097021 ACOT7 0,393 4,32E-02 
ENSG00000088836 SLC4A11 -0,291 4,33E-02 
ENSG00000152495 CAMK4 0,236 4,33E-02 
ENSG00000136450 SRSF1 -0,242 4,34E-02 
ENSG00000121931 LRIF1 -0,209 4,34E-02 
ENSG00000150672 DLG2 0,295 4,35E-02 
ENSG00000116497 S100PBP 0,220 4,35E-02 
ENSG00000102981 PARD6A 0,365 4,35E-02 
ENSG00000011243 AKAP8L -0,197 4,35E-02 
ENSG00000111481 COPZ1 -0,226 4,35E-02 
ENSG00000077514 POLD3 0,251 4,36E-02 
ENSG00000139626 ITGB7 0,241 4,36E-02 
ENSG00000111641 NOP2 -0,276 4,36E-02 
ENSG00000013364 MVP -0,376 4,36E-02 
ENSG00000106397 PLOD3 -0,242 4,37E-02 
ENSG00000112984 KIF20A 0,263 4,38E-02 
ENSG00000149187 CELF1 -0,243 4,38E-02 
ENSG00000250615  -0,570 4,38E-02 
ENSG00000271605 MILR1 0,286 4,39E-02 
ENSG00000230975  0,365 4,39E-02 
ENSG00000198648 STK39 0,219 4,39E-02 
ENSG00000105085 MED26 0,249 4,40E-02 
ENSG00000160216 AGPAT3 -0,213 4,40E-02 
ENSG00000110108 TMEM109 0,225 4,41E-02 
ENSG00000152457 DCLRE1C 0,266 4,41E-02 
ENSG00000122359 ANXA11 0,218 4,42E-02 
ENSG00000163072 NOSTRIN 0,546 4,43E-02 
ENSG00000122778 KIAA1549 -0,510 4,43E-02 
ENSG00000159761 C16orf86 0,593 4,43E-02 
ENSG00000136877 FPGS 0,236 4,44E-02 
ENSG00000266340  -0,304 4,44E-02 
ENSG00000140030 GPR65 -0,303 4,44E-02 
ENSG00000112182 BACH2 0,217 4,45E-02 
ENSG00000109736 MFSD10 -0,218 4,47E-02 
ENSG00000135077 HAVCR2 -0,608 4,47E-02 
ENSG00000186871 ERCC6L 0,229 4,47E-02 
ENSG00000157680 DGKI 0,195 4,48E-02 
ENSG00000006607 FARP2 0,236 4,48E-02 
ENSG00000215440 NPEPL1 -0,574 4,49E-02 
ENSG00000131351 HAUS8 0,251 4,49E-02 
ENSG00000180776 ZDHHC20 0,201 4,49E-02 
ENSG00000132824 SERINC3 -0,209 4,49E-02 
ENSG00000139531 SUOX -0,434 4,50E-02 
ENSG00000155330 C16orf87 0,219 4,51E-02 
ENSG00000143252 SDHC -0,227 4,51E-02 
ENSG00000169403 PTAFR 0,222 4,52E-02 
ENSG00000203875 SNHG5 0,207 4,53E-02 
ENSG00000048540 LMO3 0,300 4,53E-02 
ENSG00000177380 PPFIA3 -0,238 4,54E-02 
ENSG00000119862 LGALSL 0,355 4,55E-02 
ENSG00000072210 ALDH3A2 -0,413 4,56E-02 
ENSG00000159363 ATP13A2 -0,253 4,56E-02 
ENSG00000140320 BAHD1 -0,214 4,57E-02 
ENSG00000171703 TCEA2 -0,265 4,58E-02 
ENSG00000106560 GIMAP2 -0,516 4,58E-02 
ENSG00000035115 SH3YL1 -0,353 4,58E-02 
ENSG00000278233 RNA5-8S5 -0,570 4,58E-02 
ENSG00000278189 RNA5-8S5 -0,570 4,58E-02 
ENSG00000277739 RNA5-8S5 -0,570 4,58E-02 
ENSG00000276700 RNA5-8S5 -0,570 4,59E-02 
ENSG00000113163 COL4A3BP -0,219 4,59E-02 
ENSG00000275757 RNA5-8S5 -0,570 4,59E-02 
ENSG00000118965 WDR35 -0,654 4,59E-02 
ENSG00000275215 RNA5-8S5 -0,570 4,59E-02 
ENSG00000171843 MLLT3 0,287 4,59E-02 
ENSG00000094631 HDAC6 -0,236 4,59E-02 
ENSG00000274917 RNA5-8S5 -0,570 4,60E-02 
ENSG00000273730 RNA5-8S5 -0,571 4,60E-02 
ENSG00000090238 YPEL3 -0,240 4,62E-02 
ENSG00000186866 POFUT2 -0,238 4,63E-02 
ENSG00000239213 NCK1-AS1 0,348 4,64E-02 
ENSG00000135925 WNT10A 0,353 4,64E-02 
ENSG00000118308 LRMP 0,258 4,65E-02 
ENSG00000172301 COPRS 0,255 4,66E-02 
ENSG00000136754 ABI1 0,237 4,68E-02 
ENSG00000089916 GPATCH2L -0,248 4,68E-02 
ENSG00000196968 FUT11 0,307 4,68E-02 
ENSG00000185028 LRRC14B 0,349 4,68E-02 
ENSG00000260280 SLX1B-SULT1A4 -0,444 4,69E-02 
ENSG00000224470 ATXN1L -0,257 4,69E-02 
ENSG00000107902 LHPP 0,389 4,69E-02 
ENSG00000163655 GMPS 0,255 4,71E-02 
ENSG00000100429 HDAC10 -0,256 4,71E-02 
ENSG00000132970 WASF3 0,324 4,72E-02 
ENSG00000183426 NPIPA1 -0,236 4,72E-02 
ENSG00000264112  -0,447 4,73E-02 
ENSG00000124193 SRSF6 -0,246 4,73E-02 
ENSG00000214021 TTLL3 -0,291 4,73E-02 
ENSG00000165732 DDX21 -0,220 4,74E-02 
ENSG00000170456 DENND5B 0,283 4,75E-02 
ENSG00000174996 KLC2 -0,217 4,75E-02 
ENSG00000205885 C1RL-AS1 -0,388 4,76E-02 
ENSG00000166575 TMEM135 0,202 4,77E-02 
ENSG00000233695 GAS6-AS1 -0,345 4,77E-02 
ENSG00000182247 UBE2E2 0,267 4,79E-02 
ENSG00000273398  -0,468 4,79E-02 
ENSG00000006625 GGCT 0,298 4,79E-02 
ENSG00000185432 METTL7A 0,254 4,79E-02 
ENSG00000173848 NET1 0,211 4,79E-02 
ENSG00000137804 NUSAP1 0,203 4,80E-02 
ENSG00000166582 CENPV 0,253 4,80E-02 
ENSG00000183010 PYCR1 -0,217 4,80E-02 
ENSG00000102098 SCML2 0,194 4,81E-02 
ENSG00000146828 SLC12A9 -0,233 4,81E-02 
ENSG00000265298  -0,585 4,82E-02 
ENSG00000263327 TAPT1-AS1 0,401 4,82E-02 
ENSG00000085511 MAP3K4 0,252 4,84E-02 
ENSG00000196576 PLXNB2 0,194 4,84E-02 
ENSG00000182379 NXPH4 0,264 4,84E-02 
ENSG00000163513 TGFBR2 0,238 4,85E-02 
ENSG00000141384 TAF4B 0,214 4,85E-02 
ENSG00000100104 SRRD 0,228 4,86E-02 
ENSG00000167984 NLRC3 0,187 4,87E-02 
ENSG00000110080 ST3GAL4 0,419 4,87E-02 
ENSG00000164300 SERINC5 -0,192 4,87E-02 
ENSG00000185480 PARPBP 0,224 4,88E-02 
ENSG00000139182 CLSTN3 -0,237 4,88E-02 
ENSG00000250251 PKD1P6 -0,239 4,89E-02 
ENSG00000102401 ARMCX3 -0,227 4,89E-02 
ENSG00000165494 PCF11 -0,235 4,89E-02 
ENSG00000049089 COL9A2 -0,299 4,90E-02 
ENSG00000065457 ADAT1 0,245 4,90E-02 
ENSG00000232613  0,542 4,90E-02 
ENSG00000196074 SYCP2 -0,701 4,90E-02 
ENSG00000105298 CACTIN -0,222 4,90E-02 
ENSG00000189007 ADAT2 -0,266 4,91E-02 
ENSG00000141030 COPS3 0,222 4,91E-02 
ENSG00000058056 USP13 0,209 4,92E-02 
ENSG00000114790 ARHGEF26 0,691 4,92E-02 
ENSG00000011478 QPCTL 0,235 4,93E-02 
ENSG00000100297 MCM5 0,236 4,94E-02 
ENSG00000205746  -0,274 4,94E-02 
ENSG00000175895 PLEKHF2 0,202 4,95E-02 
ENSG00000115128 SF3B6 -0,213 4,96E-02 
ENSG00000006534 ALDH3B1 -0,498 4,96E-02 
ENSG00000103335 PIEZO1 -0,212 4,97E-02 
ENSG00000216775  -0,296 4,97E-02 
ENSG00000104738 MCM4 0,260 4,98E-02 
ENSG00000010818 HIVEP2 0,183 4,99E-02 
 
Annex 3. Table of the differentially expressed proteins (FDR<10%) in miR-28 overexpressing BL 
cells versus Control BL cells 
Gene Name Ensembl Gene ID FDR 
A1BG ENSG00000121410 0,0127 
A2M ENSG00000175899 0,0425 
ABAT ENSG00000183044 0,0341 
ABCC5 ENSG00000114770 0,0000 
ABHD16A ENSG00000235676 0,0000 
ABHD16A ENSG00000204427 0,0000 
ABHD16A ENSG00000236063 0,0000 
ABHD16A ENSG00000206403 0,0000 
ABHD16A ENSG00000224552 0,0000 
ABHD16A ENSG00000231488 0,0000 
ABHD16A ENSG00000230475 0,0000 
ACSBG1 ENSG00000103740 0,0632 
ACTG1 ENSG00000184009 0,0330 
AKT2 ENSG00000105221 0,0320 
ALB ENSG00000163631 0,0023 
ALKBH6 ENSG00000239382 0,0324 
ANAPC11 ENSG00000141552 0,0089 
ANKRD39 ENSG00000213337 0,0022 
APOM ENSG00000235754 0,0114 
APOM ENSG00000227567 0,0114 
APOM ENSG00000204444 0,0114 
APOM ENSG00000206409 0,0114 
APOM ENSG00000231974 0,0114 
APOM ENSG00000226215 0,0114 
APOM ENSG00000224290 0,0114 
ARHGAP19 ENSG00000213390 0,0086 
ARL6IP4 ENSG00000182196 0,0896 
ATP6AP2 ENSG00000182220 0,0096 
BBS9 ENSG00000122507 0,0000 
BCL11A ENSG00000119866 0,0499 
BCL6B ENSG00000161940 0,0076 
BCL7C ENSG00000099385 0,0000 
BRAT1 ENSG00000106009 0,0423 
BTBD1 ENSG00000064726 0,0076 
BTF3 ENSG00000145741 0,0097 
C16orf13 ENSG00000130731 0,0001 
C19orf25 ENSG00000119559 0,0006 
C1orf140 ENSG00000234754 0,0000 
C5orf30 ENSG00000181751 0,0436 
CALM1 ENSG00000198668 0,0636 
CAMK2A ENSG00000070808 0,0810 
CASP2 ENSG00000106144 0,0067 
CCDC106 ENSG00000173581 0,0273 
CCDC81 ENSG00000149201 0,0042 
CCDC88B ENSG00000168071 0,0113 
CCK ENSG00000187094 0,0495 
CCNDBP1 ENSG00000166946 0,0017 
CCNYL1 ENSG00000163249 0,0325 
CCRN4L ENSG00000151014 0,0000 
CD74 ENSG00000019582 0,0982 
CDC20 ENSG00000117399 0,0008 
CDC25C ENSG00000158402 0,0396 
CDC6 ENSG00000094804 0,0223 
CENPB ENSG00000125817 0,0113 
CENPP ENSG00000188312 0,0484 
CHEK1 ENSG00000149554 0,0415 
CHIC2 ENSG00000109220 0,0583 
CHMP6 ENSG00000176108 0,0708 
CHURC1 ENSG00000258289 0,0013 
CKAP2L ENSG00000169607 0,0040 
CLUH ENSG00000132361 0,0000 
CNTD2 ENSG00000105219 0,0000 
CNTN3 ENSG00000113805 0,0000 
COPZ2 ENSG00000005243 0,0000 
COX17 ENSG00000138495 0,0426 
CSNK1A1 ENSG00000113712 0,0000 
CXorf57 ENSG00000147231 0,0048 
CYBA ENSG00000051523 0,0000 
CYP51A1 ENSG00000001630 0,0143 
DAZAP2 ENSG00000183283 0,0000 
DBI ENSG00000155368 0,0034 
DCD ENSG00000161634 0,0005 
DCLRE1B ENSG00000118655 0,0354 
DENND2D ENSG00000162777 0,0578 
DENND4B ENSG00000198837 0,0972 
DERL1 ENSG00000136986 0,0733 
DHPS ENSG00000095059 0,0940 
DHRS7 ENSG00000100612 0,0905 
DIP2A ENSG00000160305 0,0140 
DSC2 ENSG00000134755 0,0094 
DSCC1 ENSG00000136982 0,0217 
E2F4 ENSG00000205250 0,0425 
EDRF1 ENSG00000107938 0,0914 
EFCAB13 ENSG00000178852 0,0000 
ELF1 ENSG00000120690 0,0149 
ELL3 ENSG00000128886 0,0686 
ERVFRD-1 ENSG00000244476 0,0002 
ESD ENSG00000139684 0,0788 
ESPL1 ENSG00000135476 0,0033 
FBXO30 ENSG00000118496 0,0917 
FCHSD2 ENSG00000137478 0,0317 
FLYWCH1 ENSG00000059122 0,0495 
FPGS ENSG00000136877 0,0094 
FYTTD1 ENSG00000122068 0,0000 
G3BP2 ENSG00000138757 0,0708 
GAB1 ENSG00000109458 0,0393 
GBA ENSG00000262446 0,0095 
GEMIN8 ENSG00000046647 0,0577 
GLB1L3 ENSG00000166105 0,0012 
GNL3L ENSG00000130119 0,0100 
GPATCH1 ENSG00000076650 0,0044 
GPHN ENSG00000171723 0,0883 
GRIP2 ENSG00000144596 0,0000 
GSDMA ENSG00000167914 0,0745 
GTSF1 ENSG00000170627 0,0223 
HBA1 ENSG00000206172 0,0000 
HDGFRP2 ENSG00000167674 0,0772 
HERPUD1 ENSG00000051108 0,0089 
HIST1H1A ENSG00000124610 0,0000 
HIST1H1C ENSG00000187837 0,0000 
HIST1H1E ENSG00000168298 0,0004 
HIST1H2AD ENSG00000196866 0,0533 
HIST1H2BC ENSG00000158373 0,0044 
HIST3H3 ENSG00000168148 0,0030 
HLCS ENSG00000159267 0,0224 
HMGB2 ENSG00000164104 0,0788 
HMGN5 ENSG00000198157 0,0000 
HNRNPD ENSG00000138668 0,0216 
HSP90AA5P ENSG00000205955 0,0886 
HSP90AB3P ENSG00000183199 0,0755 
HTR2B ENSG00000135914 0,0632 
IFRG15 ENSG00000169905 0,0240 
IGHM ENSG00000211899 0,0288 
IGJ ENSG00000132465 0,0833 
IGLL5 ENSG00000254709 0,0000 
IL17RB ENSG00000056736 0,0093 
IL4R ENSG00000077238 0,0051 
ILF3 ENSG00000129351 0,0585 
INPP5K ENSG00000132376 0,0918 
IP6K1 ENSG00000176095 0,0699 
ITGB7 ENSG00000139626 0,0710 
JARID2 ENSG00000008083 0,0000 
JPH4 ENSG00000092051 0,0048 
KANK1 ENSG00000107104 0,0818 
KCNG1 ENSG00000026559 0,0000 
KDM5A ENSG00000073614 0,0709 
KLHDC3 ENSG00000124702 0,0002 
KLHL38 ENSG00000175946 0,0900 
KLHL6 ENSG00000172578 0,0032 
KRT1 ENSG00000167768 0,0005 
KRT10 ENSG00000186395 0,0000 
KRT13 ENSG00000171401 0,0018 
KRT17 ENSG00000128422 0,0011 
KRT5 ENSG00000186081 0,0005 
LARP4 ENSG00000161813 0,0211 
LDHA ENSG00000134333 0,0660 
LIMD2 ENSG00000136490 0,0842 
LOH12CR2 ENSG00000205791 0,0000 
LPGAT1 ENSG00000123684 0,0045 
LPHN3 ENSG00000150471 0,0699 
LRRC58 ENSG00000163428 0,0495 
LXN ENSG00000079257 0,0494 
MANF ENSG00000145050 0,0995 
MAP4 ENSG00000047849 0,0677 
MAP9 ENSG00000164114 0,0001 
MAX ENSG00000125952 0,0033 
MBD3 ENSG00000071655 0,0142 
MDH1 ENSG00000014641 0,0590 
METAP2 ENSG00000111142 0,0771 
MFN1 ENSG00000171109 0,0018 
MICALL1 ENSG00000100139 0,0440 
MID1IP1 ENSG00000165175 0,0023 
MORF4L1 ENSG00000185787 0,0366 
MOV10L1 ENSG00000073146 0,0000 
MRFAP1 ENSG00000179010 0,0053 
MSMO1 ENSG00000052802 0,0635 
MTMR3 ENSG00000100330 0,0001 
MTR ENSG00000116984 0,0505 
MUS81 ENSG00000172732 0,0200 
MVP ENSG00000013364 0,0008 
NARF ENSG00000141562 0,0000 
NBPF7 ENSG00000215864 0,0000 
NDUFA1 ENSG00000125356 0,0660 
NNT ENSG00000112992 0,0000 
NRAP ENSG00000197893 0,0001 
NRIP1 ENSG00000180530 0,0217 
NTHL1 ENSG00000065057 0,0274 
NUDT4 ENSG00000173598 0,0000 
NUP93 ENSG00000102900 0,0004 
NXF1 ENSG00000162231 0,0000 
OCRL ENSG00000122126 0,0918 
OR51V1 ENSG00000176742 0,0002 
ORMDL2 ENSG00000123353 0,0880 
PACS1 ENSG00000175115 0,0055 
PAN2 ENSG00000135473 0,0017 
PCDHGA6 ENSG00000253731 0,0904 
PCGF2 ENSG00000278644 0,0051 
PCGF2 ENSG00000277258 0,0051 
PDAP1 ENSG00000106244 0,0561 
PER2 ENSG00000132326 0,0425 
PIGO ENSG00000165282 0,0382 
PIWIL2 ENSG00000197181 0,0364 
PKMYT1 ENSG00000127564 0,0899 
PLCD3 ENSG00000161714 0,0000 
PLK1 ENSG00000166851 0,0171 
PMS1 ENSG00000064933 0,0363 
POLK ENSG00000122008 0,0000 
POLM ENSG00000122678 0,0497 
POLR2M ENSG00000255529 0,0009 
POMP ENSG00000132963 0,0908 
PQLC3 ENSG00000162976 0,0217 
PRMT10 ENSG00000164169 0,0006 
PROCR ENSG00000101000 0,0657 
PRR4 ENSG00000277454 0,0000 
PRR4 ENSG00000263247 0,0000 
PRR4 ENSG00000111215 0,0000 
PSAT1 ENSG00000135069 0,0623 
PSD4 ENSG00000125637 0,0754 
PSIP1 ENSG00000164985 0,0018 
PSMD4 ENSG00000159352 0,0884 
PTMA ENSG00000187514 0,0435 
PTPN18 ENSG00000072135 0,0089 
PTTG1 ENSG00000164611 0,0000 
RANBP17 ENSG00000204764 0,0001 
RBM38 ENSG00000132819 0,0434 
RNF14 ENSG00000013561 0,0000 
RNF149 ENSG00000163162 0,0871 
RPAP2 ENSG00000122484 0,0623 
RPL35 ENSG00000136942 0,0500 
RPP25L ENSG00000164967 0,0372 
RPS27A ENSG00000143947 0,0038 
RSL24D1 ENSG00000137876 0,0311 
RTN4 ENSG00000115310 0,0000 
RTTN ENSG00000176225 0,0003 
S1PR2 ENSG00000267534 0,0240 
SAMD9L ENSG00000177409 0,0123 
SCNN1G ENSG00000166828 0,0910 
SDR16C5 ENSG00000170786 0,0051 
SEL1L3 ENSG00000091490 0,0011 
SELO ENSG00000073169 0,0538 
SETD5 ENSG00000168137 0,0428 
SETMAR ENSG00000170364 0,0000 
SFT2D3 ENSG00000173349 0,0096 
SFXN5 ENSG00000144040 0,0000 
SHCBP1 ENSG00000171241 0,0563 
SIPA1L2 ENSG00000116991 0,0000 
SKP2 ENSG00000145604 0,0051 
SLC4A7 ENSG00000033867 0,0019 
SMTNL2 ENSG00000188176 0,0891 
SNX17 ENSG00000115234 0,0010 
SOAT1 ENSG00000057252 0,0055 
SPAG5 ENSG00000076382 0,0880 
SPATA7 ENSG00000042317 0,0002 
SPG21 ENSG00000090487 0,0658 
SPTY2D1 ENSG00000179119 0,0291 
SREBF2 ENSG00000198911 0,0191 
SRY ENSG00000184895 0,0142 
SULT2B1 ENSG00000088002 0,0260 
SYNM ENSG00000182253 0,0581 
TADA2B ENSG00000173011 0,0014 
TAT ENSG00000198650 0,0003 
TBC1D23 ENSG00000036054 0,0000 
TFAP2A ENSG00000137203 0,0016 
TFB2M ENSG00000162851 0,0806 
TIMM17A ENSG00000134375 0,0171 
TKTL1 ENSG00000007350 0,0000 
TLR9 ENSG00000239732 0,0950 
TMEM123 ENSG00000152558 0,0768 
TNFSF11 ENSG00000120659 0,0012 
TPD52 ENSG00000076554 0,0423 
TPI1 ENSG00000111669 0,0586 
TPM1 ENSG00000140416 0,0646 
TRABD ENSG00000170638 0,0994 
TRIM9 ENSG00000100505 0,0080 
TRPM4 ENSG00000130529 0,0491 
TSEN54 ENSG00000182173 0,0000 
TTC12 ENSG00000149292 0,0005 
TTLL11 ENSG00000175764 0,0122 
TUT1 ENSG00000149016 0,0080 
TVP23C ENSG00000175106 0,0000 
TXNDC15 ENSG00000113621 0,0580 
UBE2S ENSG00000108106 0,0808 
UBE2T ENSG00000077152 0,0633 
URM1 ENSG00000167118 0,0002 
USP1 ENSG00000162607 0,0127 
USP46 ENSG00000109189 0,0000 
VPS53 ENSG00000141252 0,0032 
WARS2 ENSG00000116874 0,0241 
WDR25 ENSG00000176473 0,0141 
WDR54 ENSG00000005448 0,0007 
WDR7 ENSG00000091157 0,0429 
XXYLT1 ENSG00000173950 0,0905 
YWHAE ENSG00000108953 0,0708 
YWHAE ENSG00000274474 0,0708 
YWHAZ ENSG00000164924 0,0187 
YWHAZ ENSG00000164924 0,0000 
ZBED1 ENSG00000214717 0,0239 
ZC3H12C ENSG00000149289 0,0000 
ZNF48 ENSG00000180035 0,0899 
ZNF532 ENSG00000074657 0,0000 
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Key Points
• miR-217 enhances the GC
reaction by dampening
genotoxic-induced Bcl-6
degradation in GC B cells.
• miR-217 is an oncogene
and its overexpression
provides a model of
miRNA-induced mature
B-cell lymphomagenesis.
microRNAs are a class of regulators of gene expression that have been shown critical
for a great number of biological processes; however, little is known of their role in
germinal center (GC) B cells. Although the GC reaction is crucial to ensure a com-
petent immune response, GC B cells are also the origin of most human lymphomas,
presumably due to bystander effects of the immunoglobulin gene remodeling that
takes place at these sites. Here we report that miR-217 is specifically upregulated in
GC B cells. Gain- and loss-of-function mousemodels reveal that miR-217 is a positive
modulator of the GC response that increases the generation of class-switched anti-
bodies and the frequency of somatic hypermutation. We find that miR-217 down-
regulates the expression of a DNA damage response and repair gene network and in
turn stabilizes Bcl-6 expression in GC B cells. Importantly, miR-217 overexpression
also promotes mature B-cell lymphomagenesis; this is physiologically relevant as
we find that miR-217 is overexpressed in aggressive human B-cell lymphomas.
Therefore, miR-217 provides a novel molecular link between the normal GC response and B-cell transformation. (Blood. 2014;
124(2):229-239)
Introduction
microRNAs (miRNAs) are negative regulators of gene expression
that inﬂuence virtually all biological processes. A high proportion of
human miRNAs are located in cancer-associated genomic regions,1
and deregulated miRNA expression is a hallmark of most cancer
types, including lymphomas.2-4 Indeed, miRNA proﬁling is in-
creasingly recognized as a valuable tool for the classiﬁcation and
even prognosis of lymphoma. However, the role of speciﬁcmiRNAs
in the development of B-cell lymphoma has rarely been addressed in
vivo;5 speciﬁcally, functional evidence for the involvement ofmiRNAs
in the development of mature B-cell lymphomas is very scarce. This
void is particularly important because the vastmajority of humanB-cell
lymphomas originate from mature B cells.
The predominance ofmatureB-cell lymphomas ismost likely due to
the unique molecular events taking place in B cells during the immune
response. B cells generate a hugely diverse repertoire of antibodies,
which enable speciﬁc immune responses against virtually any pathogen
the organismmay encounter. Antibody diversity is achieved in 2 stages.
The ﬁrst takes place during B-cell differentiation through V(D)J
recombination. The second stage is unique to mature B cells that have
encountered antigen and takes place in germinal centers (GCs), allowing
the generation of higher afﬁnity memory B cells and plasma cells.
The GC reaction involves the clonal expansion of antigen-
speciﬁc B lymphocytes and the generation of B-cell subclones with
related antigen speciﬁcities, from which those expressing immuno-
globulinswith improved afﬁnity for the antigenare positively selected.6
Molecularly, this is triggered by the so-called somatic hypermutation
(SHM), which introduces point mutations on the variable region of
the Ig molecule—responsible for antigen recognition. In addition,
GCs are the home of the class switch recombination (CSR) re-
action, a region-speciﬁc recombination reaction between 2 switch
regions of the immunoglobulin heavy chain (IgH) locus that
generates antibodies with different isotypes. SHM and CSR are
both initiated by activation-induced deaminase (AID), which
deaminates cytosines on the immunoglobulin locus.7 This initial
lesion on DNA is subsequently processed by DNA repair and
recombination factors to allow the ﬁxation of a mutation, in the
case of SHM, or the generation of a DNA double-strand break and
a recombination reaction, in the case of CSR.8
The fact that inactivation of AID causes an immunodeﬁciency in
humans9 highlights the importance of the GC reaction in the immune
response. However, the generation of mutations and double-strand
breaks associated with the GC reaction entails a risk for the genome
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integrity of mature B lymphocytes, resulting in a permissive
environment for lymphomagenesis.10-12 Indeed, the most prom-
inent hallmark of mature B-cell lymphomas is the presence of
recurrent chromosomal translocations that involve the immuno-
globulin locus and an oncogene.13,14 These illegitimate junctions
are a direct consequence of AID activity in the GC reaction, because
AID deﬁciency prevents the generation of c-myc-IgH translocations
associatedwithBurkitt lymphoma (BL)15-17 and reduces the incidence
of mature B-cell lymphoma in different mouse models.15,18 In
addition, Bcl-6, a transcriptional repressor indispensable for the
GC reaction, seems to provide an environment tolerant to the DNA
damage associated with AID-dependent events, which contributes to
its oncogenic activity.19 Remarkably, close to 80% of all human
B-cell lymphomas originate from B cells that are GC experienced—
generally known as mature B-cell lymphomas13—the most aggressive
of which are BL and diffuse large B-cell lymphomas (DLBCLs).
Tight regulation of the GC reaction is thus critical with regard
both to the efﬁcacy of the immune response and to lymphoma
development. miRNAs promote subtle changes in gene expres-
sion through imperfect pairing with their target mRNAs.20,21
Very often a single miRNA can bind hundreds of different target
mRNAs, thus acting as a regulator of a gene network rather than
individual genes.20,22 miRNAs have previously been implicated
in the regulation of the immune response and tumorigenic processes
andmice whose GCB cells are depleted of miRNAsmount inefﬁcient
GC responses.23 However, there is little direct evidence for the role
of individual miRNAs in this context, and to date, only miR-155 has
been clearly associated with the GC response.24-26 Here we show that
miR-217 is upregulated after in vitro and in vivo stimulation of mature
B cells. Using gain and loss of function in vivo models, we found that
miR-217 is a positive regulator of the GC reaction and an oncogene in
GC B cells.
Methods
miR-217 detection by miRNA microarray hybridization and
quantitative reverse transcriptase-polymerase chain reaction
RNA was extracted with Trizol (Invitrogen). Mouse miRNA microarray
analysis was performed with paired samples of nonstimulated and stimulated
B cells.27 For quantitative reverse transcriptase-polymerase chain reaction
(qRT-PCR) of the miR-217 precursor, total RNA was converted to cDNA
using random primers (Roche), reversed transcribed with SuperScript II
(Invitrogen), and quantiﬁed by SYBRGreen assay (Applied Biosystems).
Primers are detailed in supplemental Methods available on the BloodWeb
site. Mature miR-217 was quantiﬁed from total RNA with miR-217
miRCURY LNA primers (Exiqon). U6 and sno-142 (Exiqon) were used
as normalization controls.
T cell-dependent immunizations
Groups of 7 to 9 littermate mice were immunized by footpad injection with
50mg of 4-hydroxy-3-nitrophenylacetyl (NP) hapten conjugated to chicken g
globulin (NP-CGG; Biosearch Technologies) in complete Freund’s adjuvant.
Figure 1. miR-217 expression is upregulated in activated B cells. (A) qRT-PCR
analysis of the expression of the (left) miR-217 precursor and (right) mature miR-217
in B cells after 1 (open bars) and 3 days (filled bars) of activation with LPS 1 IL4.
Data from 3 (miR-217 precursor) and 2 (mature miR-217) independent experiments
are shown (P 5 .05 for miR-217 precursor and P 5 .27 for miR-217). Each
experiment was performed with 2 individual mice. (B) qRT-PCR of the (left) miR-217
precursor and (right) mature miR-217 in resting (open bars) or GC (filled bars) B cells
isolated from spleens of wild-type C57BL/6 mice 10 days after immunization with
sheep red blood cells. Data are means 6 standard deviation from 2 independent
experiments with 10 total immunized mice (P5 .0002 for miR-217 precursor and P5 .01
for miR-217). Two-tailed Student t test: P values: *P , .05. (C) Quantification of
miR-217 expression in human resting (CD191CD272IgD2) and GC (CD191CD101)
samples as measured by miRNA array hybridization (data were obtained from
GSE29493, P 5 .003, 2-tailed Student t test). (D) Representative fluorescence-
activated cell sorter (FACS) analysis of bone marrow from miR-217TG, miR-217KI
Figure 1 (continued) and littermate control mice. Plots show the expression of (left)
B220/CD19 in total live lymphocytes, (center) IgD/IgM gated in B2201CD191 cells,
and (right) CD25/B220 gated in B2201CD191IgM2IgD2 cells. The proportion of cells
is indicated in each gated in B2201 cells. (E) Quantification of the proportions and
absolute cell numbers of developing bone marrow B-cell subsets in control (open
bars), (upper) miR-217TG (filled bars), and (lower) miR-217KI mice (filled bars). The
proportions of different B-cell subsets were quantified within the B2201 population.
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Mice were euthanized 14 days after immunization for analysis of primary
response orwere reimmunizedwith 50mg of NP-CGG in incomplete Freund’s
adjuvant.
Somatic mutation analysis
For analysis of mutations at the Sm and JH4 regions, GC B cells were
puriﬁed by cell sorting of pooled Peyer’s patches (4-6 animals per
genotype). DNA was extracted, and the Sm and JH4 regions were
PCR-ampliﬁed using speciﬁc oligonucleotides (supplemental Methods).
Ampliﬁcation products were puriﬁed and sequenced by next-generation
sequencing (NGS)28 or cloned and sequenced by conventional Sanger
sequencing.
RNAseq analysis and miRNA target prediction
GC (CD191Fas1GL71) B cells frompooled Peyer’s patches (4-6 animals per
genotype) from control and miR-217TG mice were isolated by cell sorting.
Total RNAwas extractedwith Trizol (Invitrogen) and sequenced byRNAseq.
Differential expression analysis was done using the edgeR package from
Bioconductor,29 and genes with P # .05 were considered for analysis.
Pathway analysis of the signiﬁcantly up- and downregulated genes in
miR-217TG vs control GC B cells was performed by ingenuity pathway
analysis software (Ingenuity Systems).
Signiﬁcantly downregulated genes in miR-217TG GC B cells were
analyzed for the presence of 835 different miRNAs target sites based on
predicted and experimentally validated miRNA-mRNA interactions. Scores
for every predictive algorithm were normalized, and the compound score of
predictive and experimental databases was calculated.30 See supplemental
Methods for more details.
miR-217 expression in Ramos cells, immunobloting, and cell
cycle analysis
Ramos cells were transduced with miR-217 pmiRNA or control vectors27
and selected by green ﬂuorescent protein (GFP) expression by ﬂow-
activated cell sorting (FACS). Cells were treated for 6 hours with etoposide
(Sigma-Aldrich) in the presence or absence of caffeine (Sigma-Aldrich),
lysed in radioimmunoprecipitation assay buffer, and immunobloted with
anti-Bcl-6 (N-3; Santa Cruz Biotechnology) or a-tubulin (Sigma-
Aldrich) antibodies or ﬁxed overnight with 70% ethanol and stained
with 2.5 mg/mL 49,6 diamidino-2-phenylindole for ﬂow cytometry cell cycle
analysis.
Human samples and animal procedures
The use of human samples was approved by the ethics committee of the
Instituto de Salud Carlos III. The studywas conducted in accordance with the
Declaration of Helsinki.
All animal procedures conformed to European Union Directive
2010/63EU and Recommendation 2007/526/EC regarding the protection
of animals used for experimental and other scientiﬁc purposes, enforced in
Spanish law under Real Decreto 1201/2005.
Figure 2. miR-217 expression in B cells enhances
the GC response. (A) Representative FACS analysis
of B2201 lymphocytes in lymph nodes after primary
(upper) or secondary (lower) NP-CGG immunization of
miR-217TG mice or littermate controls. (B) miR-217TG
mice (closed circles) or littermate controls (open circles)
were immunized by subcutaneous injection of NP-CGG
in complete Freund’s adjuvant, and 14 days after
immunization, lymph nodes were analyzed for the
presence of GC B cells (Fas1GL71) and switched
B cells (IgG11). Mice injected with PBS (open triangles)
were used as nonimmunized controls. Each symbol
represents an individual mouse. Data were normalized
to the mean value of control mice in each experiment;
results are shown for a total of 4 experiments
performed with 4 independent miR-217TG mouse lines
(P 5 .01 for GC B cells and P 5 .08 for switched
B cells). (C) Fourteen days after a primary immuniza-
tion as in B, mice were reimmunized by subcutaneous
injection of NP-CGG and analyzed 7 days later. Symbol
code as in B. Data from 2 independent experiments
was normalized to the mean response of control mice
in each experiment (P 5 .019 for GC and P 5 .018
for switched B cells). (D) Spleen memory IgG11 B cells
analyzed by flow cytometry 1 year after NP-CGG
immunization of miR-217KI mice. The FACS plots show
the frequency of cells in the gate referred to proportion
within B2201 cells. Symbol code as in B (P 5 .003).
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Results
miR-217 expression is upregulated in activated B cells
To identify miRNAs that play a role during B-cell activation, we
proﬁled miRNA expression in mature B cells during in vitro acti-
vation with lipopolysaccharide (LPS) 1 interleukin (IL)4, which
promotes AID expression, SHM in the switch regions, and CSR.
Microarray analysis showed that one of the few miRNAs whose
expression is upregulated during this process is miR-21727 (sup-
plemental Figure 1A). Induction of precursor and mature miR-217
during B-cell activation in vitro was conﬁrmed by qRT-PCR
(Figure 1A). In addition, we generated GCs in vivo by immunizing
mice with sheep red blood cells and conducted qRT-PCR on puriﬁed
resting and GC B cells. miR-217 precursor and mature miR-217
expression increased by ﬁve- and eightfold, respectively, in GC
cells (Figure 1B). Similarly, we found that miR-217 expression
is increased in GC human B cells compared with resting B cells
(Figure 1C). Together, these results show that miR-217 ex-
pression is induced during B-cell activation both in mouse and
humans.
Generation of B cell-specific miR-217 mouse models
To investigate the role of miR-217 during B-cell activation, we
generated 2 independent mouse models of B cell-speciﬁc miR-217
overexpression. In the ﬁrst, 4 independent transgenic mouse lines
were generated with a construct encoding themiR-217 precursor and
a GFP reporter gene under the control of regulatory elements of the
mouse k light chain (Igk) gene (miR-217TG). In the second strategy,
the miR-217 precursor/GFP construct was preceded by a transcrip-
tional stop cassette ﬂanked by LoxP sites and inserted within the
endogenous Rosa26 locus (ROSA26miR217ki/1 mice) (supplemental
Figure 1B; supplemental Methods); speciﬁc expression of miR-217
in B cells was achieved by crossing ROSA26miR217ki/1 mice with
CD192Creki/1mice (hereafter, miR-217KI mice). ROSA26miR2171/1
CD192Creki/1 mice were used as controls. B cells from miR-217TG
and miR-217KI mice showed full GFP and miR-217 expression
in mature splenic B cells (supplemental Figure 1C-D). GFP ex-
pression was not detected in non-B-cell lineages, such as T,
myeloid, or epithelial cells (data not shown). The proportions and
absolute numbers of bone marrow and peripheral B cells in the
miR-217TG and miR-217KI models were similar to those in wild-type
littermate controls (Figure 1D-E), indicating that the miR-217TG and
miR-217KI mouse models allowB cell-speciﬁc miR-217 overexpres-
sion without perturbing B-cell differentiation.
miR-217 expression enhances the GC reaction
To address the role ofmiR-217 expression duringB-cell activation in
GCs, we analyzed the B-cell response to a T cell-dependent antigen
in miR-217TG mice. We ﬁrst immunized miR-217TG mice and wild-
type littermate controls with NP-CGG. As an immunization control,
micewere injectedwith phosphate-buffered saline (PBS). The lymph
nodes of NP-CGG-immunized wild-type mice contained GC B cells
(Fas1GL71) and B cells that had undergone CSR (IgG11); but in
miR-217TG mice, the response to NP-CGG immunization was
greater, with 22% more GC B cells (P5 .01) and 20% more IgG11
B cells (P5 .08; Figure 2A-B). A similarly enhancedGC response to
NP-CGG immunization was found in miR-217KI mice (supplemen-
tal Figure 2A). We next analyzed the secondary B-cell immune
response in control and miR-217TG mice. The enhancement of the
GC reaction in miR-217TG mice was notably greater in secondary
immunization assays, with 40% more Fas1GL71 B cells and 60%
more IgG11-switched B cells than controls (P 5 .019 and .018,
respectively; Figure 2A,C). In addition, we found that the proportion
of CD1381 plasma cells is larger inmiR-217TGmice than in controls
(P 5 .02; supplemental Figure 2B). To analyze the inﬂuence of
miR-217 overexpression on the long-lived memory B-cell compart-
ment, we quantiﬁed IgG11 B cells in spleens from control and
miR-217KImice 1 year after immunization. Theproportion ofmemory
B cells was 40% higher inmiR-217KI mice than in controls (P5 .003;
Figure 2D).
To further characterize the role ofmiR-217 in theGC reaction, we
examined the extent of SHM inmiR-217TGmice in vivo.We isolated
Fas1GL71GCBcells fromPeyer’s patches of control andmiR-217TG
mice and quantiﬁed the mutation frequency in an intronic DNA
region downstream of the JH4 segment of the IgH locus, a region that
accumulates mutations but cannot be subject to afﬁnity maturation
events. Conventional Sanger sequencing of the JH4 intronic region
showed thatmiR-217TGBcells have a highermutation load thanwild-
type controls (control, 2.13 1023/bp and miR-217TG, 3.73 1023/bp,
P 5 .028; Figure 3A). Likewise, GC B cells from miR-217KI mice
accumulated more mutations downstream of JH4 than did wild-type
controls (supplemental Figure 2C). Similar results were obtained
Figure 3. miR-217 expression in B cells enhances SHM. (A-B) Quantification of
mutations in the JH4 intronic sequence of GC (Fas
1GL71) B cells isolated from
pooled Peyer’s patches of 6 control and 6 miR-217TG mice: (A) Sanger sequencing.
Segment sizes in the pie charts are proportional to the number of sequences carrying
the number of mutations indicated at the periphery. Mutation frequencies are
indicated below each chart, and the total numbers of independent sequences
analyzed are indicated in the chart centers. Statistical significance was determined
by a 2-tailed Student t test (P 5 .028). (B) NGS quantification of the total JH4
mutation frequency and of the mutation frequency at cytosines within the RGYW/
WRCY AID hotspots in JH4 sequences in GC B cells from control (open bars) and
miR-217TG mice (filled bars). The mutation frequency in the JH4 sequence of AID
2/2
splenic B cells is shown in hatched bars. A total of 300 000 kb/genotype was
sequenced. Statistical significance of the mean mutation frequency at each position
was determined by a paired Student t test (P5 1.93 1029 for total mutation frequency
and P 5 .002 for mutation frequency at WRCY hotspots).
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when we analyzed SHM frequency at the JH4 intronic region by
NGS, which allows large numbers of mutations to be analyzed at
very high depth.28 No mutations were detected in B cells isolated
from AID2/2 mice, used as a negative control. We detected total
mutation frequencies of 1.7 3 1023/bp in control animals and
3.7 3 1023/bp in miR-217TG mice (P 5 1.9 3 1029), a 2.2-fold
difference (Figure 3B). This difference was even higher (2.7-fold)
when the analysis was limited to cytosines located in AID mu-
tational hotspots RGYW/WRCY (where R 5 A/G, Y 5 C/T,
and W 5 A/T) (5.8 3 1023/bp in controls vs 15.6 3 1023/bp in
miR-217TG; Figure 3B), conﬁrming that miR-217 overexpression
in B cells increases the load of SHM in GCs. These results indicate
that overexpression of miR-217 in B cells increases the efﬁciency
of GC formation, CSR and SHM, and the generation of terminally
differentiated B cells in vivo.
Inhibition of endogenous miR-217 impairs the GC reaction
To address whether endogenous miR-217 expression plays a phys-
iological role in GCs, we generated bone marrowmouse chimeras in
whichendogenousmiR-217expressionwas inhibitedby the expression
of a miR-217 sponge (miR-217SPG) construct (Figure 4A), where
sequences complementary to miR-217 were cloned in tandem within
the 39untranslated region of a reporter gene and thus function as
competitive inhibitors for the binding of the miRNA to its
endogenous binding sites.31,32 Bone marrow cells from wild-type
mice were transduced with miR-217SPG or control retroviruses
and transferred into lethally irradiated CD45.1 congenic recipient
mice and immunized 4 weeks later with NP-CGG. Chimeric mice
injected with PBS were used as immunization negative controls.
Spleen and lymph nodes from immunized miR-217SPG mice
contained fewer GC and IgG11 switched B cells than immunized
control chimeric mice, and indeed, the proportions of these cell
subsets in immunized miR-217SPG mice were as low as in PBS-
injected, nonimmunized animals (Figure 4B-C). We next analyzed
SHM in Peyer’s patch GC B cells from miR-217SPG and control
chimeric mice by NGS. We found that miR-217SPG GC B cells had a
25% lower mean mutation frequency than control B cells at the JH4
intronic region (P 5 3.7 3 1025; Figure 4D). Very similar results
were obtained when we analyzed the mutation load in a fragment of
the m switch region (Sm) of IgH (P 5 4 3 1024), where mutations
Figure 4. Inhibition of endogenous miR-217 expres-
sion in B cells impairs the GC response. (A) miR-
217-Sponge (miR-217SPG) retroviral construct. Four
miR-217 complementary sites, separated by 4-nt
spacers, were placed downstream of GFP in the MGP
vector. (B-C) GC response of mouse chimeras recon-
stituted with control or miR-217SPG retrovirally trans-
duced bone marrow precursors analyzed 14 days after
NP-CGG immunization. (B) Representative FACS anal-
ysis of B2201 GC cells (Fas1GL71) in (upper) lymph
nodes and (lower) spleen and of switched (IgG11) lymph
node cells after NP-CGG immunization. Plots are gated
on CD45.11GFP1 cells. (C) Quantification of GC and
switched B cells in mouse chimeras reconstituted with
control (open circles) or miR-217 SPG (in red) retrovirally
transduced bone marrow precursors. Nonimmunized
mice injected with PBS (triangles) were included as
immunization controls. Each symbol represents an
individual mouse. Data are normalized to the mean
response of control mice of 2 independent experiments.
Statistical significance was determined by a 2-tailed
Student t test vs control immunized mice (P 5 .12 for
LN GCs, P 5 .05 for SP GCs, and P 5 .04 for switched
B-cell generation). (D) NGS quantification of mutations
in (left) JH4 and (right) Sm sequences in GFP
1CD45.11
GC (Fas1GL71) B cells isolated from pooled Peyer’s
patches of 8 control (open bars) and 8 miR-217SPG
(red bars) mouse chimeras. Data are from 2 (JH4) and
1 (Sm) independent experiments. At least 190 000 kb
was sequenced per genotype. Statistical significance
of the mean total mutation frequency at each position
was determined by a paired Student t test (P5 3.731025
for JH4 SHM and P5 43 10
24 for Sm SHM).
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accumulate concomitantly with CSR (Figure 4D). These results thus
show that inhibition of endogenous miR-217 attenuates the GC
reaction and decreases the frequency of somaticmutations associated
with both the SHM and the CSR reactions.
miR-217 regulates a DNA damage response and repair gene
network and stabilizes Bcl-6 expression in GC B cells
To identify the genes regulated by miR-217 in activated B cells, we
performed a genome-wide comparison of the gene expression
proﬁles of miR-217TG and wild-type GC B cells by RNAseq.
Comparison of GC B cells from Peyer’s patches of miR-217TG and
wild-type mice identiﬁed 1740 differentially expressed genes with
P# .05 (supplemental Table 1), 1236 of which were downregulated.
This set of downregulated genes was signiﬁcantly enriched in
predicted miR-217 targets (P5 9.753 1027; Figure 5A), suggesting
that a high proportion of the downregulated genes identiﬁed in
miR-217TGGCBcells are directmiR-217 targets. To identify the gene
networks altered bymiR-217 expression in GCB cells, we performed
a bioinformatics analysis on the genes differentially expressed
Figure 5. miR-217 regulates a DNA damage re-
sponse and repair gene network and dampens Bcl-6
degradation in GC B cells. (A-B) RNAseq analysis
of genome-wide gene expression in control and
miR-217TG GC B cells isolated from Peyer’s patches.
Pools of 4 to 6 mice per genotype were used in each
experiment. Data from 2 independent experiments are
shown. (A) Enrichment in miRNA prediction targets
within the 1236 mRNAs whose expression was down-
regulated in miR-217TG vs control GC B cells. The GEO
accession number for the RNAseq data is GSE47877.
(B) Ingenuity pathway analysis of the genes differen-
tially expressed in control vs miR-217TG GC B cells,
showing enrichment for a DDR and repair gene network
among the genes regulated by miR-217 (P 5 10231).
Downregulated genes are shown in green; upregulated
genes are shown in red. (C) Quantification of Nbs1,
Xrcc2, Lig4, and Pds5b expression in Ramos
cells transduced with control (open bars) or miR-217
(filled bars) retrovirus analyzed by qRT-PCR. Two-
tailed Student t test with P values: *P , .05. (D) Cell
cycle analysis of etoposide-treated control- and
miR-217-transduced Ramos cells. Representative
cell cycle plots of untreated (2Etop) or etoposide-
treated (6 hours, 10 mM) (1Etop) Ramos cells. Fraction
of cells in S cycle 6 standard deviation is shown. The
lower graph depicts the change in the proportion of
cells at each phase of cell cycle in response to
etoposide treatment (open bars, control-transduced
cells; black bars, miR-217-transduced cells). Bars
represent means 6 standard deviations from 3 in-
dependent experiments (P 5 .004 for S phase cells,
2-tailed Student t test). (E) (Upper) Immunoblot of
Bcl-6 in Ramos cells transduced with control or miR-
217 retrovirus treated for 6 hours with the indicated
doses of etoposide. (Lower) Immunoblot of Bcl-6 in
miR-217-transduced cells left untreated (2Etoposide) or
treated with 10 mM Etposide for 6 hours (1Etoposide) in
the presence of increases doses of caffeine (0 mM [2],
2 mM [1], and 5 mM [11 ]. (F) Analysis of Bcl-6
expression in GC cells by flow cytometry. (Upper)
Representative dot plots of Fas, GL7, and Bcl-6
staining of Peyer’s patch B cells. Quantification of
Bcl-6 expression levels in B2201Fas1GL71 GC B cells
from Peyer’s patches of littermate controls (white bar)
and miR-217KI mice (black bar) (MFI, mean fluo-
rescence intensity; n 5 3 mice/genotype, P 5 .0006,
2-tailed Student t test). (G) Bcl-6 expression in spleens
of control and miR-217TG mice analyzed by immu-
nohistochemical staining. A representative picture
is shown. The proportion of Bcl-61 stained in follicle
areas was quantified in 205 and 201 spleen follicles
of control and 10 miR-217TG mice, respectively. Statistical
significance was determined by 2-tailed Student t test
(P 5 .0008).
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in miR-217TG vs control GC (Fas1GL71) B cells. Ingenuity pathway
analysis revealed that miR-217 regulates a DNA damage response
(DDR) and repair gene network inGCB cells (P5 10231; Figure 5B).
Interestingly, this gene network contained 2 main hubs, RNA pol II
and replication protein A, which are directly linked to AID
activity.33-37 ThemiR-217-regulated gene network included a number
of genes linked to the DDR (Nbs1 and Rad50 components of the
Mre11-Rad50-Nbs1 [MRN] complex),38 DNA repair and CSR (Wrn,
Lig4, and Xrcc2),11,39,40 and genes of the cohesin complex (SMC2,
SMC3, PDS5B, and SA2) involved in chromatid cohesion, as well as
inDNAreplication, transcription, recombination, and repair41,42; all of
them were downregulated by miR-217.
Bcl-6 expression is regulated by the DDR through a signaling
pathway that promotes Bcl-6 degradation.43Aswe found thatmiR-217
downregulates the expression of a number of genes involved inDDR
and repair in GC B cells, we hypothesized that miR-217 could
stabilize Bcl-6 expression in these cells. To test this hypothesis, we
transduced Ramos cells, a human BL GC B-cell line, with miR-217-
GFP and control retroviral vectors and analyzed Bcl-6 expression on
genotoxic stress induction. We ﬁrst veriﬁed that genes linked to the
DDR and downregulated by miR-217 expression in mouse GC
B cells (Nbs1, Xrcc2, Lig4, and Pds5b) were also downregulated by
miR-217 in human Ramos cells (Figure 5C). To determine if miR-217
impacts on the response to genotoxic stress, we analyzed the effect
of etoposide treatment on the cell cycle of control- and miR-217-
transduced Ramos cells. Expectedly, we found that etoposide-
induced DDR promoted an increase in the fraction of cells in the
Sphaseof the cell cycle, consistentwith a replicative delay (Figure 5D).
However, this S phase increase was milder in miR-217-transduced
cells (Figure 5D), which suggested that miR-217 may contribute to
bypass the DDR response induced by etoposide. Immunoblot analysis
showed that etoposide treatment of control Ramos cells rapidly
induced Bcl-6 degradation (Figure 5E), in agreement with previous
results.43 However, Ramos cells overexpressing miR-217 were
Figure 6. miR-217 expression promotes mature
B-cell lymphomas. (A-D) Thirty-four control and 40
miR-217KI mice were monitored over 90 weeks for the
appearance of B-cell lymphoma. (A) Representative
pictures of (right) a nontumoral control spleen and (left)
a miR-217KI spleen with splenomegaly. (B) Quantifica-
tion of B-cell lymphoma incidence in control mice and
miR-217KI mice. The proportions of FL (black), DLBCL
(white), or other lymphomas (gray) are shown. Statis-
tical significance was determined by 2-tailed Student
t test (P 5 .028). (C) Representative hematoxilin and
eosin (H&E) and immunohistochemical stainings for
Pax5, CD3, and Bcl-6 in spleens from miR-217KI mice
with B-cell lymphomas. Scale bar is 50 mm. NT,
nontumoral; SBL, small B-cell lymphoma. (D) PCR
analysis of V(D)J rearrangements in tumor samples
from miR-217KI mice. DNA was isolated from total
spleen and amplified using a V-degenerate primer in
combination with an antisense primer downstream of
JH4. Sequencing results are shown in Table 2. Mouse
IDs are shown. MW, molecular weight marker. (E)
Quantification of B-cell lymphoma incidence in control
(open bars) and miR-217KI (filled bars) Ink4a/Arf2/2 and
p532/2 mice. Statistical significance was determined by
2-tailed Student t test (P 5 .03 in miR217KI Ink4a/Arf2/2
vs control Ink4a/Arf2/2 and P 5 .33 in miR217KI p532/2
vs control p532/2). (F) miR-217 relative expression in
human control samples (open circles, peripheral blood
CD191 B cells; open squares, tonsils; open triangles,
lymph nodes), in BL samples (closed circles) and in
DLBCL samples (closed triangles, GC B GCB-DLBCL;
closed squares, activated B cell, ABC-DLBCL) as
determined by qRT-PCR. Statistical significance was
determined by 2-tailed Student t test (P 5 .05 for BL).
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partially protected against genotoxic stress-induced Bcl-6 degrada-
tion and showed increased Bcl-6 expression levels (Figure 5E).
Caffeine treatment protected miR-217 Ramos cells from etoposide-
induced Bcl-6 degradation, indicating that an ataxia telangiectasia
mutated/ataxia telangiectasia and Rad3-related–dependent pathway
is involved in this process (Figure 5E, lower panels). Analysis of
Bcl-6 protein levels in GC B cells from control and miR-217KI
mice further conﬁrmed that miR-217 expression promotes the
accumulation of Bcl-6 (Figure 5F). Finally, quantiﬁcation of Bcl-6
expression in spleens from miR-217TG and control mice revealed
that miR-217TG mice have larger Bcl-61 follicle areas in spleens
(P 5 .0008; Figure 5G). Overall, these data indicate that miR-217
regulates the GC reaction by modulating the expression levels of
a gene network involved in DDR and repair and by dampening
genotoxic stress-induced Bcl-6 degradation in GC B cells.
Deregulated miR-217 expression promotes mature
B-cell lymphomas
GCB cells are highly prone to oncogenic transformation. Our results
show that miR-217 is a positive regulator of the GC reaction, pre-
sumably by downregulating the expression of DNA repair genes
and by stabilizing Bcl-6 expression, which could enhance the sus-
ceptibility of these cells to oncogenic events. To test whether miR-217
overexpression in B cells affects the development of mature B-cell
lymphomas, we monitored the incidence of B-cell lymphoma in
a group of 34 control and 40 miR-217KI mice. Mice were euthanized
and analyzed at an end point of 90 weeks or earlier if they showed
signs of disease. miR-217KImice showed early signs of diseasemore
frequently than control mice did (14 miR-217KI and 7 control mice
had to be euthanized before 90weeks; supplemental Figure 3A). miR-
217KI mice had larger spleens than control animals, with a fraction
showing clear splenomegaly (20% vs 0% spleens larger than 20mm;
Fisher’s exact test, P5 .0058; Figure 6A; Table 1). Histopatholog-
ical evaluation of the spleens showed that a large proportion (33%) of
miR-217KI mice developed B-cell lymphoma (P 5 .028 vs control
mice; Figure 6B). Flow cytometry analysis of lymphomas from
miR-217KI mice showed frequent alterations in the expression of the
B-cell surface molecules B220, IgD, IgM, and Igk (supplemental
Figure 3B; Table 1). We found that lymphomas in miR-217KI mice
had features of mature GC or post-GC B-cell origin.44 Most (70%)
were classiﬁed as follicular lymphomas (FL), although we also
observed other mature B-cell lymphomas, such as DLBCL and
B-cell plasmacytomas (PCT) (Figure 6B-C; Table 1). To further
characterize the origin of these lymphomas, we performed molecular
analysis of their V(D)J rearrangements by PCR ampliﬁcation and
sequencing.We found that a fraction of the lymphomas yieldedunique
ampliﬁcation bands (Figure 6D), which were conﬁrmed to correspond
with single rearrangements (Table 2), thus providing proof of their
clonal origin. In addition, all of the rearrangements subject to this
analysis contained mutations (SHM1) in their V genes (Table 2) and
an additional fraction showed Bcl-6 expression (Figure 6C; Table 1),
conﬁrming their GC/post-GC origin.
To examine the contribution of tumor suppressor pathways to
limiting the B-cell lymphomagenesis induced by miR-217, we
analyzed the incidence of B-cell lymphoma inmiR-217KI mice in the
Ink4a/Arf2/2 and p532/2 backgrounds. Ink4a/Arf2/2 and p532/2
mice often developed histiocytic sarcomas (40%) and T-cell
lymphomas (70%), respectively (data not shown).45-47 In addition,
we found that roughly 20%of both control Ink4a/Arf2/2 and p532/2
tumor suppressor-deﬁcient mice generated B-cell lymphomas. This
incidence was not signiﬁcantly altered by miR-217 overexpression
in the p532/2 background, but in the Ink4a/Arf2/2 background,
miR-217 overexpression increased B-cell lymphoma incidence to
43% (Figure 6E), although the mean survival of miR-217KI Ink4a/
Arf2/2mice was not signiﬁcantly altered (supplemental Figure 3A).
B-cell lymphomas in miR-217KI Ink4a/Arf2/2 mice showed histo-
pathological features of mature GC or post-GC B-cell lymphomas
(supplemental Figure 3). These results suggest that the Ink4a/Arf,
but not the p53, tumor suppressor pathway acts as a surveillance
mechanism against the lymphomagenic events induced by miR-217
in mature B cells.
To determine if miR-217 expression levels are altered in mature
B-cell human lymphomas, we conducted a qRT-PCR analysis of
miR-217 expression in a collection of BL and DLBCL samples.
Expression ofmiR-217was higher in BL andDLBCL than in control
tonsil, lymph node, and peripheral blood B-cell samples (BL vs
control, P 5 .05; Figure 6F). In agreement with these ﬁndings,
analysis of published data of copy number variation in a cohort of
DLBCL cases revealed that the genomic region that contains the
miR-217 chromosomal location (MCR 1694) is ampliﬁed in a
fraction of the cases48 (GSE11318). Together, these data indicate
that miR-217 gain of function is associated with human mature
B-cell lymphomas.
Table 1. Characterization of B-cell lymphomas in miR-217KI mice
Mouse ID* B-cell lymphoma† Grade‡ Splenomegaly§ Phenotype{
BPT048 FL Mature B cell, B2201 CD191 sIgM1 sIgk1 Fas1GL71, Pax5low BCL61; numerous infiltrating T cells
BPT100 FL Yes Mature B cells, Pax51 BCL62 and N/A
BPT105 FL Mature B cell, B2201 CD191 sIgM2 sIgk1, Pax51 BCL61
BPT106 FL Mature B cell, B2201 CD191 sIgM2 sIgk1, Pax5low BCL61
BPT109 PCT Aggressive Mature B cell, Pax5- BCL6- and N/A
BPT124 FL Aggressive Mature B cell, B220low CD191 sIgMhigh sIgk1, Pax5low BCL6-
BPT137 FL Mature B cell, B2201 CD191 sIgMlow sIgk1, Pax51 BCL6-
BPT148 DLBCL Aggressive Yes Mature B cell, B2201 CD191 sIgMlow sIgk1, Pax5low BCL61; numerous infiltrating T cells
BPT224 DLBCL Aggressive Yes Mature B cell, B2201 CD191 sIgMlow sIgklow, Pax5low BCL61; numerous infiltrating T cells
BPT226 FL Aggressive Yes Mature B cell, B2201 CD191 sIgMlow sIgklow, Pax5low BCL61; numerous infiltrating T cells
BPT234 SBL Mature B cell, B2201 CD191 sIgMhigh sIgk1, Pax51 BCL6-
BPT263 FL Yes Mature B cell, B220high CD191 sIgM1 sIgk1, Pax51 BCL61
BPT266 FL Aggressive Mature B cell, B2201 CD191 sIgMlow sIgk1, Pax5low BCL62
*Mouse identification number.
†SBL, small B-cell lymphoma.
‡Lymphoma classification grade.
§Splenomegaly: spleens larger than 20 mm length.
{Phenotype of tumoral cells determined by morphological features, flow cytometry, and immunohistochemica stainings. N/A, not analyzed.
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Discussion
The results presented in this study identify miR-217 as a positive
regulator of the GC reaction and as an oncogene that promotes
mature B-cell lymphomagenesis. miR-217 is speciﬁcally upregulated
as a result of B-cell stimulation in the context of the GC reaction
during the immune response, and our gain and loss of function
approaches directly establish the functional relevance of miR-217 in
vivo. miR-217 overexpression boosted the number of GCB cells and
promoted the SHM and CSR reactions, and conversely, inhibition of
endogenous miR-217 limited these events. Interestingly, miR-217
gain of function did not promote any measurable alterations in B-cell
differentiation, suggesting that the function of miR-217 in the B-cell
lineage is restricted to the context ofGCs and antibodydiversiﬁcation.
miRNAs modulate the expression of gene networks in a cell
context-speciﬁc manner.20,22 Here, RNAseq analysis showed that
miR-217 regulates the expression of a gene network involved in
DDR and repair, including Rad50, Nbs1,Wrn, Lig4, andXRCC2, as
well as a set of genes of the cohesin complex, all of which are down-
regulated by miR-217. GC B cells are intrinsically prone to genome
instability: (1) they are programmed to undergo AID-mediated gene
remodeling; (2) the intense proliferation of GC B cells subjects them
to replicative stress6; and (3) the GC reaction depends on Bcl-6, a
master transcriptional repressor that dampens the DDR inGCB cells
and whose deregulation generates B-cell lymphomas.18,49 Our data
show that miR-217 downregulates a network of genes that sense and
repair genotoxic events on DNA, which in turn can increase the
tolerance of GC B cells to DNA damage, very much like Bcl-6.
Notably, we found that miR-217 protects Bcl-6 from genotoxic
stress-induced degradation,43 suggesting that bothmolecules are part
of the same network that renders GC cells permissive to genomic
instability and prone to malignant transformation.
Consistent with this idea, we found that miR-217 overexpression
promotes B-cell lymphomagenesis. Interestingly, mice that over-
express miR-217 resemble Bcl-6-overexpressing Im-HABCL6 mice
in that both show increased GC formation and develop long latency
mature B-cell lymphomas.49 We also found that Ink4a/Arf but not
p53 loss sensitizes B cells to miR-217-promoted lymphomagenesis.
Although it is possible that a protective role of p53 is masked by
the early appearance of T-cell lymphomas in p532/2 mice, our data
suggest that Ink4a rather than the Arf-p53 oncogenic stress pathway
plays the predominant role in protecting GC B cells against the
transforming activity of miR-217. This result is in agreement with the
ﬁnding that Ink4a protein is frequently lost through gene methylation
or deletion in aggressive B-cell lymphomas, whereas ARF silencing
is a rarer event.50-53
Deregulation of miRNA expression in human B-cell lymphomas
has been extensively documented.1-4,48 In some instances, the
functional relevance of miRNA deregulation has been tested in
genetically modiﬁed mouse models. This is the case of Em-miR-155
transgenic mice, which developed acute lymphoblastic leukemia/high
grade lymphoma54,55 or miR15/miR16 deﬁciency, which promoted
chronic lymphocytic leukemia,56 among other examples.57,58 Evi-
dence for miRNAs involved inGC or post-GC lymphomagenesis was
thus far restricted to the combined action of the miR-17-92 miRNA
cluster.59 Here we ﬁnd that miR-217 overexpression in B cells
promotes lymphomas of GC or post-GC origin, most likely by
impinging on the regulation of the DDR and Bcl-6. Accordingly,
we found increased levels of miR-217 in BL and DLBCL, 2 of the
most aggressive lymphomas arising from GCs. Our results identify
miR-217 as a novel molecular link between the GC response and
B-cell transformation and provide an in vivo model of mature B-cell
lymphomagenesis.
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Summary: MicroRNAs (miRNAs) have emerged as a new class of gene
expression regulators whose functions influence a myriad of biological
processes, from developmental decisions through immune responses
and numerous pathologies, including cancer and autoimmunity. miR-
NAs are small RNA molecules that drive post-transcriptional negative
regulation of gene expression by promoting the degradation or transla-
tional block of their target mRNAs. Here, we review some of the data
relating to the role of miRNAs in the regulation of the B-cell lineage,
with a special focus on results obtained in vivo. We start by giving a
general overview of miRNA activity, including the issue of target speci-
ficity and the experimental approaches more widely used to analyze
the function of these molecules. We then go on to discuss the function
of miRNAs during B-cell differentiation in the bone marrow and in the
periphery as well as during the humoral immune response. Finally, we
describe a few examples of the contribution of miRNAs, both as onc-
ogenes and tumor suppressors, to the development of B-cell neoplasias.
Keywords: microRNA, bone marrow, germinal center, Dicer, Lymphomagenesis
General concepts on microRNA biology
Two decades ago, the Ambros’ and Ruvkun’s laboratories
(1, 2) identified lin-4 as a small RNA that controls the larval
development in the worm Caenorhabditis elegans through the
negative regulation of lin-14. Strikingly, this RNA exerted
its function not through the generation of a protein product
but seemingly through pairing with complementary
sequences in the 3′ untranslated region (3′ UTR) of lin-14
mRNA. It was not until 2000 that a second small RNA, let-
7, was shown to also control developmental transitions in
C. elegans by the negative regulation of target mRNAs (3).
Let-7 homologs were subsequently found in other organ-
isms, including mammals (4), and soon a collection of sev-
eral dozens of these small RNA molecules were cloned from
worms, flies, and mammals and were collectively called mi-
croRNAs (miRNAs) (5–7). Today thousands of miRNAs
have been identified in nearly 200 species (more than 1000
in humans alone), and they are recognized as a previously
unforeseen regulatory layer of gene regulation critical to a
plethora of biological processes. In mammals, miRNAs are
predicted to control the activity of approximately 50% of all
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protein-coding genes (8). Besides miRNAs, other classes of
silencing small RNAs have been identified in animals, plants,
and fungi, including small interfering RNAs (siRNAs) and
piwi-interacting RNAs (piRNAs), which are not discussed
here (reviewed in 9).
Several salient features of miRNAs distinguish them from
classical regulators of gene expression, such as transcription
factors and repressors. First, miRNAs do not encode a pro-
tein product, but instead they are biologically active as RNA
molecules. Second, miRNAs are exclusively negative regula-
tors of gene expression and act post-transcriptionally, either
by promoting degradation of mRNA targets or by blocking
their translation. This feature is thought to allow a fast and
very precise regulatory response. Finally, miRNA activity on
its target mRNAs typically results in a relatively mild (<two-
fold) reduction in protein levels, which has led to the view
that miRNAs act primarily as reinforcers of transcriptional
programs conferring robustness to biological processes (10).
However, the regulatory activity of miRNAs is in many
respects similar to that of transcription factors and transcrip-
tional repressors. Thus, like transcriptional regulators, a sin-
gle miRNA can potentially regulate many targets to provide
coordinated and simultaneous regulation of a network of
genes in a particular tissue or at a specific developmental
stage. Likewise, although target recognition by transcrip-
tional regulators and miRNAs is based on nucleotide
sequence specificity, in both cases, nucleotide sequence
alone is insufficient to accurately predict functional targets.
These similarities have important implications for the under-
standing of the physiological activity of miRNAs.
miRNA biogenesis, target specificity, and regulation
miRNAs are 21- to 24-nucleotide long RNA molecules that
are processed from longer RNA precursors (pri-miRNAs).
Pri-miRNAs are either transcribed as independent genes or
are included within intronic sequences of other genes. Pri-
miRNAs fold into hairpins that are sequentially cleaved by
two RNAseIII endonucleases, called Drosha and Dicer. Dro-
sha cleavage generates a 70-nucleotide long pre-miRNA
that is exported to the cytoplasm, where Dicer further pro-
cesses it into a 20–25 bp RNA duplex. One strand of this
duplex is the mature miRNA, which is loaded onto the miR-
NA-induced silencing complex (RISC). The main compo-
nents of the RISC complex are Argonaute (AGO) proteins,
which pair with the mature miRNA and guide it to its tar-
gets, and GW182 proteins, which act as downstream effec-
tors for silencing. miRNA-RISC complexes bind to their
target mRNAs and either induce their degradation or block
their translation [the topic of miRNA biogenesis has been
extensively discussed in excellent recent reviews (11–13)].
The regulatory activity of miRNAs on target mRNAs is
primarily determined by nucleotide sequence complemen-
tarity; however, the small size of miRNAs provides a rela-
tively limited sequence for defining target specificity. In
plants, miRNAs often pair with their targets through exten-
sive complementarity. In contrast, in animals quasiperfect
alignment between miRNA and target mRNA is much more
unusual, and typically, the interaction involves the forma-
tion of partial duplexes that contain mismatches and nucleo-
tide wobbles (14). The most important motif in a mature
miRNA for determining target specificity resides in the 5′
end, particularly in the stretch from nucleotides 2–7, called
the seed. Accordingly, the 5′ end is the most conserved por-
tion of miRNA sequences in metazoans. It has been pro-
posed that imperfect pairing at the 5′ region can be
compensated in some cases by interactions through the 3′
end of the miRNA. Expectedly, these features are not strin-
gent enough to faithfully predict miRNA targets on the basis
of sequence complementarity alone. Numerous algorithms
and predictive tools have been developed to aid in this task,
which incorporate both sequence complementarity and evo-
lutionary conservation criteria. These analyses estimate that a
single miRNA can be expected to target several hundred
mRNAs. However, the divergence between the predictions
obtained with different algorithms makes the identification
of miRNA functional targets one of the most challenging
issues in the field (8, 15).
Gene silencing by miRNAs obviously entails that their
expression be tightly regulated. Cellular miRNA levels are
regulated by a variety of molecular mechanisms, including
transcription, processing, and intercellular transport. Tran-
scription of miRNA genes is regulated in a similar fashion
to that of protein-coding genes and is frequently driven by
RNApolII. High-throughput approaches have shown that a
significant fraction of miRNAs use their own transcription
initiation regions, including miRNAs located in intergenic
regions and others embedded within introns, and that tran-
scriptional initiation can take place as far as 40 Kb from the
pre-miRNA sequences (16, 17). However, there are rela-
tively few detailed transcriptional analyses of individual
miRNAs. Notably, myc and MYCN have been shown to reg-
ulate miRNAs with oncogenic and tumor suppressor poten-
tial, and p53 drives the expression of miRNAs that promote
apoptosis and cell-cycle arrest (18–21). In addition, various
miRNAs have been shown to regulate their own expression
through positive and negative feedback loops (reviewed in
© 2013 John Wiley & Sons A/S. Published by Blackwell Publishing Ltd
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11). Although regulation of miRNA processing is far from
being fully understood, it seems clear that the expression
and activity of Drosha and Dicer endonucleases are critical
and that these are affected by their dsRNA-binding protein
partners, DGCR8 and TAR. In turn, the exact position
cleaved by Drosha and Dicer can affect not only the
sequence identity of the mature miRNA but also its loading
onto the RISC complex (reviewed in 11). A mechanism of
intercellular regulation by miRNAs has emerged that can
constitute a critical additional layer to control their activity.
It was first observed in plants and nematodes that RNA
silencing signals can spread from the producing cells and
travel from cell to cell and over long distances (reviewed in
22). This concept has more recently been expanded to
mammals, where miRNAs have been found contained in
exosomes, secreted vesicles that can act as intercellular com-
municators (23, 24). Indeed, exosomal miRNAs regulate the
expression of target genes in recipient cells during the
immune synapsis, thus providing a transcellular mechanism
of gene regulation (24). Notably, exosomes contain a spe-
cific repertoire of miRNAs that differs from that found in
the cytosol, indicating the existence of a mechanism for
selective sorting into these vesicles (23–25). The levels of
mature miRNAs in a cell are thus influenced by the rate of
transcription of the primary miRNA transcript, the efficiency
of the processing of this transcript into mature miRNAs, and
the active transport of mature species from neighboring
cells.
Approaches to the study of miRNA function
A number of experimental approaches are typically used to
gain insights into miRNA function. Perhaps the most global
strategy used to dissect the role of miRNAs in specific tissues
or at defined developmental stages in vivo has been the analy-
sis of mouse models in which the generation of mature
miRNAs as a whole is prevented by blocking their biogene-
sis from precursors. This is the case of Dicer-deficient mice.
Germline deletion of Dicer leads to severe developmental
defects and embryonic lethality (26), but conditional abla-
tion of this gene has provided extensive information on the
requirement of miRNAs for lymphocyte differentiation and
function (27, 28). An obvious limitation of this approach is
the difficulty of pinpointing the role of a specific miRNA in
the observed phenotype by in vivo reconstitution with miR-
NA transgenes, as their maturation would also be blocked in
the absence of Dicer. This issue can now be resolved by tak-
ing advantage of the identification of miR-451, whose
expression levels are refractory to Dicer loss of function
(29–31). The backbone of miR-451 can be used to repro-
gram the biogenesis of heterologous miRNAs, thus render-
ing them Dicer independent (31). This strategy will help
the precise identification of individual miRNAs relevant to
the phenotype conferred by Dicer-mediated global miRNA
ablation.
One of the most popular approaches used to identify
physiologically important miRNAs in biological processes is
the systematic study of miRNA expression profiles. Initially
these studies were performed by directional cloning and
miRNA array analyses, but these strategies are being
replaced by next-generation sequencing and high-through-
put qRT-PCR [miRNA profiling techniques were recently
reviewed (32)]. The underlying assumption of these analy-
ses is that significant miRNA expression in a particular tissue
or at a specific differentiation stage very likely reflects func-
tional relevance. This assumption should, however, be taken
cautiously, in view of the recent estimate that over 60% of
all miRNAs expressed in a particular cell type appear to have
no silencing activity (33). In spite of this, it is reasonable to
consider differential miRNA expression across sequential
developmental or differentiation stages as a good indicator
that those particular miRNAs play a role in the biological
process under study.
miRNA function can be analyzed by gain- or loss-of-func-
tion strategies, both in vivo and in vitro. Expression libraries
have been used to identify miRNAs relevant to B-cell func-
tion (34, 35), and a number of transgenic and knockout
mouse models have been generated to address the role of
miRNAs in lymphocyte lineages (reviewed in 28, 36, 37).
In addition, miRNA loss of function can be achieved by the
use of miRNA sponges – RNA molecules harboring repeated
anti-sense miRNA sequences that can sequester miRNA mol-
ecules from their endogenous targets, acting as competitive
inhibitors (38). Sponges have been successfully used to
block the activity of miRNAs in the hematopoietic system in
vivo after retroviral transduction and bone marrow transplan-
tation (39, 40).
The ultimate challenge in the study of miRNA function is
the identification of physiological targets. Predictive algo-
rithms, such as miRanda, TargetScan, or PicTar, are widely
used for this task, although they pose the limitations
described above. More recently, cross-linking immunopre-
cipitation (CLIP) of RISC components has been used in
combination with high-throughput sequencing of RNA
(HITS-CLIP) to identify miRNAs that physically interact with
the silencing machinery and with potential target mRNAs
in vivo (41, 42). However, this strategy does not provide
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definite proof that the identified interactions are functional.
Very often, miRNA–mRNA target predictions or interactions
have been validated in functional assays where putative tar-
get sequences are fused to a reporter gene, such as lucifer-
ase, whose expression is assessed in the presence or absence
of the candidate miRNA. The limitation of this approach is
that the context of the target sequence and the expression
levels of both the reporter and the miRNA fail to reflect the
natural cellular context in which the silencing takes place.
To overcome this issue, mice have been generated in which
mutations are introduced into the 3′ UTR of the putative
mRNA target to disrupt miRNA binding in vivo (43, 44),
thus allowing definitive validation of the silencing potential
of a particular miRNA–mRNA target interaction. Notably,
several studies have succeeded in pinpointing a particular
mRNA target as the main contributor to the activity of a
miRNA in in vivo complementation experiments, some of
which will be discussed in detail below. However, it is
important to keep in mind that miRNAs resemble transcrip-
tion factors, in that they can operate as molecular switches
through the simultaneous regulation of a large number of
targets. Indeed, microarray analysis and quantitative proteo-
mics approaches by stable isotope labeling with amino acids
(SILAC) have shown that individual miRNAs can promote
the downregulation of hundreds of genes, a large fraction
of which are potential direct targets (45–47). Therefore,
a thorough search for miRNA targets should combine a
prediction analysis (either in silico by the use of prediction
algorithms or experimentally through HITS-CLIP) with
high-throughput studies of the shift in gene expression
induced by the miRNA (for instance by RNA-Seq or SILAC).
miRNA-mediated control of early B-cell differentiation
Each individual B cell expresses a B-cell receptor (BCR) for
antigen with a unique specificity, so that the total pool of
mature B cells is capable of producing antibodies that specif-
ically recognize and respond to virtually any foreign antigen.
This involves the generation of a hugely diverse repertoire
of BCR specificities. The BCR is composed of two identical
immunoglobulin heavy (IgH) chains and two identical
immunoglobulin light (IgL) chains. In all vertebrates, the
genes encoding antibody variable regions are composed of
groups of gene segments called V, D, and J (for the IgH
locus) or V and J (for the IgL locus). During B-cell differen-
tiation, a segment from each V (D) and J group is assem-
bled to give rise to a VDJ (or VJ) rearrangement; this
combinatorial event is the basis of the primary antibody
diversity. Assembly of antibody genes takes place through a
process of site-specific recombination called V(D)J recombi-
nation and involves the introduction of DNA double-strand
breaks (DSBs) at specific recognition signal sequences flank-
ing the V, D, and J elements by recombination activating
genes (RAG1 and RAG2), followed by repair. Developing B
cells in the bone marrow (or fetal liver) first assemble their
IgH locus in two successive steps, DHJH and VHDHJH, at the
so-called progenitor B (pro-B) stage. Pro-B cells that achieve
a productive IgH rearrangement express an Igl chain
together with the surrogate chains k5 and VpreB (pre-BCR).
pre-BCR expression leads to a phase of vigorous clonal cell
expansion of precursor B (pre-B) cells and the subsequent
rearrangement of the IgL locus. As a result, a mature BCR is
expressed for the first time in immature B cells, which are
then ready to leave the bone marrow. Given the stochastic
nature of V(D)J recombination, this developmental process
is coupled to selective events that guarantee that only cells
where a rearrangement has given rise to a functional pre-
BCR and BCR receive the appropriate survival signals,
whereas the rest undergo apoptosis. In addition, central and
peripheral tolerance checkpoints ensure the elimination or
inactivation of B cells expressing BCRs with self-reactive
specificities (48) (Fig. 1).
The first miRNA reported to have a role in B-cell differen-
tiation in the bone marrow was miR-181a (49). In this
early study, miR-181a was identified as a miRNA differen-
tially expressed in T and B cells and whose ectopic expres-
sion by retroviral transduction and bone marrow
reconstitution promoted a substantial increase in the genera-
tion of B cells, both in vitro and in vivo (49). Interestingly,
miR-181a was later shown to play an important role in the
modulation of the thresholds of TCR signaling in thymo-
cytes (50, 51), providing a nice example of a miRNA play-
ing distinct roles in different cell lineages, presumably by
affecting different sets of target genes. miR-181 is a family
of miRNAs composed of the closely related miR-181a-d,
which are expressed from three polycistronic transcripts
(miR-181a1b1, miR-181a2b2, and miR-181cd) where mature
miR-181a and miR-181b can be generated from two inde-
pendent clusters. In agreement with the results obtained in
overexpression experiments (49), miR-181ab1-deficient mice
showed a mild decrease in the number of peripheral and
germinal center (GC) B cells (52). Important questions
remaining regarding the role of this interesting miRNA
cluster in B-cell differentiation include the identity of the
precise developmental stage(s) affected in gain- and loss-
of-function approaches. It will also be important to assess
the role of the miR-181ab2 cluster in the B-cell lineage and
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to identify its mRNA targets. In the following section, we
discuss the function of miR-181b in GC B cells.
The global importance of miRNA regulatory mechanisms
in the B-cell lineage was directly assessed in mice in which
Dicer was deleted at the earliest stage of B-cell differentiation
(mb1-Creki/+ Dicerfl/fl mice) (53). miRNAs proved to be cru-
cial, as Dicer-deficient mice displayed a severe block of B-cell
differentiation at the pro-B to pre-B transition, at least partly
due to massive apoptosis of Dicer-deficient pre-B cells, which
resulted in an almost complete absence of B cells in the
periphery. Combined bioinformatic analysis of miRNA and
mRNA profiles showed that seeds for the miR-17~92 cluster
were particularly enriched in the 3′ UTRs of the mRNAs
found to be upregulated in Dicer-deficient pro-B cells (53).
The miR-17~92 cluster consists of six miRNAs that are pro-
cessed from the same precursor transcript and was shown
early on to have oncogenic potential (54), as discussed
below. Indeed, miR-17~92 plays a major role in B-cell differ-
entiation, shown by the fact that germline deletion of this
cluster also blocks the pro-B to pre-B checkpoint (55). Two
of the top predicted targets of miR-17~92 were the pro-apop-
totic gene Bim and the tumor suppressor PTEN, both of
which are strongly upregulated in Dicer-deficient animals
(53). Accordingly, Bim expression was also upregulated in
miR-17~92-deficient mice (55), and both Bim and PTEN
were downregulated in mice with ectopic overexpression of
this cluster. The Dicer phenotype could be partially rescued
by a Bcl2 transgene and by Bim deficiency (53), indicating a
critical role of miR-17~92 in the regulation of Bim-induced
apoptosis at this developmental stage (Fig. 2).
The same pro-B to pre-B transition in B-cell differentia-
tion seems to be also regulated by another miRNA, miR-34a
(40). The miR-34 family is transcriptionally regulated by
p53 (19, 56, 57), and expression of these miRNAs is altered
in various cancers (58), although their germline deletion in
the mouse does not seem to influence cancer predisposition
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(59). Ectopic expression of miR-34a in bone marrow cells
followed by reconstitution experiments promoted an
increase in the proportion of pro-B cells and a concomitant
decrease in pre-B-cell numbers (40). Conversely, knock-
down of miR-34a with a sponge construct increased the
numbers of mature B cells. Target prediction combined with
functional assays showed that Foxp1 is a bona fide target of
miR-34a (40). Foxp1 is a transcription factor whose loss
results in a severe blockade in B-cell development (60).
Indeed, a rescue vector containing a 3′ UTR-less Foxp1
together with miR-34a was able to increase the number of
pre-B cells, indicating that Foxp1 downregulation is a criti-
cal event in the developmental block induced by miR-34a
(40). Although the downstream effectors of Foxp1 at this
stage are not well characterized, this study identifies a p53-
miR-34a-Foxp1 axis that may be critical for pre-B-cell
survival.
miR-150 has pleiotropic effects on B-cell differentiation
and function through the regulation of c-myb. c-myb is a
transcription factor whose inactivation in the B-cell lineage
leads to several defects, including a partial block at the pro-
B to pre-B transition and a decrease in conventional follicu-
lar cells and a subset of B cells, called B1 cells, which are
responsible for the production of natural antibodies
(61–63). miR-150 expression was detected in mature B and
T cells (64, 65) and shown to target c-myb (66). Rajewsky
and coworkers (66) performed a comprehensive analysis of
miR-150 function in the B-cell lineage through germline
deletion and ectopic expression approaches. They found that
miR-150 deficiency leads to B1-cell expansion and an
enhanced humoral immune response (see below), whereas
ectopic expression of miR-150 blocks the pro-B to pre-B
transition of bone marrow differentiation, most likely due
to an increased rate of cell death (66). A similar develop-
mental block was observed in a parallel study in which
miR-150 was overexpressed in vivo by retroviral transduction
of precursor cells followed by bone marrow transplantation
(65). Importantly, although miR-150 overexpression only
mildly reduced c-myb levels, this decrease was physiologi-
cally relevant, as mice with a heterozygous mutation in
c-myb were impaired at the same pro-B to pre-B matura-
tional stage (66). These data provide an example of how
miRNAs can play key regulatory roles by keeping protein
expression levels within the exquisite narrow range that
guarantees optimal functionality.
miRNAs have also been shown to regulate the generation
of B cells of fetal origin. The let-7 family of miRNAs acts as
regulators of stem-cell differentiation and had also been
implicated in tumor suppression (67). Lin28 are small RNA-
binding proteins (Lin28a and Lin28b) that regulate the
activity of let-7 miRNAs by blocking their biogenesis (68).
Lin28 is expressed in ES cells (69) and is a good predictor
of cells that become induced pluripotent stem cells (iPSCs)
(70). Indeed, ectopic expression of Lin28 (together with
Sox2, Oct4, and Nanog) is able to reprogram human
somatic cells to iPSCs (70). The immune system emerges in
waves during development; the first of which arises during
the fetal life and has unique properties, such as the efficient
generation of innate-like lymphocytes, including B1 cells
and cdT cells. A recent study showed that ectopic expression
of Lin28b in adult bone marrow hematopoietic progenitors
can reprogram these cells toward fetal-like hematopoiesis,
favoring the development of B1 and marginal zone B cells
(as well as cdT cells) at the expense of B2, or conventional
B cells (71). An additional layer of complexity was added to
this regulatory network with the finding that Lin28a is neg-
atively regulated by miR-125 (39). In turn, miR-125 over-
expression in bone marrow precursors promotes
myelopoiesis and compromises B-cell differentiation by
impairing the transition to the pre-B stage (39).
Generation of mature B cells involves a complex differenti-
ation program that has long been known to be regulated by
a number of transcription factors, including Pax5, PU.1, E2a,
and Ebf (72). The data summarized above show that miRNAs
are also determining factors in the intricate network that reg-
ulates these events. Different miRNAs have been shown to
act as positive (miR17-92) or negative (miR34a, miR-150,
miR-125) regulators of B-cell generation (Fig. 1). Interest-
ingly, alterations to the expression of these miRNAs in the
bone marrow appear to principally affect the pro-B to pre-B
transition, probably reflecting the importance of an optimal
balance between proliferation and cell death at the develop-
mental checkpoint governed by pre-BCR expression. In this
regard, it is important to bear in mind that in the case of
miR-34a, mir-150, and miR-125, this developmental block
was observed in overexpression experiments and that roles
for these miRNAs at their endogenous levels at this particular
stage are not completely established. This is a difficult issue
to tackle, given the multiple effects some of these miRNAs
have at different stages of B-cell differentiation and function
and in some cases in other lineages as well. Another interest-
ing consideration stemming from these reports concerns
general regulatory mechanisms by miRNAs. In the case of
miR-34a and miR-150, the two major identified targets are
the transcription factors Foxp1 and c-myb, respectively.
These findings reveal that although they are primarily
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post-transcriptional regulators, miRNAs can be involved in
more complex loops of gene expression regulation, for
instance by acting upstream of transcriptional regulators,
possibly by promoting relatively subtle shifts in their expres-
sion levels.
miRNAs in peripheral B-cell development and function
Terminal B-cell differentiation takes place in the spleen and
peripheral lymphoid tissues and serves to improve the com-
petence and diversify the effector functions of B lympho-
cytes. Bone-marrow-derived immature B cells transit in the
periphery to their final maturation through a number of
transitional stages and give rise to either follicular (FO) or
marginal zone (MZ) B cells (Fig. 1). These subsets are func-
tionally distinct: FO cells are mainly localized in B-cell folli-
cles and mount classical, T-cell-dependent responses,
whereas MZ B cells reside in the marginal zone areas of the
spleen and can respond rapidly to blood-borne pathogens
(73, 74). This maturational transition is associated with the
peripheral B-cell tolerance checkpoint that constrains the
generation of lymphocytes expressing autoreactive BCRs
(75). The FO versus MZ fate decision is functionally cou-
pled to BCR signaling (74, 76), and it has been suggested
that B cells bearing autoreactive BCRs are preferentially dri-
ven to an MZ fate (77, 78). When FO B cells encounter an
antigen they can engage in the GC reaction, a complex bio-
logical process that generates long-lived memory B cells and
plasma cells. At the molecular level, this GC program
involves two reactions that further diversify the Ig genes,
somatic hypermutation (SHM), and class switch recombina-
tion (CSR), both of which are initiated by the activity of
activation-induced deaminase (AID). SHM introduces nucle-
otide changes in the V(D)J rearranged variable region of the
IgH and IgL chains, allowing the production of B cells with
a higher affinity for antigen. CSR is a region-specific recom-
bination reaction that replaces the primary l constant region
with a downstream constant region, giving rise to antibod-
ies with different isotypes and therefore more specialized
effector functions (reviewed in 79–82). AID-mediated diver-
sification of the Ig genes entails the generation of DNA
mutations or DSB intermediates. However, AID activity can
also introduce mutations and generate DSB in other genes.
Remarkably, these DSB intermediates have been shown to
promote the generation of chromosomal translocations that
juxtapose the Ig loci to heterologous genomic sites, including
oncogenes, which are known to have lymphomagenic
potential (83–87). This bystander effect of AID activity
establishes a direct connection with the high propensity of
germinal center B cells to undergo lymphomagenic transfor-
mation. Finally, B cells exit the GC as antibody-secreting
plasma cells or long-lived memory B cells (Fig. 1).
Work from several groups has helped to characterize the
miRNA expression profiles of mature human and mouse B-
cell subsets. Two major studies analyzed miRNA expression
profiles in B cells by small RNA library sequencing. Tuschl
and coworkers (88) sequenced 250 small RNA libraries from
different organ systems, including 98 small RNA libraries
from the human hematopoietic system. This work provided
miRNA cloning frequency data from human total bone mar-
row, mature B lymphocytes, and hematopoietic tumor
biopsy samples, as well as from naive and in vitro-stimulated
mouse spleen B lymphocytes. An important finding of this
analysis is that only a third of the analyzed miRNAs were
expressed with a high degree of tissue- or cell-type specific-
ity (88). An independent study focused on identifying the
human mature B-cell miRNome and generated small RNA
libraries from naive, GC, and memory human B cells and
from a Burkitt lymphoma cell line. This study identified 178
miRNAs expressed in normal or transformed B-cell libraries,
including 75 previously unreported miRNAs. Interestingly,
this work revealed that a large fraction of the most abundant
miRNAs is shared by naive and memory B cells. In contrast,
GC B cells have a more distinct miRNA profile, suggesting
specific functions of these miRNAs in this B-cell type (89).
More recently, Cassellas and coworkers (90) combined miR-
NA-, mRNA-, and ChiP-Seq next-generation sequencing
techniques to further characterize the miRNome during lym-
phopoiesis. In the context of B lymphocytes, they analyzed
miRNA expression of essentially all stages of mouse B-cell
ontogeny from pro-B cells to terminally differentiated plasma
cells, as well as all the mature human B-cell subsets. In addi-
tion, their data showed that miRNA expression is tightly reg-
ulated by epigenetic, transcriptional, and post-transcriptional
mechanisms during mouse lymphopoiesis (90). Together,
these studies provide an invaluable resource for singling out
miRNAs that might play important roles in B-cell differentia-
tion and function. In this regard, it would be extremely use-
ful to perform a bioinformatics analysis to carefully compare
the sensitivity of these analyses and the conservation of miR-
NA expression in humans and mouse.
Two studies have used conditional Dicer ablation to
address the effect of total miRNA depletion in mature B cells.
To analyze the impact of miRNA depletion on terminal B-cell
differentiation, our group generated a CD19-CreKi/+Dicerfl/fl
mouse model (91). CD19-Cre promotes progressive deletion
in the B-cell lineage, which is completed at late stages of
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bone marrow differentiation (92). Dicer ablation in CD19-
CreKi/+Dicerfl/fl mice did not significantly alter bone marrow
differentiation, but resulted in a decrease in the generation
of mature splenic and lymph node B cells. Peripheral B-cell
subsets were altered in CD19-CreKi/+Dicerfl/fl mice, with
reduced numbers of conventional FO B cells and a relatively
increased proportion of MZ B cells. To examine the miRNAs
that might determine the FO versus MZ B-cell fate, we com-
pared miRNA expression profiles in control FO and MZ cells
by microarray analysis. Strikingly, all differentially expressed
miRNAs were expressed at higher amounts in FO B cells than
in MZ B cells, suggesting that miRNAs are more determinant
players in FO B-cell differentiation. Bioinformatics analysis
was conducted to determine whether genes with a known
role in FO- versus MZ-cell generation were among the pre-
dicted targets of the differentially expressed miRNAs; this
analysis predicted that miR-185, a miRNA overexpressed in
FO B cells, would target Btk, a kinase that transduces signals
downstream of the BCR. Btk has been shown to be involved
in the generation or recruitment of autoreactive B cells to the
MZ area (78). We found that overexpression of miR-185 in
primary B cells decreased Btk expression and that, con-
versely, Btk expression was increased in Dicer-deficient B
cells. In the absence of Dicer, BCR signaling was enhanced,
as measured by the levels of Erk phosphorylation and the rate
of CSR in in vitro-stimulated B cells. In addition, Btk overex-
pression in wildtype cells increased, whereas miR-185
expression decreased, CSR efficiency upon BCR stimulation.
These results show that miR-185 inhibits BCR signaling
through Btk downregulation and suggest that altered BCR
signaling is responsible for the biased selection and commit-
ment of CD19-CreKi/+Dicerfl/fl peripheral B cells. This notion
was further reinforced by the finding that CD19-CreKi/
+Dicerfl/fl peripheral cells express a skewed BCR repertoire,
suggesting that the establishment of tolerance is incomplete
in Dicer-deficient B cells. Dicer deficiency promoted
increased titers of autoantibodies in aged females, which led
to immune complex depositions in kidney sections, lympho-
cyte infiltration, and overall damage of glomerulus architec-
ture, characteristic of autoimmune disease (91). In
agreement with these findings, Hendriks and coworkers (93)
recently reported an autoimmune pathology in transgenic
mice overexpressing Btk in B cells. These authors developed
two transgenic mouse models for Btk overexpression in the
B-cell lineage that achieved a three- to sevenfold increase of
Btk levels. Their analysis revealed that Btk-overexpressing B
cells are selectively hyperresponsive to BCR signaling and
show enhanced Ca2+ influx, NF-jB activation, resistance to
Fas-mediated apoptosis, and defective elimination of self-
reactive B cells. These mice, accordingly, develop a systemic
lupus erythematosus (SLE)-like autoimmune disorder, char-
acterized by autoantibody formation, kidney damage, and
perivascular lymphocyte infiltration. However, the autoim-
mune syndrome of these mice is not identical to that found
in the CD19-CreKi/+Dicerfl/fl model, as Btk transgenic mice
do not show gender-biased disease. This difference could be
due to variations in the levels of Btk overexpression in B cells
in the two models, to variations in strain susceptibility to
develop autoimmune disease, or to the contribution of other
dysregulated genes in the Dicer-deficient model. Moreover,
in the collagen-induced arthritis and MRL-Fas(lpr) lupus
models, treatment with a selective Btk inhibitor reduces
autoantibody production and the development of autoim-
mune disease (94). Thus, different reports provide evidence
that the regulation of Btk expression levels in B cells plays an
important role in the development of autoimmune disorders.
Together, our results have revealed a crucial role for miRNAs
in terminal B-cell differentiation and the establishment of B-
cell tolerance (Fig. 2).
A second study developed Aicda-CreKi/+Dicerfl/fl mice to
address the impact of global miRNA depletion on the differ-
entiation of antigen-activated B cells in the context of GC
responses (95). In this model, Cre recombinase expression is
under the physiological control of AID expression, so that
Dicer is depleted specifically in antigen-activated B cells. This
study showed that the absence of miRNAs severely compro-
mises the GC response and that no memory B and plasma
antibody-secreting cells are generated in AicdaCreKi/+Dicerfl/fl
mice, establishing that miRNAs are essential for the B-cell
response to T-dependent antigens. This is in part due to a
defect in the proliferation of Dicer-deficient GC B cells,
which expressed high levels of several negative regulators of
genes involved in cell proliferation, including eight cyclin-
dependent kinase inhibitory (CDKi) genes. Importantly, the
authors found that a high proportion of the miRNAs
reported to be expressed at high levels in GC B cells (90)
were predicted to target all eight CDKi genes examined. The
authors also showed that Dicer-deficient GC B cells have an
increased apoptosis rate and expressed high levels of the pro-
apoptotic molecule Bim (95). This study demonstrates that
miRNAs are essential for antigen-dependent immunization
responses and exemplify the complexity of the effects that
miRNAs can induce in a particular cellular context (Fig. 2).
The role of several individual miRNAs expressed in the
B-cell lineage has been studied using different genetic gain-
and loss-of-function approaches in in vitro and in vivo models.
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One of the most extensively studied miRNAs in mature B
cells is miR-155. miR-155 has emerged as a pivotal miRNA
in the hematopoietic system and has a significant impact on
the biology of multiple immune cells, including B and T
lymphocytes, monocytes, dendritic cells, and natural killer
cells (96–101), and also plays an oncogenic role in some of
these lineages (99, 102–104). miR-155 is expressed in
mature B cells and is upregulated in GC B cells as well as in
in vitro-activated B cells (89, 90, 97, 105). Three independent
studies showed that miR-155 is required for the GC response
(96, 97, 106). miR-155-germline-deficient mice have an
impaired humoral response to immunization, resulting in
reduced numbers of GC B cells and reduced amounts of
secreted switched antigen-specific antibodies (96, 97). In
contrast, mice that conditionally overexpress miR-155 in
mature B cells had increased numbers of GC B cells and
showed high antigen-specific antibody secretion upon T-cell-
dependent immunization (97). Functional characterization of
the cell subsets involved in the GC response showed that
miR-155 was required for the proper function of DC, T, and
B cells (96, 97). In vitro, stimulation of miR155/ B cells
resulted in reduced IgG1 production (96) and defective
secretion of cytokines (TNF and LT-a) known to be critical
for GC formation (97). Confirming these results, analysis of
miR155/ mouse chimeras showed that in vivo B cells
require miR-155 for the production of switched and high-
affinity antibodies in a cell-autonomous manner (106). The
gene expression profile of wildtype and miR155/ B cells
revealed that miR-155 regulates many genes in activated B
cells (101 genes were significantly increased in miR-155-
deficient B cells) (106), a significant proportion of which
presumably are direct miR-155 targets (60 of them contain
at least one seed match for miR-155 in their 3′ UTR). Two
of these putative miR-155 targets have been confirmed.
Turner and coworkers (106) showed that the transcription
factor PU.1 is a direct target of miR-155 in activated B cells
and that its overexpression impairs CSR in in vitro-stimulated
wildtype B cells. PU.1 had previously been implicated in
early B-cell differentiation (72) and in the signaling pathway
downstream of the BCR (107). These results therefore add a
new role for PU.1 in the B-cell lineage, presumably as a neg-
ative regulator of plasma cell differentiation controlled by
miR-155. Interestingly, the other characterized target of
miR-155 in activated B cells is AID, the enzyme that initiates
SHM and CSR. miR-155 is one of the top miRNAs predicted
to target AID by algorithms such as TargetScan and miRanda.
To assess whether AID is a direct target of miR-155 in B
cells, Nussenzweig and coworkers (43) generated a knock-in
mouse model in which the conserved miR-155 binding site
in the 3′ UTR of the AID gene was mutated (Aicda155). Ai-
cda155 B cells showed a modest increase in AID levels (two-
to threefold higher than controls), demonstrating that AID is
a direct target of miR-155 in vivo. Accordingly, Aicda155 B
cells showed increased CSR and c-myc/IgH translocation fre-
quency in in vitro stimulation assays (43). Interestingly, the
increase in the c-myc/IgH translocation frequency in Ai-
cda155 B cells (four- to sixfold compared with control) was
lower than in miR-155/ B cells (15-fold compared with
control) (43), indicating that miR-155 targets additional
mRNAs that cooperate to prevent AID-induced translocations
in B cells. A similar mouse model was independently gener-
ated that harbored an AID BAC transgene with a mutated
miR-155-binding site (44). The authors found that this
mutation also resulted in higher AID expression levels in vivo
and higher levels of CSR in in vitro-stimulated splenic B cells
(44). In addition, the dysregulated expression of AID in
these mice increased the mutation rate in an off-target gene
for AID activity and was associated with impaired affinity
maturation (44). Together, these two studies provide the
most physiological approaches used so far for the identifica-
tion of a bona fide miRNA target in the B-cell lineage. At the
same time they reveal a functional paradox, in that although
miR-155 acts globally as a positive regulator of several
aspects of the GC reaction (96, 97, 106), it is at the same
time a negative regulator of AID (43, 44), one of the key
players in the same reaction (Fig. 3). Recent data provide evi-
dence that might help to reconcile these results. Bcl-6, a
transcriptional repressor required for the GC reaction, has
been found to repress the expression of miR-155 (108).
Although apparently counterintuitive, it is possible that miR-
PU.1
AID
miR155miR181b
c-myc/IgH translocations
Lymphoblastic leukemia 
High grade lymphoma
Generation of switched 
plasma B cells
i
Fig. 3. Roles of miR-181b and miR-155 in mature B cells. miR-
181b and miR-155 target AID, an essential enzyme for CSR and SHM
in GC B cells that can also promote the generation of oncogenic
chromosomal c-myc/IgH translocations. Moreover, miR-155 inhibits
the generation of c-myc/IgH translocations by targeting other, not yet
identified, genes. miR-155 is also required for the GC response and
promotes the generation of class-switched cells by targeting the
transcription factor PU.1. In addition, miR-155 overexpression in B
cells has been shown to induce B-cell lymphomagenesis.
© 2013 John Wiley & Sons A/S. Published by Blackwell Publishing Ltd
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155 and Bcl-6 are required at different times during the GC
reaction. Two functionally and anatomically distinct areas
can be distinguished in GCs, called light (LZ) and dark (DZ)
zones. The DZ is the main location for B-cell clonal expan-
sion and antigen receptor diversification, whereas the LZ is
the site of antigen-driven selection. B cells perform iterative
migratory cycles between the two zones to achieve affinity
maturation (109). Bcl-6 might act as a positive regulator of
AID expression and presumably other GC genes through
miR-155 repression in the DZ, and conversely miR-155
expression in the LZ might regulate other aspects of the GC
reaction, for instance by inhibiting PU.1. According to this
speculation, miR-155 activity would therefore be spatiotem-
porally compartmentalized to provide various fine regulatory
checkpoints during B-cell activation.
AID expression is regulated by yet another miRNA, miR-
181b (35). miR-181b was identified in a screen of 150 miR-
NA clones aimed at identifying miRNAs involved in the reg-
ulation of the GC reaction. Ectopic expression of miR-181b
during B-cell activation profoundly decreased the CSR rate.
miR-181b expression levels are regulated concomitantly with
B-cell activation (35, 90). The CSR impairment induced by
miR-181b was not caused by altered proliferation, survival,
or plasma cell differentiation. To identify putative miR-181b
targets, we profiled mRNA expression shifts upon miR-181b
overexpression. We found that 20% of the mRNAs expressed
in B cells were downregulated in miR-181b expressing cells
and that 60% of them contained miR-181b seed sequences
in their 3′ UTRs. Interestingly, AID was one of the most
downregulated of the mRNAs that contained miR-181b seed
sequences. mir-181b overexpression reduced AID protein
levels to approximately 50% of the levels found in control B
cells. This reduction is physiologically relevant, as AID
expression levels in activated B cell are limiting both for the
CSR reaction and for the generation of c-myc/IgH chromo-
some translocations, as revealed in AID+/ mice (110, 111).
In turn, the reduction in AID levels promoted by miR-181b
parallels decreased efficiency in CSR. We further showed that
the putative binding sequences in the AID 3′ UTR can be
directly targeted by miR-181b. Interestingly, AID and miR-
181b have complementary expression profiles, with AID lev-
els low in resting B cells and increasingly sharply in CSR-
stimulated B cells, whereas miR-181b expression is highest
in non-stimulated cells and drops upon stimulation. The
same complementary expression pattern was found when
miR-181b and AID expression levels were analyzed in a col-
lection of Burkitt, mantle cell lymphoma, and diffuse large
B-cell lymphoma (DLBCL) human B-cell lines, supporting
the idea that high expression of miR-181b prevents the accu-
mulation of high levels of AID transcripts (35). Overall, these
studies suggest that AID levels in B cells are controlled by
different miRNAs with non-overlapping functions, so that
whereas miR-181b would prevent premature AID activity in
resting B cells and allow proper AID transcriptional activation
upon stimulation, miR-155 would prevent excessive accu-
mulation of AID transcripts in activated B cells (Fig. 3).
Other miRNAs have been implicated in the regulation of
different aspects of mature B-cell biology, including the GC
reaction and plasma B-cell differentiation. miR-125b, a
highly expressed miRNA in macrophages that participates in
myeloid differentiation and myeloid leukemia (112, 113), is
also specifically expressed in a subset of GC B cells (114,
115). miR-125b was shown to directly target BLIMP1 (B-
lymphocyte-induced maturation protein-1) and IRF4 (inter-
feron regulatory factor-4), two transcription factors essential
for post-GC plasma B-cell differentiation (114–116). Accord-
ingly, overexpression of miR-125b in B cells inhibited
plasma B-cell differentiation and Ig secretion in vitro (114).
This miRNA could therefore enhance B-cell diversification
during the GC response by limiting their premature differen-
tiation into plasma cells. Another miRNA implicated in
mature B-cell function is miR-150, in addition to its role
during B-cell differentiation. miR-150 expression is tightly
regulated during B-cell differentiation, being low in develop-
ing B cells, peaking in mature B cells, and dropping upon B-
cell activation (66). Rajewsky and coworkers (66) reported
that miR150/ mice show increased secretion of antigen-
specific Igs in T-cell-dependent responses. Their data suggest
that this may be due to enhanced expression of c-Myb in GC
B cells. This is supported by the increased expression of the
prosurvival protein Bcl2, a direct c-Myb target gene, and the
reduction in cell death observed in activated mir150/ B
cells upon IgM cross-linking (66). In addition, we recently
identified miR-217 as a novel positive regulator of GC reac-
tions, finding that its expression is upregulated in activated
and GC B cells (authors’ unpublished observations). To study
miR-217 function in mature B cells in vivo, we generated B-
cell-specific gain- and loss-of-function mouse models. miR-
217 overexpression in B cells enhances T-cell-dependent
immunization responses, improving the efficiency of GC for-
mation, CSR and SHM, as well as the generation of plasma
and terminally differentiated memory B cells. Conversely,
when we inhibited endogenous miR-217 expression in B
cells the generation of class-switched cells was diminished,
and the efficiency of SHM was lower than in control cells.
These results show that miR-217 plays a physiological role
© 2013 John Wiley & Sons A/S. Published by Blackwell Publishing Ltd
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in the secondary diversification of Ig genes in the context of
the GC reaction (Fig. 1).
Several miRNAs have been identified that regulate termi-
nal B-cell differentiation and function, including antigen-
dependent and -independent antibody repertoire diversifica-
tion and the establishment of B-cell tolerance. These regula-
tory schemes often involve mild changes in gene
expression, which, however, result in profound functional
alterations. In addition, expression profiling of miRNAs dur-
ing B-cell activation allows predicting that new players will
emerge with critical roles in these events. Dissecting their
functional interrelationships will undoubtedly be an exciting
challenge.
miRNAs in B-cell lymphomas
Dysregulation of miRNA expression is a common event in
cancer, including B-cell lymphomas, and miRNA profiling is
increasingly recognized as a valuable tool for cancer classifi-
cation (117–121). Formal proof of the direct role of miRNAs
in B-cell lymphoma development came from the generation
of mouse models in which alterations to miRNA expression
levels had an impact on B-cell lymphoma incidence. These
studies revealed that miRNAs can function both as oncogenes
(oncomiRs) and as tumor suppressor genes.
In the first study to demonstrate that miRNAs could pro-
mote lymphomagenesis, enforced expression of the miR-
17~92 polycistron in hematopoietic stem cells from El-myc
transgenic mice accelerated the generation of B-cell lympho-
mas when these cells were transplanted into lethally irradi-
ated recipient animals (54). In contrast, overexpression of
miR-17~92 in wildtype lymphocytes did not induce frank
B-cell lymphomas, although these mice died prematurely
from lymphoproliferative disease and autoimmunity (122),
indicating that the miR-17~92 cluster contributes to but it
is not sufficient for lymphomagenesis in vivo. Lymphoprolif-
eration and autoimmunity were due partly to repression of
the tumor suppressor PTEN and the pro-apoptotic protein
Bim, exerted directly by miR-17~92 in lymphocytes (53,
55, 122). When the tumorigenic potential of the individual
miRNAs of the miR-17~92 polycistron was assessed in the
El-myc B-cell lymphoma model, miR-19 emerged as the
key proto-oncogenic component (123, 124). The proto-
oncogenic activity of miR-19 was shown, at least in part, to
be due to its promotion of cell survival through the repres-
sion of the tumor suppressor PTEN and the activation of the
AKT mTOR pathway (123, 124).
In contrast to miR-17~92, overexpression of miR-155 in
developing B cells is sufficient for neoplasia development
(104). miR-155 expression is increased in various lymphoid
malignancies, including chronic lymphocytic leukemia
(CLL) and DLBCL (102, 124). The oncogenic potential of
miR-155 was assessed in B-cell-specific El/VH miR-155
transgenic mice, which develop transplantable acute lym-
phoblastic leukemia (ALL)/high-grade lymphoma in which
SHIP and C/EBPb downregulation by miR-155 could be
functionally relevant (104, 126, 127). miR-155 might pro-
mote B-cell lymphomagenesis by targeting additional pro-
teins, including HGAL, an inhibitor of lymphocyte cell
motility (128), and SMAD5, whose downregulation renders
lymphoma cells resistant to the growth-inhibitory effects of
TGFb pathway (129). Other targets that might contribute to
the proto-oncogenic potential of miR-155 include the mis-
match repair proteins Msh2, Msh6, and Mlh1 (130), or
other proliferation-related genes (131), which could endow
miR-155 with mutator activity. miR-155 is thus a miRNA
with lymphomagenic potential, although the exact mecha-
nism by which it promotes transformation is far from being
understood and seems to involve several different targets
and pathways. It also remains unknown whether AID and
PU.1, known to be targeted by miR-155, play a negative or
positive role in the development of miR-155-induced lym-
phomagenesis or, alternatively, if miR-155 regulates differ-
ent targets at distinct developmental stages.
An interesting new concept in the oncomiR field arose
from the work of Slack and collaborators (132), who
showed that miR-21 contributes not only to the develop-
ment of lymphoma but also to tumor maintenance. miR-21
is overexpressed in most tumor types, including B-cell
malignancies (119, 133–135). A combination of Cre and
Tet-off technologies was used to generate a mouse model
that allowed conditional and inducible miR-21 overexpres-
sion in neural stem cells and the hematopoietic system
(132). miR-21 overexpression in this mouse model pro-
moted the generation of a transplantable pre-B-cell lym-
phoma (132). Notably, switching off miR-21 expression in
established tumors caused a rapid tumor regression medi-
ated by a combination of apoptosis and proliferative arrest
(132). These results demonstrate that miR-21 is a genuine
oncogene and present the first case of ‘oncomiR addiction’,
which may open new avenues for therapy.
Other studies have evidenced the proto-oncogenic role of
various miRNAs in B-cell lymphomas. miR-29, a miRNA
whose expression is dysregulated in B-CLL, induces the gen-
eration of a CD5+ B-CLL-like disease when overexpressed in
El-miR-29 transgenic mice (136). miR-125b, a GC miRNA
that is overexpressed in B-cell precursor ALL and DLBCL
© 2013 John Wiley & Sons A/S. Published by Blackwell Publishing Ltd
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(115, 137, 138), induces clonal B-cell lymphomas in El-
miR-125b transgenic mice (137). Finally, miR-217, a posi-
tive regulator of the GC reaction, promotes the generation
of mature B-cell lymphomas in a B-cell-specific overexpres-
sion mouse model, establishing a functional link between
the physiology of this developmental program and the
molecular events leading to lymphomagenesis (authors’
unpublished results).
miRNA profiling in lymphomas reveals that particular
miRNAs are located in genomic regions that are frequently
deleted in cancer (139–141). However, the first evidence
that miRNAs could function as tumor suppressors in B-cell
lymphomas in vivo came from the work of Mendell and
coworkers (20), who showed that c-myc-induced repres-
sion of a set of miRNAs contributed to lymphoma growth.
These authors found that Myc induction in two models of
B-cell lymphoma resulted in widespread downregulation of
miRNA expression, presumably via direct binding to their
promoters (20). Importantly, re-expression of a set of c-
myc repressed miRNAs including mi-R34a, miR-150, miR-
195/497, and miR-15a/16-1, abrogated the tumorigenic
potential of B-cell lymphoma cells in SCID (sever combined
immunodeficient) mice (20). Conditional knockout models
have been used to directly assess the contribution to B lym-
phomagenesis of the minimal deleted region (MDR) within
13q14, which is deleted in more than 50% of B-CLL
(142). MDR-13q14 encodes the DLEU2, a long non-coding
RNA, and the miR15a/16 cluster (5, 139). Interestingly,
mice in which only the miRNA cluster was deleted showed
a clonal preleukemic expansion of CD5+ B cells, whereas
mice in which the MDR was deleted developed a more
aggressive CLL-like disease (142). This study further
showed that the miR15a/16-1 cluster limits the prolifera-
tion of B cells by targeting multiple genes involved in the
G0/G1-S phase transition (142). However, the more
aggressive phenotype of MDR-deleted mice suggests that
additional genetic elements within the MDR locus contrib-
ute to the tumor suppressive function. Another study
revealed a role for a set of p53-induced miRNAs in multi-
ple myeloma (MM), a neoplasm of plasma B cells (143).
The tumor suppressor p53 promotes the expression of
miR-192, miR-194, and miR-215, which in turn directly
target MDM2, a negative regulator of p53 (143). This reg-
ulatory loop could be valuable, as re-expression of these
miRNAs in MM cell lines increased the therapeutic action
of a MDM2 inhibitor in vitro and in a mouse xenograft
model (143). In addition, this set of miRNAs impaired the
migration and invasion of MM cell lines in NOD-SCID mice
through the inhibition of IGF-1 and IGF1-R (143). Finally,
miR-146a has been shown to function as a tumor suppres-
sor miRNA for myeloid and B cells in vivo (144). miR-146a
is expressed in various immune cell types, and its expres-
sion is deregulated in different cancers, including DLBCL
and CLL B-cell lymphomas (115, 145, 146). Germline
miR-146a-deficient mice develop a chronic inflammatory
phenotype that progresses to splenic myeloid sarcoma and,
less frequently, into B-cell lymphomas (144). The authors
went on to show that this effect of miR-146a is mostly
due to negative regulation of NF-jB by miR-146a, with
deletion of the NF-jB p50 subunit effectively rescuing the
myeloproliferative disease (144). These data provide a good
example of a link between miRNA regulatory activity,
inflammation, and cancer. Overall, these studies open a
new perspective to the understanding of the molecular
mechanisms underlying oncogenic transformation, in which
miRNAs can play a fundamental, previously unforeseen
role.
Concluding remarks
The last few years have seen an outburst of research into the
regulation of diverse biological processes by miRNAs.
Within the B-cell lineage, this effort has led to the identifi-
cation of a number of miRNAs that impinge on critical dif-
ferentiation or activation checkpoints, including miR-181,
miR-17~92, miR-34, miR-150, and miR-155. A number of
miRNAs are, moreover, now known to contribute to B-cell
lymphoma development, either as oncogenes or as tumor
suppressors. A considerable effort has been made in this and
other fields to pinpoint individual mRNA targets that could
account for the functional impact of a miRNA. However, it
is already evident that miRNAs very often play pleiotropic
roles in intertwined regulatory networks and that high-
throughput approaches seem to be required to identify more
complete sets of target genes at defined developmental
stages. Continuing implementation of proteomics
approaches, gene expression analysis by next-generation
sequencing, and HITS-CLIP techniques will undoubtedly
prove invaluable. Importantly, miRNAs are emerging as a
new class of molecules with clinical potential. Their value as
diagnostic and even prognostic markers is already a reality
in cancer and other pathologies. Moreover, the possibility of
manipulating the expression of miRNAs in vivo by the deliv-
ery of miRNAs or miRNA inhibitors has opened new and
exciting therapeutic perspectives for the treatment of numer-
ous diseases. We await new developments in this rapidly
expanding field with anticipation.
© 2013 John Wiley & Sons A/S. Published by Blackwell Publishing Ltd
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